{"generated":"2026-10-06","source":"ClinicalTrials.gov API v2","sourceUrl":"https://clinicaltrials.gov/","trials":[{"nct_id":"NCT00088699","title":"Rapid Antidepressant Effects of Ketamine in Major Depression","acronym":"","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":67,"start_date":"2004-07-26","completion_date":"2017-07-31","last_update":"2018-10-12","substances":"ketamine","conditions":"Depression; Mood Disorders; Major Depresssion","sponsor":"National Institute of Mental Health (NIMH)","sponsor_class":"NIH","has_results":true,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct00088699","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00088699"},{"nct_id":"NCT00090064","title":"MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":23,"start_date":"2004-03-12","completion_date":"2008-05-02","last_update":"2025-06-06","substances":"mdma","conditions":"Posttraumatic Stress Disorder","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":true,"site_count":1,"countries":"United States","us_states":"South Carolina","lsd_com_url":"https://lsd.com/trials/nct00090064","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00090064"},{"nct_id":"NCT00235768","title":"The NeXT Study; The Netherlands XTC Toxicity Study","acronym":"","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":225,"start_date":"2002-04","completion_date":"","last_update":"2005-10-10","substances":"mdma","conditions":"Ecstasy (Drug); N-Methyl-3,4-Methylenedioxymethamphetamine; Psychopathology","sponsor":"UMC Utrecht","sponsor_class":"OTHER","has_results":false,"site_count":3,"countries":"Netherlands","us_states":"","lsd_com_url":"https://lsd.com/trials/nct00235768","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00235768"},{"nct_id":"NCT00252174","title":"MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer","acronym":"","status":"TERMINATED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":2,"start_date":"2007-02","completion_date":"2010-12","last_update":"2017-11-14","substances":"mdma","conditions":"Anxiety Disorder; Cancer","sponsor":"Brigham and Women's Hospital","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct00252174","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00252174"},{"nct_id":"NCT00254306","title":"Functional Brain Imaging in Recreational Users of Ecstasy","acronym":"","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":18,"start_date":"2006-01","completion_date":"2011-07","last_update":"2011-07-07","substances":"mdma","conditions":"Amphetamine-Related Disorders","sponsor":"Hadassah Medical Organization","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Israel","us_states":"","lsd_com_url":"https://lsd.com/trials/nct00254306","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00254306"},{"nct_id":"NCT00302744","title":"Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety","acronym":"","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2004-04","completion_date":"2008-12","last_update":"2025-03-13","substances":"psilocybin","conditions":"Anxiety","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct00302744","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00302744"},{"nct_id":"NCT00329394","title":"Systemic Ketamine for the Improvement of Post-Operative Analgesia at the Alcohol-Dependent Patient","acronym":"","status":"SUSPENDED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":56,"start_date":"2006-04","completion_date":"2008-09","last_update":"2008-10-08","substances":"ketamine","conditions":"Alcoholic Patient; Carcinological Surgery ORL","sponsor":"University Hospital, Clermont-Ferrand","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"France","us_states":"","lsd_com_url":"https://lsd.com/trials/nct00329394","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00329394"},{"nct_id":"NCT00353938","title":"Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":14,"start_date":"2006-09-13","completion_date":"2009-09-02","last_update":"2024-07-15","substances":"mdma","conditions":"Posttraumatic Stress Disorder","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":true,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct00353938","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00353938"},{"nct_id":"NCT00402298","title":"Randomized Placebo-controlled Study of MDMA-assisted Therapy in People With PTSD - Israel","acronym":"","status":"TERMINATED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":5,"start_date":"2007-05-27","completion_date":"2009-03","last_update":"2025-06-05","substances":"mdma","conditions":"Posttraumatic Stress Disorder","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":true,"site_count":1,"countries":"Israel","us_states":"","lsd_com_url":"https://lsd.com/trials/nct00402298","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00402298"},{"nct_id":"NCT00419003","title":"Research Study for Major Depressive Disorder: Investigation of Glutamate Medications","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":26,"start_date":"2006-12","completion_date":"2008-07","last_update":"2019-07-31","substances":"ketamine","conditions":"Major Depression","sponsor":"Baylor College of Medicine","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct00419003","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00419003"},{"nct_id":"NCT00465595","title":"Psychopharmacology of Psilocybin in Cancer Patients","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":56,"start_date":"2007-04","completion_date":"2014-12","last_update":"2018-07-19","substances":"psilocybin","conditions":"Depressive Symptoms; Anxiety; Cancer","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct00465595","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00465595"},{"nct_id":"NCT00548964","title":"Continuation Ketamine in Major Depression","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":36,"start_date":"2007-10","completion_date":"2013-07","last_update":"2014-05-23","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"James Murrough","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct00548964","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00548964"},{"nct_id":"NCT00588952","title":"Ketamine/Placebo Family History Positive Study","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":99,"start_date":"2001-03","completion_date":"2015-06","last_update":"2021-10-06","substances":"ketamine","conditions":"Alcoholism","sponsor":"Yale University","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct00588952","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00588952"},{"nct_id":"NCT00646087","title":"Ketamine Frequency Treatment for Major Depressive Disorder","acronym":"","status":"WITHDRAWN","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2008-03","completion_date":"","last_update":"2011-06-06","substances":"ketamine","conditions":"Treatment Resistant Depression","sponsor":"Essentia Health","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Minnesota","lsd_com_url":"https://lsd.com/trials/nct00646087","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00646087"},{"nct_id":"NCT00680433","title":"Ketamine as an Anaesthetic Agent in Electroconvulsive Therapy (ECT)","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":83,"start_date":"2008-04","completion_date":"2012-10","last_update":"2013-03-29","substances":"ketamine","conditions":"Major Depressive Episode","sponsor":"Northside Clinic, Australia","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Australia","us_states":"","lsd_com_url":"https://lsd.com/trials/nct00680433","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00680433"},{"nct_id":"NCT00736307","title":"Autologous Transplantation of Cultivated Limbal Stem Cells on Amniotic Membrane in Limbal Stem Cell Deficiency (LSD) Patients","acronym":"","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2007-10","completion_date":"2009-07","last_update":"2011-07-15","substances":"lsd","conditions":"Limbal Stem Cell Deficiency","sponsor":"Royan Institute","sponsor_class":"OTHER_GOV","has_results":false,"site_count":2,"countries":"Iran","us_states":"","lsd_com_url":"https://lsd.com/trials/nct00736307","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00736307"},{"nct_id":"NCT00749203","title":"Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)","acronym":"KetPTSD","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":41,"start_date":"2009-01","completion_date":"2013-09","last_update":"2018-02-14","substances":"ketamine","conditions":"Stress Disorders, Post-Traumatic; PTSD; Depression; Anxiety Disorder","sponsor":"Dennis Charney","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct00749203","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00749203"},{"nct_id":"NCT00768430","title":"Optimization of IV Ketamine for Treatment Resistant Depression","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":73,"start_date":"2008-11","completion_date":"2012-09","last_update":"2014-01-31","substances":"ketamine","conditions":"Major Depressive Disorder (MDD); Treatment Resistant Depression (TRD)","sponsor":"Baylor College of Medicine","sponsor_class":"OTHER","has_results":true,"site_count":2,"countries":"United States","us_states":"New York; Texas","lsd_com_url":"https://lsd.com/trials/nct00768430","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00768430"},{"nct_id":"NCT00802282","title":"Psilocybin and Spiritual Practice","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":75,"start_date":"2009-08","completion_date":"2014-02","last_update":"2016-02-24","substances":"psilocybin","conditions":"Healthy","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct00802282","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00802282"},{"nct_id":"NCT00838305","title":"Role of Serotonin in Acute and Subacute MDMA Effects","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":13,"start_date":"2009-02","completion_date":"2009-12","last_update":"2013-05-31","substances":"mdma","conditions":"MDMA Mechanism of Action","sponsor":"California Pacific Medical Center Research Institute","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct00838305","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00838305"},{"nct_id":"NCT00886886","title":"Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2009-04","completion_date":"2009-12","last_update":"2013-01-25","substances":"mdma","conditions":"Mood Disorder; Substance-related Disorders; Amphetamine-related Disorders","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct00886886","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00886886"},{"nct_id":"NCT00895804","title":"Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2001-06","completion_date":"2002-03","last_update":"2009-06-15","substances":"mdma","conditions":"Mood Disorder; Substance-Related Disorders; Amphetamine-Related Disorders","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct00895804","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00895804"},{"nct_id":"NCT00920387","title":"Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2008-02","completion_date":"2011-04-14","last_update":"2023-07-12","substances":"lsd","conditions":"Anxiety","sponsor":"Multidisciplinary Association for Psychedelic Studies","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct00920387","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00920387"},{"nct_id":"NCT00947791","title":"Treatment Study of Bipolar Depression","acronym":"","status":"TERMINATED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":1,"start_date":"2009-07","completion_date":"2009-10","last_update":"2017-05-17","substances":"ketamine","conditions":"Bipolar Disorder","sponsor":"Icahn School of Medicine at Mount Sinai","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct00947791","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00947791"},{"nct_id":"NCT00956085","title":"Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive Disorder","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2009-08","completion_date":"2015-12","last_update":"2017-06-21","substances":"ketamine","conditions":"Obsessive-Compulsive Disorder","sponsor":"New York State Psychiatric Institute","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct00956085","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00956085"},{"nct_id":"NCT00957359","title":"Psilocybin Cancer Anxiety Study","acronym":"","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":29,"start_date":"2009-02","completion_date":"2018-09-06","last_update":"2020-10-20","substances":"psilocybin","conditions":"Cancer","sponsor":"NYU Langone Health","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct00957359","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00957359"},{"nct_id":"NCT00979693","title":"Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma","acronym":"","status":"WITHDRAWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2012-01","completion_date":"2013-04","last_update":"2023-12-26","substances":"psilocybin","conditions":"Anxiety; Stage IV Melanoma","sponsor":"Multidisciplinary Association for Psychedelic Studies","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Florida","lsd_com_url":"https://lsd.com/trials/nct00979693","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00979693"},{"nct_id":"NCT00990067","title":"Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2009-11","completion_date":"2010-05","last_update":"2013-01-25","substances":"mdma","conditions":"Mood Disorder; Substance-Related Disorders; Amphetamine-Related Disorders","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct00990067","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT00990067"},{"nct_id":"NCT01046630","title":"Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":128,"start_date":"2009-12","completion_date":"2011-03","last_update":"2014-10-13","substances":"ketamine","conditions":"Depression","sponsor":"AstraZeneca","sponsor_class":"INDUSTRY","has_results":false,"site_count":2,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01046630","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01046630"},{"nct_id":"NCT01053403","title":"Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition.","acronym":"2C","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2010-04","completion_date":"2010-12","last_update":"2013-05-31","substances":"mdma","conditions":"MDMA Discontinuation Syndrome","sponsor":"California Pacific Medical Center Research Institute","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct01053403","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01053403"},{"nct_id":"NCT01100255","title":"Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD)","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":15,"start_date":"2010-04","completion_date":"2015-12","last_update":"2017-02-20","substances":"ketamine","conditions":"Obsessive-Compulsive Disorder","sponsor":"New York State Psychiatric Institute","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct01100255","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01100255"},{"nct_id":"NCT01101659","title":"Ketamine Challenge Study With JNJ-40411813","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2010-02","completion_date":"","last_update":"2014-04-08","substances":"ketamine","conditions":"Perceptual Disorders; Confusion; Schizophrenia","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"Germany","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01101659","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01101659"},{"nct_id":"NCT01135758","title":"Study of Depression-Ketamine-Brain Function","acronym":"","status":"TERMINATED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2010-06","completion_date":"2015-06","last_update":"2015-12-07","substances":"ketamine","conditions":"Major Depression","sponsor":"Markus KOSEL","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01135758","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01135758"},{"nct_id":"NCT01136278","title":"Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA)","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2010-07","completion_date":"2010-12","last_update":"2013-01-25","substances":"mdma","conditions":"Mood Disorder; Substance-Related Disorders; Amphetamine-Related Disorders","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01136278","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01136278"},{"nct_id":"NCT01140620","title":"Effects of Ketamine and Risperidone on Cognition","acronym":"Schiz_2","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":87,"start_date":"2010-06","completion_date":"2010-11","last_update":"2016-11-09","substances":"ketamine","conditions":"Healthy Volunteers; Schizophrenia","sponsor":"University of Manchester","sponsor_class":"OTHER","has_results":false,"site_count":3,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01140620","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01140620"},{"nct_id":"NCT01148342","title":"Neurobiology and Pharmacokinets of Acute MDMA Administration","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":187,"start_date":"2004-02-10","completion_date":"","last_update":"2019-12-12","substances":"mdma","conditions":"Substance-Related Disorders","sponsor":"National Institute on Drug Abuse (NIDA)","sponsor_class":"NIH","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct01148342","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01148342"},{"nct_id":"NCT01165294","title":"The Effect of Ketamine on Attentiveness","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2009-10","completion_date":"","last_update":"2010-08-06","substances":"ketamine","conditions":"Schizophrenia","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","sponsor_class":"INDUSTRY","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01165294","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01165294"},{"nct_id":"NCT01179009","title":"Treatment Resistant Depression (Pilot)","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2012-04","completion_date":"2014-06-06","last_update":"2023-09-15","substances":"ketamine","conditions":"Depressive Disorder, Treatment-Resistant","sponsor":"Washington University School of Medicine","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Missouri","lsd_com_url":"https://lsd.com/trials/nct01179009","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01179009"},{"nct_id":"NCT01209845","title":"Ketamine for Low Mood States in the ER","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":14,"start_date":"2010-04","completion_date":"2010-12","last_update":"2020-08-24","substances":"ketamine","conditions":"Depression; Suicide Ideation","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct01209845","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01209845"},{"nct_id":"NCT01211405","title":"Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":26,"start_date":"2010-11-10","completion_date":"2015-06-04","last_update":"2025-06-05","substances":"mdma","conditions":"Posttraumatic Stress Disorder","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":true,"site_count":1,"countries":"United States","us_states":"South Carolina","lsd_com_url":"https://lsd.com/trials/nct01211405","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01211405"},{"nct_id":"NCT01260649","title":"N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression","acronym":"","status":"TERMINATED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":17,"start_date":"2010-11-01","completion_date":"2012-10-26","last_update":"2017-05-22","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Massachusetts General Hospital","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct01260649","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01260649"},{"nct_id":"NCT01270672","title":"Pharmacological Interaction Between Carvedilol and Methylenedioxymethamphetamine (MDMA)","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2011-01","completion_date":"2011-05","last_update":"2018-12-11","substances":"mdma","conditions":"Mood Disorder; Substance-Related Disorders; Amphetamine-Related Disorders","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01270672","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01270672"},{"nct_id":"NCT01296802","title":"Investigation of Serotonin Neurotransmission in MDMA Users Using Combinated Dexfenfluramine Challenge and PET Imaging","acronym":"DEXFEN_PET","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2006-04","completion_date":"2008-07","last_update":"2011-12-15","substances":"mdma","conditions":"Amphetamine-Related Disorders; Amphetamine Abuse","sponsor":"University of Zurich","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01296802","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01296802"},{"nct_id":"NCT01304147","title":"Intranasal Ketamine in Treatment-Resistant Depression","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2011-10","completion_date":"2014-10","last_update":"2017-02-08","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"James Murrough","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct01304147","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01304147"},{"nct_id":"NCT01306760","title":"The Use of Ketamine as an Anaesthetic During Electroconvulsive Therapy","acronym":"KANECT","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2011-03","completion_date":"2014-02","last_update":"2016-09-08","substances":"ketamine","conditions":"Depression","sponsor":"University of Aberdeen","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01306760","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01306760"},{"nct_id":"NCT01309581","title":"Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in Depression","acronym":"","status":"TERMINATED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":3,"start_date":"2010-04","completion_date":"2010-10","last_update":"2013-08-30","substances":"ketamine","conditions":"Major Depression; Bipolar Depression","sponsor":"James Murrough","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct01309581","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01309581"},{"nct_id":"NCT01349231","title":"Ketamine Infusion for Obsessive-Compulsive Disorder","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2009-02","completion_date":"2011-12","last_update":"2014-06-09","substances":"ketamine","conditions":"Obsessive-compulsive Disorder","sponsor":"Yale University","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct01349231","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01349231"},{"nct_id":"NCT01367119","title":"Ketamine Anesthesia in Electroconvulsive Therapy","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":38,"start_date":"2011-05","completion_date":"2012-03","last_update":"2013-08-08","substances":"ketamine","conditions":"Depression","sponsor":"Mayo Clinic","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Minnesota","lsd_com_url":"https://lsd.com/trials/nct01367119","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01367119"},{"nct_id":"NCT01371110","title":"Intravenous Ketamine in the Treatment of Obsessive-Compulsive Disorder","acronym":"IVKetamine","status":"TERMINATED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":3,"start_date":"2012-06","completion_date":"2015-06","last_update":"2018-01-18","substances":"ketamine","conditions":"Obsessive Compulsive Disorder","sponsor":"Wayne Goodman MD","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct01371110","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01371110"},{"nct_id":"NCT01386177","title":"Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2011-07","completion_date":"2012-01","last_update":"2018-12-11","substances":"mdma","conditions":"Mood Disorder; Substance-Related Disorders; Amphetamine-Related Disorders","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01386177","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01386177"},{"nct_id":"NCT01400204","title":"Naturalistic Study Into the Hangover Effects of MDMA","acronym":"","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":39,"start_date":"2010-12","completion_date":"2011-02","last_update":"2011-07-22","substances":"mdma","conditions":"Hangover","sponsor":"Utrecht Institute for Pharmaceutical Sciences","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Netherlands","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01400204","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01400204"},{"nct_id":"NCT01404754","title":"Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers","acronym":"MT-1","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":107,"start_date":"2011-04-09","completion_date":"2022-08-05","last_update":"2024-10-31","substances":"mdma","conditions":"Psychological Effects of Study Drug","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":false,"site_count":3,"countries":"United States","us_states":"Colorado; New Mexico; South Carolina","lsd_com_url":"https://lsd.com/trials/nct01404754","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01404754"},{"nct_id":"NCT01441505","title":"A Study of Ketamine as an Antidepressant","acronym":"","status":"UNKNOWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":42,"start_date":"2011-09","completion_date":"2014-12","last_update":"2013-02-22","substances":"ketamine","conditions":"Major Depressive Episode","sponsor":"The University of New South Wales","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Australia","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01441505","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01441505"},{"nct_id":"NCT01447472","title":"-Methylenedioxymethamphetamine (MDMA, Ecstasy) Induced Changes in Drug Metabolism: Gender and Genetic Polymorphisms","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":27,"start_date":"2003-05","completion_date":"2009-05","last_update":"2011-10-06","substances":"mdma","conditions":"Metabolism; Interaction","sponsor":"Parc de Salut Mar","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Spain","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01447472","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01447472"},{"nct_id":"NCT01458327","title":"Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":3,"start_date":"2010-12-15","completion_date":"2014-06-27","last_update":"2024-01-24","substances":"mdma","conditions":"Posttraumatic Stress Disorder","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":true,"site_count":1,"countries":"United States","us_states":"South Carolina","lsd_com_url":"https://lsd.com/trials/nct01458327","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01458327"},{"nct_id":"NCT01465685","title":"Emotional Effects of Methylphenidate and MDMA in Healthy Subjects","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2011-12","completion_date":"2012-12","last_update":"2016-01-21","substances":"mdma","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01465685","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01465685"},{"nct_id":"NCT01504659","title":"Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder","acronym":"IKBP","status":"TERMINATED","phases":"PHASE2; PHASE3","study_type":"INTERVENTIONAL","enrollment":5,"start_date":"2012-07","completion_date":"2016-11","last_update":"2017-03-16","substances":"ketamine","conditions":"Bipolar Disorder","sponsor":"Juvenile Bipolar Research Foundation","sponsor_class":"OTHER","has_results":false,"site_count":4,"countries":"United States","us_states":"Connecticut; New Jersey; New York","lsd_com_url":"https://lsd.com/trials/nct01504659","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01504659"},{"nct_id":"NCT01507181","title":"Ketamine For Suicidal Ideation","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2012-01","completion_date":"2014-09","last_update":"2017-02-08","substances":"ketamine","conditions":"Suicidal Ideation","sponsor":"James Murrough","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct01507181","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01507181"},{"nct_id":"NCT01534494","title":"Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2012-01","completion_date":"2013-09","last_update":"2023-09-26","substances":"psilocybin","conditions":"Alcohol Dependence","sponsor":"University of New Mexico","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New Mexico","lsd_com_url":"https://lsd.com/trials/nct01534494","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01534494"},{"nct_id":"NCT01551329","title":"Ketamine for Depression and Alcohol Dependence","acronym":"KetamineDep","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":5,"start_date":"2012-03","completion_date":"2015-11","last_update":"2020-03-09","substances":"ketamine","conditions":"Depression; Alcohol Dependence","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct01551329","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01551329"},{"nct_id":"NCT01557712","title":"Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks","acronym":"KETADEP","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":25,"start_date":"2012-03","completion_date":"2017-01","last_update":"2017-02-24","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"University Hospital, Grenoble","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"France","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01557712","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01557712"},{"nct_id":"NCT01558063","title":"Ketamine in the Treatment of Depression","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":38,"start_date":"2012-02","completion_date":"2015-05","last_update":"2019-12-10","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Columbia University","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct01558063","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01558063"},{"nct_id":"NCT01573741","title":"Study of Ketamine as an Antidepressant in Major Depressive Disorder","acronym":"","status":"UNKNOWN","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":35,"start_date":"2012-02","completion_date":"2012-12","last_update":"2012-05-04","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Shi Jinyun","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01573741","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01573741"},{"nct_id":"NCT01582945","title":"Ketamine Infusion for Treatment-resistant Major Depressive Disorder","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":14,"start_date":"2012-04","completion_date":"2014-09","last_update":"2017-04-20","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Massachusetts General Hospital","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct01582945","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01582945"},{"nct_id":"NCT01613820","title":"Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder","acronym":"","status":"WITHDRAWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2015-09","completion_date":"2017-02","last_update":"2018-02-19","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Massachusetts General Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct01613820","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01613820"},{"nct_id":"NCT01616407","title":"Effects of MDMA and Methylphenidate on Social Cognition","acronym":"","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2012-08","completion_date":"2012-12","last_update":"2018-12-11","substances":"mdma","conditions":"Social Cognition","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01616407","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01616407"},{"nct_id":"NCT01627782","title":"A Study of Ketamine in Patients With Treatment-resistant Depression","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":68,"start_date":"2012-08-06","completion_date":"2013-09-12","last_update":"2025-04-29","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Janssen Research & Development, LLC","sponsor_class":"INDUSTRY","has_results":true,"site_count":13,"countries":"United States","us_states":"Alabama; Arkansas; Colorado; Connecticut; Georgia; Maryland; New Jersey; New York; Pennsylvania; South Carolina; Texas; Utah","lsd_com_url":"https://lsd.com/trials/nct01627782","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01627782"},{"nct_id":"NCT01640080","title":"A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2012-06-27","completion_date":"2013-06-03","last_update":"2025-04-29","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Janssen Research & Development, LLC","sponsor_class":"INDUSTRY","has_results":false,"site_count":9,"countries":"Belgium; Germany; Poland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01640080","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01640080"},{"nct_id":"NCT01667926","title":"Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":37,"start_date":"2013-01","completion_date":"2015-10","last_update":"2017-04-20","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Massachusetts General Hospital","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct01667926","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01667926"},{"nct_id":"NCT01680172","title":"Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer","acronym":"","status":"TERMINATED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":5,"start_date":"2012-08","completion_date":"2015-02","last_update":"2016-02-29","substances":"ketamine","conditions":"Cancer; Depression; Anxiety","sponsor":"Mayo Clinic","sponsor_class":"OTHER","has_results":true,"site_count":2,"countries":"United States","us_states":"Arizona","lsd_com_url":"https://lsd.com/trials/nct01680172","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01680172"},{"nct_id":"NCT01689740","title":"Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2013-01-17","completion_date":"2016-04-07","last_update":"2025-06-06","substances":"mdma","conditions":"Posttraumatic Stress Disorder (PTSD)","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":true,"site_count":1,"countries":"Israel","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01689740","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01689740"},{"nct_id":"NCT01691092","title":"PET Imaging of mGLuR5 With Drug Challenge","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":79,"start_date":"2012-06","completion_date":"2016-02","last_update":"2017-04-21","substances":"ketamine","conditions":"Major Depressive Disorder; Post-Traumatic Stress Disorder (PTSD)","sponsor":"Yale University","sponsor_class":"OTHER","has_results":true,"site_count":3,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct01691092","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01691092"},{"nct_id":"NCT01700829","title":"Ketamine in the Treatment of Suicidal Depression","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":82,"start_date":"2012-06","completion_date":"2017-01-12","last_update":"2020-03-11","substances":"ketamine","conditions":"Major Depressive Disorder; Suicidal Ideation","sponsor":"New York State Psychiatric Institute","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct01700829","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01700829"},{"nct_id":"NCT01749098","title":"A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":29,"start_date":"2012-12","completion_date":"2014-02","last_update":"2019-11-21","substances":"ketamine","conditions":"Schizophrenia","sponsor":"Biogen","sponsor_class":"INDUSTRY","has_results":false,"site_count":2,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct01749098","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01749098"},{"nct_id":"NCT01768767","title":"Trial of Ketamine and Lithium Therapy in Bipolar Depression","acronym":"","status":"WITHDRAWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2013-01","completion_date":"2013-01","last_update":"2023-03-01","substances":"ketamine","conditions":"Bipolar Depression","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01768767","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01768767"},{"nct_id":"NCT01771874","title":"Influence of Bupropion on the Effects of MDMA","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2013-01","completion_date":"2013-05","last_update":"2016-01-21","substances":"mdma","conditions":"Healthy; Substance-related Disorders","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01771874","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01771874"},{"nct_id":"NCT01793610","title":"Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":29,"start_date":"2013-05-13","completion_date":"2015-12-03","last_update":"2025-06-05","substances":"mdma","conditions":"Posttraumatic Stress Disorder","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":true,"site_count":1,"countries":"United States","us_states":"Colorado","lsd_com_url":"https://lsd.com/trials/nct01793610","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01793610"},{"nct_id":"NCT01809340","title":"The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression","acronym":"","status":"TERMINATED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":29,"start_date":"2013-06","completion_date":"2014-07","last_update":"2015-06-30","substances":"ketamine","conditions":"Depressive Disorder","sponsor":"Janssen Research & Development, LLC","sponsor_class":"INDUSTRY","has_results":false,"site_count":12,"countries":"Belgium; France; Netherlands; Spain","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01809340","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01809340"},{"nct_id":"NCT01816958","title":"Neuromodulation to Facilitate the Effect of Ketamine","acronym":"TMS/ketamine","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":35,"start_date":"2011-01","completion_date":"2012-11","last_update":"2013-03-22","substances":"ketamine","conditions":"Depression; Chronic Pain; Substance Abuse","sponsor":"The Neuroscience Center, LLC","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Illinois","lsd_com_url":"https://lsd.com/trials/nct01816958","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01816958"},{"nct_id":"NCT01833897","title":"NMDA Antagonists in Bipolar Depression","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":8,"start_date":"2013-03","completion_date":"2014-07","last_update":"2016-06-01","substances":"ketamine","conditions":"Bipolar Disorder","sponsor":"New York State Psychiatric Institute","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct01833897","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01833897"},{"nct_id":"NCT01849419","title":"Effects of MDMA on Social and Emotional Processing","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":65,"start_date":"2010-07","completion_date":"2013-03","last_update":"2014-12-18","substances":"mdma","conditions":"Drug Addiction","sponsor":"University of Chicago","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Illinois","lsd_com_url":"https://lsd.com/trials/nct01849419","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01849419"},{"nct_id":"NCT01868802","title":"Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population","acronym":"","status":"UNKNOWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2013-09","completion_date":"2016-05","last_update":"2015-03-17","substances":"ketamine","conditions":"Depressive Disorder,; Treatment-Resistant Depression","sponsor":"Paul J. Lamothe","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Mexico","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01868802","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01868802"},{"nct_id":"NCT01870219","title":"Effects of Sevoflurane and Ketamine on QT in Electroconvulsive Therapy","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2012-02","completion_date":"2013-04","last_update":"2013-06-06","substances":"ketamine","conditions":"Major Depression; Electroconvulsive Therapy","sponsor":"Inonu University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Turkey (Türkiye)","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01870219","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01870219"},{"nct_id":"NCT01878942","title":"Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study","acronym":"","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2013-06","completion_date":"2014-02","last_update":"2016-01-21","substances":"lsd","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01878942","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01878942"},{"nct_id":"NCT01879826","title":"Pediatric Laser Acupuncture and Renal Biopsy","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":81,"start_date":"2013-07","completion_date":"2015-11","last_update":"2020-01-22","substances":"ketamine","conditions":"Pain; Anxiety","sponsor":"University of California, San Francisco","sponsor_class":"OTHER","has_results":true,"site_count":2,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct01879826","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01879826"},{"nct_id":"NCT01880593","title":"Ketamine Plus Lithium in Treatment-Resistant Depression","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":34,"start_date":"2013-07","completion_date":"2016-11","last_update":"2018-07-31","substances":"ketamine","conditions":"Depression","sponsor":"Icahn School of Medicine at Mount Sinai","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct01880593","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01880593"},{"nct_id":"NCT01881763","title":"Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":31,"start_date":"2010-06","completion_date":"2017-03","last_update":"2023-03-09","substances":"ketamine","conditions":"Unipolar Depression; Bipolar Depression","sponsor":"Northwell Health","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct01881763","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01881763"},{"nct_id":"NCT01887990","title":"Treatment of Suicidal Ideation With Intravenous Ketamine Infusion","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":18,"start_date":"2012-05","completion_date":"2014-01","last_update":"2017-05-15","substances":"ketamine","conditions":"Depression; Suicidal Ideation","sponsor":"University of Alabama at Birmingham","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Alabama","lsd_com_url":"https://lsd.com/trials/nct01887990","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01887990"},{"nct_id":"NCT01892995","title":"Ketamine for Acute Suicidal Ideation in the Emergency Department: Randomized Controlled Trial","acronym":"LDK-SI","status":"UNKNOWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":53,"start_date":"2015-06","completion_date":"2017-12","last_update":"2015-02-16","substances":"ketamine","conditions":"Suicide","sponsor":"Brooke Army Medical Center","sponsor_class":"FED","has_results":false,"site_count":1,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct01892995","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01892995"},{"nct_id":"NCT01920555","title":"Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":99,"start_date":"2014-12","completion_date":"2017-01","last_update":"2018-06-19","substances":"ketamine","conditions":"Treatment Resistant Depression","sponsor":"Massachusetts General Hospital","sponsor_class":"OTHER","has_results":true,"site_count":6,"countries":"United States","us_states":"California; Connecticut; Massachusetts; New York; Texas","lsd_com_url":"https://lsd.com/trials/nct01920555","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01920555"},{"nct_id":"NCT01935115","title":"Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":27,"start_date":"2013-09","completion_date":"2016-03","last_update":"2017-09-13","substances":"ketamine","conditions":"Treatment Resistant Depression","sponsor":"University of Saskatchewan","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01935115","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01935115"},{"nct_id":"NCT01943994","title":"Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":82,"start_date":"2008-09","completion_date":"2023-05-01","last_update":"2025-05-25","substances":"psilocybin","conditions":"Nicotine Dependence","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":true,"site_count":2,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct01943994","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01943994"},{"nct_id":"NCT01944293","title":"Ketamine for Suicidality in Bipolar Depression","acronym":"","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2013-09","completion_date":"2017-09","last_update":"2020-03-11","substances":"ketamine","conditions":"Bipolar Disorder; Major Depressive Episode; Suicidal Ideation","sponsor":"New York State Psychiatric Institute","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct01944293","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01944293"},{"nct_id":"NCT01945047","title":"Action of Ketamine in Treatment-Resistant Depression","acronym":"","status":"COMPLETED","phases":"PHASE2; PHASE3","study_type":"INTERVENTIONAL","enrollment":46,"start_date":"2013-05","completion_date":"2017-12","last_update":"2018-06-26","substances":"ketamine","conditions":"Treatment-resistant Depression","sponsor":"University of Ottawa","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01945047","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01945047"},{"nct_id":"NCT01951508","title":"Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study","acronym":"","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2013-10","completion_date":"2014-12","last_update":"2016-01-21","substances":"mdma","conditions":"Healthy; Substance-related Disorder; Mood Disorder","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01951508","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01951508"},{"nct_id":"NCT01957410","title":"A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder","acronym":"","status":"TERMINATED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":13,"start_date":"2014-02","completion_date":"2015-09","last_update":"2017-01-27","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Janssen Research & Development, LLC","sponsor_class":"INDUSTRY","has_results":true,"site_count":1,"countries":"United States","us_states":"North Carolina","lsd_com_url":"https://lsd.com/trials/nct01957410","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01957410"},{"nct_id":"NCT01958593","title":"Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD","acronym":"","status":"TERMINATED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":6,"start_date":"2014-10-14","completion_date":"2015-09-10","last_update":"2025-06-05","substances":"mdma","conditions":"Posttraumatic Stress Disorder","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":true,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct01958593","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01958593"},{"nct_id":"NCT01969227","title":"The Effects of Ketamine on Respiratory Stimulation and Transpulmonary Pressures","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":15,"start_date":"2014-01","completion_date":"2022-12","last_update":"2026-05-19","substances":"ketamine","conditions":"Mechanical Ventilation; Airway Patency; Respiratory Depression","sponsor":"Massachusetts General Hospital","sponsor_class":"OTHER","has_results":true,"site_count":2,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct01969227","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01969227"},{"nct_id":"NCT01988311","title":"Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2013-05","completion_date":"2014-01","last_update":"2014-05-20","substances":"psilocybin","conditions":"Psilocybin; Hallucinogens; Pharmacologic Actions; Central Nervous System Agents; Therapeutic Uses; Psychotropic Drugs","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct01988311","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01988311"},{"nct_id":"NCT01998958","title":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","acronym":"SYNAPSE","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":108,"start_date":"2014-01-27","completion_date":"2015-07-21","last_update":"2025-04-29","substances":"ketamine","conditions":"Treatment Resistant Depressive Disorder","sponsor":"Janssen Research & Development, LLC","sponsor_class":"INDUSTRY","has_results":true,"site_count":25,"countries":"Belgium; Japan; United States","us_states":"Alabama; California; Connecticut; Florida; Georgia; Illinois; Maryland; New York; Pennsylvania; Tennessee","lsd_com_url":"https://lsd.com/trials/nct01998958","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01998958"},{"nct_id":"NCT02008396","title":"Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2014-04-11","completion_date":"2017-04-28","last_update":"2025-06-05","substances":"mdma","conditions":"Social Anxiety in Autistic Adults","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":true,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct02008396","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02008396"},{"nct_id":"NCT02012335","title":"Ketamine Use in Electroconvulsive Therapy","acronym":"","status":"WITHDRAWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2014-01","completion_date":"2016-01","last_update":"2015-03-19","substances":"ketamine","conditions":"Depression","sponsor":"Hospital de Clinicas de Porto Alegre","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Brazil","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02012335","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02012335"},{"nct_id":"NCT02037035","title":"Examining The Effect Of Ketamine On Glutamate/Glutamine Cycling","acronym":"","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":36,"start_date":"2013-07","completion_date":"2021-06","last_update":"2021-09-08","substances":"ketamine","conditions":"Depression","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct02037035","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02037035"},{"nct_id":"NCT02037126","title":"Psilocybin-facilitated Treatment for Cocaine Use","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2015-05","completion_date":"2024-05","last_update":"2026-05-18","substances":"psilocybin","conditions":"Cocaine-Related Disorders","sponsor":"University of Alabama at Birmingham","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Alabama","lsd_com_url":"https://lsd.com/trials/nct02037126","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02037126"},{"nct_id":"NCT02037503","title":"The Effect of Ketamine on Mechanises Underlying Suicidal Ideation and Drug-resistant Major Depression","acronym":"","status":"UNKNOWN","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":100,"start_date":"2014-01","completion_date":"2020-05","last_update":"2020-04-02","substances":"ketamine","conditions":"Suicidal Ideation; Major Depressive Disorder; Healthy Participants","sponsor":"Tel-Aviv Sourasky Medical Center","sponsor_class":"OTHER_GOV","has_results":false,"site_count":1,"countries":"Israel","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02037503","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02037503"},{"nct_id":"NCT02048423","title":"An Open Prospective Trial of IV Ketamine in Suicidal Adolescents","acronym":"","status":"UNKNOWN","phases":"PHASE2; PHASE3","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2013-06","completion_date":"2015-06","last_update":"2014-01-29","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Nationwide Children's Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Ohio","lsd_com_url":"https://lsd.com/trials/nct02048423","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02048423"},{"nct_id":"NCT02061293","title":"A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":95,"start_date":"2014-06","completion_date":"2021-07-30","last_update":"2022-11-08","substances":"psilocybin","conditions":"Alcohol Dependence","sponsor":"NYU Langone Health","sponsor_class":"OTHER","has_results":true,"site_count":2,"countries":"United States","us_states":"New Mexico; New York","lsd_com_url":"https://lsd.com/trials/nct02061293","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02061293"},{"nct_id":"NCT02062658","title":"Extending Ketamine's Effects in OCD With Exposure and Response Prevention (EX/RP)","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2013-12","completion_date":"2015-12","last_update":"2016-12-29","substances":"ketamine","conditions":"Obsessive-Compulsive Disorder","sponsor":"New York State Psychiatric Institute","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct02062658","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02062658"},{"nct_id":"NCT02078817","title":"Ketamine in Adolescents With Treatment-Resistant Depression","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":14,"start_date":"2014-09","completion_date":"2018-03","last_update":"2020-01-27","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"University of Minnesota","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Minnesota","lsd_com_url":"https://lsd.com/trials/nct02078817","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02078817"},{"nct_id":"NCT02083926","title":"Ketamine Infusion for Social Anxiety Disorder","acronym":"","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":18,"start_date":"2015-01-02","completion_date":"2016-09-27","last_update":"2021-03-18","substances":"ketamine","conditions":"Social Anxiety Disorder","sponsor":"Yale University","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct02083926","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02083926"},{"nct_id":"NCT02094898","title":"Ketamine for Depression and Suicide Risk","acronym":"Ketamine","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2014-09","completion_date":"2016-07","last_update":"2017-08-11","substances":"ketamine","conditions":"Depression; Suicide","sponsor":"Mayo Clinic","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Minnesota","lsd_com_url":"https://lsd.com/trials/nct02094898","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02094898"},{"nct_id":"NCT02102802","title":"Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD","acronym":"","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":10,"start_date":"2014-01","completion_date":"2015-08-03","last_update":"2024-11-05","substances":"mdma","conditions":"Posttraumatic Stress Disorder","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United States","us_states":"South Carolina","lsd_com_url":"https://lsd.com/trials/nct02102802","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02102802"},{"nct_id":"NCT02106325","title":"Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":21,"start_date":"2013-12","completion_date":"2016-02","last_update":"2018-09-14","substances":"ketamine","conditions":"Depression","sponsor":"NYU Langone Health","sponsor_class":"OTHER","has_results":true,"site_count":2,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct02106325","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02106325"},{"nct_id":"NCT02122562","title":"Ketamine Alcohol (in Treatment-Resistant Depression)","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2014-04-23","completion_date":"2028-09","last_update":"2026-05-01","substances":"ketamine","conditions":"Magnetic Resonance Imaging; Major Depression; Alcoholism","sponsor":"Mark Niciu","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Iowa","lsd_com_url":"https://lsd.com/trials/nct02122562","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02122562"},{"nct_id":"NCT02133001","title":"A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":68,"start_date":"2014-05-23","completion_date":"2016-02-01","last_update":"2025-04-29","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Janssen Research & Development, LLC","sponsor_class":"INDUSTRY","has_results":true,"site_count":14,"countries":"United States","us_states":"Alabama; California; Connecticut; Georgia; Iowa; Maryland; Michigan; Minnesota; Ohio; Pennsylvania; Texas","lsd_com_url":"https://lsd.com/trials/nct02133001","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02133001"},{"nct_id":"NCT02145091","title":"Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2014-05","completion_date":"2019-12-26","last_update":"2019-12-30","substances":"psilocybin","conditions":"Healthy","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct02145091","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02145091"},{"nct_id":"NCT02163707","title":"UW Psilocybin Pharmacokinetics Study","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2014-06","completion_date":"2015-12","last_update":"2020-04-15","substances":"psilocybin","conditions":"Healthy","sponsor":"University of Wisconsin, Madison","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Wisconsin","lsd_com_url":"https://lsd.com/trials/nct02163707","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02163707"},{"nct_id":"NCT02165449","title":"Biomarkers of Fast Acting Therapies in Major Depression","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2014-06","completion_date":"2019-08","last_update":"2019-08-28","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"University of California, Los Angeles","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct02165449","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02165449"},{"nct_id":"NCT02183272","title":"Emergency Ketamine Treatment of Suicidal Ideation","acronym":"","status":"UNKNOWN","phases":"PHASE2; PHASE3","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2016-08","completion_date":"2017-11","last_update":"2016-08-05","substances":"ketamine","conditions":"Depression; Suicidal Ideation; Suicidal Impulses","sponsor":"University of Cincinnati","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Ohio","lsd_com_url":"https://lsd.com/trials/nct02183272","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02183272"},{"nct_id":"NCT02206776","title":"Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCD","acronym":"","status":"TERMINATED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":2,"start_date":"2014-09","completion_date":"2015-05","last_update":"2017-05-03","substances":"ketamine","conditions":"Obsessive-Compulsive Disorder","sponsor":"New York State Psychiatric Institute","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct02206776","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02206776"},{"nct_id":"NCT02219867","title":"Ketamine Infusions for Major Depression Disorder","acronym":"Ketamie","status":"UNKNOWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2014-08","completion_date":"2016-01","last_update":"2014-08-29","substances":"ketamine","conditions":"Depressive Disorder, Major","sponsor":"Sheba Medical Center","sponsor_class":"OTHER_GOV","has_results":false,"site_count":1,"countries":"Israel","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02219867","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02219867"},{"nct_id":"NCT02232789","title":"Abuse Liability and Human Pharmacology of Mephedrone","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2014-09","completion_date":"2014-12","last_update":"2014-12-04","substances":"mdma","conditions":"Amphetamine-Related Disorders","sponsor":"Parc de Salut Mar","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Spain","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02232789","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02232789"},{"nct_id":"NCT02234011","title":"A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder","acronym":"","status":"TERMINATED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":1,"start_date":"2014-09","completion_date":"2016-01","last_update":"2017-05-12","substances":"ketamine","conditions":"Obsessive-Compulsive Disorder","sponsor":"Mclean Hospital","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct02234011","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02234011"},{"nct_id":"NCT02243813","title":"Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2015-03","completion_date":"2024-05-31","last_update":"2024-06-18","substances":"psilocybin","conditions":"Healthy","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct02243813","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02243813"},{"nct_id":"NCT02267980","title":"Effect of the Addition of Ketamine to Sevoflurane Anesthesia in Electroconvulsive Therapy","acronym":"","status":"UNKNOWN","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2014-07","completion_date":"2014-10","last_update":"2014-10-20","substances":"ketamine","conditions":"Depressive Disorder","sponsor":"Inonu University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Turkey (Türkiye)","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02267980","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02267980"},{"nct_id":"NCT02284204","title":"Sevoflurane Associated With Oral Midazolam and Ketamine for Dental Sedation","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":27,"start_date":"2012-01","completion_date":"2014-08","last_update":"2017-01-11","substances":"ketamine","conditions":"Dental Anxiety","sponsor":"Universidade Federal de Goias","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Brazil","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02284204","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02284204"},{"nct_id":"NCT02289248","title":"Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2015-02","completion_date":"2016-10","last_update":"2017-03-01","substances":"ketamine","conditions":"Depression","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct02289248","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02289248"},{"nct_id":"NCT02295787","title":"Intranasal Ketamine for Late-Life Depression and Suicidal Ideation","acronym":"","status":"WITHDRAWN","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2015-07","completion_date":"2015-07","last_update":"2017-03-03","substances":"ketamine","conditions":"Depression; Suicide; Suicidal Ideation","sponsor":"Massachusetts General Hospital","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02295787","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02295787"},{"nct_id":"NCT02299440","title":"Effects of Ketamine in the Acute Phase of Suicidal Ideation","acronym":"KETIS","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":156,"start_date":"2015-04","completion_date":"2019-11-21","last_update":"2025-12-01","substances":"ketamine","conditions":"Suicidal Ideation","sponsor":"Centre Hospitalier Universitaire de Nīmes","sponsor_class":"OTHER","has_results":false,"site_count":9,"countries":"France","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02299440","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02299440"},{"nct_id":"NCT02304796","title":"Unified Cognitive-Behavioral Therapy (CBT) vs. Combined CBT and Dance/Movement Therapy (DMT) for Anxiety Disorders","acronym":"","status":"UNKNOWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2015-01","completion_date":"2016-09","last_update":"2016-04-14","substances":"dmt","conditions":"Anxiety Disorders","sponsor":"Shalvata Mental Health Center","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Israel","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02304796","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02304796"},{"nct_id":"NCT02305394","title":"Effect of Subanesthetic Dose of Ketamine Combined With Propofol on Cognitive Function in Depressive Patients Undergoing Electroconvulsive Therapy","acronym":"","status":"UNKNOWN","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":132,"start_date":"2015-01","completion_date":"2016-12","last_update":"2014-12-02","substances":"ketamine","conditions":"Depressive Symptoms; Impaired Cognition; Electroconvulsive Therapy","sponsor":"First Affiliated Hospital of Chongqing Medical University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02305394","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02305394"},{"nct_id":"NCT02308969","title":"Neuronal Correlates of Altered States of Consciousness","acronym":"5HT2A-fMRI","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2014-12","completion_date":"2015-09","last_update":"2015-09-25","substances":"lsd","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02308969","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02308969"},{"nct_id":"NCT02336308","title":"A Randomized, Double-Blind Study of Placebo vs. Ketamine For Use During Dressing Changes in Critically Ill Burn Patients","acronym":"","status":"WITHDRAWN","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2015-01","completion_date":"2015-01","last_update":"2015-11-26","substances":"ketamine","conditions":"Thermal Hyperalgesia; Anxiety; Pain","sponsor":"University of Colorado, Denver","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Colorado","lsd_com_url":"https://lsd.com/trials/nct02336308","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02336308"},{"nct_id":"NCT02360280","title":"Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":62,"start_date":"2015-04-01","completion_date":"2018-10-22","last_update":"2024-04-25","substances":"ketamine","conditions":"Treatment-resistant Depression","sponsor":"VA Office of Research and Development","sponsor_class":"FED","has_results":true,"site_count":1,"countries":"United States","us_states":"Minnesota","lsd_com_url":"https://lsd.com/trials/nct02360280","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02360280"},{"nct_id":"NCT02378415","title":"Subanesthetic IV Bolus Ketamine in the Treatment of Acute Depression","acronym":"","status":"TERMINATED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2011-12","completion_date":"2013-06","last_update":"2015-03-04","substances":"ketamine","conditions":"Acute Depression","sponsor":"United States Naval Medical Center, San Diego","sponsor_class":"FED","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct02378415","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02378415"},{"nct_id":"NCT02397889","title":"Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD)","acronym":"","status":"COMPLETED","phases":"PHASE2; PHASE3","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2015-05-18","completion_date":"2020-01-27","last_update":"2021-03-11","substances":"ketamine","conditions":"Posttraumatic Stress Disorder (PTSD)","sponsor":"Icahn School of Medicine at Mount Sinai","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct02397889","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02397889"},{"nct_id":"NCT02398136","title":"To Test the Potential Efficacy of Repeated Intranasal Administration of Ketamine as a Treatment for PTSD","acronym":"","status":"WITHDRAWN","phases":"PHASE2; PHASE3","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2014-12","completion_date":"2014-12","last_update":"2015-03-25","substances":"ketamine","conditions":"PTSD","sponsor":"Adriana Feder","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02398136","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02398136"},{"nct_id":"NCT02401139","title":"Ketamine Trial for the Treatment of Depression","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2015-03","completion_date":"2015-07","last_update":"2023-03-30","substances":"ketamine","conditions":"Unipolar Depression","sponsor":"The University of New South Wales","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"Australia","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02401139","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02401139"},{"nct_id":"NCT02403687","title":"Prospective Analgesic Compound Efficacy (PACE) Study","acronym":"PACE","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":300,"start_date":"2015-06","completion_date":"2016-12","last_update":"2018-02-01","substances":"ketamine","conditions":"Arthritis; Tendonitis; Gout; Radiculopathy; Muscle Spasms; Synovitis; Migraine; Headache","sponsor":"Express Specialty Pharmacy","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02403687","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02403687"},{"nct_id":"NCT02414932","title":"Ketamine for Depression Relapse Prevention Following ECT","acronym":"KEEP-WELL","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":6,"start_date":"2015-04","completion_date":"2017-04-07","last_update":"2021-05-06","substances":"ketamine","conditions":"Depression","sponsor":"St Patrick's Hospital, Ireland","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"Ireland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02414932","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02414932"},{"nct_id":"NCT02417064","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","acronym":"TRANSFORM-1","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":346,"start_date":"2015-08-10","completion_date":"2018-02-20","last_update":"2025-04-29","substances":"ketamine","conditions":"Treatment-resistant Depression","sponsor":"Janssen Research & Development, LLC","sponsor_class":"INDUSTRY","has_results":true,"site_count":90,"countries":"Belgium; Brazil; Canada; Estonia; France; Hungary; Mexico; Slovakia; United States","us_states":"Alabama; Arkansas; California; Florida; Illinois; Kansas; Maryland; Massachusetts; Minnesota; Missouri; Nebraska; New York; North Carolina; Ohio; Oklahoma; Pennsylvania; Rhode Island; Texas; Vermont; Washington; Wisconsin","lsd_com_url":"https://lsd.com/trials/nct02417064","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02417064"},{"nct_id":"NCT02418195","title":"miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":247,"start_date":"2015-04-20","completion_date":"2020-12-30","last_update":"2022-08-30","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"University of Alabama at Birmingham","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Alabama","lsd_com_url":"https://lsd.com/trials/nct02418195","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02418195"},{"nct_id":"NCT02418585","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","acronym":"TRANSFORM-2","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":236,"start_date":"2015-08-07","completion_date":"2017-06-01","last_update":"2025-04-29","substances":"ketamine","conditions":"Treatment-resistant Depression","sponsor":"Janssen Research & Development, LLC","sponsor_class":"INDUSTRY","has_results":true,"site_count":48,"countries":"Czechia; Germany; Poland; Spain; United States","us_states":"Alabama; California; Florida; Georgia; Illinois; Maryland; Massachusetts; Pennsylvania; Texas","lsd_com_url":"https://lsd.com/trials/nct02418585","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02418585"},{"nct_id":"NCT02418702","title":"A Study to Decrease Suicidal Thinking Using Ketamine","acronym":"","status":"WITHDRAWN","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2016-08","completion_date":"2016-08","last_update":"2019-09-03","substances":"ketamine","conditions":"Depression; Suicide","sponsor":"United States Naval Medical Center, San Diego","sponsor_class":"FED","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct02418702","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02418702"},{"nct_id":"NCT02421263","title":"The Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Religious Professionals","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2015-04","completion_date":"2020-06-05","last_update":"2022-02-14","substances":"psilocybin","conditions":"Religious or Spiritual Problem","sponsor":"NYU Langone Health","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct02421263","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02421263"},{"nct_id":"NCT02422186","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","acronym":"TRANSFORM-3","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":139,"start_date":"2015-08-20","completion_date":"2017-08-10","last_update":"2025-04-29","substances":"ketamine","conditions":"Depressive Disorder, Treatment-Resistant","sponsor":"Janssen Research & Development, LLC","sponsor_class":"INDUSTRY","has_results":true,"site_count":69,"countries":"Belgium; Brazil; Bulgaria; Finland; France; Lithuania; Poland; South Africa; Spain; Sweden; United Kingdom; United States","us_states":"California; Connecticut; Florida; Georgia; Iowa; Maryland; Massachusetts; New York; Ohio; Pennsylvania; Texas; Virginia; Washington","lsd_com_url":"https://lsd.com/trials/nct02422186","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02422186"},{"nct_id":"NCT02422290","title":"Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)","acronym":"","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":5,"start_date":"2015-03","completion_date":"2018-02-21","last_update":"2020-08-17","substances":"ketamine","conditions":"Obsessive-Compulsive Disorder","sponsor":"New York State Psychiatric Institute","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct02422290","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02422290"},{"nct_id":"NCT02422303","title":"Effects of Low Dose Ketamine Given at Induction of Anesthesia on Postoperative Mood in Patients With Depressive Symptoms","acronym":"","status":"TERMINATED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2015-12","completion_date":"2016-09","last_update":"2018-02-15","substances":"ketamine","conditions":"Depression; Major Depressive Disorder","sponsor":"The University of Texas Health Science Center at San Antonio","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct02422303","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02422303"},{"nct_id":"NCT02427568","title":"MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":18,"start_date":"2015-05-14","completion_date":"2017-04-25","last_update":"2025-06-05","substances":"mdma","conditions":"Anxiety","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":true,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct02427568","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02427568"},{"nct_id":"NCT02429011","title":"MRI Studies of Emotion in Depression","acronym":"","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":135,"start_date":"2011-07-15","completion_date":"2016-05-31","last_update":"2017-04-06","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Icahn School of Medicine at Mount Sinai","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct02429011","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02429011"},{"nct_id":"NCT02442739","title":"Ketamine for Preventing Depression in Patients Undergoing Treatment for Pancreatic or Head and Neck Cancers","acronym":"","status":"WITHDRAWN","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2016-08-15","completion_date":"2017-11-03","last_update":"2018-11-06","substances":"ketamine","conditions":"Head and Neck Cancer; Pancreatic Cancer; Depression","sponsor":"Cedars-Sinai Medical Center","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct02442739","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02442739"},{"nct_id":"NCT02451072","title":"The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":25,"start_date":"2015-03","completion_date":"2016-01","last_update":"2016-02-01","substances":"lsd","conditions":"Healthy","sponsor":"Psychiatric University Hospital, Zurich","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02451072","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02451072"},{"nct_id":"NCT02452060","title":"Study on the Use of Low Dose Ketamine After Gastric Bypass and Gastrectomy","acronym":"","status":"COMPLETED","phases":"PHASE2; PHASE3","study_type":"INTERVENTIONAL","enrollment":90,"start_date":"2014-10","completion_date":"2017-04-13","last_update":"2020-03-16","substances":"ketamine","conditions":"Pain; Postoperative Depression","sponsor":"NYU Langone Health","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct02452060","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02452060"},{"nct_id":"NCT02455258","title":"Dancing for Better Aging: Evaluating the Impact of a Dance/Movement Therapy (D/MT) Program for Older Adults","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":75,"start_date":"2015-03","completion_date":"2016-04","last_update":"2016-07-27","substances":"dmt","conditions":"Aging","sponsor":"Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02455258","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02455258"},{"nct_id":"NCT02461927","title":"Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder","acronym":"","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":65,"start_date":"2015-01-01","completion_date":"2023-10-30","last_update":"2025-04-10","substances":"ketamine","conditions":"Major Depressive Disorder; Alcohol Use Disorder","sponsor":"VA Office of Research and Development","sponsor_class":"FED","has_results":true,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct02461927","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02461927"},{"nct_id":"NCT02471560","title":"Tecfidera and the Gut Microbiota","acronym":"TECONGUT","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":36,"start_date":"2015-11-06","completion_date":"2017-06-12","last_update":"2021-09-05","substances":"dmt","conditions":"Multiple Sclerosis, Relapsing-Remitting","sponsor":"Biogen","sponsor_class":"INDUSTRY","has_results":false,"site_count":7,"countries":"Norway","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02471560","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02471560"},{"nct_id":"NCT02487485","title":"Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":23,"start_date":"2016-03","completion_date":"2020-01","last_update":"2020-07-16","substances":"ketamine","conditions":"Depression","sponsor":"Yale University","sponsor_class":"OTHER","has_results":true,"site_count":2,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct02487485","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02487485"},{"nct_id":"NCT02493868","title":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","acronym":"SUSTAIN-1","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":719,"start_date":"2015-10-01","completion_date":"2018-02-15","last_update":"2025-04-29","substances":"ketamine","conditions":"Depressive Disorder, Treatment-Resistant","sponsor":"Janssen Research & Development, LLC","sponsor_class":"INDUSTRY","has_results":true,"site_count":155,"countries":"Belgium; Brazil; Canada; Czechia; Estonia; France; Germany; Hungary; Mexico; Poland; Slovakia; Spain; Sweden; Turkey (Türkiye); United States","us_states":"Alabama; Arkansas; California; Connecticut; Florida; Georgia; Illinois; Kansas; Louisiana; Maryland; Massachusetts; Michigan; Minnesota; Missouri; Nebraska; New York; North Carolina; Oklahoma; Pennsylvania; Rhode Island; Texas; Virginia; Wisconsin","lsd_com_url":"https://lsd.com/trials/nct02493868","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02493868"},{"nct_id":"NCT02497287","title":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","acronym":"SUSTAIN-2","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":802,"start_date":"2015-09-30","completion_date":"2017-10-28","last_update":"2025-04-29","substances":"ketamine","conditions":"Treatment-resistant Depression","sponsor":"Janssen Research & Development, LLC","sponsor_class":"INDUSTRY","has_results":true,"site_count":109,"countries":"Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Finland; France; Germany; Lithuania; Malaysia; Mexico; Poland; South Africa; South Korea; Spain; Sweden; Taiwan; Turkey (Türkiye); United Kingdom; United States","us_states":"Connecticut; Florida; Georgia; Iowa; Kansas; Maryland; Massachusetts; New York; Ohio; Pennsylvania; South Carolina; Texas; Washington","lsd_com_url":"https://lsd.com/trials/nct02497287","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02497287"},{"nct_id":"NCT02501941","title":"Spreading Depolarization and Ketamine Suppression","acronym":"SAKS","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2015-07","completion_date":"2017-01-01","last_update":"2024-01-11","substances":"ketamine","conditions":"Cortical Spreading Depolarization; Cortical Spreading Depression; Subarachoid Hemorrhage; Traumatic Brain Injury","sponsor":"University of New Mexico","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New Mexico","lsd_com_url":"https://lsd.com/trials/nct02501941","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02501941"},{"nct_id":"NCT02522377","title":"Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":15,"start_date":"2015-08","completion_date":"2018-03-01","last_update":"2019-08-29","substances":"ketamine","conditions":"Treatment Resistant Depression; Major Depressive Disorder; Severe Depression","sponsor":"The Cleveland Clinic","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Ohio","lsd_com_url":"https://lsd.com/trials/nct02522377","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02522377"},{"nct_id":"NCT02532153","title":"The Impact of Ketamine on the Reward Circuitry of Suicidal Patients","acronym":"","status":"WITHDRAWN","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2017-02","completion_date":"2017-02","last_update":"2017-03-03","substances":"ketamine","conditions":"Suicidal Ideation; Suicide","sponsor":"Massachusetts General Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct02532153","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02532153"},{"nct_id":"NCT02543983","title":"Neurobiology of Suicide","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":325,"start_date":"2015-12-01","completion_date":"2030-07-21","last_update":"2026-09-09","substances":"ketamine","conditions":"Healthy Volunteers; Depression","sponsor":"National Institute of Mental Health (NIMH)","sponsor_class":"NIH","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct02543983","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02543983"},{"nct_id":"NCT02544607","title":"Ketamine for Depression: An MRI Study","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":25,"start_date":"2016-03","completion_date":"2017-12-29","last_update":"2019-04-16","substances":"ketamine","conditions":"Depression; Anxious Depression; Major Depressive Disorder","sponsor":"Massachusetts General Hospital","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct02544607","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02544607"},{"nct_id":"NCT02556060","title":"Lamotrigine for Ketamine Dependence Trial","acronym":"","status":"COMPLETED","phases":"PHASE2; PHASE3","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2015-09","completion_date":"2017-05-01","last_update":"2018-02-01","substances":"ketamine","conditions":"Addiction","sponsor":"Taipei City Hospital","sponsor_class":"OTHER_GOV","has_results":false,"site_count":1,"countries":"Taiwan","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02556060","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02556060"},{"nct_id":"NCT02556606","title":"Ketamine for Treatment Resistant Late-Life Depression","acronym":"","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":33,"start_date":"2015-10-01","completion_date":"2020-03-31","last_update":"2022-01-11","substances":"ketamine","conditions":"Treatment Resistant Depressive Disorder","sponsor":"VA Office of Research and Development","sponsor_class":"FED","has_results":true,"site_count":1,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct02556606","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02556606"},{"nct_id":"NCT02577250","title":"Ketamine Infusions for PTSD and Treatment-Resistant Depression","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2015-05","completion_date":"2016-06","last_update":"2019-05-14","substances":"ketamine","conditions":"Depressive Disorder, Treatment-Resistant; Stress Disorders, Post-Traumatic","sponsor":"Minneapolis Veterans Affairs Medical Center","sponsor_class":"FED","has_results":false,"site_count":1,"countries":"United States","us_states":"Minnesota","lsd_com_url":"https://lsd.com/trials/nct02577250","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02577250"},{"nct_id":"NCT02579642","title":"Effects of Low-dose Ketamine as an Adjunct to Propofol-based Anesthesia for Electroconvulsive Therapy","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":48,"start_date":"2015-10","completion_date":"2019-05","last_update":"2021-04-28","substances":"ketamine","conditions":"Depressive Disorder","sponsor":"University of Alberta","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02579642","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02579642"},{"nct_id":"NCT02579928","title":"Ketamine Infusion for Adolescent Depression and Anxiety","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":17,"start_date":"2015-10","completion_date":"2018-09-28","last_update":"2020-07-14","substances":"ketamine","conditions":"Major Depressive Disorder; Anxiety Disorder","sponsor":"Yale University","sponsor_class":"OTHER","has_results":true,"site_count":2,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct02579928","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02579928"},{"nct_id":"NCT02593643","title":"Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.","acronym":"","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":9,"start_date":"2016-01","completion_date":"2017-04","last_update":"2017-07-26","substances":"ketamine","conditions":"Major Depressive Disorder; Bipolar I Disorder; Bipolar II Disorder; Bipolar Depression; Suicidal Ideation","sponsor":"Sunnybrook Health Sciences Centre","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02593643","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02593643"},{"nct_id":"NCT02610712","title":"Clinical Trial of the Use of Ketamine in Treatment Resistant Depression","acronym":"","status":"UNKNOWN","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2014-05","completion_date":"2017-12","last_update":"2016-09-21","substances":"ketamine","conditions":"Depressive Disorder, Treatment-Resistant","sponsor":"National Institute of Neurology and Neurosurgery, Mexico","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Mexico","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02610712","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02610712"},{"nct_id":"NCT02624596","title":"Understanding How Ketamine Brings About Rapid Improvement in OCD","acronym":"MKET","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":120,"start_date":"2016-08-16","completion_date":"2021-06-20","last_update":"2026-08-13","substances":"ketamine","conditions":"Obsessive-Compulsive Disorder","sponsor":"Stanford University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct02624596","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02624596"},{"nct_id":"NCT02644629","title":"Intra-nasal vs. Intra-venous Ketamine Administration","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":45,"start_date":"2016-04","completion_date":"2020-05","last_update":"2020-10-28","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Shalvata Mental Health Center","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Israel","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02644629","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02644629"},{"nct_id":"NCT02649231","title":"Ketamine for Reduction of Alcoholic Relapse","acronym":"KARE","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":96,"start_date":"2016-10","completion_date":"2020-02","last_update":"2021-10-05","substances":"ketamine","conditions":"Primary Alcohol Use Disorder","sponsor":"University College, London","sponsor_class":"OTHER","has_results":true,"site_count":2,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02649231","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02649231"},{"nct_id":"NCT02655692","title":"CAP-Ketamine for Antidepressant Resistant PTSD","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":163,"start_date":"2016-04-18","completion_date":"2020-07-01","last_update":"2022-06-02","substances":"ketamine","conditions":"PTSD; Posttraumatic Stress Disorder","sponsor":"VA Office of Research and Development","sponsor_class":"FED","has_results":true,"site_count":3,"countries":"United States","us_states":"Connecticut; Minnesota; Texas","lsd_com_url":"https://lsd.com/trials/nct02655692","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02655692"},{"nct_id":"NCT02659085","title":"Ketamine as an Alternative Treatment to ECT in Major Depressive Disorder","acronym":"","status":"COMPLETED","phases":"PHASE2; PHASE3","study_type":"INTERVENTIONAL","enrollment":198,"start_date":"2015-02","completion_date":"2019-08","last_update":"2019-12-19","substances":"ketamine","conditions":"Depressive Disorder, Major","sponsor":"Pouya Movahed Rad","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Sweden","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02659085","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02659085"},{"nct_id":"NCT02661061","title":"Ketamine for Relapse Prevention in Recurrent Depressive Disorder","acronym":"KINDRED","status":"TERMINATED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":9,"start_date":"2015-12","completion_date":"2018-05-23","last_update":"2020-01-13","substances":"ketamine","conditions":"Depression; Relapse; Recurrent Depressive Disorder; Major Depressive Disorder","sponsor":"St Patrick's Hospital, Ireland","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"Ireland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02661061","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02661061"},{"nct_id":"NCT02669043","title":"Physiological and Cognitive Biomarkers for Ketamine's Antidepressant Effects","acronym":"","status":"TERMINATED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":8,"start_date":"2016-07","completion_date":"2017-02","last_update":"2018-04-23","substances":"ketamine","conditions":"Depression","sponsor":"Massachusetts General Hospital","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct02669043","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02669043"},{"nct_id":"NCT02675530","title":"Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":33,"start_date":"2007-12","completion_date":"2011-12","last_update":"2016-02-05","substances":"ketamine","conditions":"Schizophrenia","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct02675530","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02675530"},{"nct_id":"NCT02717052","title":"Positron Emission Tomography Assessment of Ketamine Binding of the Serotonin Transporter","acronym":"","status":"UNKNOWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":74,"start_date":"2016-05","completion_date":"2019-12-31","last_update":"2018-10-15","substances":"ketamine","conditions":"Depression; Ketamine","sponsor":"Medical University of Vienna","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Austria","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02717052","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02717052"},{"nct_id":"NCT02727998","title":"Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure Therapy","acronym":"PTSD","status":"TERMINATED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":28,"start_date":"2015-12","completion_date":"2021-11-28","last_update":"2022-10-17","substances":"ketamine","conditions":"Posttraumatic Stress Disorder","sponsor":"Yale University","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct02727998","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02727998"},{"nct_id":"NCT02734602","title":"Imaging SV2A in Mood Disorders","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"NA","study_type":"INTERVENTIONAL","enrollment":130,"start_date":"2016-04","completion_date":"2027-01","last_update":"2026-06-08","substances":"ketamine","conditions":"Major Depressive Disorder; Post-Traumatic Stress Disorder","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct02734602","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02734602"},{"nct_id":"NCT02752724","title":"Ketamine Anesthesia for Improvement of Depression in ECT","acronym":"KAID","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":52,"start_date":"2016-03","completion_date":"2017-04","last_update":"2018-06-06","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"VA Puget Sound Health Care System","sponsor_class":"FED","has_results":false,"site_count":1,"countries":"United States","us_states":"Washington","lsd_com_url":"https://lsd.com/trials/nct02752724","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02752724"},{"nct_id":"NCT02761330","title":"Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia","acronym":"RCC2","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":17,"start_date":"2016-04","completion_date":"2019-09-11","last_update":"2021-06-28","substances":"ketamine","conditions":"Depression; Delirium; Seizures; Cognitive Disorders","sponsor":"Washington University School of Medicine","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Missouri","lsd_com_url":"https://lsd.com/trials/nct02761330","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02761330"},{"nct_id":"NCT02766192","title":"TIMBER Psychotherapy and Ketamine Single Infusion in Chronic PTSD","acronym":"","status":"UNKNOWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2013-08","completion_date":"2017-12","last_update":"2016-05-09","substances":"ketamine","conditions":"PTSD","sponsor":"The Cooper Health System","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New Jersey","lsd_com_url":"https://lsd.com/trials/nct02766192","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02766192"},{"nct_id":"NCT02772211","title":"D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression","acronym":"","status":"UNKNOWN","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2016-06","completion_date":"2016-12","last_update":"2016-05-13","substances":"ketamine","conditions":"Treatment Resistant Depression","sponsor":"Sheba Medical Center","sponsor_class":"OTHER_GOV","has_results":false,"site_count":1,"countries":"Israel","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02772211","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02772211"},{"nct_id":"NCT02782104","title":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","acronym":"SUSTAIN-3","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":1148,"start_date":"2016-06-09","completion_date":"2022-12-30","last_update":"2025-04-29","substances":"ketamine","conditions":"Depressive Disorder, Treatment-Resistant","sponsor":"Janssen Research & Development, LLC","sponsor_class":"INDUSTRY","has_results":true,"site_count":173,"countries":"Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Czechia; Estonia; Finland; France; Germany; Hungary; Lithuania; Malaysia; Mexico; Poland; Slovakia; South Africa; South Korea; Spain; Sweden; Taiwan; Turkey (Türkiye); United Kingdom; United States","us_states":"Alabama; Arkansas; California; Connecticut; Florida; Georgia; Illinois; Iowa; Kansas; Louisiana; Maryland; Massachusetts; Michigan; Missouri; Nebraska; New York; North Carolina; Ohio; Oklahoma; Pennsylvania; Rhode Island; South Carolina; Texas; Virginia; Wisconsin","lsd_com_url":"https://lsd.com/trials/nct02782104","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02782104"},{"nct_id":"NCT02783430","title":"Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease","acronym":"KETAPAL","status":"COMPLETED","phases":"PHASE2; PHASE3","study_type":"INTERVENTIONAL","enrollment":42,"start_date":"2016-09-08","completion_date":"2024-03-08","last_update":"2025-12-16","substances":"ketamine","conditions":"Depression","sponsor":"University Hospital, Lille","sponsor_class":"OTHER","has_results":false,"site_count":9,"countries":"France","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02783430","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02783430"},{"nct_id":"NCT02823977","title":"Ketamine vs. Placebo as Adjunctive Therapies for Severe Alcohol Withdrawal","acronym":"","status":"WITHDRAWN","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2018-02","completion_date":"2018-12","last_update":"2018-01-19","substances":"ketamine","conditions":"Alcohol Withdrawal","sponsor":"University of Colorado, Denver","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Colorado","lsd_com_url":"https://lsd.com/trials/nct02823977","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02823977"},{"nct_id":"NCT02836288","title":"Study of Oral Ketamine Versus Placebo for Treating Depression in Patients Undergoing Treatment for Cancer","acronym":"","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":4,"start_date":"2016-12-20","completion_date":"2018-05-29","last_update":"2018-11-06","substances":"ketamine","conditions":"Cancer; Depression","sponsor":"Scott A. Irwin, MD, PhD","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct02836288","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02836288"},{"nct_id":"NCT02876172","title":"MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD","acronym":"","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2016-07-03","completion_date":"2017-12-16","last_update":"2025-06-04","substances":"mdma","conditions":"Posttraumatic Stress Disorder","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":true,"site_count":1,"countries":"United States","us_states":"South Carolina","lsd_com_url":"https://lsd.com/trials/nct02876172","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02876172"},{"nct_id":"NCT02882711","title":"The UTHealth Ketamine Project","acronym":"","status":"TERMINATED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2016-11-07","completion_date":"2017-08-16","last_update":"2020-11-24","substances":"ketamine","conditions":"Treatment Resistant Depression; Major Depressive Disorder; Bipolar Disorder","sponsor":"The University of Texas Health Science Center, Houston","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct02882711","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02882711"},{"nct_id":"NCT02911597","title":"Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)","acronym":"Ket_Nal","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2016-09","completion_date":"2018-02","last_update":"2018-04-24","substances":"ketamine","conditions":"Depression","sponsor":"Stanford University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct02911597","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02911597"},{"nct_id":"NCT02914769","title":"Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression","acronym":"","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":35,"start_date":"2014-02","completion_date":"2016-12","last_update":"2025-04-06","substances":"dmt","conditions":"Major Depression","sponsor":"Universidade Federal do Rio Grande do Norte","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"Brazil","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02914769","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02914769"},{"nct_id":"NCT02918318","title":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":202,"start_date":"2016-12-12","completion_date":"2019-08-19","last_update":"2025-04-29","substances":"ketamine","conditions":"Depression","sponsor":"Janssen Pharmaceutical K.K.","sponsor_class":"INDUSTRY","has_results":true,"site_count":43,"countries":"Japan","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02918318","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02918318"},{"nct_id":"NCT02919579","title":"A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive Disorder","acronym":"DriveSaFe2","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":27,"start_date":"2016-10-07","completion_date":"2018-06-29","last_update":"2025-04-27","substances":"ketamine","conditions":"Depressive Disorder, Major","sponsor":"Janssen Research & Development, LLC","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"Netherlands","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02919579","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02919579"},{"nct_id":"NCT02924090","title":"Hyperventilation Combined With Etomidate or Ketamine Anesthesia in ECT Treatment of Major Depression","acronym":"","status":"UNKNOWN","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":48,"start_date":"2016-09","completion_date":"2017-12","last_update":"2016-10-21","substances":"ketamine","conditions":"Depression","sponsor":"University of Manitoba","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02924090","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02924090"},{"nct_id":"NCT02935595","title":"Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients","acronym":"ketamine","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":9,"start_date":"2016-10-14","completion_date":"2017-08-16","last_update":"2022-01-13","substances":"ketamine","conditions":"Treatment Resistant Depression","sponsor":"The University of Texas Health Science Center, Houston","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct02935595","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02935595"},{"nct_id":"NCT02935725","title":"A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":22,"start_date":"2016-10","completion_date":"2017-11","last_update":"2017-11-27","substances":"ketamine","conditions":"Schizophrenia","sponsor":"Autifony Therapeutics Limited","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02935725","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02935725"},{"nct_id":"NCT02950467","title":"Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2018-01-05","completion_date":"2019-12-31","last_update":"2021-01-07","substances":"psilocybin","conditions":"Distress; Depression; Grief","sponsor":"Joshua Woolley","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct02950467","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02950467"},{"nct_id":"NCT02954562","title":"Correlates of Anxiety Associated With a Life-threatening Illness","acronym":"","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":12,"start_date":"2015-11-07","completion_date":"2017-07-01","last_update":"2024-11-05","substances":"mdma","conditions":"Anxiety","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct02954562","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02954562"},{"nct_id":"NCT02971605","title":"Persisting Effects of Psilocybin","acronym":"","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":13,"start_date":"2017-07-01","completion_date":"2018-08-21","last_update":"2019-09-10","substances":"psilocybin","conditions":"Healthy","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct02971605","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02971605"},{"nct_id":"NCT02974010","title":"Sequential Therapy for the Treatment of Severe Bipolar Depression.","acronym":"STABIL-B","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":22,"start_date":"2018-01-15","completion_date":"2018-08-31","last_update":"2021-05-25","substances":"ketamine","conditions":"Bipolar Depression; Suicidal Ideas; Suicidal Ideation; Suicide, Attempted","sponsor":"NeuroRx, Inc.","sponsor_class":"INDUSTRY","has_results":true,"site_count":4,"countries":"United States","us_states":"Alabama; Florida; North Carolina; Texas","lsd_com_url":"https://lsd.com/trials/nct02974010","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02974010"},{"nct_id":"NCT02981173","title":"Psilocybin for the Treatment of Cluster Headache","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":25,"start_date":"2016-12-05","completion_date":"2022-06-30","last_update":"2023-12-15","substances":"psilocybin","conditions":"Cluster Headache","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct02981173","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02981173"},{"nct_id":"NCT02987985","title":"Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy","acronym":"","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2017-10-15","completion_date":"2019-09-20","last_update":"2021-08-10","substances":"ketamine","conditions":"Anesthesia; General Anesthesia; Analgesics, Opioid; Postoperative Complications; Pathologic Processes; Physiologic Effects of Drugs; Narcotics; Analgesics; Sleep Disordered Breathing; Obstructive Sleep Apnea of Child; Tonsillectomy; Respiratory Depression; Dexmedetomidine; Ketamine; Lidocaine; Gabapentin; Pulse Oximetry","sponsor":"University of Saskatchewan","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02987985","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02987985"},{"nct_id":"NCT02992496","title":"Investigation of Antidepressant Efficacy of Oral Ketamine Treatment","acronym":"","status":"UNKNOWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2017-04-24","completion_date":"2020-12","last_update":"2019-09-03","substances":"ketamine","conditions":"Major Depressive Episode","sponsor":"Medical University of Vienna","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Austria","us_states":"","lsd_com_url":"https://lsd.com/trials/nct02992496","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02992496"},{"nct_id":"NCT02997722","title":"The Effect of Ketamine on the Length of Hospital Stay of Patients Hospitalized With Suicidal Ideation.","acronym":"","status":"TERMINATED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":4,"start_date":"2017-03-02","completion_date":"2017-05-19","last_update":"2020-06-02","substances":"ketamine","conditions":"Suicidal Ideation","sponsor":"Allen Richert","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Mississippi","lsd_com_url":"https://lsd.com/trials/nct02997722","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT02997722"},{"nct_id":"NCT03019822","title":"Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing","acronym":"LAM","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":28,"start_date":"2017-02-01","completion_date":"2018-08-11","last_update":"2018-10-15","substances":"lsd; mdma","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03019822","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03019822"},{"nct_id":"NCT03027362","title":"Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":28,"start_date":"2017-01","completion_date":"2019-09-30","last_update":"2020-02-05","substances":"ketamine","conditions":"Depressive Disorder, Major","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct03027362","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03027362"},{"nct_id":"NCT03039192","title":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide","acronym":"Aspire I","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":226,"start_date":"2017-06-09","completion_date":"2018-12-18","last_update":"2025-04-29","substances":"ketamine","conditions":"Depressive Disorder, Major","sponsor":"Janssen Research & Development, LLC","sponsor_class":"INDUSTRY","has_results":true,"site_count":56,"countries":"Bulgaria; Estonia; Germany; Hungary; Malaysia; Slovakia; South Africa; South Korea; Spain; Taiwan; United States","us_states":"Alabama; Arizona; California; Connecticut; Illinois; Kentucky; Louisiana; Maryland; New York; North Carolina; Ohio; South Carolina; Texas","lsd_com_url":"https://lsd.com/trials/nct03039192","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03039192"},{"nct_id":"NCT03043430","title":"Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients","acronym":"","status":"TERMINATED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2016-05","completion_date":"2023-04","last_update":"2023-04-25","substances":"ketamine","conditions":"Anxiety; Pediatric ALL; Procedural Anxiety","sponsor":"Brooke Army Medical Center","sponsor_class":"FED","has_results":false,"site_count":1,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct03043430","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03043430"},{"nct_id":"NCT03050541","title":"Effects of MDMA on Emotional and Social Memories","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":84,"start_date":"2014-12","completion_date":"2016-09","last_update":"2018-06-29","substances":"mdma","conditions":"Healthy","sponsor":"University of Chicago","sponsor_class":"OTHER","has_results":true,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03050541","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03050541"},{"nct_id":"NCT03051945","title":"Endogenous Opioid Modulation by Ketamine","acronym":"","status":"WITHDRAWN","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2019-08","completion_date":"2019-08-01","last_update":"2020-01-28","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"University of Utah","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Utah","lsd_com_url":"https://lsd.com/trials/nct03051945","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03051945"},{"nct_id":"NCT03053830","title":"Open Label Ketamine Treatment for Major Depressive Disorder in Veterans","acronym":"Ket-MDD","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":11,"start_date":"2017-01-31","completion_date":"2018-09-26","last_update":"2023-09-18","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"VA Connecticut Healthcare System","sponsor_class":"FED","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct03053830","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03053830"},{"nct_id":"NCT03065335","title":"Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder","acronym":"","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":150,"start_date":"2017-05-25","completion_date":"2027-01-01","last_update":"2026-09-22","substances":"ketamine","conditions":"Healthy Volunteer; Major Depressive Disorder; Depression","sponsor":"National Institute of Mental Health (NIMH)","sponsor_class":"NIH","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct03065335","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03065335"},{"nct_id":"NCT03086148","title":"Ketamine and Postoperative Depressive Symptom-PASSION","acronym":"","status":"COMPLETED","phases":"PHASE2; PHASE3","study_type":"INTERVENTIONAL","enrollment":84,"start_date":"2017-07-05","completion_date":"2018-08-24","last_update":"2020-07-07","substances":"ketamine","conditions":"Ketamine; Depressive Symptom; Neurosurgery; Perioperative Period","sponsor":"Beijing Tiantan Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03086148","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03086148"},{"nct_id":"NCT03088384","title":"Ketamine Infusion Therapy for PTSD in Combat Veterans","acronym":"","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":30,"start_date":"2016-11-28","completion_date":"2018-09-27","last_update":"2018-10-02","substances":"ketamine","conditions":"Stress Disorders, Post-Traumatic","sponsor":"Klarisana Physician Services PLLC","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct03088384","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03088384"},{"nct_id":"NCT03097133","title":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide","acronym":"Aspire II","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":230,"start_date":"2017-06-15","completion_date":"2019-04-11","last_update":"2025-04-29","substances":"ketamine","conditions":"Depressive Disorder, Major","sponsor":"Janssen Research & Development, LLC","sponsor_class":"INDUSTRY","has_results":true,"site_count":61,"countries":"Argentina; Austria; Belgium; Brazil; Canada; Czechia; France; Lithuania; Poland; Spain; Turkey (Türkiye); United States","us_states":"California; Connecticut; Florida; Georgia; Illinois; Louisiana; Maryland; Nevada; New York; North Carolina; Ohio; Tennessee; Wisconsin","lsd_com_url":"https://lsd.com/trials/nct03097133","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03097133"},{"nct_id":"NCT03102736","title":"Ketamine and Nitroprusside for Depression","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2017-02-14","completion_date":"2019-06-12","last_update":"2020-07-02","substances":"ketamine","conditions":"Depression","sponsor":"Icahn School of Medicine at Mount Sinai","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct03102736","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03102736"},{"nct_id":"NCT03113968","title":"ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)","acronym":"ELEKT-D","status":"COMPLETED","phases":"PHASE2; PHASE3","study_type":"INTERVENTIONAL","enrollment":403,"start_date":"2017-04-07","completion_date":"2022-10-28","last_update":"2023-09-28","substances":"ketamine","conditions":"Treatment Resistant Depression; Electroconvulsive Therapy; ECT; Ketamine; Psychiatric Disorder; Depression; Major Depressive Disorder; Major Depressive Episode; Unipolar Depression","sponsor":"Bo Hu","sponsor_class":"OTHER","has_results":true,"site_count":5,"countries":"United States","us_states":"Connecticut; Maryland; New York; Ohio; Texas","lsd_com_url":"https://lsd.com/trials/nct03113968","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03113968"},{"nct_id":"NCT03134066","title":"Neurocognitive Features of Patients With Treatment-Resistant Depression","acronym":"","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":13,"start_date":"2016-09","completion_date":"2017-08-09","last_update":"2020-03-11","substances":"ketamine","conditions":"Treatment Resistant Depression","sponsor":"Massachusetts General Hospital","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03134066","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03134066"},{"nct_id":"NCT03149991","title":"A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":51,"start_date":"2017-09-14","completion_date":"2019-03-31","last_update":"2020-07-24","substances":"ketamine","conditions":"Depression","sponsor":"Massachusetts General Hospital","sponsor_class":"OTHER","has_results":true,"site_count":6,"countries":"United States","us_states":"California; Illinois; Massachusetts; New York","lsd_com_url":"https://lsd.com/trials/nct03149991","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03149991"},{"nct_id":"NCT03153579","title":"LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders","acronym":"LSD-assist","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":46,"start_date":"2017-06-23","completion_date":"2021-12-15","last_update":"2021-12-22","substances":"lsd","conditions":"Patients; Anxiety Disorders","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03153579","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03153579"},{"nct_id":"NCT03156504","title":"The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.","acronym":"Bio-K","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":75,"start_date":"2017-06-01","completion_date":"2020-02-12","last_update":"2022-03-15","substances":"ketamine","conditions":"Major Depression; Bipolar I Disorder; Bipolar II Disorder; Unipolar Depression","sponsor":"Mayo Clinic","sponsor_class":"OTHER","has_results":true,"site_count":4,"countries":"United States","us_states":"Maryland; Michigan; Minnesota; Ohio","lsd_com_url":"https://lsd.com/trials/nct03156504","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03156504"},{"nct_id":"NCT03181529","title":"Effects of Psilocybin in Major Depressive Disorder","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":27,"start_date":"2017-08-10","completion_date":"2020-12-02","last_update":"2021-12-15","substances":"psilocybin","conditions":"Major Depressive Disorder","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct03181529","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03181529"},{"nct_id":"NCT03181763","title":"Evaluation of MDMA on Startle Response","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":34,"start_date":"2017-03-14","completion_date":"2020-08-01","last_update":"2025-03-04","substances":"mdma","conditions":"Startle Response","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United States","us_states":"Georgia","lsd_com_url":"https://lsd.com/trials/nct03181763","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03181763"},{"nct_id":"NCT03185819","title":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":147,"start_date":"2017-10-05","completion_date":"2023-03-31","last_update":"2025-04-29","substances":"ketamine","conditions":"Depressive Disorder, Major","sponsor":"Janssen Research & Development, LLC","sponsor_class":"INDUSTRY","has_results":true,"site_count":51,"countries":"Belgium; Brazil; Bulgaria; France; Hungary; Italy; Poland; Spain; United States","us_states":"Connecticut; Georgia; Illinois; Indiana; Iowa; Louisiana; Maryland; New York; North Carolina; Ohio; Tennessee; Texas","lsd_com_url":"https://lsd.com/trials/nct03185819","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03185819"},{"nct_id":"NCT03194594","title":"Dexamethasone and Ketamine on Change of Postoperative Mood","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":93,"start_date":"2017-05-02","completion_date":"2017-06-01","last_update":"2017-06-21","substances":"ketamine","conditions":"Depressive Symptoms","sponsor":"Wonkwang University Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"South Korea","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03194594","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03194594"},{"nct_id":"NCT03216941","title":"Randomised Trial Ketiapine Olanzapine Fast Sedation Agitated Patients Emergency Ward","acronym":"IM-OK-FAST","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":500,"start_date":"2015-01-01","completion_date":"2016-01-01","last_update":"2017-07-13","substances":"ketamine","conditions":"Psychomotor Agitation; Psychiatric Disorder; Emergency Psychiatric; Tranquilizers","sponsor":"Universidad Nacional de Rosario","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Argentina","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03216941","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03216941"},{"nct_id":"NCT03221569","title":"Ketamine v. Ketorolac for Management of Generalized Tension Type Headache","acronym":"","status":"UNKNOWN","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2016-02-01","completion_date":"2020-02-01","last_update":"2018-07-06","substances":"ketamine","conditions":"Migraine","sponsor":"The Brooklyn Hospital Center","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct03221569","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03221569"},{"nct_id":"NCT03237286","title":"Intravenous Ketamine Plus Neurocognitive Training for Depression","acronym":"","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":154,"start_date":"2017-12-01","completion_date":"2022-10-18","last_update":"2024-03-19","substances":"ketamine","conditions":"Depression","sponsor":"Rebecca Price","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Pennsylvania","lsd_com_url":"https://lsd.com/trials/nct03237286","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03237286"},{"nct_id":"NCT03256162","title":"Ketamine as an Adjunctive Therapy for Major Depression","acronym":"KARMA-dep","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":25,"start_date":"2017-09-07","completion_date":"2018-09-21","last_update":"2020-01-18","substances":"ketamine","conditions":"Major Depressive Episode; Unipolar Depression; Bipolar Depression","sponsor":"St Patrick's Hospital, Ireland","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"Ireland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03256162","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03256162"},{"nct_id":"NCT03272698","title":"ECT with Ketamine Anesthesia Vs High Intensity Ketamine with ECT Rescue for Treatment-Resistant Depression","acronym":"","status":"RECRUITING","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":62,"start_date":"2017-09-01","completion_date":"2025-12-31","last_update":"2025-01-23","substances":"ketamine","conditions":"Treatment Resistant Depression; Ketamine","sponsor":"University of Saskatchewan","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03272698","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03272698"},{"nct_id":"NCT03275896","title":"Evaluation of the Efficacy of Descemet Membrane Transplantation for the Treatment of Fuchs' Endothelial Dystrophy","acronym":"","status":"UNKNOWN","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2016-09","completion_date":"2020-12","last_update":"2017-09-08","substances":"dmt","conditions":"Fuchs' Endothelial Dystrophy","sponsor":"Singapore National Eye Centre","sponsor_class":"OTHER_GOV","has_results":false,"site_count":1,"countries":"Singapore","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03275896","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03275896"},{"nct_id":"NCT03282123","title":"Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":38,"start_date":"2017-11-16","completion_date":"2019-08-10","last_update":"2025-06-05","substances":"mdma","conditions":"PTSD","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":true,"site_count":12,"countries":"United States","us_states":"California; Colorado; Connecticut; Louisiana; Massachusetts; New York; South Carolina; Wisconsin","lsd_com_url":"https://lsd.com/trials/nct03282123","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03282123"},{"nct_id":"NCT03289949","title":"The Neurobiological Effect of 5-HT2AR Modulation","acronym":"NeuroPharm2","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":200,"start_date":"2017-03-03","completion_date":"2030-06-01","last_update":"2024-12-16","substances":"psilocybin","conditions":"Basic Science","sponsor":"Gitte Moos Knudsen","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Denmark","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03289949","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03289949"},{"nct_id":"NCT03290625","title":"Intranasal Sedation With Dexmedetomidine and Ketamine in Pediatric Dentistry (NASO II)","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2017-11-09","completion_date":"2019-09-12","last_update":"2020-06-30","substances":"ketamine","conditions":"Caries of Infancy; Dental Anxiety","sponsor":"Universidade Federal de Goias","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Brazil","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03290625","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03290625"},{"nct_id":"NCT03290963","title":"Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine","acronym":"","status":"WITHDRAWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2017-11-30","completion_date":"2018-12","last_update":"2018-08-16","substances":"ketamine","conditions":"Treatment Resistant Depression","sponsor":"William V. Bobo, M.D.","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Minnesota","lsd_com_url":"https://lsd.com/trials/nct03290963","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03290963"},{"nct_id":"NCT03300947","title":"Psilocybin for Treatment of Obsessive Compulsive Disorder","acronym":"PSILOCD","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":15,"start_date":"2019-01-02","completion_date":"2023-10-30","last_update":"2024-08-30","substances":"psilocybin","conditions":"Obsessive-compulsive Disorder (OCD)","sponsor":"University of Arizona","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Arizona","lsd_com_url":"https://lsd.com/trials/nct03300947","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03300947"},{"nct_id":"NCT03305055","title":"RCT: Fentanyl Plus Ketamine Versus Fentanyl Alone for Acute Burn Pain","acronym":"","status":"TERMINATED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":4,"start_date":"2017-12-16","completion_date":"2018-03-28","last_update":"2019-03-12","substances":"ketamine","conditions":"Acute Pain; Wound Care; Posttraumatic Stress Disorder","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct03305055","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03305055"},{"nct_id":"NCT03312894","title":"Efficacy and Safety of TAK-653 in Treatment-Resistant Depression","acronym":"","status":"WITHDRAWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2018-02-15","completion_date":"2019-02-28","last_update":"2018-02-22","substances":"ketamine","conditions":"Treatment-Resistant Depression","sponsor":"Millennium Pharmaceuticals, Inc.","sponsor_class":"INDUSTRY","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03312894","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03312894"},{"nct_id":"NCT03321136","title":"Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)","acronym":"LDR","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2017-11-28","completion_date":"2019-07-05","last_update":"2019-08-28","substances":"lsd","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03321136","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03321136"},{"nct_id":"NCT03336541","title":"Low-dose Ketamine and Postpartum Depression in Parturients With Prenatal Depression","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":64,"start_date":"2017-11-23","completion_date":"2018-05-14","last_update":"2021-12-13","substances":"ketamine","conditions":"Perinatal Depression; Ketamine; Cesarean Delivery; Postpartum Depression","sponsor":"Peking University First Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03336541","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03336541"},{"nct_id":"NCT03341689","title":"Psilocybin for the Treatment of Migraine Headache","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":14,"start_date":"2017-11-01","completion_date":"2021-04-30","last_update":"2023-10-12","substances":"psilocybin","conditions":"Migraine Headache","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct03341689","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03341689"},{"nct_id":"NCT03356483","title":"Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":31,"start_date":"2018-11-13","completion_date":"2024-07-25","last_update":"2024-11-20","substances":"psilocybin","conditions":"Obsessive-Compulsive Disorder","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct03356483","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03356483"},{"nct_id":"NCT03367533","title":"Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":13,"start_date":"2018-11-29","completion_date":"2022-07-08","last_update":"2025-02-07","substances":"ketamine","conditions":"Depressive Disorder, Major; Post Traumatic Stress Disorder; Bipolar Disorder","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct03367533","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03367533"},{"nct_id":"NCT03380442","title":"Psilocybin and Depression","acronym":"Psilo101","status":"UNKNOWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2018-09","completion_date":"2020-01","last_update":"2017-12-21","substances":"psilocybin; ketamine","conditions":"Severe Depression","sponsor":"University of Helsinki","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03380442","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03380442"},{"nct_id":"NCT03380728","title":"Ibogaine in the Treatment of Alcoholism: an Open-label Escalating-dose Trial","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":9,"start_date":"2022-10-30","completion_date":"2024-10-30","last_update":"2024-11-26","substances":"ibogaine","conditions":"Alcoholism","sponsor":"University of Sao Paulo","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Brazil","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03380728","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03380728"},{"nct_id":"NCT03396601","title":"NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression","acronym":"SevereBD","status":"UNKNOWN","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":150,"start_date":"2019-06-25","completion_date":"2024-12-31","last_update":"2024-01-19","substances":"ketamine","conditions":"Bipolar Depression; Suicidal Ideation","sponsor":"NeuroRx, Inc.","sponsor_class":"INDUSTRY","has_results":false,"site_count":2,"countries":"United States","us_states":"Florida; Texas","lsd_com_url":"https://lsd.com/trials/nct03396601","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03396601"},{"nct_id":"NCT03410446","title":"Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":22,"start_date":"2018-07-16","completion_date":"2021-11-27","last_update":"2022-05-06","substances":"ketamine","conditions":"Depression; Cancer; Palliative Care","sponsor":"University Health Network, Toronto","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03410446","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03410446"},{"nct_id":"NCT03417193","title":"Opioid Free Anesthesia and Major Spine Surgery","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":48,"start_date":"2018-01-29","completion_date":"2023-02-16","last_update":"2023-02-21","substances":"ketamine","conditions":"Opioid Use; Postoperative Pain; Spine Disease","sponsor":"Lebanese American University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Lebanon","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03417193","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03417193"},{"nct_id":"NCT03429075","title":"Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms","acronym":"Psilodep-RCT","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":59,"start_date":"2019-01-07","completion_date":"2020-04-17","last_update":"2024-10-24","substances":"psilocybin","conditions":"Depressive Disorder, Major","sponsor":"Imperial College London","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03429075","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03429075"},{"nct_id":"NCT03434041","title":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","acronym":"","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":252,"start_date":"2018-05-25","completion_date":"2021-04-13","last_update":"2025-04-29","substances":"ketamine","conditions":"Depressive Disorder, Treatment-Resistant","sponsor":"Janssen Research & Development, LLC","sponsor_class":"INDUSTRY","has_results":true,"site_count":30,"countries":"China; United States","us_states":"Georgia; Louisiana; Maryland; Massachusetts; New York; Oklahoma","lsd_com_url":"https://lsd.com/trials/nct03434041","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03434041"},{"nct_id":"NCT03436121","title":"Single-dose Ketamine for the Reduction of Pain and Depression in the Emergency Department","acronym":"","status":"WITHDRAWN","phases":"PHASE2; PHASE3","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2019-12","completion_date":"2020-02-05","last_update":"2020-02-11","substances":"ketamine","conditions":"Acute Pain; Depression","sponsor":"Maria Pacella","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03436121","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03436121"},{"nct_id":"NCT03458143","title":"Respiratory Depression During an Analgosedation Combining Remifentanil and Ketamine in TCI for Oocyte Retrieval","acronym":"","status":"UNKNOWN","phases":"","study_type":"OBSERVATIONAL","enrollment":20,"start_date":"2018-02-12","completion_date":"2018-03-31","last_update":"2018-03-13","substances":"ketamine","conditions":"Oocyte Retrieval; Sedation, Conscious; Ventilatory Depression","sponsor":"Erasme University Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Belgium","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03458143","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03458143"},{"nct_id":"NCT03469089","title":"Touchscreen-based Cognitive Tests in Healthy Volunteers","acronym":"","status":"UNKNOWN","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2018-03-12","completion_date":"2018-05-16","last_update":"2018-10-16","substances":"ketamine","conditions":"Cognitive Symptom; Schizophrenia","sponsor":"University of Eastern Finland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Finland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03469089","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03469089"},{"nct_id":"NCT03470675","title":"Postpartum Perineal Pain After Obstetric Anal Sphincter Injuries","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":67,"start_date":"2018-06-27","completion_date":"2024-05-20","last_update":"2026-04-24","substances":"ketamine","conditions":"Pain; Postpartum Depression","sponsor":"Northwestern University","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Illinois","lsd_com_url":"https://lsd.com/trials/nct03470675","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03470675"},{"nct_id":"NCT03473431","title":"Effect of Ketamine in Depressive Symptoms of Elderly Patients With Visual Impairment.","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":90,"start_date":"2018-04-15","completion_date":"2018-06-30","last_update":"2019-02-28","substances":"ketamine","conditions":"Depression in Old Age; Ketamine","sponsor":"Instituto Mexicano del Seguro Social","sponsor_class":"OTHER_GOV","has_results":false,"site_count":1,"countries":"Mexico","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03473431","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03473431"},{"nct_id":"NCT03485287","title":"Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD (Canada)","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":4,"start_date":"2018-03-13","completion_date":"2019-06-04","last_update":"2025-06-10","substances":"mdma","conditions":"Posttraumatic Stress Disorder","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":true,"site_count":2,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03485287","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03485287"},{"nct_id":"NCT03485339","title":"Substance Misuse To Psychosis for Ketamine (SToP-K)","acronym":"","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":162,"start_date":"2018-06-12","completion_date":"2020-03-01","last_update":"2020-07-31","substances":"ketamine","conditions":"Ketamine Abuse; Psychotic Disorders; Substance Use Disorders; Schizophrenia; Genetic Predisposition","sponsor":"The University of Hong Kong","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"Hong Kong","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03485339","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03485339"},{"nct_id":"NCT03502551","title":"ED Treatment of Suicidal Patients With Ketamine Infusion","acronym":"","status":"WITHDRAWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2019-04-01","completion_date":"2019-06-30","last_update":"2019-05-01","substances":"ketamine","conditions":"Suicide; Suicidal Ideation","sponsor":"University of California, Davis","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct03502551","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03502551"},{"nct_id":"NCT03507634","title":"Opioid Free Anesthesia in Bariatric Surgery","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":80,"start_date":"2018-04-11","completion_date":"2020-06-30","last_update":"2020-09-29","substances":"ketamine","conditions":"Opioid Use; Postoperative Pain; Postoperative Nausea and Vomiting; Bariatric Surgery Candidate","sponsor":"Lebanese American University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Lebanon","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03507634","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03507634"},{"nct_id":"NCT03527316","title":"Effect of Methylenedioxymethamphetamine (MDMA) (Serotonin Release) on Fear Extinction","acronym":"MFE","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2019-10-18","completion_date":"2020-12-10","last_update":"2022-01-19","substances":"mdma","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03527316","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03527316"},{"nct_id":"NCT03537014","title":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)","acronym":"","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":100,"start_date":"2018-11-21","completion_date":"2020-08-11","last_update":"2025-06-06","substances":"mdma","conditions":"Posttraumatic Stress Disorder","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":true,"site_count":15,"countries":"Canada; Israel; United States","us_states":"California; Colorado; Louisiana; Massachusetts; New York; South Carolina; Wisconsin","lsd_com_url":"https://lsd.com/trials/nct03537014","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03537014"},{"nct_id":"NCT03539887","title":"Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse","acronym":"","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":33,"start_date":"2018-05-01","completion_date":"2022-01-15","last_update":"2023-03-01","substances":"ketamine","conditions":"Suicidal Ideation; Depression; Alcohol Abuse","sponsor":"The University of Texas Health Science Center, Houston","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct03539887","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03539887"},{"nct_id":"NCT03554174","title":"Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":18,"start_date":"2018-02-27","completion_date":"2021-07-08","last_update":"2025-11-05","substances":"psilocybin","conditions":"Major Depressive Disorder","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct03554174","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03554174"},{"nct_id":"NCT03573349","title":"Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":18,"start_date":"2019-01-03","completion_date":"2026-12","last_update":"2026-07-02","substances":"ketamine","conditions":"Major Depressive Disorder; Treatment Resistant Depression; Bipolar Depression","sponsor":"Mayo Clinic","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Minnesota","lsd_com_url":"https://lsd.com/trials/nct03573349","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03573349"},{"nct_id":"NCT03596424","title":"Dexmedetomidine and Ketamine in VATS Surgery","acronym":"","status":"RECRUITING","phases":"NA","study_type":"INTERVENTIONAL","enrollment":120,"start_date":"2018-02-01","completion_date":"2025-12-01","last_update":"2024-12-02","substances":"ketamine","conditions":"Postoperative Pain; Opioid Use","sponsor":"Ciusss de L'Est de l'Île de Montréal","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03596424","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03596424"},{"nct_id":"NCT03604744","title":"Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin","acronym":"LSD-psilo","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":28,"start_date":"2019-03-27","completion_date":"2021-04-10","last_update":"2021-04-27","substances":"lsd; psilocybin","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03604744","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03604744"},{"nct_id":"NCT03606538","title":"MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2026-03-29","completion_date":"2028-12","last_update":"2024-10-30","substances":"mdma","conditions":"Pharmacokinetics; Hepatic Impairment","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United States","us_states":"Tennessee","lsd_com_url":"https://lsd.com/trials/nct03606538","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03606538"},{"nct_id":"NCT03609190","title":"A Multimodal Neuroimaging Study of Brain Activation Patterns Under Ketamine","acronym":"","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2015-01","completion_date":"2018-12","last_update":"2019-03-20","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Psychiatric University Hospital, Zurich","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03609190","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03609190"},{"nct_id":"NCT03628755","title":"Effectiveness of Digital Manipulation of Thyroid Cartilage and Fluency Shaping Therapy for the Management of Stuttering in Adult","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":54,"start_date":"2018-09-01","completion_date":"2019-06-30","last_update":"2019-07-26","substances":"dmt","conditions":"Developmental Stuttering","sponsor":"Isra University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Pakistan","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03628755","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03628755"},{"nct_id":"NCT03644719","title":"Effectiveness of a Brief Cognitive and Behavioral Skills Program on Stage Transitions for Chronic Ketamine Abusers","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":409,"start_date":"2014-08-19","completion_date":"2017-03-19","last_update":"2018-08-23","substances":"ketamine","conditions":"Substance Use Disorders","sponsor":"National Taiwan University","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03644719","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03644719"},{"nct_id":"NCT03658330","title":"Naltrexone Plus Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":5,"start_date":"2016-05","completion_date":"2016-10","last_update":"2018-09-07","substances":"ketamine","conditions":"Major Depressive Disorder; Alcohol Use Disorder","sponsor":"VA Connecticut Healthcare System","sponsor_class":"FED","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03658330","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03658330"},{"nct_id":"NCT03666390","title":"Using a Low Dose of Ketamine vs. Active Placebo in Treating Severe Depression and Suicide","acronym":"","status":"UNKNOWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":48,"start_date":"2018-09-10","completion_date":"2021-12-31","last_update":"2018-09-19","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Taipei Veterans General Hospital, Taiwan","sponsor_class":"OTHER_GOV","has_results":false,"site_count":1,"countries":"Taiwan","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03666390","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03666390"},{"nct_id":"NCT03666494","title":"Ketamine Co-induction for Patients With Major Depressive Disorder","acronym":"","status":"UNKNOWN","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2018-12","completion_date":"2019-12","last_update":"2018-09-13","substances":"ketamine","conditions":"Ketamine; Depression; Anesthesia","sponsor":"University of Saskatchewan","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03666494","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03666494"},{"nct_id":"NCT03674671","title":"Ketamine Versus Electroconvulsive Therapy in Depression","acronym":"","status":"SUSPENDED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":240,"start_date":"2018-10-29","completion_date":"2025-12","last_update":"2023-09-01","substances":"ketamine","conditions":"Depressive Disorder, Major; Bipolar Depression","sponsor":"University of Ottawa","sponsor_class":"OTHER","has_results":false,"site_count":4,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03674671","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03674671"},{"nct_id":"NCT03715127","title":"Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":55,"start_date":"2019-03-11","completion_date":"2021-10-12","last_update":"2022-04-29","substances":"psilocybin","conditions":"Depressive Disorder, Major","sponsor":"University of Zurich","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03715127","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03715127"},{"nct_id":"NCT03721900","title":"Ketamine for Major Depressive Disorder","acronym":"","status":"UNKNOWN","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":14,"start_date":"2018-12-28","completion_date":"2019-06-06","last_update":"2019-04-25","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Shenox Pharmaceuticals, LLC","sponsor_class":"INDUSTRY","has_results":false,"site_count":3,"countries":"United States","us_states":"Maryland; Massachusetts; Ohio","lsd_com_url":"https://lsd.com/trials/nct03721900","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03721900"},{"nct_id":"NCT03736980","title":"Beyond the Self and Back: Neuropharmacological Mechanisms Underlying the Dissolution of the Self","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":140,"start_date":"2013-10-01","completion_date":"2018-12-31","last_update":"2020-11-04","substances":"psilocybin","conditions":"Healthy","sponsor":"University of Zurich","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03736980","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03736980"},{"nct_id":"NCT03742557","title":"Evaluation of Schemes of Administration of Intravenous Ketamine in Depression","acronym":"","status":"UNKNOWN","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2018-10-01","completion_date":"2020-01-01","last_update":"2019-09-10","substances":"ketamine","conditions":"Treatment Resistant Depression","sponsor":"National Institute of Neurology and Neurosurgery, Mexico","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Mexico","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03742557","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03742557"},{"nct_id":"NCT03752918","title":"The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD.","acronym":"","status":"WITHDRAWN","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2024-05","completion_date":"2028-01","last_update":"2026-05-19","substances":"mdma","conditions":"Post Traumatic Stress Disorder","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct03752918","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03752918"},{"nct_id":"NCT03753737","title":"Personality Disorders and Substance Use Disorders in a Sexual Context in the Man Having Sex With Other Men Population","acronym":"PSYCHEMS","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":94,"start_date":"2018-11-22","completion_date":"2019-04-29","last_update":"2019-05-22","substances":"ketamine","conditions":"Substance Use Disorders","sponsor":"Hospices Civils de Lyon","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"France","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03753737","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03753737"},{"nct_id":"NCT03756129","title":"Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":70,"start_date":"2019-02-08","completion_date":"2020-03-23","last_update":"2021-10-08","substances":"ketamine","conditions":"Depressive Disorder, Treatment-Resistant","sponsor":"Novartis Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":true,"site_count":12,"countries":"Spain; United States","us_states":"Alabama; California; Florida; Georgia; Illinois; Maryland; New Jersey","lsd_com_url":"https://lsd.com/trials/nct03756129","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03756129"},{"nct_id":"NCT03775200","title":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","acronym":"P-TRD","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":233,"start_date":"2019-03-01","completion_date":"2021-07-30","last_update":"2023-04-24","substances":"psilocybin","conditions":"Treatment Resistant Depression","sponsor":"COMPASS Pathways","sponsor_class":"INDUSTRY","has_results":true,"site_count":25,"countries":"Canada; Czechia; Denmark; Germany; Ireland; Netherlands; Portugal; Spain; United Kingdom; United States","us_states":"California; Georgia; Louisiana; Maryland; New York; Texas","lsd_com_url":"https://lsd.com/trials/nct03775200","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03775200"},{"nct_id":"NCT03781128","title":"Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache","acronym":"LCH","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2019-01-02","completion_date":"2025-12","last_update":"2025-02-07","substances":"lsd","conditions":"Cluster Headache","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03781128","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03781128"},{"nct_id":"NCT03788694","title":"Intranasal Ketamine for Suicidal Ideation in Veterans","acronym":"","status":"WITHDRAWN","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2020-01-01","completion_date":"2020-01-31","last_update":"2023-08-07","substances":"ketamine","conditions":"Suicidal Ideation","sponsor":"Bronx Veterans Medical Research Foundation, Inc","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct03788694","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03788694"},{"nct_id":"NCT03788889","title":"Alcohol Withdrawal Syndrome Treated With Adjunctive Phenobarbital or Ketamine","acronym":"PKAT","status":"WITHDRAWN","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2019-04-12","completion_date":"2019-04-12","last_update":"2019-09-19","substances":"ketamine","conditions":"Alcohol Withdrawal Syndrome","sponsor":"Santa Barbara Cottage Hospital","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03788889","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03788889"},{"nct_id":"NCT03790358","title":"Mood Effects of Serotonin Agonists","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":80,"start_date":"2018-05-01","completion_date":"2023-01-27","last_update":"2024-01-24","substances":"lsd","conditions":"Healthy","sponsor":"University of Chicago","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"United States","us_states":"Illinois","lsd_com_url":"https://lsd.com/trials/nct03790358","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03790358"},{"nct_id":"NCT03790618","title":"Effect of Stimulant Drugs on Social Perception","acronym":"ESP","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":36,"start_date":"2016-06-01","completion_date":"2018-08-01","last_update":"2024-01-05","substances":"mdma","conditions":"Healthy; MDMA ('Ecstasy')","sponsor":"University of Chicago","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Illinois","lsd_com_url":"https://lsd.com/trials/nct03790618","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03790618"},{"nct_id":"NCT03806985","title":"Effects of Psilocybin in Concussion Headache","acronym":"","status":"TERMINATED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2019-03-28","completion_date":"2023-06-27","last_update":"2023-10-12","substances":"psilocybin","conditions":"Post-Traumatic Headache","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct03806985","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03806985"},{"nct_id":"NCT03813121","title":"The Effects of Sedatives on Tobacco Use Disorder","acronym":"SED-TUD","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2019-06-01","completion_date":"2021-08-31","last_update":"2022-10-06","substances":"ketamine","conditions":"Tobacco Use Disorder","sponsor":"Wake Forest University Health Sciences","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Arkansas","lsd_com_url":"https://lsd.com/trials/nct03813121","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03813121"},{"nct_id":"NCT03829124","title":"Comparison of Ketamine Combine Propofol vs Propofol Anesthesia in Schizophrenia Electroconvulsive Therapy","acronym":"","status":"UNKNOWN","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":1,"start_date":"2019-05-24","completion_date":"2021-01-19","last_update":"2019-05-29","substances":"ketamine","conditions":"Schizophrenia","sponsor":"Chang Gung Memorial Hospital","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03829124","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03829124"},{"nct_id":"NCT03829579","title":"Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)","acronym":"","status":"APPROVED_FOR_MARKETING","phases":"","study_type":"EXPANDED_ACCESS","enrollment":"","start_date":"","completion_date":"","last_update":"2025-06-22","substances":"ketamine","conditions":"Depressive Disorder, Treatment-Resistant","sponsor":"Janssen Research & Development, LLC","sponsor_class":"INDUSTRY","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03829579","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03829579"},{"nct_id":"NCT03852160","title":"A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression","acronym":"","status":"WITHDRAWN","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2019-12-01","completion_date":"2021-07-25","last_update":"2025-04-27","substances":"ketamine","conditions":"Depressive Disorder, Treatment-Resistant","sponsor":"Janssen-Cilag International NV","sponsor_class":"INDUSTRY","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03852160","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03852160"},{"nct_id":"NCT03853577","title":"Characterization of Altered Waking States of Consciousness in Healthy Humans","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":25,"start_date":"2020-07-08","completion_date":"2021-04-25","last_update":"2021-04-29","substances":"psilocybin","conditions":"Altered Waking States of Consciousness in Healthy Humans","sponsor":"University of Zurich","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03853577","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03853577"},{"nct_id":"NCT03861988","title":"Intraoperative Ketamine Versus Saline in Depressed Patients Undergoing Anesthesia for Non-cardiac Surgery","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":45,"start_date":"2019-08-22","completion_date":"2022-09-22","last_update":"2023-10-05","substances":"ketamine","conditions":"Major Depressive Disorder; Surgery; Orthopedic Disorder","sponsor":"Stanford University","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct03861988","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03861988"},{"nct_id":"NCT03866174","title":"A Study of Psilocybin for Major Depressive Disorder (MDD)","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":347,"start_date":"2020-01-23","completion_date":"2022-06-28","last_update":"2026-04-22","substances":"psilocybin","conditions":"Depressive Disorder, Major","sponsor":"Usona Institute","sponsor_class":"OTHER","has_results":true,"site_count":11,"countries":"United States","us_states":"California; Connecticut; Florida; Georgia; Illinois; Maryland; New Jersey; New York; Utah; Wisconsin","lsd_com_url":"https://lsd.com/trials/nct03866174","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03866174"},{"nct_id":"NCT03866252","title":"LSD Therapy for Persons Suffering From Major Depression","acronym":"LAD","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2019-11-01","completion_date":"2022-09-29","last_update":"2025-04-23","substances":"lsd","conditions":"Major Depressive Disorder","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03866252","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03866252"},{"nct_id":"NCT03889756","title":"Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy","acronym":"SAD-KIDS","status":"TERMINATED","phases":"PHASE2; PHASE3","study_type":"INTERVENTIONAL","enrollment":3,"start_date":"2019-07-17","completion_date":"2019-12-18","last_update":"2023-04-24","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Yale University","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct03889756","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03889756"},{"nct_id":"NCT03896256","title":"Ketamine for Refractory Chronic Migraine: a Pilot Study","acronym":"","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":6,"start_date":"2019-03-22","completion_date":"2020-01-01","last_update":"2020-03-11","substances":"ketamine","conditions":"Migraine Headache With Intractable Migraine","sponsor":"Thomas Jefferson University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Pennsylvania","lsd_com_url":"https://lsd.com/trials/nct03896256","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03896256"},{"nct_id":"NCT03912974","title":"Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":27,"start_date":"2019-07-04","completion_date":"2020-11-26","last_update":"2020-12-01","substances":"psilocybin","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03912974","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03912974"},{"nct_id":"NCT03915938","title":"Ketamine's Effect Changes the Cortical Electrophysiological Activity Related to Semantic Affective Dimension of Pain","acronym":"","status":"COMPLETED","phases":"PHASE2; PHASE3","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2017-01-02","completion_date":"2017-11-30","last_update":"2019-04-16","substances":"ketamine","conditions":"Acute Pain; Chronic Pain, Widespread; Schizophrenia","sponsor":"Hospital de Clinicas de Porto Alegre","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03915938","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03915938"},{"nct_id":"NCT03927378","title":"Low-dose S-Ketamine and Postpartum Depression in Parturients With Prenatal Depression","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":364,"start_date":"2020-06-19","completion_date":"2022-08-03","last_update":"2023-04-04","substances":"ketamine","conditions":"Prenatal Depression; Ketamine; Postpartum Depression","sponsor":"Peking University First Hospital","sponsor_class":"OTHER","has_results":false,"site_count":7,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03927378","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03927378"},{"nct_id":"NCT03934710","title":"Mood Effects of Serotonin Agonists Extended","acronym":"MESA-E","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":56,"start_date":"2019-04-20","completion_date":"2021-06-07","last_update":"2023-11-29","substances":"lsd","conditions":"Healthy","sponsor":"University of Chicago","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Illinois","lsd_com_url":"https://lsd.com/trials/nct03934710","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03934710"},{"nct_id":"NCT03947099","title":"Ketamine Infusion Therapy for the Treatment of PTSD in Paramedics","acronym":"","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":7,"start_date":"2019-05-02","completion_date":"2021-02-22","last_update":"2021-02-26","substances":"ketamine","conditions":"Stress Disorders, Post-Traumatic; Anxiety Disorders","sponsor":"Klarisana Physician Services PLLC","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct03947099","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03947099"},{"nct_id":"NCT03960658","title":"Ketamine and Prolonged Exposure in PTSD","acronym":"","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2019-04-03","completion_date":"2019-11-18","last_update":"2021-03-22","substances":"ketamine","conditions":"Post-traumatic Stress Disorder","sponsor":"Minneapolis Veterans Affairs Medical Center","sponsor_class":"FED","has_results":true,"site_count":1,"countries":"United States","us_states":"Minnesota","lsd_com_url":"https://lsd.com/trials/nct03960658","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03960658"},{"nct_id":"NCT03965858","title":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":88,"start_date":"2019-02-25","completion_date":"2020-03-15","last_update":"2020-04-28","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Celon Pharma SA","sponsor_class":"INDUSTRY","has_results":false,"site_count":12,"countries":"Poland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03965858","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03965858"},{"nct_id":"NCT03965871","title":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":88,"start_date":"2019-03-28","completion_date":"2021-01-03","last_update":"2021-03-19","substances":"ketamine","conditions":"Bipolar Depression","sponsor":"Celon Pharma SA","sponsor_class":"INDUSTRY","has_results":false,"site_count":12,"countries":"Poland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct03965871","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03965871"},{"nct_id":"NCT03973268","title":"Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression","acronym":"","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":70,"start_date":"2020-01-21","completion_date":"2027-02-01","last_update":"2026-09-10","substances":"ketamine","conditions":"Depression; Major Depressive Disorder; Major Depression","sponsor":"National Institute of Mental Health (NIMH)","sponsor_class":"NIH","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct03973268","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03973268"},{"nct_id":"NCT03977675","title":"The Role of HNKs in the Antidepressant Effect of Ketamine","acronym":"","status":"TERMINATED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":8,"start_date":"2019-05-15","completion_date":"2020-07-02","last_update":"2021-01-22","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Columbia University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct03977675","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03977675"},{"nct_id":"NCT03986489","title":"Mindfulness-based Dance/Movement Therapy for Chronic Low Back Pain","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":66,"start_date":"2019-04-15","completion_date":"2022-03-31","last_update":"2026-10-05","substances":"dmt","conditions":"Chronic Low-back Pain","sponsor":"Drexel University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Pennsylvania","lsd_com_url":"https://lsd.com/trials/nct03986489","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT03986489"},{"nct_id":"NCT04003948","title":"Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2020-10-28","completion_date":"2024-04-26","last_update":"2025-01-17","substances":"ibogaine","conditions":"Drug Dependence; Drug Use Disorders; Opioid Dependence","sponsor":"International Center for Ethnobotanical Education, Research, and Service","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Spain","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04003948","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04003948"},{"nct_id":"NCT04011592","title":"Efficacy And Tolerability Of Sub-Anesthetic Ketamine In Postpartum Depression","acronym":"","status":"TERMINATED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":1,"start_date":"2019-03-04","completion_date":"2019-09-09","last_update":"2021-10-19","substances":"ketamine","conditions":"Post Partum Depression","sponsor":"The University of Texas Health Science Center, Houston","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct04011592","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04011592"},{"nct_id":"NCT04021433","title":"Ketamine for Treatment Resistant MDD","acronym":"","status":"UNKNOWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2018-09-01","completion_date":"2020-10-01","last_update":"2019-07-16","substances":"ketamine","conditions":"Depressive Disorder, Major","sponsor":"Hadassah Medical Organization","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Israel","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04021433","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04021433"},{"nct_id":"NCT04022226","title":"EEG Characteristics in ECT","acronym":"","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":11,"start_date":"2019-10-01","completion_date":"2020-10-01","last_update":"2024-10-26","substances":"ketamine","conditions":"Electroconvulsive Therapy; Direct Current Electroencephalogram; Ketamine; Spreadind Depression","sponsor":"University of New Mexico","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New Mexico","lsd_com_url":"https://lsd.com/trials/nct04022226","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04022226"},{"nct_id":"NCT04030169","title":"Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":21,"start_date":"2020-06-24","completion_date":"2023-12-14","last_update":"2025-01-28","substances":"mdma","conditions":"PTSD","sponsor":"MAPS Europe B.V.","sponsor_class":"INDUSTRY","has_results":true,"site_count":6,"countries":"Czechia; Germany; Netherlands; Norway; United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04030169","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04030169"},{"nct_id":"NCT04032301","title":"Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":67,"start_date":"2019-09-30","completion_date":"2024-09-16","last_update":"2025-06-27","substances":"ketamine","conditions":"Post-Traumatic Stress Disorders; Major Depressive Disorder","sponsor":"University of Minnesota","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Minnesota","lsd_com_url":"https://lsd.com/trials/nct04032301","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04032301"},{"nct_id":"NCT04037085","title":"Ketamine to Improve Recovery After Cesarean Delivery - Part 1","acronym":"KINETIC","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":8,"start_date":"2019-10-09","completion_date":"2021-08-01","last_update":"2022-12-20","substances":"ketamine","conditions":"Obstetric Pain; Postpartum Depression; Breastfeeding; Pain, Acute; Pain, Chronic; Obstetric Anesthesia Problems; Drug Effect; Opioid Use","sponsor":"Grace Lim, MD, MS","sponsor_class":"OTHER","has_results":true,"site_count":2,"countries":"United States","us_states":"Pennsylvania","lsd_com_url":"https://lsd.com/trials/nct04037085","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04037085"},{"nct_id":"NCT04052568","title":"Effects of Psilocybin in Anorexia Nervosa","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":22,"start_date":"2019-08-26","completion_date":"2022-01-05","last_update":"2023-05-06","substances":"psilocybin","conditions":"Anorexia Nervosa","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct04052568","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04052568"},{"nct_id":"NCT04053036","title":"Effects of Drugs on Responses to Brain and Emotional Processes","acronym":"MAT","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":22,"start_date":"2019-08-08","completion_date":"2021-04-12","last_update":"2024-11-25","substances":"mdma","conditions":"Autism Spectrum Disorder; Healthy","sponsor":"University of Chicago","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Illinois","lsd_com_url":"https://lsd.com/trials/nct04053036","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04053036"},{"nct_id":"NCT04057989","title":"Retrospective Evaluation of Ketamine Effectiveness for the Treatment of Acute Battlefield Related Pain","acronym":"","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":80,"start_date":"2014-08","completion_date":"2017-08","last_update":"2019-08-15","substances":"ketamine","conditions":"Pain, Acute; Analgesia; Amputation, Traumatic; Post Traumatic Stress Disorder; Trauma, Brain","sponsor":"Defense and Veterans Center for Integrative Pain Management","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct04057989","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04057989"},{"nct_id":"NCT04060108","title":"Stanford Regulating Circuits of the Brain Study - MDMA","acronym":"RBRAIN-MDMA","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":22,"start_date":"2021-11-02","completion_date":"2024-01-01","last_update":"2026-01-02","substances":"mdma","conditions":"Healthy","sponsor":"Stanford University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct04060108","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04060108"},{"nct_id":"NCT04073433","title":"Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers (MT-2)","acronym":"","status":"WITHDRAWN","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2024-12","completion_date":"2025-12","last_update":"2024-10-31","substances":"mdma","conditions":"Psychological Effects of Study Drug","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04073433","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04073433"},{"nct_id":"NCT04077437","title":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)","acronym":"","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":121,"start_date":"2020-09-02","completion_date":"2022-10-30","last_update":"2025-06-06","substances":"mdma","conditions":"Posttraumatic Stress Disorder","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":true,"site_count":14,"countries":"Israel; United States","us_states":"California; Colorado; Connecticut; Louisiana; Massachusetts; New York; South Carolina; Wisconsin","lsd_com_url":"https://lsd.com/trials/nct04077437","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04077437"},{"nct_id":"NCT04082858","title":"Ketamine Interleaved With Electroconvulsive Therapy for Depression","acronym":"","status":"TERMINATED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":3,"start_date":"2020-01-06","completion_date":"2020-06-03","last_update":"2021-09-09","substances":"ketamine","conditions":"Depression","sponsor":"St Patrick's Hospital, Ireland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Ireland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04082858","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04082858"},{"nct_id":"NCT04091971","title":"Ketamine Treatment Effects on Synaptic Plasticity in Depression","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":9,"start_date":"2020-10-09","completion_date":"2022-05-01","last_update":"2023-11-13","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"New York State Psychiatric Institute","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct04091971","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04091971"},{"nct_id":"NCT04099771","title":"Ketamine for Mood Disorders With Suicidal Ideation","acronym":"","status":"UNKNOWN","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2019-07-01","completion_date":"2021-12-31","last_update":"2021-03-02","substances":"ketamine","conditions":"Depressive Disorder, Major; Suicidal Ideation","sponsor":"The Miriam Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Rhode Island","lsd_com_url":"https://lsd.com/trials/nct04099771","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04099771"},{"nct_id":"NCT04101474","title":"Role Of Ketamine in Treatment-Resistant Major Depressive Disorder And Its Effect on Suicidality","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":36,"start_date":"2020-09-01","completion_date":"2021-10-01","last_update":"2025-03-05","substances":"ketamine","conditions":"Treatment Resistant Depression","sponsor":"Assiut University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Egypt","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04101474","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04101474"},{"nct_id":"NCT04103892","title":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":146,"start_date":"2019-09-05","completion_date":"2022-09-21","last_update":"2025-10-14","substances":"ketamine","conditions":"Adjunctive Treatment of Major Depressive Disorder","sponsor":"Clexio Biosciences Ltd.","sponsor_class":"INDUSTRY","has_results":true,"site_count":46,"countries":"Puerto Rico; United States","us_states":"Arkansas; California; Colorado; Florida; Georgia; Maryland; Massachusetts; Michigan; Missouri; Nebraska; Nevada; New Jersey; New York; North Carolina; Ohio; Pennsylvania; Texas; Utah; Washington","lsd_com_url":"https://lsd.com/trials/nct04103892","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04103892"},{"nct_id":"NCT04108234","title":"A Study of HR071603(Ketamine Nasal Spray) in Healthy Subjects","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2019-10-24","completion_date":"2021-06-01","last_update":"2022-06-16","substances":"ketamine","conditions":"Depression","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04108234","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04108234"},{"nct_id":"NCT04116528","title":"Opiate Suicide Study in Patients With Major Depression","acronym":"AFSP","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2020-08-01","completion_date":"2025-04-28","last_update":"2026-05-22","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Stanford University","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct04116528","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04116528"},{"nct_id":"NCT04123314","title":"Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease","acronym":"","status":"RECRUITING","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2021-03-24","completion_date":"2027-06-30","last_update":"2026-09-04","substances":"psilocybin","conditions":"Depressive Symptoms; Depression; Alzheimer Disease; Mild Cognitive Impairment","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct04123314","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04123314"},{"nct_id":"NCT04129086","title":"Ketamine for Acute Pain Management After Trauma","acronym":"KAPT","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":305,"start_date":"2020-07-01","completion_date":"2022-03-30","last_update":"2023-04-21","substances":"ketamine","conditions":"Trauma Injury; Pain; Opioid Use","sponsor":"The University of Texas Health Science Center, Houston","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct04129086","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04129086"},{"nct_id":"NCT04141501","title":"Clinical and Mechanistic Effects of Psilocybin in Alcohol Addicted Patients","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":37,"start_date":"2020-06-08","completion_date":"2023-03-14","last_update":"2023-09-21","substances":"psilocybin","conditions":"Alcohol Use Disorder","sponsor":"University of Zurich","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04141501","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04141501"},{"nct_id":"NCT04154150","title":"Ketamine + Cognitive Training for Suicidality in the Medical Setting: Pilot","acronym":"","status":"TERMINATED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2019-12-19","completion_date":"2022-03-15","last_update":"2024-07-22","substances":"ketamine","conditions":"Suicide, Attempted","sponsor":"Rebecca Price","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Pennsylvania","lsd_com_url":"https://lsd.com/trials/nct04154150","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04154150"},{"nct_id":"NCT04158778","title":"Bristol Imperial MDMA in Alcoholism Study","acronym":"BIMA","status":"UNKNOWN","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2018-04-18","completion_date":"2020-06-12","last_update":"2019-11-12","substances":"mdma","conditions":"Alcohol Use Disorder","sponsor":"Imperial College London","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04158778","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04158778"},{"nct_id":"NCT04161066","title":"Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine","acronym":"","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2021-01-13","completion_date":"2026-12","last_update":"2026-07-07","substances":"psilocybin","conditions":"Opioid Use Disorder","sponsor":"University of Wisconsin, Madison","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Wisconsin","lsd_com_url":"https://lsd.com/trials/nct04161066","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04161066"},{"nct_id":"NCT04177706","title":"Ketamine for the Treatment of Opioid Use Disorder and Depression","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":21,"start_date":"2020-12-17","completion_date":"2022-11-21","last_update":"2024-08-07","substances":"ketamine","conditions":"Depression; Opioid-use Disorder; Opioid Abuse","sponsor":"Medical University of South Carolina","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"South Carolina","lsd_com_url":"https://lsd.com/trials/nct04177706","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04177706"},{"nct_id":"NCT04179266","title":"Effect of Ketamine Intranasal Spray in Treatment of Chronic Cluster Headache","acronym":"","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":23,"start_date":"2019-11-20","completion_date":"2020-05-12","last_update":"2021-02-24","substances":"ketamine","conditions":"Cluster Headache","sponsor":"CCH Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"Denmark","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04179266","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04179266"},{"nct_id":"NCT04205890","title":"Intravenous Ketamine Effects on Functional Neuroanatomy","acronym":"","status":"WITHDRAWN","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2020-05-02","completion_date":"2020-05-28","last_update":"2020-06-01","substances":"ketamine","conditions":"Depression","sponsor":"Neurological Associates of West Los Angeles","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct04205890","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04205890"},{"nct_id":"NCT04209296","title":"Chart Review of Patients Undergoing Ketamine Infusions","acronym":"","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":891,"start_date":"2019-12-03","completion_date":"2023-09-14","last_update":"2024-08-12","substances":"ketamine","conditions":"Major Depressive Disorder; Bipolar Disorder; Obsessive-Compulsive Disorder; Post Traumatic Stress Disorder","sponsor":"Brain and Cognition Discovery Foundation","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04209296","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04209296"},{"nct_id":"NCT04216888","title":"Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine","acronym":"","status":"COMPLETED","phases":"PHASE2; PHASE3","study_type":"INTERVENTIONAL","enrollment":9,"start_date":"2019-06-26","completion_date":"2020-12-28","last_update":"2021-01-22","substances":"ketamine","conditions":"Depressive Disorder, Treatment-Resistant","sponsor":"Dan Iosifescu","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct04216888","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04216888"},{"nct_id":"NCT04218539","title":"Repeat Dosing of Psilocybin in Migraine Headache","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":18,"start_date":"2021-08-10","completion_date":"2023-11-05","last_update":"2024-02-09","substances":"psilocybin","conditions":"Migraine Headache","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct04218539","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04218539"},{"nct_id":"NCT04220125","title":"Preoperative Ketamine and Perioperative Depression","acronym":"","status":"WITHDRAWN","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2022-09-01","completion_date":"2023-02-02","last_update":"2023-02-06","substances":"ketamine","conditions":"Depressive Disorder","sponsor":"Northwestern University","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04220125","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04220125"},{"nct_id":"NCT04226963","title":"A Naturalistic Study of Ketamine for Treatment Resistant Mood Disorders","acronym":"GDKet","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":80,"start_date":"2019-12-04","completion_date":"2022-07-04","last_update":"2023-09-28","substances":"ketamine","conditions":"Treatment Resistant Depression; Bipolar Depression; Ketamine; Major Depressive Disorder","sponsor":"Medical University of Gdansk","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Poland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04226963","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04226963"},{"nct_id":"NCT04227704","title":"Ketamine to Prevent PPD After Cesarean","acronym":"PoCKet","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":25,"start_date":"2020-11-12","completion_date":"2021-08-09","last_update":"2023-01-26","substances":"ketamine","conditions":"Postpartum Depression","sponsor":"Washington University School of Medicine","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Missouri","lsd_com_url":"https://lsd.com/trials/nct04227704","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04227704"},{"nct_id":"NCT04227756","title":"Comparative Acute Effects of LSD, Psilocybin and Mescaline","acronym":"LPM","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":32,"start_date":"2020-05-19","completion_date":"2022-09-02","last_update":"2024-01-24","substances":"lsd; psilocybin; mescaline","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04227756","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04227756"},{"nct_id":"NCT04234776","title":"Intramuscular Ketamine Versus Aripiprazole and Escitalopram in the Treatment of Resistant Depression","acronym":"KETProject","status":"UNKNOWN","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":88,"start_date":"2018-04-03","completion_date":"2020-06-03","last_update":"2020-01-21","substances":"ketamine","conditions":"Depressive Disorder","sponsor":"University of Sao Paulo","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Brazil","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04234776","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04234776"},{"nct_id":"NCT04239963","title":"Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression","acronym":"","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":60,"start_date":"2020-08-17","completion_date":"2024-08-28","last_update":"2024-10-30","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Mclean Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct04239963","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04239963"},{"nct_id":"NCT04242914","title":"The Effect of Intravenous Ketamine on Non Suicidal Self Injuries.","acronym":"","status":"UNKNOWN","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2019-02-25","completion_date":"2021-02-24","last_update":"2020-01-27","substances":"ketamine","conditions":"Non Suicidal Self Injury","sponsor":"Tel-Aviv Sourasky Medical Center","sponsor_class":"OTHER_GOV","has_results":false,"site_count":1,"countries":"Israel","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04242914","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04242914"},{"nct_id":"NCT04260607","title":"Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department","acronym":"","status":"TERMINATED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":1,"start_date":"2020-01-14","completion_date":"2021-04-24","last_update":"2025-05-14","substances":"ketamine","conditions":"Suicide; Suicide Threat; Depression Severe","sponsor":"Naval Medical Center Camp Lejeune","sponsor_class":"FED","has_results":true,"site_count":1,"countries":"United States","us_states":"North Carolina","lsd_com_url":"https://lsd.com/trials/nct04260607","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04260607"},{"nct_id":"NCT04260620","title":"Delphinus SoftVue™ ROC Reader Study (DMT SV RRS3)","acronym":"DMT SV RRS3","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":32,"start_date":"2020-02-08","completion_date":"2020-03-03","last_update":"2021-02-03","substances":"dmt","conditions":"Breast Cancer Detection; Dense Breast Parenchyma; Benign Breast Findings; Normal Breast Screening; Abnormal Breast Screening","sponsor":"Delphinus Medical Technologies, Inc.","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United States","us_states":"Michigan","lsd_com_url":"https://lsd.com/trials/nct04260620","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04260620"},{"nct_id":"NCT04260659","title":"Opioid Free vs Opioid Based Anesthesia for Laparoscopic Sleeve Gastrectomy","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":59,"start_date":"2020-02-04","completion_date":"2022-10-06","last_update":"2023-03-08","substances":"ketamine","conditions":"Obesity; Postoperative Pain; Postoperative Nausea; Postoperative Vomiting; Opioid Use","sponsor":"Medical University of Warsaw","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Poland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04260659","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04260659"},{"nct_id":"NCT04264026","title":"MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD","acronym":"VALLMDMA_001","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":5,"start_date":"2021-07-29","completion_date":"2025-05-01","last_update":"2025-07-20","substances":"mdma","conditions":"Post Traumatic Stress Disorder; Combat Stress Disorders","sponsor":"VA Loma Linda Health Care System","sponsor_class":"FED","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct04264026","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04264026"},{"nct_id":"NCT04266288","title":"Effectiveness of Ketamine for Depression and Suicidal Ideation in the Emergency Department","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":29,"start_date":"2019-10-18","completion_date":"2020-05-31","last_update":"2020-09-01","substances":"ketamine","conditions":"Depression; Depression Severe; Depression Acute; Depression and Suicide; Suicidal Ideation","sponsor":"MercyOne Des Moines Medical Center","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Iowa","lsd_com_url":"https://lsd.com/trials/nct04266288","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04266288"},{"nct_id":"NCT04280055","title":"Prophylactic Effects of Psilocybin on Chronic Cluster Headache","acronym":"EPOCH","status":"TERMINATED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2020-01-21","completion_date":"2020-11-01","last_update":"2022-08-10","substances":"psilocybin","conditions":"Cluster Headache","sponsor":"Gitte Moos Knudsen","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Denmark","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04280055","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04280055"},{"nct_id":"NCT04283058","title":"Low Dose Ketamine Infusion for the Treatment of Resistant Depression","acronym":"","status":"WITHDRAWN","phases":"","study_type":"OBSERVATIONAL","enrollment":0,"start_date":"2020-06-29","completion_date":"2020-12-29","last_update":"2020-05-01","substances":"ketamine","conditions":"Depression","sponsor":"Loma Linda University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct04283058","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04283058"},{"nct_id":"NCT04303325","title":"Effect of Esketamine on Postoperative Depression、Gut Microbiota、Bispectral Index Data of Depression Patients Undergoing Breast Cancer Operation (ESPOD-BI)","acronym":"ESPOD-BI","status":"UNKNOWN","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":72,"start_date":"2021-10-08","completion_date":"2024-10-30","last_update":"2024-07-22","substances":"ketamine","conditions":"Depression","sponsor":"China Medical University, China","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04303325","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04303325"},{"nct_id":"NCT04313712","title":"Pre-post Evaluation of the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Repeated Blast Exposure","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":30,"start_date":"2021-11-15","completion_date":"2025-02","last_update":"2024-12-20","substances":"ibogaine","conditions":"Blast or Combat Exposure; Head Injury Trauma","sponsor":"Stanford University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct04313712","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04313712"},{"nct_id":"NCT04322968","title":"Ketamine Infusion for Comorbid PTSD and Chronic Pain","acronym":"","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":41,"start_date":"2018-01-09","completion_date":"2019-06-04","last_update":"2020-12-22","substances":"ketamine","conditions":"PTSD; Chronic Pain","sponsor":"VA Ann Arbor Healthcare System","sponsor_class":"FED","has_results":true,"site_count":1,"countries":"United States","us_states":"Michigan","lsd_com_url":"https://lsd.com/trials/nct04322968","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04322968"},{"nct_id":"NCT04338321","title":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder","acronym":"ESCAPE-TRD","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":676,"start_date":"2020-08-21","completion_date":"2022-01-20","last_update":"2025-04-29","substances":"ketamine","conditions":"Depressive Disorder, Major","sponsor":"Janssen-Cilag International NV","sponsor_class":"INDUSTRY","has_results":true,"site_count":171,"countries":"Argentina; Austria; Belgium; Brazil; Bulgaria; Czechia; Denmark; Finland; Germany; Greece; Hungary; Israel; Kazakhstan; Malaysia; Netherlands; Norway; Poland; Portugal; South Africa; South Korea; Sweden; Taiwan; Turkey (Türkiye); United Arab Emirates","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04338321","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04338321"},{"nct_id":"NCT04352621","title":"Study to Assess the Effects of Intranasal Ketamine Along With rTMS for Patients With Treatment-resistant Major Depressive Disorder (TRD)","acronym":"","status":"UNKNOWN","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2020-05-01","completion_date":"2022-05-01","last_update":"2020-04-20","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"University of Cincinnati","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04352621","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04352621"},{"nct_id":"NCT04353024","title":"Effects of Dimethyltryptamine in Healthy Subjects","acronym":"DMT","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":31,"start_date":"2021-06-18","completion_date":"2022-08-29","last_update":"2022-10-12","substances":"dmt","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04353024","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04353024"},{"nct_id":"NCT04353921","title":"PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder","acronym":"","status":"TERMINATED","phases":"","study_type":"OBSERVATIONAL","enrollment":26,"start_date":"2020-06-30","completion_date":"2022-10-18","last_update":"2026-05-04","substances":"psilocybin","conditions":"Major Depressive Disorder","sponsor":"Usona Institute","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Florida","lsd_com_url":"https://lsd.com/trials/nct04353921","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04353921"},{"nct_id":"NCT04399070","title":"The Effect of S-ketamine for Patients Undergoing Electroconvulsive Therapy (ECT)","acronym":"ECT","status":"UNKNOWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":150,"start_date":"2020-08-01","completion_date":"2020-12-30","last_update":"2020-07-22","substances":"ketamine","conditions":"Depression, Bipolar; Depression, Unipolar; Major Depressive Disorder; Manic-Depressive - Now Depressed","sponsor":"Yan Qiu","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04399070","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04399070"},{"nct_id":"NCT04410913","title":"Pilot Trial of Visual Healing® in Psilocybin-assisted Therapy for Alcohol Use Disorder","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2021-02-18","completion_date":"2023-02","last_update":"2023-01-17","substances":"psilocybin","conditions":"Alcohol Use Disorder","sponsor":"Keith Heinzerling","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct04410913","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04410913"},{"nct_id":"NCT04414943","title":"Low-dose S-ketamine in Women With Prenatal Depression","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":364,"start_date":"2020-06-19","completion_date":"2022-08-03","last_update":"2023-04-04","substances":"ketamine","conditions":"Prenatal Depression; Ketamine; Postpartum Depression","sponsor":"Peking University First Hospital","sponsor_class":"OTHER","has_results":false,"site_count":7,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04414943","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04414943"},{"nct_id":"NCT04421105","title":"A Double-blind, Placebo-controlled Study to Evaluate Very Low Dose LSD in Healthy Volunteers Aged 55-75 Years","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":48,"start_date":"2015-06-29","completion_date":"2015-10-30","last_update":"2020-06-09","substances":"lsd","conditions":"Healthy Volunteers","sponsor":"Eleusis Therapeutics","sponsor_class":"INDUSTRY","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04421105","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04421105"},{"nct_id":"NCT04421651","title":"Dance Movement Therapy in the Treatment of Depressed Patients: A Randomised Controlled Trial","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":109,"start_date":"2017-01-01","completion_date":"2018-10-01","last_update":"2020-06-09","substances":"dmt","conditions":"Depression","sponsor":"University of Jyvaskyla","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04421651","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04421651"},{"nct_id":"NCT04424225","title":"Visual Surround Suppression and Perceptual Expectation Under Psilocybin","acronym":"","status":"TERMINATED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2021-08-30","completion_date":"2023-09-01","last_update":"2025-06-27","substances":"psilocybin","conditions":"Perception Disturbance; Visual Suppression; Psychedelic Experiences","sponsor":"University of Minnesota","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Minnesota","lsd_com_url":"https://lsd.com/trials/nct04424225","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04424225"},{"nct_id":"NCT04425473","title":"Esketamine and Perioperative Depressive Symptoms","acronym":"","status":"COMPLETED","phases":"PHASE2; PHASE3","study_type":"INTERVENTIONAL","enrollment":435,"start_date":"2021-02-19","completion_date":"2024-06-23","last_update":"2025-08-01","substances":"ketamine","conditions":"Depressive Symptoms; Esketamine; Perioperative Complication; Major Surgery","sponsor":"Beijing Tiantan Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04425473","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04425473"},{"nct_id":"NCT04433845","title":"The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.","acronym":"","status":"UNKNOWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":15,"start_date":"2021-03-01","completion_date":"2023-01-15","last_update":"2022-10-25","substances":"psilocybin","conditions":"Treatment Resistant Depression","sponsor":"Sheppard Pratt Health System","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct04433845","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04433845"},{"nct_id":"NCT04433858","title":"An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)","acronym":"","status":"UNKNOWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":27,"start_date":"2021-03-01","completion_date":"2025-06-01","last_update":"2024-08-09","substances":"psilocybin","conditions":"Treatment Resistant Depression","sponsor":"Sheppard Pratt Health System","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"United States","us_states":"California; Maryland","lsd_com_url":"https://lsd.com/trials/nct04433858","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04433858"},{"nct_id":"NCT04438512","title":"A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD","acronym":"EAMP1","status":"NO_LONGER_AVAILABLE","phases":"","study_type":"EXPANDED_ACCESS","enrollment":"","start_date":"","completion_date":"","last_update":"2024-11-05","substances":"mdma","conditions":"Post Traumatic Stress Disorder","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":false,"site_count":2,"countries":"United States","us_states":"Maryland; North Carolina","lsd_com_url":"https://lsd.com/trials/nct04438512","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04438512"},{"nct_id":"NCT04454684","title":"A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders","acronym":"MED1","status":"WITHDRAWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2026-02","completion_date":"2028-08-10","last_update":"2024-10-31","substances":"mdma","conditions":"Anorexia Nervosa Restricting Type; Binge-Eating Disorder","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04454684","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04454684"},{"nct_id":"NCT04459234","title":"Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC","acronym":"KETACANCER","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":81,"start_date":"2021-02-02","completion_date":"2023-02-06","last_update":"2023-09-11","substances":"ketamine","conditions":"Cancer; Chronic Pain; Neuropathic Pain; Opioid Use","sponsor":"Centre Leon Berard","sponsor_class":"OTHER","has_results":false,"site_count":12,"countries":"France","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04459234","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04459234"},{"nct_id":"NCT04471818","title":"Ketamine or Placebo in Patients With Major Depression and Advanced Cancer","acronym":"KODIAC","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":19,"start_date":"2019-09-19","completion_date":"2023-06-01","last_update":"2023-09-28","substances":"ketamine","conditions":"Major Depressive Disorder; Advanced Cancer","sponsor":"Instituto Nacional de Cancerologia de Mexico","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Mexico","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04471818","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04471818"},{"nct_id":"NCT04476446","title":"An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives","acronym":"","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":41,"start_date":"2020-09-08","completion_date":"2023-06-16","last_update":"2023-09-14","substances":"ketamine","conditions":"Depression","sponsor":"Janssen-Cilag, S.A.","sponsor_class":"INDUSTRY","has_results":false,"site_count":8,"countries":"Mexico","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04476446","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04476446"},{"nct_id":"NCT04480918","title":"University of Iowa Interventional Psychiatry Service Patient Registry","acronym":"","status":"RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":1000,"start_date":"2020-11-02","completion_date":"2050-08","last_update":"2026-03-03","substances":"ketamine","conditions":"Treatment Resistant Depression; Major Depressive Episode; Major Depression; Major Depressive Disorder; Bipolar Disorder; Bipolar Depression; Obsessive-Compulsive Disorder","sponsor":"Mark Niciu","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Iowa","lsd_com_url":"https://lsd.com/trials/nct04480918","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04480918"},{"nct_id":"NCT04488874","title":"Sodium Lactate and Brain Relaxation (LSD)","acronym":"LSD","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2020-09-29","completion_date":"2023-05-31","last_update":"2023-09-13","substances":"lsd","conditions":"Sodium Lactate; Intracranial Hypertension; Brain Relaxation","sponsor":"Centre Hospitalier Universitaire de Besancon","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"France","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04488874","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04488874"},{"nct_id":"NCT04501653","title":"Precision Functional Brain Mapping in Psilocybin","acronym":"Psilocybin PFM","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":11,"start_date":"2021-06-01","completion_date":"2023-03-19","last_update":"2025-10-31","substances":"psilocybin","conditions":"Psilocybin","sponsor":"Washington University School of Medicine","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Missouri","lsd_com_url":"https://lsd.com/trials/nct04501653","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04501653"},{"nct_id":"NCT04504175","title":"Ketamine for Older Adults Pilot","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":25,"start_date":"2020-10-22","completion_date":"2021-11-30","last_update":"2023-02-14","substances":"ketamine","conditions":"Treatment Resistant Depression; Refractory Depression; Therapy-Resistant Depression; Late Life Depression; Geriatric Depression","sponsor":"Washington University School of Medicine","sponsor_class":"OTHER","has_results":true,"site_count":5,"countries":"Canada; United States","us_states":"California; Missouri; New York; Pennsylvania","lsd_com_url":"https://lsd.com/trials/nct04504175","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04504175"},{"nct_id":"NCT04505189","title":"Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study","acronym":"","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":21,"start_date":"2021-05-28","completion_date":"2023-12-11","last_update":"2024-06-17","substances":"psilocybin","conditions":"Anorexia Nervosa","sponsor":"Imperial College London","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04505189","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04505189"},{"nct_id":"NCT04516902","title":"Effects of MDMA Co-administration on the Response to LSD in Healthy Subjects","acronym":"LSD-MDMA","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2021-01-01","completion_date":"2022-08-22","last_update":"2022-08-23","substances":"lsd; mdma","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04516902","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04516902"},{"nct_id":"NCT04519957","title":"Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)","acronym":"","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":66,"start_date":"2020-07-20","completion_date":"2022-08-11","last_update":"2022-09-22","substances":"psilocybin","conditions":"Treatment Resistant Depression","sponsor":"COMPASS Pathways","sponsor_class":"INDUSTRY","has_results":false,"site_count":8,"countries":"Czechia; Ireland; Netherlands; United Kingdom; United States","us_states":"California; Georgia; Texas","lsd_com_url":"https://lsd.com/trials/nct04519957","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04519957"},{"nct_id":"NCT04522804","title":"Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer","acronym":"HOPE","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2021-10-04","completion_date":"2022-06-11","last_update":"2024-03-20","substances":"psilocybin","conditions":"Cancer","sponsor":"University of Utah","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Utah","lsd_com_url":"https://lsd.com/trials/nct04522804","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04522804"},{"nct_id":"NCT04558294","title":"Effect of Ketanserin After LSD Administration","acronym":"L-Ket","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2020-10-16","completion_date":"2021-08-28","last_update":"2021-10-21","substances":"lsd","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04558294","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04558294"},{"nct_id":"NCT04560660","title":"Ketamine-enhanced Prolonged Exposure Therapy in PTSD","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":73,"start_date":"2021-03-09","completion_date":"2025-07-01","last_update":"2026-08-11","substances":"ketamine","conditions":"PTSD","sponsor":"VA Office of Research and Development","sponsor_class":"FED","has_results":true,"site_count":1,"countries":"United States","us_states":"Minnesota","lsd_com_url":"https://lsd.com/trials/nct04560660","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04560660"},{"nct_id":"NCT04562779","title":"Inpatient Single Dose Interventions for Alcohol Use Disorder","acronym":"","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":44,"start_date":"2021-01-19","completion_date":"2022-01-01","last_update":"2024-05-02","substances":"ketamine","conditions":"Alcohol Use Disorder, Severe","sponsor":"Denver Health and Hospital Authority","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Colorado","lsd_com_url":"https://lsd.com/trials/nct04562779","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04562779"},{"nct_id":"NCT04578938","title":"Ketamine + Cognitive Training for Suicidality in the Medical Setting","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":200,"start_date":"2021-03-15","completion_date":"2026-12-02","last_update":"2026-03-24","substances":"ketamine","conditions":"Suicide, Attempted","sponsor":"Rebecca Price","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Pennsylvania","lsd_com_url":"https://lsd.com/trials/nct04578938","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04578938"},{"nct_id":"NCT04587778","title":"Imaging Neural Correlates of Ketamine Using PET/MR","acronym":"RSKet","status":"UNKNOWN","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":65,"start_date":"2020-10-05","completion_date":"2025-03-31","last_update":"2024-03-04","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Medical University of Vienna","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Austria","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04587778","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04587778"},{"nct_id":"NCT04592809","title":"Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents","acronym":"TASK","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2022-10-03","completion_date":"2025-07-01","last_update":"2025-11-28","substances":"ketamine","conditions":"Suicide, Attempted; Suicide and Depression; Suicide Threat","sponsor":"University of Texas Southwestern Medical Center","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct04592809","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04592809"},{"nct_id":"NCT04593563","title":"The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder","acronym":"","status":"UNKNOWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2020-09-01","completion_date":"2022-10","last_update":"2021-10-15","substances":"psilocybin","conditions":"Major Depressive Disorder","sponsor":"Maryland Oncology Hematology, PA","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct04593563","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04593563"},{"nct_id":"NCT04599855","title":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":477,"start_date":"2020-11-04","completion_date":"2024-01-31","last_update":"2025-04-25","substances":"ketamine","conditions":"Depressive Disorder, Treatment-Resistant","sponsor":"Janssen Research & Development, LLC","sponsor_class":"INDUSTRY","has_results":true,"site_count":54,"countries":"United States","us_states":"Alabama; Arkansas; California; Connecticut; Florida; Georgia; Illinois; Kansas; Maryland; Massachusetts; Michigan; Missouri; New York; Ohio; Oklahoma; Pennsylvania; Rhode Island; Texas; Virginia","lsd_com_url":"https://lsd.com/trials/nct04599855","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04599855"},{"nct_id":"NCT04613453","title":"Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine","acronym":"","status":"TERMINATED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2022-01-21","completion_date":"2024-07-31","last_update":"2025-08-26","substances":"ketamine","conditions":"Adolescent Suicide; Adolescent Depression","sponsor":"Yale University","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct04613453","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04613453"},{"nct_id":"NCT04620759","title":"Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder","acronym":"PsiloMDDAUD","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":90,"start_date":"2021-04-14","completion_date":"2026-03-02","last_update":"2026-03-13","substances":"psilocybin","conditions":"Major Depressive Disorder; Alcohol Use Disorder","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct04620759","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04620759"},{"nct_id":"NCT04622904","title":"Lidocaine and Magnesium and Ketamine in Gynecological Surgery","acronym":"annie-sophia","status":"UNKNOWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":90,"start_date":"2020-11-14","completion_date":"2023-11","last_update":"2022-10-27","substances":"ketamine","conditions":"Pain, Postoperative; Pain, Acute; Pain, Chronic; Pain, Neuropathic; Lidocaine; Ketamine; Magnesium; Central Nervous System Depressants; Analgesics; Neurotransmitter Agents; Analgesics, Non-narcotic","sponsor":"Aretaieion University Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Greece","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04622904","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04622904"},{"nct_id":"NCT04625283","title":"The Impact of Perioperative Ketamine Infusion on Surgical Recovery","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":1570,"start_date":"2021-04-12","completion_date":"2024-01-26","last_update":"2025-02-04","substances":"ketamine","conditions":"Opioid Use; Enhanced Recovery After Surgery; Anesthesia; Ketamine; Pain, Postoperative","sponsor":"Vanderbilt University Medical Center","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Tennessee","lsd_com_url":"https://lsd.com/trials/nct04625283","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04625283"},{"nct_id":"NCT04630964","title":"The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density","acronym":"PSIPET","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":35,"start_date":"2021-01-01","completion_date":"2023-04-19","last_update":"2024-04-19","substances":"psilocybin","conditions":"Major Depressive Disorder; Depression","sponsor":"Section for Affective Disorders; Northern Stockholm Psychiatry","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Sweden","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04630964","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04630964"},{"nct_id":"NCT04640636","title":"IM Ketamine vs Midazolam for Suicidal ER Patients","acronym":"","status":"SUSPENDED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":90,"start_date":"2021-02-09","completion_date":"2027-09","last_update":"2026-05-26","substances":"ketamine","conditions":"Depression, Unipolar; Depression, Bipolar; Suicidal Ideation","sponsor":"New York State Psychiatric Institute","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct04640636","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04640636"},{"nct_id":"NCT04640831","title":"Safety of GH001 in Healthy Volunteers","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":22,"start_date":"2019-03-13","completion_date":"2019-10-04","last_update":"2023-08-15","substances":"dmt","conditions":"Healthy Volunteers","sponsor":"GH Research Ireland Limited","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"Netherlands","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04640831","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04640831"},{"nct_id":"NCT04648137","title":"Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls","acronym":"OxyMA","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2021-02-05","completion_date":"2022-04-11","last_update":"2022-04-13","substances":"mdma","conditions":"Diabetes Insipidus","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04648137","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04648137"},{"nct_id":"NCT04656301","title":"Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2021-02-26","completion_date":"2022-11-02","last_update":"2023-03-13","substances":"psilocybin","conditions":"Body Dysmorphic Disorders","sponsor":"New York State Psychiatric Institute","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct04656301","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04656301"},{"nct_id":"NCT04656886","title":"Ketamine's Actions on Rumination Mechanisms as an Antidepressant","acronym":"KARMA","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":37,"start_date":"2014-09","completion_date":"2018-05","last_update":"2020-12-07","substances":"ketamine","conditions":"Remission in Depression","sponsor":"King's College London","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04656886","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04656886"},{"nct_id":"NCT04657107","title":"The Efficacy and Safety of S-ketamine in Elective Cesarean Section","acronym":"ES-CS","status":"UNKNOWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":402,"start_date":"2020-12-01","completion_date":"2021-12-15","last_update":"2020-12-08","substances":"ketamine","conditions":"Anesthesia; Analgesia; Depression; Cesarean Section; Parturition","sponsor":"Beijing Obstetrics and Gynecology Hospital","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04657107","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04657107"},{"nct_id":"NCT04658420","title":"A Single Ketamine Infusion Combined With Music for Suicidal Ideation","acronym":"","status":"UNKNOWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":200,"start_date":"2021-07-01","completion_date":"2022-12","last_update":"2021-05-07","substances":"ketamine","conditions":"Suicidal Ideation; Depressive Episode","sponsor":"The University of Texas Health Science Center at Tyler","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct04658420","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04658420"},{"nct_id":"NCT04661514","title":"Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2021-05-01","completion_date":"2022-03-10","last_update":"2022-07-25","substances":"psilocybin","conditions":"Anorexia Nervosa","sponsor":"University of California, San Diego","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct04661514","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04661514"},{"nct_id":"NCT04669665","title":"A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":164,"start_date":"2020-12-17","completion_date":"2023-06-17","last_update":"2023-09-28","substances":"ketamine","conditions":"Depressive Disorder, Major; Suicidal","sponsor":"Seelos Therapeutics, Inc.","sponsor_class":"INDUSTRY","has_results":false,"site_count":21,"countries":"United States","us_states":"California; Florida; Georgia; Illinois; Maryland; Mississippi; New York; Ohio; Texas; Utah; West Virginia","lsd_com_url":"https://lsd.com/trials/nct04669665","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04669665"},{"nct_id":"NCT04670081","title":"Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression","acronym":"EPIsoDE","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":144,"start_date":"2021-06-10","completion_date":"2024-02-27","last_update":"2025-01-20","substances":"psilocybin","conditions":"Treatment-resistant Depression","sponsor":"Central Institute of Mental Health, Mannheim","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"Germany","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04670081","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04670081"},{"nct_id":"NCT04673383","title":"SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients","acronym":"","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":66,"start_date":"2021-02-04","completion_date":"2022-10-01","last_update":"2024-03-27","substances":"dmt","conditions":"Major Depressive Disorder","sponsor":"Small Pharma Ltd","sponsor_class":"INDUSTRY","has_results":false,"site_count":2,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04673383","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04673383"},{"nct_id":"NCT04695405","title":"Pharmacogenetics Associated With IV Ketamine","acronym":"","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":85,"start_date":"2021-01-21","completion_date":"2021-07-02","last_update":"2021-08-18","substances":"ketamine","conditions":"Treatment Resistant Depression","sponsor":"Brain and Cognition Discovery Foundation","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04695405","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04695405"},{"nct_id":"NCT04698603","title":"Clinical Study of GH001 in Depression","acronym":"","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2019-11-12","completion_date":"2021-11-06","last_update":"2023-08-15","substances":"dmt","conditions":"Treatment Resistant Depression; Major Depressive Disorder; Depression","sponsor":"GH Research Ireland Limited","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"Netherlands","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04698603","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04698603"},{"nct_id":"NCT04701866","title":"Music as an Intervention to Improve Hemodynamic Tolerability of Ketamine in Depression","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":32,"start_date":"2021-01-11","completion_date":"2022-08-24","last_update":"2022-10-04","substances":"ketamine","conditions":"Depressive Disorder, Treatment-Resistant; Depressive Disorder, Major; Unipolar Depression; Depression, Bipolar","sponsor":"Douglas Mental Health University Institute","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04701866","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04701866"},{"nct_id":"NCT04711005","title":"Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":74,"start_date":"2021-01-11","completion_date":"2023-04-30","last_update":"2024-06-06","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"National Institute of Mental Health (NIMH)","sponsor_class":"NIH","has_results":true,"site_count":1,"countries":"United States","us_states":"North Carolina","lsd_com_url":"https://lsd.com/trials/nct04711005","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04711005"},{"nct_id":"NCT04711915","title":"Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2021-03-17","completion_date":"2026-07-01","last_update":"2025-08-03","substances":"dmt","conditions":"Major Depressive Disorder; Depression","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct04711915","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04711915"},{"nct_id":"NCT04714359","title":"A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD","acronym":"MAPPUSX","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":87,"start_date":"2021-03-08","completion_date":"2023-11-01","last_update":"2025-06-06","substances":"mdma","conditions":"PTSD","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":true,"site_count":15,"countries":"Canada; Israel; United States","us_states":"California; Colorado; Louisiana; Massachusetts; New York; South Carolina; Wisconsin","lsd_com_url":"https://lsd.com/trials/nct04714359","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04714359"},{"nct_id":"NCT04714541","title":"Modified Ketogenic Diet and Ketamine for Anorexia Nervosa","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":5,"start_date":"2021-04-12","completion_date":"2022-07-26","last_update":"2022-11-04","substances":"ketamine","conditions":"Anorexia Nervosa","sponsor":"Homeostasis Therapeutics, LLC","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct04714541","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04714541"},{"nct_id":"NCT04716335","title":"Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy Subjects","acronym":"","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":34,"start_date":"2020-12-01","completion_date":"2021-07-19","last_update":"2022-10-04","substances":"dmt","conditions":"Emotions; Mood; Cognitive Function 1, Social; Empathy","sponsor":"Psychiatric University Hospital, Zurich","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04716335","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04716335"},{"nct_id":"NCT04718792","title":"Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study","acronym":"","status":"UNKNOWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2023-02-09","completion_date":"2024-07-21","last_update":"2024-07-12","substances":"psilocybin","conditions":"Alcohol Use Disorder (AUD)","sponsor":"Anders Fink-Jensen, MD, DMSci","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Denmark","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04718792","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04718792"},{"nct_id":"NCT04730596","title":"Cognitive Dysfunction After Cataract Surgery","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":90,"start_date":"2021-02-01","completion_date":"2021-04-15","last_update":"2021-04-20","substances":"ketamine","conditions":"POCD - Postoperative Cognitive Dysfunction","sponsor":"Tanta University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Egypt","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04730596","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04730596"},{"nct_id":"NCT04739865","title":"The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":19,"start_date":"2020-08-10","completion_date":"2021-10-14","last_update":"2023-11-09","substances":"psilocybin","conditions":"Treatment Resistant Depression","sponsor":"COMPASS Pathways","sponsor_class":"INDUSTRY","has_results":true,"site_count":2,"countries":"Ireland; United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct04739865","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04739865"},{"nct_id":"NCT04754061","title":"PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL)","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2024-01-08","completion_date":"2026-10-01","last_update":"2026-07-10","substances":"psilocybin","conditions":"Depression, Anxiety; Distress, Emotional","sponsor":"Ottawa Hospital Research Institute","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04754061","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04754061"},{"nct_id":"NCT04757675","title":"S-ketamin Premedication in Pediatric EENT Surgery","acronym":"","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":320,"start_date":"2021-03-01","completion_date":"2021-09-01","last_update":"2022-04-27","substances":"ketamine","conditions":"Emotions; Separation Anxiety; Pain, Procedural","sponsor":"Eye & ENT Hospital of Fudan University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04757675","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04757675"},{"nct_id":"NCT04760652","title":"Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention","acronym":"ENDURE","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":93,"start_date":"2021-03-05","completion_date":"2025-06-30","last_update":"2026-09-16","substances":"ketamine","conditions":"Depression and Suicide","sponsor":"Yale University","sponsor_class":"OTHER","has_results":true,"site_count":3,"countries":"United States","us_states":"Alabama; Connecticut; Georgia","lsd_com_url":"https://lsd.com/trials/nct04760652","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04760652"},{"nct_id":"NCT04763343","title":"Ketamine Treatment of Youth Suicide Attempters","acronym":"","status":"RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2022-06-27","completion_date":"2027-02-28","last_update":"2026-07-16","substances":"ketamine","conditions":"Suicide, Attempted","sponsor":"Tatiana Falcone, MD","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Ohio","lsd_com_url":"https://lsd.com/trials/nct04763343","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04763343"},{"nct_id":"NCT04771767","title":"Combined Ketamine and eCBT Intervention for PTSD","acronym":"","status":"UNKNOWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2021-08-01","completion_date":"2024-03-31","last_update":"2022-08-11","substances":"ketamine","conditions":"Post-Traumatic Stress Disorder","sponsor":"Queen's University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04771767","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04771767"},{"nct_id":"NCT04772222","title":"Dexmedetomidine Use in Infants Undergoing Cooling Due to Neonatal Encephalopathy (DICE Trial)","acronym":"DICE","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2022-06-20","completion_date":"2025-01-17","last_update":"2026-03-06","substances":"dmt","conditions":"Hypoxic-Ischemic Encephalopathy; Pain","sponsor":"University of Utah","sponsor_class":"OTHER","has_results":true,"site_count":5,"countries":"United States","us_states":"Utah","lsd_com_url":"https://lsd.com/trials/nct04772222","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04772222"},{"nct_id":"NCT04777110","title":"The Effectiveness and Safety of Esketamine in Modified Electroconvulsive Therapy","acronym":"","status":"UNKNOWN","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":396,"start_date":"2021-08","completion_date":"2022-08","last_update":"2021-07-20","substances":"ketamine","conditions":"Esketamine; ECT; Depression","sponsor":"First Affiliated Hospital of Chongqing Medical University","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04777110","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04777110"},{"nct_id":"NCT04784143","title":"Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD","acronym":"MPVA6","status":"TERMINATED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":26,"start_date":"2021-11-08","completion_date":"2024-06-25","last_update":"2025-07-15","substances":"mdma","conditions":"PTSD","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct04784143","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04784143"},{"nct_id":"NCT04814381","title":"Ketamine + Magnesium for Chronic Cluster Headache (KETALGIA)","acronym":"KETALGIA","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":93,"start_date":"2021-09-15","completion_date":"2025-12-23","last_update":"2026-05-08","substances":"ketamine","conditions":"Refractory Chronic Cluster Headache","sponsor":"University Hospital, Clermont-Ferrand","sponsor_class":"OTHER","has_results":false,"site_count":14,"countries":"France","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04814381","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04814381"},{"nct_id":"NCT04824157","title":"Ketamine IV Classic Protocol : Five Years Follow up","acronym":"","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":11,"start_date":"2019-08-08","completion_date":"2020-02-28","last_update":"2021-04-01","substances":"ketamine","conditions":"Major Depressive Disorder; Drug Abuse; Medications; Relapse","sponsor":"Sheba Medical Center","sponsor_class":"OTHER_GOV","has_results":false,"site_count":1,"countries":"Israel","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04824157","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04824157"},{"nct_id":"NCT04829318","title":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","acronym":"ESCAPE-LTE","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":183,"start_date":"2021-04-26","completion_date":"2024-07-22","last_update":"2025-09-18","substances":"ketamine","conditions":"Depressive Disorder, Major","sponsor":"Janssen-Cilag Ltd.","sponsor_class":"INDUSTRY","has_results":true,"site_count":59,"countries":"Argentina; Belgium; Bulgaria; Czechia; Finland; Germany; Greece; Hungary; Malaysia; Poland; South Africa; South Korea; Taiwan; Turkey (Türkiye)","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04829318","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04829318"},{"nct_id":"NCT04834427","title":"Safety and Efficacy Evaluation of S (+) - Ketamine in Children","acronym":"","status":"UNKNOWN","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":3000,"start_date":"2022-04-20","completion_date":"2024-12-01","last_update":"2024-03-08","substances":"ketamine","conditions":"S-ketamine; Esketamine; Acute Pain; Postoperative Pain; Analgesia; Hyperalgesia; Delirium; Depression, Anxiety; Children","sponsor":"Chinese PLA General Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04834427","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04834427"},{"nct_id":"NCT04842045","title":"Pilot RECAP Study in Healthy Volunteers","acronym":"RECAP","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":8,"start_date":"2021-05-21","completion_date":"2022-11-17","last_update":"2023-05-19","substances":"psilocybin","conditions":"Psychedelic Experiences; Amnesia","sponsor":"University of Wisconsin, Madison","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Wisconsin","lsd_com_url":"https://lsd.com/trials/nct04842045","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04842045"},{"nct_id":"NCT04843462","title":"Add-on Therapy With Edupression.Com® on Therapy Resistant Depressive Patients Treated With Nasal Esketamine Spray","acronym":"Esketamin+","status":"UNKNOWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":70,"start_date":"2021-04-29","completion_date":"2023-04-14","last_update":"2022-05-24","substances":"ketamine","conditions":"Major Depressive Disorder; Therapy Resistant Depression","sponsor":"Lukas Pezawas","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Austria","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04843462","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04843462"},{"nct_id":"NCT04847206","title":"Effects of MDMA-like Substances in Healthy Subjects","acronym":"MDMA-like","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":23,"start_date":"2021-12-01","completion_date":"2024-06-18","last_update":"2024-08-14","substances":"mdma","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04847206","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04847206"},{"nct_id":"NCT04847245","title":"Esketamine Adjuvant Therapy for Patients With Chronic Visceral Pain Comorbid Major Depressive Disorder","acronym":"","status":"UNKNOWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":80,"start_date":"2021-05-01","completion_date":"2022-12-31","last_update":"2021-04-19","substances":"ketamine","conditions":"Chronic Visceral Pain; Major Depressive Disorder","sponsor":"Peking University","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04847245","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04847245"},{"nct_id":"NCT04849013","title":"Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness","acronym":"MDR","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2021-08-11","completion_date":"2023-03-27","last_update":"2023-03-29","substances":"mescaline","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04849013","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04849013"},{"nct_id":"NCT04850911","title":"Reward Emotion Learning and Ketamine Study","acronym":"RELAKS","status":"UNKNOWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":70,"start_date":"2021-08-25","completion_date":"2023-05","last_update":"2023-03-28","substances":"ketamine","conditions":"Depression; Major Depressive Disorder; Treatment Resistant Depression","sponsor":"University of Oxford","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04850911","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04850911"},{"nct_id":"NCT04850937","title":"Effect of Low-dose Esketamine on Postoperative Depression in Patients With Breast Cancer","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":90,"start_date":"2021-02-10","completion_date":"2021-04-10","last_update":"2022-07-28","substances":"ketamine","conditions":"Depression","sponsor":"Yangzhou University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04850937","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04850937"},{"nct_id":"NCT04856124","title":"Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine","acronym":"","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":10,"start_date":"2018-09-01","completion_date":"2020-12-15","last_update":"2021-04-23","substances":"ketamine","conditions":"Treatment Resistant Depression","sponsor":"Psych Atlanta","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Georgia","lsd_com_url":"https://lsd.com/trials/nct04856124","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04856124"},{"nct_id":"NCT04858711","title":"Opioid-free Anesthesia With a Mixture of Dexmedetomidine-lidocaine-ketamine","acronym":"","status":"UNKNOWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2021-04-01","completion_date":"2023-09-30","last_update":"2022-10-24","substances":"ketamine","conditions":"Pain, Postoperative; Pain, Acute; Pain, Chronic; Pain, Neuropathic; Pain, Nociceptive; Ketamine; Dexmedetomidine; Lidocaine; Central Nervous System Depressants; Analgesia; Analgesics; Analgesics Non-narcotic","sponsor":"Aretaieion University Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Greece","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04858711","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04858711"},{"nct_id":"NCT04860661","title":"Esketamine on Postpartum Depression in Cesarean Section Women","acronym":"EKET","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":336,"start_date":"2021-05-01","completion_date":"2024-03-31","last_update":"2024-08-06","substances":"ketamine","conditions":"Esketamine; Postpartum Depression","sponsor":"Ailin Luo","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04860661","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04860661"},{"nct_id":"NCT04865653","title":"LSD Base and LSD Tartrate Bioequivalence and Bioavailability in Healthy Subjects","acronym":"LSD-Bio","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2022-03-17","completion_date":"2023-10-11","last_update":"2024-02-14","substances":"lsd","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04865653","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04865653"},{"nct_id":"NCT04871425","title":"Ketamine Versus Fentanyl for Surgical Abortions","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":110,"start_date":"2021-04-27","completion_date":"2021-10-14","last_update":"2022-03-24","substances":"ketamine","conditions":"Abortion in First Trimester; Pain, Procedural; Opioid Use","sponsor":"University of Washington","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Washington","lsd_com_url":"https://lsd.com/trials/nct04871425","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04871425"},{"nct_id":"NCT04876066","title":"Use of Transmucosal Ketamine in Post Stroke Depression","acronym":"","status":"UNKNOWN","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":21,"start_date":"2020-11-30","completion_date":"2022-11","last_update":"2022-04-29","substances":"ketamine","conditions":"Post-stroke Depression","sponsor":"West Virginia University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"West Virginia","lsd_com_url":"https://lsd.com/trials/nct04876066","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04876066"},{"nct_id":"NCT04882839","title":"Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe OCD","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":15,"start_date":"2024-11-25","completion_date":"2026-06-01","last_update":"2025-11-19","substances":"psilocybin","conditions":"Obsessive-compulsive Disorder","sponsor":"Beersheva Mental Health Center","sponsor_class":"OTHER_GOV","has_results":false,"site_count":1,"countries":"Israel","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04882839","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04882839"},{"nct_id":"NCT04889664","title":"Adding Trauma-focused Psychotherapy to Ketamine Treatment for Chronic PTSD","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2021-06-04","completion_date":"2023-10-14","last_update":"2024-10-08","substances":"ketamine","conditions":"PTSD","sponsor":"Icahn School of Medicine at Mount Sinai","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct04889664","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04889664"},{"nct_id":"NCT04894864","title":"Opioid Free Anesthesia-Analgesia Strategy and Surgical Stress in Elective Open Abdominal Aortic Aneurysm Repair","acronym":"","status":"RECRUITING","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2020-10-08","completion_date":"2026-09-01","last_update":"2026-06-16","substances":"ketamine","conditions":"Elective Surgical Procedures; Postoperative Pain; Anesthesia; Opioid Use; Abdominal Aortic Aneurysm Without Rupture; Vascular Surgical Procedure; Interleukin 6; Immunomodulators","sponsor":"University of Crete","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Greece","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04894864","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04894864"},{"nct_id":"NCT04905121","title":"Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)","acronym":"","status":"TERMINATED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":4,"start_date":"2021-08-11","completion_date":"2022-04-22","last_update":"2022-10-12","substances":"psilocybin","conditions":"Short Lasting Unilateral Neuralgiform Headache Attacks","sponsor":"Beckley Psytech Limited","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04905121","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04905121"},{"nct_id":"NCT04916548","title":"Repeated Neurocognitive Measurements in Depressed Patients","acronym":"","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":15,"start_date":"2021-09-16","completion_date":"2023-07-15","last_update":"2024-08-20","substances":"ketamine","conditions":"Depression, Unipolar","sponsor":"Rebecca Price","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Pennsylvania","lsd_com_url":"https://lsd.com/trials/nct04916548","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04916548"},{"nct_id":"NCT04924257","title":"ECT vs. Esketamine","acronym":"ETES","status":"WITHDRAWN","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2021-07-28","completion_date":"2023-08","last_update":"2022-08-05","substances":"ketamine","conditions":"Treatment Resistant Depression; Major Depressive Disorder","sponsor":"Medical University Innsbruck","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Austria","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04924257","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04924257"},{"nct_id":"NCT04932434","title":"Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease","acronym":"PDP1","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2021-08-15","completion_date":"2024-12-31","last_update":"2026-09-03","substances":"psilocybin","conditions":"Parkinson Disease; Depression; Anxiety","sponsor":"Joshua Woolley, MD, PhD","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct04932434","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04932434"},{"nct_id":"NCT04939649","title":"Ketamine As an Adjunctive Therapy for Major Depression (2)","acronym":"KARMA-Dep2","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":63,"start_date":"2021-09-13","completion_date":"2024-04-18","last_update":"2025-02-13","substances":"ketamine","conditions":"Major Depressive Episode; Unipolar Depression; Bipolar Depression","sponsor":"University of Dublin, Trinity College","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Ireland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04939649","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04939649"},{"nct_id":"NCT04944017","title":"Ketamine for the Treatment of Depression in Parkinson's Disease","acronym":"KET-PD","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":51,"start_date":"2021-11-23","completion_date":"2025-09-24","last_update":"2025-12-08","substances":"ketamine","conditions":"Parkinson's Disease; Depression","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct04944017","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04944017"},{"nct_id":"NCT04950608","title":"Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care","acronym":"PATH","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":15,"start_date":"2022-03-09","completion_date":"2024-07-27","last_update":"2026-02-17","substances":"psilocybin","conditions":"Hospice; Psilocybin; Demoralization; Terminal Illness; Cancer-related Problem/Condition; Psychotherapy; Terminal Cancer; Cancer Terminal","sponsor":"Yvan Beaussant, MD, MSci","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct04950608","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04950608"},{"nct_id":"NCT04955470","title":"Ketamine Infusion for Rapid Reduction of Suicidality in Pediatrics","acronym":"Keta4SI","status":"TERMINATED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":15,"start_date":"2022-06-01","completion_date":"2023-09-01","last_update":"2024-12-18","substances":"ketamine","conditions":"Suicidal Ideation","sponsor":"University of British Columbia","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04955470","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04955470"},{"nct_id":"NCT04959253","title":"Psilocybin in Depression Resistant to Standard Treatments","acronym":"PsiDeR","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2021-06-21","completion_date":"2024-12-18","last_update":"2026-08-28","substances":"psilocybin","conditions":"Treatment Resistant Depression","sponsor":"King's College London","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04959253","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04959253"},{"nct_id":"NCT04968938","title":"Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD","acronym":"NUMCAP1","status":"WITHDRAWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2022-08","completion_date":"2023-08","last_update":"2024-11-01","substances":"mdma","conditions":"Posttraumatic Stress Disorder","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04968938","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04968938"},{"nct_id":"NCT04977674","title":"Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine","acronym":"GO-MARK","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":27,"start_date":"2021-09-27","completion_date":"2023-02-13","last_update":"2023-03-02","substances":"ketamine","conditions":"Depressive Disorder, Treatment-Resistant","sponsor":"King's College London","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04977674","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04977674"},{"nct_id":"NCT04982796","title":"Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2022-07-07","completion_date":"2026-12-31","last_update":"2026-04-22","substances":"psilocybin","conditions":"Amphetamine-Related Disorders","sponsor":"Portland VA Research Foundation, Inc","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Washington","lsd_com_url":"https://lsd.com/trials/nct04982796","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04982796"},{"nct_id":"NCT04989972","title":"Assessing the Efficacy of Micro-dosed Psilocybin on Reducing Anxiety & Depression Levels in Adults","acronym":"","status":"WITHDRAWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2022-09-15","completion_date":"2023-06-20","last_update":"2022-06-30","substances":"psilocybin","conditions":"Anxiety and Depression","sponsor":"Wake Network, Inc.","sponsor_class":"NETWORK","has_results":false,"site_count":1,"countries":"Jamaica","us_states":"","lsd_com_url":"https://lsd.com/trials/nct04989972","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT04989972"},{"nct_id":"NCT05004896","title":"Ketamine for Treatment-Resistant Bipolar Disorder","acronym":"KET-BD","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":71,"start_date":"2022-07-04","completion_date":"2025-11-14","last_update":"2026-03-05","substances":"ketamine","conditions":"Bipolar Disorder; Bipolar Depression; Bipolar I Disorder; Bipolar II Disorder","sponsor":"Joshua Rosenblat","sponsor_class":"OTHER","has_results":false,"site_count":3,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05004896","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05004896"},{"nct_id":"NCT05026203","title":"Effectiveness of Ketamine Treatment for Three Consecutive Days in Depression","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2021-09-01","completion_date":"2022-07-31","last_update":"2024-03-15","substances":"ketamine","conditions":"Depression","sponsor":"Mahidol University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Thailand","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05026203","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05026203"},{"nct_id":"NCT05029401","title":"A Study of Oral Ibogaine in Opioid Withdrawal","acronym":"","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":116,"start_date":"2021-04-01","completion_date":"2024-01-16","last_update":"2024-08-06","substances":"ibogaine","conditions":"Opiate Withdrawal Syndrome","sponsor":"atai Therapeutics, Inc.","sponsor_class":"INDUSTRY","has_results":false,"site_count":2,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05029401","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05029401"},{"nct_id":"NCT05029466","title":"Psilocybin for Treatment-Resistant Depression","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2021-11-19","completion_date":"2023-07-22","last_update":"2023-07-27","substances":"psilocybin","conditions":"Treatment Resistant Depression","sponsor":"Brain and Cognition Discovery Foundation","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05029466","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05029466"},{"nct_id":"NCT05032833","title":"Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":36,"start_date":"2021-09-22","completion_date":"2022-07-07","last_update":"2022-10-12","substances":"dmt","conditions":"Pharmacokinetics in Healthy Adults","sponsor":"Beckley Psytech Limited","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05032833","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05032833"},{"nct_id":"NCT05035927","title":"Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":5,"start_date":"2022-03-16","completion_date":"2024-03-07","last_update":"2024-11-19","substances":"psilocybin","conditions":"Binge Eating Disorder","sponsor":"TRYP Therapeutics","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United States","us_states":"Florida","lsd_com_url":"https://lsd.com/trials/nct05035927","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05035927"},{"nct_id":"NCT05042466","title":"Northwest Therapies Trauma Psilocybin Study Compassionate Use Study","acronym":"NWTTPS","status":"UNKNOWN","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2023-09-03","completion_date":"2025-08-30","last_update":"2022-11-16","substances":"psilocybin","conditions":"Trauma, Nervous System","sponsor":"NWTraumatherapies","sponsor_class":"NETWORK","has_results":false,"site_count":1,"countries":"United States","us_states":"Montana","lsd_com_url":"https://lsd.com/trials/nct05042466","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05042466"},{"nct_id":"NCT05042765","title":"Entheogen Resurgence","acronym":"SERPNTS","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":102,"start_date":"2021-09-16","completion_date":"2022-01-12","last_update":"2022-01-27","substances":"dmt","conditions":"Psychedelic Experiences","sponsor":"Vireo Health","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct05042765","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05042765"},{"nct_id":"NCT05045378","title":"Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2022-03-15","completion_date":"2024-11-30","last_update":"2025-09-05","substances":"ketamine","conditions":"Treatment-resistant Depression; Major Depressive Disorder","sponsor":"Taipei Veterans General Hospital, Taiwan","sponsor_class":"OTHER_GOV","has_results":false,"site_count":1,"countries":"Taiwan","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05045378","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05045378"},{"nct_id":"NCT05046184","title":"Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets","acronym":"UNIKET","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":165,"start_date":"2022-05-05","completion_date":"2025-04-30","last_update":"2025-05-08","substances":"ketamine","conditions":"Major Depressive Disorder; Healthy Controls","sponsor":"University of Texas Southwestern Medical Center","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct05046184","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05046184"},{"nct_id":"NCT05051449","title":"Ketamine for OUD and Comorbid Depression (OUDCD)","acronym":"","status":"TERMINATED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":5,"start_date":"2022-04-04","completion_date":"2023-11-17","last_update":"2024-03-07","substances":"ketamine","conditions":"Opioid Use Disorder; Depressive Disorder","sponsor":"University of Maryland, Baltimore","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct05051449","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05051449"},{"nct_id":"NCT05065294","title":"Psilocybin Therapy for Depression in Bipolar II Disorder","acronym":"BAP","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":14,"start_date":"2022-01-28","completion_date":"2024-08-01","last_update":"2024-09-25","substances":"psilocybin","conditions":"Bipolar II Disorder","sponsor":"University of California, San Francisco","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct05065294","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05065294"},{"nct_id":"NCT05066282","title":"Long-Term Safety and Effectiveness of MDMA-Assisted Therapy for PTSD","acronym":"MPLONG","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":186,"start_date":"2021-03-01","completion_date":"2024-05-16","last_update":"2024-10-30","substances":"mdma","conditions":"PTSD","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":false,"site_count":4,"countries":"Canada; Israel; United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct05066282","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05066282"},{"nct_id":"NCT05067244","title":"A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD)","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2021-10-04","completion_date":"2024-11-01","last_update":"2024-11-14","substances":"mdma","conditions":"Post Traumatic Stress Disorder","sponsor":"Remedy","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05067244","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05067244"},{"nct_id":"NCT05068791","title":"Psilocybin-facilitated Treatment for Chronic Pain","acronym":"","status":"RECRUITING","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2023-11-01","completion_date":"2026-12-31","last_update":"2026-03-11","substances":"psilocybin","conditions":"Fibromyalgia, Primary","sponsor":"University of Alabama at Birmingham","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Alabama","lsd_com_url":"https://lsd.com/trials/nct05068791","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05068791"},{"nct_id":"NCT05086250","title":"Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer","acronym":"","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2022-10-20","completion_date":"2026-03-06","last_update":"2026-08-13","substances":"ketamine","conditions":"Anxiety; Pancreatic Cancer","sponsor":"Cedars-Sinai Medical Center","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct05086250","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05086250"},{"nct_id":"NCT05089526","title":"Opioid-free Anesthesia in Laparoscopic Cholecystectomies","acronym":"","status":"UNKNOWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":70,"start_date":"2021-10-11","completion_date":"2023-06-30","last_update":"2023-02-24","substances":"ketamine","conditions":"Pain, Postoperative; Pain, Acute; Pain, Chronic; Cholecystectomy; Ketamine; Dexmedetomidine; Lidocaine; Central Nervous System Depressants; Analgesia; Analgesics; Analgesic Non-narcotic","sponsor":"Aretaieion University Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Greece","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05089526","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05089526"},{"nct_id":"NCT05095792","title":"Effect of Ketamine on Neurological Activity as Measured by Electroencephalogram (EEG)","acronym":"","status":"TERMINATED","phases":"","study_type":"OBSERVATIONAL","enrollment":1,"start_date":"2021-11-09","completion_date":"2022-10-21","last_update":"2024-11-14","substances":"ketamine","conditions":"Treatment-resistant Depression","sponsor":"Entheon Biomedical Corp.","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct05095792","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05095792"},{"nct_id":"NCT05105061","title":"Intramuscular Ketamine for Suicidal Ideation","acronym":"","status":"WITHDRAWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2022-02","completion_date":"2022-03-24","last_update":"2022-04-05","substances":"ketamine","conditions":"Suicidal Ideation","sponsor":"Icahn School of Medicine at Mount Sinai","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct05105061","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05105061"},{"nct_id":"NCT05123716","title":"Drug Effects on Interpersonal Interaction","acronym":"DEI","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2021-08-01","completion_date":"2022-05-01","last_update":"2022-06-15","substances":"mdma","conditions":"Interaction, Social","sponsor":"University of Chicago","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Illinois","lsd_com_url":"https://lsd.com/trials/nct05123716","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05123716"},{"nct_id":"NCT05128162","title":"Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":17,"start_date":"2023-09-27","completion_date":"2024-06-12","last_update":"2025-04-16","substances":"psilocybin","conditions":"Fibromyalgia","sponsor":"Kevin Boehnke","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Michigan","lsd_com_url":"https://lsd.com/trials/nct05128162","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05128162"},{"nct_id":"NCT05137938","title":"Intranasal Ketamine in Ultra-REsistant Depression (SURE-ECT Non Responders)","acronym":"SURE-ECT","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":25,"start_date":"2021-10-25","completion_date":"2023-07-24","last_update":"2023-08-14","substances":"ketamine","conditions":"Depression","sponsor":"Centre for Addiction and Mental Health","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05137938","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05137938"},{"nct_id":"NCT05138068","title":"Social Anxiety MDMA-Assisted Therapy Investigation","acronym":"SAMATI","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":90,"start_date":"2022-04-13","completion_date":"2025-02-06","last_update":"2025-08-28","substances":"mdma","conditions":"Social Anxiety Disorder","sponsor":"Jason B Luoma","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Oregon","lsd_com_url":"https://lsd.com/trials/nct05138068","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05138068"},{"nct_id":"NCT05147402","title":"Food Effects on Bioavailability of MDMA in Healthy Volunteers","acronym":"MPKF","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":14,"start_date":"2022-07-28","completion_date":"2022-12-02","last_update":"2024-10-30","substances":"mdma","conditions":"Pharmacokinetics","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United States","us_states":"Tennessee","lsd_com_url":"https://lsd.com/trials/nct05147402","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05147402"},{"nct_id":"NCT05155969","title":"Intravenous Esketamine on Prevention of Postoperative Depression in Patients Undergoing Cardiac Surgery","acronym":"","status":"UNKNOWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":80,"start_date":"2021-12-01","completion_date":"2021-12-05","last_update":"2021-12-14","substances":"ketamine","conditions":"Postoperative Depression","sponsor":"Anshi Wu","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05155969","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05155969"},{"nct_id":"NCT05160220","title":"Naturalistic Study of Microdosing With Psilocybin","acronym":"NATMICRO","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":34,"start_date":"2021-01-20","completion_date":"2021-06-30","last_update":"2021-12-16","substances":"psilocybin","conditions":"Cognitive Change; Creativity; Mood Change; Sleep","sponsor":"National Council of Scientific and Technical Research, Argentina","sponsor_class":"OTHER_GOV","has_results":false,"site_count":1,"countries":"Argentina","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05160220","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05160220"},{"nct_id":"NCT05163496","title":"Frontline Clinician Psilocybin Study","acronym":"","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2022-03-03","completion_date":"2023-12-30","last_update":"2025-03-18","substances":"psilocybin","conditions":"Burnout, Caregiver; Burnout, Professional; COVID-19; Depression; Post Traumatic Stress Disorder; Moral Injury","sponsor":"University of Washington","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Washington","lsd_com_url":"https://lsd.com/trials/nct05163496","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05163496"},{"nct_id":"NCT05163691","title":"Pharmacokinetics of GH001 in Healthy Volunteers","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":46,"start_date":"2021-06-21","completion_date":"2021-10-23","last_update":"2021-12-20","substances":"dmt","conditions":"Healthy Volunteers","sponsor":"GH Research Ireland Limited","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"Netherlands","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05163691","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05163691"},{"nct_id":"NCT05168735","title":"Ketamine + Mindfulness for Depression","acronym":"","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":43,"start_date":"2022-02-01","completion_date":"2023-08-01","last_update":"2024-08-20","substances":"ketamine","conditions":"Depression, Unipolar","sponsor":"Rebecca Price","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Pennsylvania","lsd_com_url":"https://lsd.com/trials/nct05168735","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05168735"},{"nct_id":"NCT05173831","title":"Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans","acronym":"MPG1","status":"WITHDRAWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2023-09","completion_date":"2024-12","last_update":"2024-10-30","substances":"mdma","conditions":"PTSD","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05173831","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05173831"},{"nct_id":"NCT05175430","title":"Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects","acronym":"SERT-LSD","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2022-10-24","completion_date":"2024-02-20","last_update":"2024-03-13","substances":"lsd","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05175430","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05175430"},{"nct_id":"NCT05177146","title":"Neural Correlates of Ketamine's Anti-suicidal Effects in Bipolar Depression","acronym":"DEEPP","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2022-05-04","completion_date":"2025-01-10","last_update":"2025-02-06","substances":"ketamine","conditions":"Bipolar Disorder (BD); Suicidality","sponsor":"Centre for Addiction and Mental Health","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05177146","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05177146"},{"nct_id":"NCT05177419","title":"Effects of LSD on Neuroplasticity in Healthy Subjects","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":45,"start_date":"2022-05-02","completion_date":"2025-03-12","last_update":"2025-04-06","substances":"lsd","conditions":"Healthy","sponsor":"University of Fribourg","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05177419","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05177419"},{"nct_id":"NCT05193318","title":"KAP for Depression in Abstinent Opioid Users","acronym":"KReDO","status":"TERMINATED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":5,"start_date":"2022-01-13","completion_date":"2023-03-20","last_update":"2024-05-06","substances":"ketamine","conditions":"Opioid Use Disorder, Severe, in Sustained Remission; Opioid Use Disorder, Severe, in Early Remission; Major Depressive Disorder","sponsor":"Medical University of South Carolina","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"South Carolina","lsd_com_url":"https://lsd.com/trials/nct05193318","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05193318"},{"nct_id":"NCT05200936","title":"Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":53,"start_date":"2021-12-17","completion_date":"2023-11-06","last_update":"2026-02-27","substances":"lsd","conditions":"ADHD; Attention Deficit Disorder","sponsor":"Definium Therapeutics US, Inc.","sponsor_class":"INDUSTRY","has_results":true,"site_count":2,"countries":"Netherlands; Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05200936","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05200936"},{"nct_id":"NCT05209217","title":"Open Study of the Neurobiological Effects of Intranasal Ketamine in Children and Adults With Bipolar Disorder","acronym":"","status":"UNKNOWN","phases":"","study_type":"OBSERVATIONAL","enrollment":20,"start_date":"2019-06-04","completion_date":"2022-12-31","last_update":"2022-01-27","substances":"ketamine","conditions":"Bipolar Disorder","sponsor":"Mclean Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct05209217","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05209217"},{"nct_id":"NCT05217706","title":"Low-Dose Intravenous Ketamine for Adolescents With Depression and Suicidal Ideation in the Emergency Department","acronym":"","status":"UNKNOWN","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2022-03-01","completion_date":"2024-01-01","last_update":"2023-02-16","substances":"ketamine","conditions":"Depression; Suicidal Ideation","sponsor":"Rady Children's Hospital, San Diego","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct05217706","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05217706"},{"nct_id":"NCT05219175","title":"MDMA for Co-occurring PTSD and OUD After Childbirth","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":15,"start_date":"2024-04-16","completion_date":"2027-04","last_update":"2026-03-16","substances":"mdma","conditions":"Stress Disorders, Post-Traumatic; Opioid Use Disorder","sponsor":"University of New Mexico","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New Mexico","lsd_com_url":"https://lsd.com/trials/nct05219175","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05219175"},{"nct_id":"NCT05220046","title":"Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":18,"start_date":"2023-04-10","completion_date":"2025-11-17","last_update":"2026-08-19","substances":"psilocybin","conditions":"Pancreas Cancer; Biliary Tract Cancer; Psychological Distress; Gastrointestinal Cancer","sponsor":"University of Nebraska","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Nebraska","lsd_com_url":"https://lsd.com/trials/nct05220046","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05220046"},{"nct_id":"NCT05220410","title":"The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2022-03-28","completion_date":"2025-05-12","last_update":"2025-12-24","substances":"psilocybin","conditions":"Treatment Resistant Depression; Suicidal Ideation","sponsor":"Sheppard Pratt Health System","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct05220410","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05220410"},{"nct_id":"NCT05224336","title":"Psilocybin-assisted Therapy for Phantom Limb Pain","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2022-10-03","completion_date":"2024-03-07","last_update":"2026-01-09","substances":"psilocybin","conditions":"Phantom Limb Pain","sponsor":"University of California, San Diego","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct05224336","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05224336"},{"nct_id":"NCT05227612","title":"Psilocybin-assisted CBT for Depression","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2023-06-27","completion_date":"2025-09-12","last_update":"2026-05-19","substances":"psilocybin","conditions":"Major Depressive Disorder","sponsor":"University of California, Los Angeles","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct05227612","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05227612"},{"nct_id":"NCT05227742","title":"Exploratory Study of Low Dose Psilocybin","acronym":"","status":"WITHDRAWN","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2023-08-15","completion_date":"2026-03","last_update":"2026-03-11","substances":"psilocybin","conditions":"Demoralization","sponsor":"University of Alabama at Birmingham","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Alabama","lsd_com_url":"https://lsd.com/trials/nct05227742","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05227742"},{"nct_id":"NCT05229913","title":"Effects of Esketamine on Postpartum Depression","acronym":"EEPD","status":"UNKNOWN","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":500,"start_date":"2022-02-20","completion_date":"2022-09-30","last_update":"2022-02-08","substances":"ketamine","conditions":"Postpartum Depression","sponsor":"Qinghai University","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05229913","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05229913"},{"nct_id":"NCT05233566","title":"Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial","acronym":"K-PASS","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":32,"start_date":"2022-04-25","completion_date":"2023-03-08","last_update":"2026-08-21","substances":"ketamine","conditions":"Postoperative Depression","sponsor":"Washington University School of Medicine","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Missouri","lsd_com_url":"https://lsd.com/trials/nct05233566","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05233566"},{"nct_id":"NCT05242029","title":"Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use","acronym":"","status":"WITHDRAWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2023-12","completion_date":"2024-02","last_update":"2024-02-02","substances":"psilocybin","conditions":"Opioid Use Disorder","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05242029","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05242029"},{"nct_id":"NCT05242081","title":"Study on Opioid-free Anesthesia Protocol With S-ketamine and Propofol","acronym":"","status":"UNKNOWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":980,"start_date":"2022-07","completion_date":"2022-12","last_update":"2022-07-20","substances":"ketamine","conditions":"Opioid Use, Unspecified; S-ketamine","sponsor":"The First Affiliated Hospital with Nanjing Medical University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05242081","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05242081"},{"nct_id":"NCT05243329","title":"Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder","acronym":"","status":"UNKNOWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2022-10-03","completion_date":"2023-10-30","last_update":"2023-06-29","substances":"psilocybin","conditions":"Treatment Resistant Disorders; Post Traumatic Stress Disorder","sponsor":"Halucenex Life Sciences Inc.","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05243329","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05243329"},{"nct_id":"NCT05249309","title":"Naturalistic Study of Ketamine in the Treatment of Depression","acronym":"","status":"UNKNOWN","phases":"","study_type":"OBSERVATIONAL","enrollment":90,"start_date":"2021-05-01","completion_date":"2022-11-01","last_update":"2023-09-25","substances":"ketamine","conditions":"Major Depressive Disorder; Bipolar Disorder; Bipolar Depression; Bipolar I Disorder; Bipolar II Disorder; Affective Disorder","sponsor":"Hospital de Clinicas de Porto Alegre","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"Brazil","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05249309","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05249309"},{"nct_id":"NCT05252598","title":"Mood and Cognitive Effects of Psilocybin in Healthy Participants","acronym":"MELO","status":"WITHDRAWN","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2023-01","completion_date":"2023-08","last_update":"2023-03-20","substances":"psilocybin","conditions":"Mood Disturbance; Mood Change; Sleep Disturbance; Drug Effect; Psychedelic Experiences; Health, Subjective; Psilocin Toxicity; Psilocybin Toxicity; Psilocybin Causing Adverse Effects in Therapeutic Use; Anxiety","sponsor":"Optimi Health Corporation","sponsor_class":"INDUSTRY","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05252598","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05252598"},{"nct_id":"NCT05259943","title":"Microdosing Psychedelics to Improve Mood","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":39,"start_date":"2023-07-15","completion_date":"2024-12-21","last_update":"2025-12-30","substances":"psilocybin","conditions":"Major Depressive Disorder","sponsor":"Rotem Petranker","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05259943","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05259943"},{"nct_id":"NCT05265546","title":"Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain","acronym":"","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":80,"start_date":"2024-03-08","completion_date":"2028-12-31","last_update":"2026-07-10","substances":"psilocybin","conditions":"Perception Disorders","sponsor":"University of California, Berkeley","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct05265546","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05265546"},{"nct_id":"NCT05268497","title":"A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression","acronym":"","status":"WITHDRAWN","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2022-09-01","completion_date":"2023-06-07","last_update":"2025-04-27","substances":"ketamine","conditions":"Depression","sponsor":"Janssen Research & Development, LLC","sponsor_class":"INDUSTRY","has_results":false,"site_count":5,"countries":"United States","us_states":"Connecticut; Illinois; Maryland; Ohio","lsd_com_url":"https://lsd.com/trials/nct05268497","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05268497"},{"nct_id":"NCT05274230","title":"Sustaining Remission From PTSD Using Tuned Vibroacoustic Stimulation (TVS) Following MDMA-Assisted Psychotherapy","acronym":"","status":"UNKNOWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":200,"start_date":"2021-12-08","completion_date":"2024-12-31","last_update":"2023-02-02","substances":"mdma","conditions":"Stress Disorders, Post-Traumatic","sponsor":"Apollo Neuroscience, Inc.","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United States","us_states":"Pennsylvania","lsd_com_url":"https://lsd.com/trials/nct05274230","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05274230"},{"nct_id":"NCT05277636","title":"Acute Effects of R- and S-MDMA in Healthy Subjects","acronym":"R-S-MDMA","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2022-10-01","completion_date":"2024-01-13","last_update":"2024-01-17","substances":"mdma","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05277636","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05277636"},{"nct_id":"NCT05294835","title":"Ketamine and Epigenetic Aging","acronym":"","status":"UNKNOWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2022-04-01","completion_date":"2022-12-31","last_update":"2022-09-08","substances":"ketamine","conditions":"Depression; Post Traumatic Stress Disorder","sponsor":"TruDiagnostic","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United States","us_states":"Kentucky","lsd_com_url":"https://lsd.com/trials/nct05294835","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05294835"},{"nct_id":"NCT05301608","title":"Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought","acronym":"","status":"RECRUITING","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2022-03-03","completion_date":"2026-12-01","last_update":"2026-07-23","substances":"psilocybin","conditions":"Healthy","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct05301608","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05301608"},{"nct_id":"NCT05305105","title":"Effects of Psilocybin in Post-Treatment Lyme Disease","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2022-07-01","completion_date":"2024-10-26","last_update":"2025-08-20","substances":"psilocybin","conditions":"Post-Treatment Lyme Disease; Chronic Lyme Disease; Lyme Disease, Chronic","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct05305105","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05305105"},{"nct_id":"NCT05308082","title":"Programme Evaluation on Effectiveness of The Use of Movement-based x 'Elderspirituality - Fu Le Mun Sum' Intervention to Support Elderly People With Depressive Symptoms","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":135,"start_date":"2021-03-01","completion_date":"2022-12-24","last_update":"2023-05-09","substances":"dmt","conditions":"Depression in Old Age","sponsor":"The University of Hong Kong","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Hong Kong","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05308082","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05308082"},{"nct_id":"NCT05312151","title":"The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":22,"start_date":"2022-06-10","completion_date":"2024-02-12","last_update":"2025-06-13","substances":"psilocybin","conditions":"Post Traumatic Stress Disorder","sponsor":"COMPASS Pathways","sponsor_class":"INDUSTRY","has_results":true,"site_count":3,"countries":"United Kingdom; United States","us_states":"Maryland; New York","lsd_com_url":"https://lsd.com/trials/nct05312151","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05312151"},{"nct_id":"NCT05317689","title":"Comparing the Effects of Psilocin and Psilocybin in Healthy Adults","acronym":"","status":"UNKNOWN","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2022-05-26","completion_date":"2025-01-16","last_update":"2025-06-10","substances":"psilocybin","conditions":"Healthy","sponsor":"University of California, San Francisco","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct05317689","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05317689"},{"nct_id":"NCT05320107","title":"The Effect of Ketamine on Aesthetics and Role for Antidepressant Effects","acronym":"","status":"UNKNOWN","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2022-06-01","completion_date":"2025-02-28","last_update":"2024-04-15","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Medical University of Vienna","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Austria","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05320107","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05320107"},{"nct_id":"NCT05322954","title":"Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder","acronym":"","status":"TERMINATED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":5,"start_date":"2023-03-03","completion_date":"2024-03-07","last_update":"2026-05-12","substances":"psilocybin","conditions":"Methamphetamine Use Disorder; Substance-Related Disorders; Chemically-Induced Disorders; Substance Use Disorders; Stimulant-Use Disorder","sponsor":"University of Wisconsin, Madison","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Wisconsin","lsd_com_url":"https://lsd.com/trials/nct05322954","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05322954"},{"nct_id":"NCT05323019","title":"Repeated Intranasal Esketamine Plus Almond Therapy in Patients With Treatment Resistant Depression","acronym":"ZYL-730-01","status":"TERMINATED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":6,"start_date":"2022-10-13","completion_date":"2023-02-01","last_update":"2023-03-24","substances":"ketamine","conditions":"Treatment Resistant Major Depressive Disorder","sponsor":"Zylorion Health","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05323019","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05323019"},{"nct_id":"NCT05327699","title":"Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine","acronym":"","status":"RECRUITING","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":140,"start_date":"2022-11-08","completion_date":"2028-03-02","last_update":"2026-05-26","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Emory University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Georgia","lsd_com_url":"https://lsd.com/trials/nct05327699","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05327699"},{"nct_id":"NCT05339074","title":"Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression","acronym":"KET-BD-Sustain","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":41,"start_date":"2022-08-11","completion_date":"2026-01-28","last_update":"2026-03-05","substances":"ketamine","conditions":"Bipolar Disorder; Bipolar Depression; Bipolar I Disorder; Bipolar II Disorder","sponsor":"Joshua Rosenblat","sponsor_class":"OTHER","has_results":false,"site_count":3,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05339074","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05339074"},{"nct_id":"NCT05344625","title":"Ketamine-Assisted PsychoTherapy ViAbility in Treating Cancer-related Emotional Distress","acronym":"KAPTIVATED","status":"WITHDRAWN","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2023-10-31","completion_date":"2024-03-15","last_update":"2024-01-24","substances":"ketamine","conditions":"Cancer-related Problem/Condition; Depressive Symptoms; Anxiety Disorders","sponsor":"Northwell Health","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05344625","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05344625"},{"nct_id":"NCT05347849","title":"Single Ascending Dose Study With BPL-003 in Healthy Subjects","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":62,"start_date":"2022-02-14","completion_date":"2024-01-19","last_update":"2024-03-18","substances":"dmt","conditions":"Pharmacokinetics in Healthy Adults","sponsor":"Beckley Psytech Limited","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05347849","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05347849"},{"nct_id":"NCT05351541","title":"Psilocybin Therapy for Chronic Low Back Pain","acronym":"POP","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2023-12-01","completion_date":"2026-07","last_update":"2026-04-29","substances":"psilocybin","conditions":"Chronic Low-back Pain","sponsor":"Joshua Woolley, MD, PhD","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct05351541","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05351541"},{"nct_id":"NCT05370911","title":"Effects of Repeated Psilocybin Dosing in OCD","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":28,"start_date":"2023-07-20","completion_date":"2026-02-17","last_update":"2026-06-04","substances":"psilocybin","conditions":"Obsessive-Compulsive Disorder","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct05370911","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05370911"},{"nct_id":"NCT05379959","title":"Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function","acronym":"MASM","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":43,"start_date":"2022-05-11","completion_date":"2022-10-24","last_update":"2024-01-24","substances":"mdma","conditions":"Stimulant Use; MDMA ('Ecstasy'); Social Behavior; Motivation","sponsor":"University of Chicago","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Illinois","lsd_com_url":"https://lsd.com/trials/nct05379959","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05379959"},{"nct_id":"NCT05381974","title":"The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD","acronym":"","status":"WITHDRAWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2022-09-15","completion_date":"2023-06-01","last_update":"2024-01-24","substances":"psilocybin","conditions":"Treatment-Resistant Major Depressive Disorder","sponsor":"Massachusetts General Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct05381974","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05381974"},{"nct_id":"NCT05383313","title":"Psilocybin Versus Ketamine in Treatment-Resistant Depression","acronym":"PSIKET_001","status":"UNKNOWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2021-05-01","completion_date":"2025-04-30","last_update":"2022-05-20","substances":"psilocybin; ketamine","conditions":"Treatment Resistant Depression","sponsor":"National Institute of Mental Health, Czech Republic","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Czechia","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05383313","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05383313"},{"nct_id":"NCT05384678","title":"Acute Dose-dependent Effects of DMT in Healthy Subjects","acronym":"DMT DR","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2022-11-15","completion_date":"2024-03-08","last_update":"2024-04-25","substances":"dmt","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05384678","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05384678"},{"nct_id":"NCT05385783","title":"A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder","acronym":"","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":57,"start_date":"2022-08-02","completion_date":"2023-10-16","last_update":"2024-03-25","substances":"psilocybin","conditions":"Major Depressive Disorder","sponsor":"Cybin IRL Limited","sponsor_class":"INDUSTRY","has_results":false,"site_count":3,"countries":"United States","us_states":"Georgia; New Jersey","lsd_com_url":"https://lsd.com/trials/nct05385783","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05385783"},{"nct_id":"NCT05398484","title":"Psilocybin Therapy in Advanced Cancer","acronym":"","status":"RECRUITING","phases":"PHASE2; PHASE3","study_type":"INTERVENTIONAL","enrollment":200,"start_date":"2023-05-24","completion_date":"2027-01-01","last_update":"2025-12-04","substances":"psilocybin","conditions":"Advanced Cancer","sponsor":"NYU Langone Health","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"United States","us_states":"Colorado; New York","lsd_com_url":"https://lsd.com/trials/nct05398484","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05398484"},{"nct_id":"NCT05399498","title":"Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":9,"start_date":"2023-11-01","completion_date":"2025-12-01","last_update":"2025-12-23","substances":"psilocybin","conditions":"Borderline Personality Disorder; Major Depressive Disorder","sponsor":"University of Chicago","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Illinois","lsd_com_url":"https://lsd.com/trials/nct05399498","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05399498"},{"nct_id":"NCT05403086","title":"Pragmatic Trial of Psilocybin Therapy in Palliative Care","acronym":"PT2PC","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":100,"start_date":"2025-01-19","completion_date":"2026-12-31","last_update":"2025-11-25","substances":"psilocybin; ketamine","conditions":"Demoralization","sponsor":"Charles S. Grob, M.D.","sponsor_class":"OTHER","has_results":false,"site_count":5,"countries":"United States","us_states":"California; Maryland","lsd_com_url":"https://lsd.com/trials/nct05403086","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05403086"},{"nct_id":"NCT05407064","title":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":198,"start_date":"2022-08-24","completion_date":"2023-10-06","last_update":"2026-02-27","substances":"lsd","conditions":"Anxiety Generalized","sponsor":"Definium Therapeutics US, Inc.","sponsor_class":"INDUSTRY","has_results":true,"site_count":22,"countries":"United States","us_states":"Arkansas; California; Colorado; Florida; Georgia; Illinois; Maryland; Massachusetts; New Jersey; Ohio; Texas; Utah; Vermont","lsd_com_url":"https://lsd.com/trials/nct05407064","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05407064"},{"nct_id":"NCT05414422","title":"A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":102,"start_date":"2022-02-01","completion_date":"2022-11-10","last_update":"2024-06-04","substances":"ketamine","conditions":"Treatment Resistant Depression","sponsor":"Perception Neuroscience","sponsor_class":"INDUSTRY","has_results":true,"site_count":21,"countries":"Germany; Poland; United States","us_states":"Arkansas; California; Florida; Georgia; New Jersey; Ohio; Texas","lsd_com_url":"https://lsd.com/trials/nct05414422","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05414422"},{"nct_id":"NCT05416229","title":"Psilocybin-assisted Therapy for Treatment of Alcohol Use Disorder","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2023-09-01","completion_date":"2025-12-22","last_update":"2026-03-24","substances":"psilocybin","conditions":"Alcohol Use Disorder","sponsor":"Anders Fink-Jensen, MD, DMSci","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Denmark","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05416229","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05416229"},{"nct_id":"NCT05421065","title":"Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2024-02-02","completion_date":"2025-08-30","last_update":"2025-11-17","substances":"psilocybin; ketamine","conditions":"Alcohol Use Disorder","sponsor":"Peggy C Nopoulos","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Iowa","lsd_com_url":"https://lsd.com/trials/nct05421065","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05421065"},{"nct_id":"NCT05422001","title":"Low-dose KETamine as an Adjunct to MOrphine for Acute Pain in the ED","acronym":"KetMo","status":"TERMINATED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":116,"start_date":"2022-05-31","completion_date":"2023-08-15","last_update":"2023-09-26","substances":"ketamine","conditions":"Acute Pain; Opioid Use","sponsor":"University of Aarhus","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Denmark","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05422001","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05422001"},{"nct_id":"NCT05438758","title":"Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study","acronym":"ZYL-730-02","status":"WITHDRAWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2023-01-15","completion_date":"2024-02-01","last_update":"2022-11-15","substances":"ketamine","conditions":"Treatment Resistant Major Depressive Disorder","sponsor":"Zylorion Health","sponsor_class":"INDUSTRY","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05438758","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05438758"},{"nct_id":"NCT05450432","title":"Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression","acronym":"","status":"RECRUITING","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":100,"start_date":"2022-10-13","completion_date":"2026-06-01","last_update":"2025-12-12","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Massachusetts General Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct05450432","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05450432"},{"nct_id":"NCT05452772","title":"5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":66,"start_date":"2023-11-01","completion_date":"2026-12","last_update":"2026-06-29","substances":"psilocybin","conditions":"Tobacco Use Disorder","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":3,"countries":"United States","us_states":"Alabama; Maryland; New York","lsd_com_url":"https://lsd.com/trials/nct05452772","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05452772"},{"nct_id":"NCT05455996","title":"MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers and First Responders","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2026-10","completion_date":"2028-01","last_update":"2026-05-05","substances":"mdma","conditions":"Post-Traumatic Stress Disorder; Adjustment Disorders","sponsor":"Nautilus Sanctuary","sponsor_class":"OTHER","has_results":false,"site_count":3,"countries":"United States","us_states":"Colorado; New York; North Carolina","lsd_com_url":"https://lsd.com/trials/nct05455996","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05455996"},{"nct_id":"NCT05464264","title":"Auditory MMN EEG in TRD in Response to Ketamine","acronym":"","status":"UNKNOWN","phases":"","study_type":"OBSERVATIONAL","enrollment":30,"start_date":"2022-10-03","completion_date":"2024-10","last_update":"2023-11-29","substances":"ketamine","conditions":"Treatment-resistant Depression (TRD)","sponsor":"Unity Health Toronto","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05464264","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05464264"},{"nct_id":"NCT05467761","title":"Bioavailability Study of Psilocybin in Normal Adults","acronym":"","status":"WITHDRAWN","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2023-06","completion_date":"2024-03","last_update":"2023-05-15","substances":"psilocybin","conditions":"Healthy","sponsor":"University of Wisconsin, Madison","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Wisconsin","lsd_com_url":"https://lsd.com/trials/nct05467761","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05467761"},{"nct_id":"NCT05468840","title":"Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation","acronym":"","status":"UNKNOWN","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2023-06","completion_date":"2023-12","last_update":"2023-02-13","substances":"ketamine","conditions":"Suicidal Ideation","sponsor":"University of Ottawa","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05468840","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05468840"},{"nct_id":"NCT05474183","title":"The Role of Ketamine and Dexmedetomidine in Opioid-Sparing Analgesia","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":90,"start_date":"2022-08-05","completion_date":"2023-05-10","last_update":"2023-05-24","substances":"ketamine","conditions":"Ketamine-Induced Mood Disorder","sponsor":"Fayoum University Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Egypt","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05474183","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05474183"},{"nct_id":"NCT05474989","title":"LSD Treatment for Persons With Alcohol Use Disorder","acronym":"LYTA","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":128,"start_date":"2026-01-27","completion_date":"2028-10-31","last_update":"2026-04-29","substances":"lsd","conditions":"Alcohol Use Disorder (AUD)","sponsor":"Felix Mueller","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05474989","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05474989"},{"nct_id":"NCT05477459","title":"LSD to Improve Cluster Headache Impact Trial","acronym":"LICIT","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":65,"start_date":"2025-04-16","completion_date":"2027-04","last_update":"2025-04-15","substances":"lsd","conditions":"Chronic Cluster Headache","sponsor":"Radboud University Medical Center","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"Netherlands","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05477459","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05477459"},{"nct_id":"NCT05478278","title":"An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2022-06-22","completion_date":"2023-08-09","last_update":"2023-08-15","substances":"psilocybin","conditions":"QTc Interval; Pharmacokinetics","sponsor":"Usona Institute","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Kansas","lsd_com_url":"https://lsd.com/trials/nct05478278","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05478278"},{"nct_id":"NCT05481736","title":"Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":32,"start_date":"2022-10-12","completion_date":"2024-11-18","last_update":"2024-12-04","substances":"psilocybin","conditions":"Anorexia Nervosa","sponsor":"COMPASS Pathways","sponsor_class":"INDUSTRY","has_results":false,"site_count":5,"countries":"Ireland; United Kingdom; United States","us_states":"California; Maryland; Texas","lsd_com_url":"https://lsd.com/trials/nct05481736","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05481736"},{"nct_id":"NCT05487885","title":"Anhedonia, Development, and Emotions: Phenotyping and Therapeutics","acronym":"ADEPT","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":123,"start_date":"2022-07-22","completion_date":"2024-12-19","last_update":"2026-03-17","substances":"ketamine","conditions":"Depression; Anhedonia","sponsor":"Erika Forbes","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Pennsylvania","lsd_com_url":"https://lsd.com/trials/nct05487885","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05487885"},{"nct_id":"NCT05488171","title":"Abuse Potential and Human Pharmacology of Methylone","acronym":"METI/FIS/1","status":"UNKNOWN","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":17,"start_date":"2021-12-01","completion_date":"2022-07-31","last_update":"2022-08-08","substances":"mdma","conditions":"Substance Use; Healthy Subjects","sponsor":"Germans Trias i Pujol Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Spain","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05488171","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05488171"},{"nct_id":"NCT05500651","title":"Dance and Movement Therapy in Patients With Schizophrenia","acronym":"DMTinSchizo","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2022-09-01","completion_date":"2022-12-06","last_update":"2023-05-23","substances":"dmt","conditions":"Schizophrenia; Negative Symptoms in Schizophrenia; Disabilities Mental; Dance Therapy","sponsor":"Amasya University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Turkey (Türkiye)","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05500651","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05500651"},{"nct_id":"NCT05505630","title":"The Effects of Sedatives on Tobacco Use Disorder Version 2","acronym":"SED-TUD2","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2023-01-31","completion_date":"2025-12-10","last_update":"2026-04-01","substances":"ketamine","conditions":"Tobacco Smoking","sponsor":"Wake Forest University Health Sciences","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"North Carolina","lsd_com_url":"https://lsd.com/trials/nct05505630","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05505630"},{"nct_id":"NCT05506462","title":"An EEG Study of Intravenous Ketamine for Major Depression Disorder","acronym":"","status":"UNKNOWN","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":35,"start_date":"2023-01","completion_date":"2024-01","last_update":"2022-08-22","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Ehave Inc.","sponsor_class":"INDUSTRY","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05506462","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05506462"},{"nct_id":"NCT05506787","title":"The Effects of Intraoperative Esketamine on Postoperative Pain and Mood in Patients With Inflammatory Bowel Disease","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":120,"start_date":"2020-09-01","completion_date":"2022-02-01","last_update":"2023-04-04","substances":"ketamine","conditions":"Crohn Disease; Depression; Esketamine","sponsor":"Jinling Hospital, China","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05506787","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05506787"},{"nct_id":"NCT05506982","title":"Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":11,"start_date":"2022-11-01","completion_date":"2024-04-25","last_update":"2025-07-23","substances":"psilocybin","conditions":"Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm","sponsor":"Emory University","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"United States","us_states":"Georgia","lsd_com_url":"https://lsd.com/trials/nct05506982","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05506982"},{"nct_id":"NCT05522673","title":"[11C]-(R)-Rolipram to Measure cAMP Signaling Before and After Ketamine","acronym":"","status":"TERMINATED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":1,"start_date":"2023-02-08","completion_date":"2023-02-08","last_update":"2024-03-05","substances":"ketamine","conditions":"Depression","sponsor":"National Institute of Mental Health (NIMH)","sponsor_class":"NIH","has_results":true,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct05522673","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05522673"},{"nct_id":"NCT05523401","title":"Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects","acronym":"2C-B","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2023-08-16","completion_date":"2024-10-20","last_update":"2025-03-05","substances":"psilocybin; mdma","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05523401","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05523401"},{"nct_id":"NCT05530668","title":"Tolerance and Potential Synergistic Effect of the Combination of Intranasal Esketamine and Non-selective MAOI","acronym":"ESKETAM","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":13,"start_date":"2022-04-11","completion_date":"2022-09-11","last_update":"2023-11-13","substances":"ketamine","conditions":"Depression Anxiety Disorder","sponsor":"University Hospital, Strasbourg, France","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"France","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05530668","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05530668"},{"nct_id":"NCT05546658","title":"Effects of Psilocybin in Obsessive Compulsive Disorder","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":35,"start_date":"2022-11-28","completion_date":"2026-12-30","last_update":"2026-09-04","substances":"psilocybin","conditions":"Obsessive-Compulsive Disorder","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct05546658","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05546658"},{"nct_id":"NCT05548075","title":"Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action","acronym":"Psilopain","status":"UNKNOWN","phases":"","study_type":"OBSERVATIONAL","enrollment":20,"start_date":"2022-08-15","completion_date":"2024-01-10","last_update":"2024-01-19","substances":"psilocybin","conditions":"Fibromyalgia","sponsor":"Imperial College London","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05548075","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05548075"},{"nct_id":"NCT05553691","title":"SPL026 With or Without SSRIs in Participants With MDD","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":18,"start_date":"2022-12-13","completion_date":"2023-08-03","last_update":"2024-06-14","substances":"dmt","conditions":"Major Depressive Disorder","sponsor":"Small Pharma Ltd","sponsor_class":"INDUSTRY","has_results":false,"site_count":2,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05553691","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05553691"},{"nct_id":"NCT05554094","title":"Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":15,"start_date":"2023-01-01","completion_date":"2025-12-31","last_update":"2026-03-04","substances":"psilocybin","conditions":"PTSD; Stress Disorders, Traumatic; Stress Disorders, Post-Traumatic; Trauma and Stressor Related Disorders; Mental Disorder","sponsor":"Ohio State University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Ohio","lsd_com_url":"https://lsd.com/trials/nct05554094","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05554094"},{"nct_id":"NCT05554627","title":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","acronym":"VAST-D II","status":"WITHDRAWN","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2023-10-27","completion_date":"2023-10-27","last_update":"2024-01-05","substances":"ketamine","conditions":"Depressive Disorder, Major","sponsor":"VA Office of Research and Development","sponsor_class":"FED","has_results":false,"site_count":26,"countries":"United States","us_states":"Alabama; Arizona; Arkansas; California; Colorado; Connecticut; Georgia; Illinois; Indiana; Massachusetts; Minnesota; Missouri; New Mexico; North Carolina; Ohio; Oklahoma; Pennsylvania; Texas; Virginia; Wisconsin","lsd_com_url":"https://lsd.com/trials/nct05554627","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05554627"},{"nct_id":"NCT05557643","title":"PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout","acronym":"PAPR","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2023-01-02","completion_date":"2024-09-20","last_update":"2024-11-12","substances":"psilocybin","conditions":"Depression; Burnout, Professional","sponsor":"University of Utah","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Utah","lsd_com_url":"https://lsd.com/trials/nct05557643","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05557643"},{"nct_id":"NCT05559931","title":"Single and Repeat Doses of DMT in Healthy Subjects","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2023-01-13","completion_date":"2026-03","last_update":"2025-01-28","substances":"dmt","conditions":"Stroke","sponsor":"Algernon Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"Netherlands","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05559931","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05559931"},{"nct_id":"NCT05562973","title":"Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder","acronym":"","status":"WITHDRAWN","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2025-01","completion_date":"2025-12","last_update":"2024-01-05","substances":"psilocybin","conditions":"Post-Traumatic Stress Disorder","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05562973","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05562973"},{"nct_id":"NCT05565352","title":"Ketamine Safety and Tolerability in Psychiatric Inpatient Care (KetGD)","acronym":"KetGD","status":"ENROLLING_BY_INVITATION","phases":"","study_type":"OBSERVATIONAL","enrollment":140,"start_date":"2022-09-01","completion_date":"2029-12-31","last_update":"2025-04-02","substances":"ketamine","conditions":"Major Depressive Disorder; Post Traumatic Stress Disorder; Obsessive-Compulsive Disorder; Somatoform Disorders; Anxiety Disorders; Dissociative Disorder","sponsor":"Medical University of Gdansk","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Poland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05565352","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05565352"},{"nct_id":"NCT05570708","title":"The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training","acronym":"TherPsySE","status":"ENROLLING_BY_INVITATION","phases":"NA","study_type":"INTERVENTIONAL","enrollment":48,"start_date":"2022-10-25","completion_date":"2029-06-01","last_update":"2025-04-14","substances":"lsd; psilocybin; mdma","conditions":"Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD","sponsor":"Felix Mueller","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05570708","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05570708"},{"nct_id":"NCT05573568","title":"Clinical Study of DMT in Healthy Adults","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":27,"start_date":"2022-06-01","completion_date":"2022-11-01","last_update":"2023-02-15","substances":"dmt","conditions":"Healthy Volunteers","sponsor":"Biomind Labs Inc.","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"Brazil","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05573568","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05573568"},{"nct_id":"NCT05577247","title":"Belief Updating in Treatment Resistant Depression","acronym":"KETABELIEF","status":"RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":60,"start_date":"2024-05-13","completion_date":"2026-12-13","last_update":"2026-04-13","substances":"ketamine","conditions":"Treatment Resistant Depression","sponsor":"Assistance Publique - Hôpitaux de Paris","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"France","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05577247","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05577247"},{"nct_id":"NCT05577585","title":"Ketamine in OCD: Efficacy and Effects on Stress and Cognition","acronym":"KET-OCD","status":"RECRUITING","phases":"NA","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2022-10-01","completion_date":"2026-06","last_update":"2025-06-25","substances":"ketamine","conditions":"Obsessive-Compulsive Disorder; Psychiatric Disorder","sponsor":"Medical University of Vienna","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Austria","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05577585","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05577585"},{"nct_id":"NCT05581797","title":"Psilocybin-assisted Interpersonal Therapy for Depression","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":5,"start_date":"2023-03-15","completion_date":"2024-05-06","last_update":"2025-04-09","substances":"psilocybin","conditions":"Depressive Disorder, Treatment-Resistant","sponsor":"University of Otago","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"New Zealand","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05581797","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05581797"},{"nct_id":"NCT05584826","title":"MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2022-10-06","completion_date":"2026-10","last_update":"2026-05-04","substances":"mdma","conditions":"Cancer; Adjustment Disorders","sponsor":"Sunstone Medical","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct05584826","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05584826"},{"nct_id":"NCT05585229","title":"Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2025-10-27","completion_date":"2026-08-31","last_update":"2025-12-04","substances":"psilocybin","conditions":"Opioid Dependence; Chronic Pain","sponsor":"University of British Columbia","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05585229","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05585229"},{"nct_id":"NCT05591105","title":"The Postoperative Lidocaine and Ketamine Effects on Morphine Requirement in Bariatric Surgery","acronym":"","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":64,"start_date":"2023-06-15","completion_date":"2023-12-30","last_update":"2024-07-03","substances":"ketamine","conditions":"Pharmacological Action; Post Operative Pain; Opioid Use; Obesity, Morbid; Anesthesia Morbidity","sponsor":"Tiva Group","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Spain","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05591105","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05591105"},{"nct_id":"NCT05592379","title":"Consciousness, Psilocybin, and Well-Being","acronym":"CoPE Pilot","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":6,"start_date":"2023-11-07","completion_date":"2025-02-19","last_update":"2025-05-16","substances":"psilocybin","conditions":"Healthy; Psychedelic Experiences; Sleep","sponsor":"University of Wisconsin, Madison","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Wisconsin","lsd_com_url":"https://lsd.com/trials/nct05592379","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05592379"},{"nct_id":"NCT05594667","title":"Effect of SSRIs on Response to Psilocybin Therapy","acronym":"","status":"WITHDRAWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2023-01-01","completion_date":"2023-03-14","last_update":"2023-07-06","substances":"psilocybin","conditions":"Depression; Major Depressive Disorder; Mild Depression; Moderate Depression; Depressive Disorder","sponsor":"Cybin Therapeutics Inc.","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05594667","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05594667"},{"nct_id":"NCT05597878","title":"Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy","acronym":"","status":"TERMINATED","phases":"PHASE2; PHASE3","study_type":"INTERVENTIONAL","enrollment":58,"start_date":"2023-04-18","completion_date":"2026-02-26","last_update":"2026-06-15","substances":"ketamine","conditions":"Pain Management; Opioid Use; Prostate Cancer","sponsor":"Wake Forest University Health Sciences","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"North Carolina","lsd_com_url":"https://lsd.com/trials/nct05597878","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05597878"},{"nct_id":"NCT05601648","title":"PET Synaptogenesis After Psilocybin In DEpression Recovery","acronym":"PET-SPIDER","status":"WITHDRAWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2023-07-01","completion_date":"2025-01-01","last_update":"2023-01-30","substances":"psilocybin","conditions":"Major Depressive Disorder; Anhedonia","sponsor":"Washington University School of Medicine","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Missouri","lsd_com_url":"https://lsd.com/trials/nct05601648","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05601648"},{"nct_id":"NCT05603104","title":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","acronym":"INTENSIFY","status":"RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":1254,"start_date":"2025-04-27","completion_date":"2028-06-30","last_update":"2026-01-22","substances":"ketamine","conditions":"Schizophrenia and Related Disorders; Major Depressive Disorder; Bipolar Depression","sponsor":"Dr. Inge Winter","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Israel","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05603104","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05603104"},{"nct_id":"NCT05604794","title":"A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":1806,"start_date":"2020-03-13","completion_date":"2022-06-16","last_update":"2024-03-20","substances":"ketamine","conditions":"Depression; Anxiety; Post Traumatic Stress Disorder","sponsor":"Field Trip Health","sponsor_class":"INDUSTRY","has_results":true,"site_count":11,"countries":"Canada; United States","us_states":"California; District of Columbia; Georgia; Illinois; New York; Texas; Washington","lsd_com_url":"https://lsd.com/trials/nct05604794","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05604794"},{"nct_id":"NCT05615948","title":"Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":15,"start_date":"2022-12-06","completion_date":"2024-05-17","last_update":"2026-04-21","substances":"ketamine","conditions":"Treatment Resistant Depression; Major Depressive Disorder; Analgesia; Ketamine; Peripheral Nervous System Agents; Central Nervous System Depressants; Neurotransmitter Agents; Anti-Inflammatory Agents; Physiological Effects of Drugs; Sensory System Agents; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Depressive Symptoms","sponsor":"Theresa Jacob, PhD, MPH","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct05615948","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05615948"},{"nct_id":"NCT05624268","title":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","acronym":"","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":258,"start_date":"2023-01-24","completion_date":"2025-05-28","last_update":"2026-08-10","substances":"psilocybin","conditions":"Treatment Resistant Depression","sponsor":"COMPASS Pathways","sponsor_class":"INDUSTRY","has_results":false,"site_count":40,"countries":"United States","us_states":"Arizona; California; Connecticut; Florida; Georgia; Illinois; Maryland; Massachusetts; Minnesota; Missouri; Nebraska; New Jersey; New York; Ohio; Oklahoma; Pennsylvania; Texas; Utah; Washington","lsd_com_url":"https://lsd.com/trials/nct05624268","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05624268"},{"nct_id":"NCT05625555","title":"Predictors of Intravenous Ketamine Response in TRD","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2024-01-19","completion_date":"2026-07","last_update":"2026-05-22","substances":"ketamine","conditions":"Treatment Resistant Depression; Major Depressive Disorder; Bipolar Disorder","sponsor":"Abraham Nunes","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05625555","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05625555"},{"nct_id":"NCT05644093","title":"IM and IV SPL026 Drug Product in Healthy Participants","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":14,"start_date":"2023-01-03","completion_date":"2023-04-05","last_update":"2024-03-22","substances":"dmt","conditions":"Major Depressive Disorder","sponsor":"Small Pharma Ltd","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05644093","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05644093"},{"nct_id":"NCT05646303","title":"Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)","acronym":"","status":"UNKNOWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":128,"start_date":"2022-05-02","completion_date":"2024-08-31","last_update":"2024-08-15","substances":"psilocybin","conditions":"Alcohol Use Disorder","sponsor":"Clairvoyant Therapeutics","sponsor_class":"INDUSTRY","has_results":false,"site_count":12,"countries":"Canada; Finland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05646303","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05646303"},{"nct_id":"NCT05651126","title":"Psilocybin in Adults With and Without Autism Spectrum Disorder","acronym":"PSILAUT","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":67,"start_date":"2022-12-12","completion_date":"2024-08-23","last_update":"2025-07-28","substances":"psilocybin","conditions":"Autism Spectrum Disorder","sponsor":"King's College London","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05651126","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05651126"},{"nct_id":"NCT05655754","title":"Comparison of Esketamine/Propofol and Methohexital Anesthesia for ECT","acronym":"Ketofol","status":"RECRUITING","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":100,"start_date":"2022-11-01","completion_date":"2025-10-31","last_update":"2025-05-08","substances":"ketamine","conditions":"ECT; Depression","sponsor":"Medical University of Vienna","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Austria","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05655754","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05655754"},{"nct_id":"NCT05661669","title":"Ketamine for the Treatment for Alcohol Use Disorder in the ED","acronym":"","status":"WITHDRAWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2023-09-01","completion_date":"2024-08-19","last_update":"2025-01-08","substances":"ketamine","conditions":"Alcohol Use Disorder","sponsor":"Brigham and Women's Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct05661669","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05661669"},{"nct_id":"NCT05670184","title":"The Effect of LSD on Neural Synchrony, Prosocial Behavior, and Relationship Quality","acronym":"","status":"UNKNOWN","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2023-01-01","completion_date":"2024-01-01","last_update":"2023-01-04","substances":"lsd","conditions":"Prosocial Behavior","sponsor":"Maastricht University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Netherlands","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05670184","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05670184"},{"nct_id":"NCT05674669","title":"A Dose-Ranging Study of 50 µg to 100 µg LSD in Healthy Volunteers","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":32,"start_date":"2015-10-20","completion_date":"2016-07-26","last_update":"2023-01-06","substances":"lsd","conditions":"Healthy","sponsor":"Eleusis Therapeutics","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05674669","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05674669"},{"nct_id":"NCT05675800","title":"Psilocybin for Major Depressive Disorder","acronym":"","status":"WITHDRAWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2024-01-01","completion_date":"2025-01-01","last_update":"2024-07-25","substances":"psilocybin","conditions":"Major Depressive Disorder","sponsor":"Washington University School of Medicine","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05675800","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05675800"},{"nct_id":"NCT05695495","title":"Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study)","acronym":"DMT BDR","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":36,"start_date":"2024-06-12","completion_date":"2025-02-02","last_update":"2025-04-11","substances":"dmt","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05695495","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05695495"},{"nct_id":"NCT05696691","title":"Ketamine & Crisis Response Plan for Suicidal Ideation in the ED","acronym":"","status":"RECRUITING","phases":"PHASE2; PHASE3","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2023-01-06","completion_date":"2026-12-31","last_update":"2026-09-30","substances":"ketamine","conditions":"Suicide","sponsor":"The University of Texas Health Science Center at San Antonio","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct05696691","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05696691"},{"nct_id":"NCT05698095","title":"Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":54,"start_date":"2022-12-27","completion_date":"2023-09-07","last_update":"2023-11-30","substances":"dmt","conditions":"Pharmacokinetics; Safety; Tolerability","sponsor":"Usona Institute","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Kansas","lsd_com_url":"https://lsd.com/trials/nct05698095","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05698095"},{"nct_id":"NCT05698394","title":"Effect of Low-dose Esketamine on Maternal Depression at 3 Years After Childbirth","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":364,"start_date":"2023-09-09","completion_date":"2025-10","last_update":"2024-12-05","substances":"ketamine","conditions":"Prenatal Depression; Ketamine; Postpartum Depression","sponsor":"Peking University First Hospital","sponsor_class":"OTHER","has_results":false,"site_count":4,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05698394","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05698394"},{"nct_id":"NCT05698511","title":"Neural and Physiological Correlates of Psychedelic Sub-states","acronym":"i2","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2023-07-31","completion_date":"2026-01-30","last_update":"2026-06-05","substances":"psilocybin","conditions":"Psychedelic Experiences; Neuroimaging; Healthy Volunteers","sponsor":"Robin Carhart-Harris, PhD, MA","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct05698511","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05698511"},{"nct_id":"NCT05705037","title":"MIH and Hypersensitivity in Children","acronym":"","status":"UNKNOWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":39,"start_date":"2022-01-10","completion_date":"2023-02-10","last_update":"2023-01-30","substances":"dmt","conditions":"Dentin Sensitivity; Molar Incisor Hypomineralization","sponsor":"Università degli Studi di Brescia","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Italy","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05705037","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05705037"},{"nct_id":"NCT05709353","title":"MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder","acronym":"MPATHY","status":"UNKNOWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":120,"start_date":"2023-09-19","completion_date":"2026-05","last_update":"2023-11-07","substances":"mdma","conditions":"PTSD; Alcohol Use Disorder; Alcohol Dependence; Post-traumatic Stress Disorder; Comorbidities and Coexisting Conditions","sponsor":"University of Sydney","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"Australia","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05709353","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05709353"},{"nct_id":"NCT05710237","title":"Does Psilocybin Require Psychedelic Effects to Treat Depression?","acronym":"PSI-RIS","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":41,"start_date":"2023-07-01","completion_date":"2026-04-14","last_update":"2026-05-07","substances":"psilocybin","conditions":"Treatment-resistant Depression","sponsor":"Centre for Addiction and Mental Health","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05710237","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05710237"},{"nct_id":"NCT05711940","title":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":572,"start_date":"2023-02-14","completion_date":"2025-11-13","last_update":"2026-08-10","substances":"psilocybin","conditions":"Treatment Resistant Depression","sponsor":"COMPASS Pathways","sponsor_class":"INDUSTRY","has_results":false,"site_count":116,"countries":"Canada; Czechia; Denmark; France; Germany; Ireland; Netherlands; Poland; Spain; Sweden; United Kingdom; United States","us_states":"Arizona; California; Florida; Georgia; Illinois; Massachusetts; Michigan; Minnesota; Missouri; Nebraska; New Jersey; New York; Ohio; Pennsylvania; Texas; Utah; Washington","lsd_com_url":"https://lsd.com/trials/nct05711940","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05711940"},{"nct_id":"NCT05716802","title":"Dance/Movement Therapy for Bone Mineral Density in Schizophrenia","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2020-07-07","completion_date":"2022-01-12","last_update":"2024-03-08","substances":"dmt","conditions":"Schizophrenia","sponsor":"Hebei Province Veterans Hospital","sponsor_class":"OTHER_GOV","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05716802","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05716802"},{"nct_id":"NCT05719909","title":"Testing the Effectiveness of Cognitive Training Among Depressed Patients Receiving Esketamine Treatment","acronym":"","status":"SUSPENDED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2023-02-14","completion_date":"2028-02-28","last_update":"2026-01-13","substances":"ketamine","conditions":"Depression","sponsor":"University of Pittsburgh","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Pennsylvania","lsd_com_url":"https://lsd.com/trials/nct05719909","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05719909"},{"nct_id":"NCT05723276","title":"Psilocybin in Functional Neurological Disorder","acronym":"PsiFUND","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2024-02-14","completion_date":"2026-04-14","last_update":"2026-07-23","substances":"psilocybin","conditions":"Functional Neurological Disorder","sponsor":"King's College London","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05723276","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05723276"},{"nct_id":"NCT05732155","title":"Preliminary Effectiveness of Individual and Group MDMA-assisted Therapy for Israeli Veterans With PTSD and Moral Injury.","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2023-06-01","completion_date":"2027-06-01","last_update":"2026-07-08","substances":"mdma","conditions":"Post Traumatic Stress Disorder; Moral Injury; MDMA ('Ecstasy')","sponsor":"HaEmek Medical Center, Israel","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Israel","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05732155","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05732155"},{"nct_id":"NCT05733546","title":"A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":102,"start_date":"2023-01-30","completion_date":"2025-09","last_update":"2025-08-19","substances":"psilocybin","conditions":"Major Depressive Disorder","sponsor":"COMPASS Pathways","sponsor_class":"INDUSTRY","has_results":false,"site_count":5,"countries":"United States","us_states":"California; Florida; Maryland; Massachusetts; Texas","lsd_com_url":"https://lsd.com/trials/nct05733546","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05733546"},{"nct_id":"NCT05737693","title":"Enhancing Week-long Psychological Treatment for PTSD With Ketamine","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":350,"start_date":"2023-08-21","completion_date":"2030-08-01","last_update":"2026-08-24","substances":"ketamine","conditions":"Posttraumatic Stress Disorder","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"Israel; United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct05737693","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05737693"},{"nct_id":"NCT05746572","title":"MDMA Plus Exposure Therapy for PTSD","acronym":"","status":"ENROLLING_BY_INVITATION","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2024-02-13","completion_date":"2026-10-31","last_update":"2026-07-08","substances":"mdma","conditions":"PTSD","sponsor":"Emory University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Georgia","lsd_com_url":"https://lsd.com/trials/nct05746572","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05746572"},{"nct_id":"NCT05752799","title":"Evaluation of the Stress Response in Bariatric Surgery With and Without the Use of Opioids","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"NA","study_type":"INTERVENTIONAL","enrollment":70,"start_date":"2023-01-01","completion_date":"2026-07-01","last_update":"2026-08-03","substances":"ketamine","conditions":"Opioid Use, Unspecified; Bariatric Surgery Candidate","sponsor":"G.Gennimatas General Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Greece","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05752799","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05752799"},{"nct_id":"NCT05753956","title":"Safety and Pharmacokinetics of GH002 in Healthy Volunteers","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":64,"start_date":"2022-12-22","completion_date":"2023-11-29","last_update":"2024-01-25","substances":"dmt","conditions":"Healthy Volunteers","sponsor":"GH Research Ireland Limited","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"Netherlands","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05753956","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05753956"},{"nct_id":"NCT05770375","title":"Tolerability of MDMA in Schizophrenia","acronym":"TMS","status":"RECRUITING","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2024-09-01","completion_date":"2027-03-01","last_update":"2026-07-17","substances":"mdma","conditions":"Schizophrenia","sponsor":"Anya Bershad, MD, PhD","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct05770375","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05770375"},{"nct_id":"NCT05780216","title":"Mindfulness and Psychedelics","acronym":"","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2023-02-20","completion_date":"2023-08-05","last_update":"2023-09-21","substances":"dmt","conditions":"Healthy Participants","sponsor":"Milan Scheidegger","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05780216","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05780216"},{"nct_id":"NCT05783817","title":"MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)","acronym":"MDMA-CBT4OCD","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2025-09-10","completion_date":"2026-12-01","last_update":"2026-03-05","substances":"mdma","conditions":"Obsessive-Compulsive Disorder","sponsor":"Carolyn Rodriguez","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct05783817","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05783817"},{"nct_id":"NCT05786066","title":"The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2023-04-03","completion_date":"2033-03","last_update":"2026-05-06","substances":"ketamine","conditions":"Depressive Disorder; Major Depressive Disorder; Bipolar Disorder; Post Traumatic Stress Disorder; Suicidal Ideation","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct05786066","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05786066"},{"nct_id":"NCT05790239","title":"MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2025-03-01","completion_date":"2028-03","last_update":"2026-08-19","substances":"mdma","conditions":"Post Traumatic Stress Disorder","sponsor":"Stephen Robert Marder","sponsor_class":"FED","has_results":false,"site_count":2,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct05790239","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05790239"},{"nct_id":"NCT05796791","title":"Ketamine and Motivational Enhancement Therapy for the Treatment of Tobacco Use Disorder","acronym":"","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":7,"start_date":"2023-05-02","completion_date":"2024-06-30","last_update":"2025-07-18","substances":"ketamine","conditions":"Tobacco Use; Smoking Cessation; Nicotine Dependence","sponsor":"Medical University of South Carolina","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"South Carolina","lsd_com_url":"https://lsd.com/trials/nct05796791","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05796791"},{"nct_id":"NCT05800860","title":"A Trial of GH001 in Patients With Treatment-resistant Depression","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":81,"start_date":"2023-05-24","completion_date":"2024-10-04","last_update":"2025-05-31","substances":"dmt","conditions":"Treatment-resistant Depression","sponsor":"GH Research Ireland Limited","sponsor_class":"INDUSTRY","has_results":false,"site_count":11,"countries":"Czechia; Germany; Ireland; Netherlands; Poland; Spain","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05800860","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05800860"},{"nct_id":"NCT05803551","title":"A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients","acronym":"","status":"TERMINATED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":1,"start_date":"2025-07-07","completion_date":"2026-07-01","last_update":"2026-08-12","substances":"ketamine","conditions":"Depression","sponsor":"Mayo Clinic","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Florida","lsd_com_url":"https://lsd.com/trials/nct05803551","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05803551"},{"nct_id":"NCT05804708","title":"Phase 2 Clinical Trial of GH001 in Postpartum Depression","acronym":"","status":"TERMINATED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2023-03-02","completion_date":"2024-08-02","last_update":"2025-02-18","substances":"dmt","conditions":"Postpartum Depression; Postnatal Depression","sponsor":"GH Research Ireland Limited","sponsor_class":"INDUSTRY","has_results":false,"site_count":4,"countries":"Netherlands; United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05804708","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05804708"},{"nct_id":"NCT05809271","title":"Acute Effects of 3,4-methylenedioxymethamphetamine (MDMA) With and Without a Booster Dose","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":25,"start_date":"2023-11-17","completion_date":"2025-03-07","last_update":"2025-03-19","substances":"mdma","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05809271","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05809271"},{"nct_id":"NCT05809609","title":"Glutamate Emotion Memory Study","acronym":"GEMS","status":"UNKNOWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2022-07-01","completion_date":"2024-11-28","last_update":"2024-05-21","substances":"ketamine","conditions":"Treatment Resistant Depression; Depression; Major Depressive Disorder","sponsor":"University of Oxford","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05809609","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05809609"},{"nct_id":"NCT05826327","title":"Effects of Epidural Labor Analgesia With Esketamine on the Incidence of Postpartum Depression in Parturients","acronym":"","status":"UNKNOWN","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":364,"start_date":"2023-05-01","completion_date":"2025-06-30","last_update":"2024-08-20","substances":"ketamine","conditions":"Postpartum Depression","sponsor":"Women's Hospital School Of Medicine Zhejiang University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05826327","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05826327"},{"nct_id":"NCT05829603","title":"Dose-finding Study for the Combination of DMT and Harmine in Healthy Subjects","acronym":"DHTP","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2023-05-05","completion_date":"2023-09-17","last_update":"2023-11-02","substances":"dmt","conditions":"Healthy","sponsor":"Reconnect Labs","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05829603","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05829603"},{"nct_id":"NCT05832255","title":"An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome","acronym":"","status":"SUSPENDED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2023-03-28","completion_date":"2024-05","last_update":"2024-05-08","substances":"psilocybin","conditions":"Fragile X Syndrome; Behavior; Cognitive Dysfunction","sponsor":"Nova Mentis Life Science Corp","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05832255","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05832255"},{"nct_id":"NCT05837845","title":"MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2025-02-10","completion_date":"2027-05","last_update":"2025-07-31","substances":"mdma","conditions":"PTSD","sponsor":"Patricia Suppes","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct05837845","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05837845"},{"nct_id":"NCT05839509","title":"Phase 2 Clinical Trial of GH001 in Bipolar II Disorder","acronym":"","status":"TERMINATED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":6,"start_date":"2023-04-06","completion_date":"2024-11-13","last_update":"2025-02-18","substances":"dmt","conditions":"Bipolar II Disorder","sponsor":"GH Research Ireland Limited","sponsor_class":"INDUSTRY","has_results":false,"site_count":7,"countries":"Germany; Netherlands; United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05839509","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05839509"},{"nct_id":"NCT05847686","title":"Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer","acronym":"","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":55,"start_date":"2023-06-27","completion_date":"2024-04-08","last_update":"2025-11-05","substances":"psilocybin","conditions":"Hematopoietic and Lymphatic System Neoplasm; Metastatic Malignant Solid Neoplasm","sponsor":"University of Washington","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Washington","lsd_com_url":"https://lsd.com/trials/nct05847686","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05847686"},{"nct_id":"NCT05855876","title":"Reversal of Battle-Related Aging (ROBRA) in a Special Operations Forces Cohort","acronym":"","status":"UNKNOWN","phases":"","study_type":"OBSERVATIONAL","enrollment":20,"start_date":"2023-07-05","completion_date":"2024-04-05","last_update":"2023-07-17","substances":"ketamine","conditions":"Post-Traumatic Stress Disorder; Traumatic Brain Injury","sponsor":"Stella Center","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Illinois","lsd_com_url":"https://lsd.com/trials/nct05855876","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05855876"},{"nct_id":"NCT05866471","title":"The ENHANCE Study: taVNS and Psilocybin","acronym":"ENHANCE","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":108,"start_date":"2025-01-27","completion_date":"2027-11","last_update":"2026-07-29","substances":"psilocybin","conditions":"Healthy; Psychedelic Experiences; Vagus Nerve Stimulation","sponsor":"University of Wisconsin, Madison","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Wisconsin","lsd_com_url":"https://lsd.com/trials/nct05866471","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05866471"},{"nct_id":"NCT05870501","title":"Synaptic Imaging and Network Activity in Treatment Resistant Depression","acronym":"SIGNATURE","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":56,"start_date":"2021-10-20","completion_date":"2023-09-13","last_update":"2024-11-18","substances":"ketamine","conditions":"Depressive Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Bipolar Disorder; Bipolar Disorder I; Bipolar Disorder II; Mood Disorders; Anhedonia","sponsor":"King's College London","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05870501","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05870501"},{"nct_id":"NCT05876481","title":"Evaluation of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military Veterans","acronym":"","status":"UNKNOWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":8,"start_date":"2023-06","completion_date":"2025-07","last_update":"2023-05-25","substances":"psilocybin","conditions":"PTSD","sponsor":"Combat Stress","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05876481","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05876481"},{"nct_id":"NCT05883540","title":"Lysergic Acid Diethylamide (LSD) in Palliative Care","acronym":"LPC","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2024-06-09","completion_date":"2027-09","last_update":"2026-04-29","substances":"lsd","conditions":"Palliative Care; Pain; Anxiety; Depression; Demoralization; Psychological Distress; Quality of Life; Caregiver Burden; Fear of Death; Existential Distress","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":4,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05883540","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05883540"},{"nct_id":"NCT05887310","title":"In Vitro Modeling of Drug-resistant Psychiatric Disorders Using Induced Pluripotent Cells","acronym":"","status":"UNKNOWN","phases":"","study_type":"OBSERVATIONAL","enrollment":50,"start_date":"2022-08-05","completion_date":"2024-08-05","last_update":"2023-06-02","substances":"ketamine","conditions":"Depressive Disorder, Treatment-Resistant","sponsor":"University of Milano Bicocca","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Italy","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05887310","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05887310"},{"nct_id":"NCT05894902","title":"Open-Label Dose-Ranging Study of Oral SM-001 in Healthy Adults","acronym":"","status":"UNKNOWN","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2023-10-01","completion_date":"2024-04-30","last_update":"2023-07-07","substances":"dmt","conditions":"Major Depression; Post Traumatic Stress Disorder","sponsor":"Advanced Integrative Medical Science Institute","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Washington","lsd_com_url":"https://lsd.com/trials/nct05894902","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05894902"},{"nct_id":"NCT05895318","title":"Perceptions of MDMA-Assisted Therapy Among Veterans With PTSD","acronym":"PMATAVP","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":30,"start_date":"2022-08-08","completion_date":"2023-03-23","last_update":"2023-06-22","substances":"mdma","conditions":"Post Traumatic Stress Disorder","sponsor":"Albany Research Institute, Inc.","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct05895318","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05895318"},{"nct_id":"NCT05901012","title":"Safety and Tolerability of DMT in Healthy Adults","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":25,"start_date":"2023-04-26","completion_date":"2023-07-17","last_update":"2023-10-11","substances":"dmt","conditions":"Safety Issues; Healthy Volunteers","sponsor":"Universidade Federal do Rio Grande do Norte","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Brazil","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05901012","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05901012"},{"nct_id":"NCT05907213","title":"Ketamine Tolerated Dose for Postpartum Depression and Pain After Cesarean Delivery (PREPARE 1)","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2023-09-25","completion_date":"2024-06-26","last_update":"2025-09-12","substances":"ketamine","conditions":"Pain, Postoperative; Depression, Postpartum","sponsor":"Grace Lim, MD, MS","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Pennsylvania","lsd_com_url":"https://lsd.com/trials/nct05907213","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05907213"},{"nct_id":"NCT05910775","title":"Role Of Non-Specific Effects in The Treatment of Depression With Esketamine","acronym":"ROSETTE","status":"TERMINATED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":1,"start_date":"2024-07-13","completion_date":"2024-12-31","last_update":"2026-01-14","substances":"ketamine","conditions":"Depressive Episode","sponsor":"Yale University","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct05910775","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05910775"},{"nct_id":"NCT05915013","title":"Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response","acronym":"","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2023-09-07","completion_date":"2032-12","last_update":"2026-05-06","substances":"ketamine","conditions":"Depressive Disorder, Major; Post Traumatic Stress Disorder","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct05915013","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05915013"},{"nct_id":"NCT05925283","title":"Clinical Study of Oral Midazolam Combined With Esketamine Administered Intranasally for Pediatric Preoperative Sedation","acronym":"","status":"UNKNOWN","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":126,"start_date":"2023-06-30","completion_date":"2023-11-30","last_update":"2023-06-29","substances":"ketamine","conditions":"Anxiety","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05925283","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05925283"},{"nct_id":"NCT05933213","title":"Comparing Mescaline Sodium Enteric-coated Tablets vs Morte-mescaline in the Treatment of Adult Lupus Nephritis","acronym":"","status":"UNKNOWN","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":205,"start_date":"2023-07-06","completion_date":"2025-07","last_update":"2023-07-06","substances":"mescaline","conditions":"Lupus Nephritis","sponsor":"Xiangya Hospital of Central South University","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05933213","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05933213"},{"nct_id":"NCT05934669","title":"IN Midazolam vs IN Dexmedetomidine vs IN Ketamine During Minimal Procedures in Pediatric ED","acronym":"","status":"RECRUITING","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":90,"start_date":"2023-11-14","completion_date":"2025-05","last_update":"2024-06-28","substances":"ketamine","conditions":"Laceration of Skin; Anxiety; Discharge Time","sponsor":"University of Oklahoma","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Oklahoma","lsd_com_url":"https://lsd.com/trials/nct05934669","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05934669"},{"nct_id":"NCT05940324","title":"Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)","acronym":"MKET2","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":150,"start_date":"2024-02-24","completion_date":"2028-11","last_update":"2026-04-24","substances":"ketamine","conditions":"Obsessive-Compulsive Disorder","sponsor":"Stanford University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct05940324","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05940324"},{"nct_id":"NCT05943665","title":"MDMA for AUD/PTSD Comorbidity","acronym":"MDMA","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":22,"start_date":"2024-02-06","completion_date":"2026-01-21","last_update":"2026-09-11","substances":"mdma","conditions":"Alcohol Use Disorder; Post Traumatic Stress Disorder","sponsor":"Carolina L Haass-Koffler","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Rhode Island","lsd_com_url":"https://lsd.com/trials/nct05943665","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05943665"},{"nct_id":"NCT05947383","title":"Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer","acronym":"2Dose","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":56,"start_date":"2023-10-23","completion_date":"2027-04-30","last_update":"2026-05-06","substances":"psilocybin","conditions":"Cancer; Major Depressive Disorder","sponsor":"Sunstone Medical","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct05947383","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05947383"},{"nct_id":"NCT05948683","title":"Prosocial Effects of MDMA","acronym":"PEM","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":33,"start_date":"2023-07-21","completion_date":"2024-07-15","last_update":"2024-08-19","substances":"mdma","conditions":"MDMA ('Ecstasy'); Social Interaction","sponsor":"University of Chicago","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Illinois","lsd_com_url":"https://lsd.com/trials/nct05948683","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05948683"},{"nct_id":"NCT05948735","title":"An Intervention Integrating Physical Therapy Exercise and Dance Movement Therapy for Preventing Falls in Older Adults","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":61,"start_date":"2023-07-06","completion_date":"2025-01-06","last_update":"2025-03-19","substances":"dmt","conditions":"Older Adults","sponsor":"University of Haifa","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Israel","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05948735","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05948735"},{"nct_id":"NCT05950711","title":"Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot Study","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":21,"start_date":"2022-03-30","completion_date":"2026-11-30","last_update":"2025-08-11","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Ohio State University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Ohio","lsd_com_url":"https://lsd.com/trials/nct05950711","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05950711"},{"nct_id":"NCT05953038","title":"LSD Occupancy of the Serotonin 2A Receptor in the Human Brain","acronym":"dOccLS","status":"ACTIVE_NOT_RECRUITING","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2023-11-08","completion_date":"2027-12","last_update":"2026-07-02","substances":"lsd","conditions":"Basic Science","sponsor":"Copenhagen University Hospital, Rigshospitalet","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Denmark","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05953038","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05953038"},{"nct_id":"NCT05958758","title":"A Community of Practice Program With Psilocybin-assisted Therapy for End-of-Life Patients","acronym":"","status":"UNKNOWN","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":64,"start_date":"2023-09-01","completion_date":"2025-04-30","last_update":"2023-07-25","substances":"psilocybin","conditions":"End of Life","sponsor":"The Roots to Thrive Society for Psychedelic Therapy","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05958758","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05958758"},{"nct_id":"NCT05961527","title":"Group MDMA-therapy for Veterans With PTSD","acronym":"Group-MVP","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":23,"start_date":"2023-10-01","completion_date":"2025-03-14","last_update":"2025-06-12","substances":"mdma","conditions":"PTSD","sponsor":"Portland VA Research Foundation, Inc","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Washington","lsd_com_url":"https://lsd.com/trials/nct05961527","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05961527"},{"nct_id":"NCT05962424","title":"HNC: Human Neural Circuits Electrophysiology During Cognition","acronym":"","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":120,"start_date":"2023-10-05","completion_date":"2030-09-01","last_update":"2026-04-22","substances":"ketamine","conditions":"Psychiatric Disorder","sponsor":"Stanford University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct05962424","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05962424"},{"nct_id":"NCT05964647","title":"Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects","acronym":"LBL","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2024-02-01","completion_date":"2025-06-30","last_update":"2025-11-17","substances":"lsd","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05964647","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05964647"},{"nct_id":"NCT05973851","title":"The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.","acronym":"INTENSIFY MDD","status":"RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":418,"start_date":"2024-08-31","completion_date":"2028-06-30","last_update":"2025-09-26","substances":"ketamine","conditions":"Major Depressive Disorder; Treatment Resistant Depression","sponsor":"Dr. Inge Winter","sponsor_class":"OTHER","has_results":false,"site_count":12,"countries":"Austria; Germany; Greece; Italy; Spain; United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05973851","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05973851"},{"nct_id":"NCT05976698","title":"LSD-Perceptual-Choice-Study","acronym":"LUCY","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2024-02-26","completion_date":"2025-02-25","last_update":"2026-05-29","substances":"lsd","conditions":"LSD Reaction","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05976698","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05976698"},{"nct_id":"NCT05979844","title":"MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD","acronym":"MDMA-bCBCT","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2023-10-06","completion_date":"2025-11-14","last_update":"2025-12-08","substances":"mdma","conditions":"PTSD; Relational Problems","sponsor":"Dr. Leslie Morland","sponsor_class":"FED","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct05979844","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05979844"},{"nct_id":"NCT05985811","title":"Ketamine Enhances Analgesia and Mood in Chronic Pain Patients","acronym":"","status":"RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":500,"start_date":"2018-02-02","completion_date":"2025-12-31","last_update":"2025-01-27","substances":"ketamine","conditions":"Mood Disorder; Opioid; Mood Insomnia","sponsor":"Salem Anaesthesia Pain Clinic","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05985811","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05985811"},{"nct_id":"NCT05991232","title":"Repeated Neurocognitive Measurements in Depressed Patients","acronym":"","status":"WITHDRAWN","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2025-05-01","completion_date":"2028-04","last_update":"2026-02-25","substances":"ketamine","conditions":"Depression, Unipolar","sponsor":"Jay Fournier","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Ohio","lsd_com_url":"https://lsd.com/trials/nct05991232","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05991232"},{"nct_id":"NCT05995769","title":"Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder","acronym":"PAP-AUD","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":128,"start_date":"2024-03-20","completion_date":"2027-10-01","last_update":"2024-05-07","substances":"psilocybin","conditions":"Alcohol Use Disorder; Alcoholism","sponsor":"University of Calgary","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct05995769","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT05995769"},{"nct_id":"NCT06001372","title":"Ketamine-assisted Psychotherapy (KAP) for Patients With Existential Distress Associated With Non-operable GI Cancers","acronym":"TREK","status":"TERMINATED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":2,"start_date":"2023-10-13","completion_date":"2023-12-22","last_update":"2025-04-16","substances":"ketamine","conditions":"Gastrointestinal Cancer; Depression; Anxiety","sponsor":"University of Utah","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Utah","lsd_com_url":"https://lsd.com/trials/nct06001372","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06001372"},{"nct_id":"NCT06001749","title":"Psilocybin in Cancer Pain Study","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":15,"start_date":"2024-09-23","completion_date":"2026-10-01","last_update":"2026-08-05","substances":"psilocybin","conditions":"Opioid-Related Disorders; Pain Management; Pain Management and Care; Advanced Cancer; Advanced Cancers","sponsor":"Yvan Beaussant, MD, MSci","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct06001749","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06001749"},{"nct_id":"NCT06005662","title":"Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder","acronym":"BIPOD-In","status":"WITHDRAWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2027-04","completion_date":"2028-07","last_update":"2026-02-23","substances":"psilocybin","conditions":"Opioid Use Disorder","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct06005662","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06005662"},{"nct_id":"NCT06012916","title":"Brain Network Dynamics of Depression During Esketamine Treatment","acronym":"K-BRAINED","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":8,"start_date":"2023-07-03","completion_date":"2024-08-30","last_update":"2024-09-19","substances":"ketamine","conditions":"Depressive Disorder, Major","sponsor":"University of North Carolina, Chapel Hill","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"North Carolina","lsd_com_url":"https://lsd.com/trials/nct06012916","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06012916"},{"nct_id":"NCT06034821","title":"Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan","acronym":"REaKT-SD","status":"ENROLLING_BY_INVITATION","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":1500,"start_date":"2023-10-01","completion_date":"2030-10-01","last_update":"2025-12-15","substances":"ketamine","conditions":"Acute Suicidal Depression (ASD)","sponsor":"Brigham and Women's Hospital","sponsor_class":"OTHER","has_results":false,"site_count":10,"countries":"Canada; United States","us_states":"California; Maryland; Massachusetts; New York; Ohio; Pennsylvania; Texas; Utah","lsd_com_url":"https://lsd.com/trials/nct06034821","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06034821"},{"nct_id":"NCT06035900","title":"Evaluation of Safety, Rate and Extent of Absorption of Psilocin Mucate","acronym":"Psilocin-1","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2023-06-21","completion_date":"2023-07-30","last_update":"2023-09-13","substances":"psilocybin","conditions":"Side Effect of Drug","sponsor":"Lobe Sciences Ltd.","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"Jordan","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06035900","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06035900"},{"nct_id":"NCT06036511","title":"Connectivity Changes Associated With Ketamine Assisted Psychotherapy for PTSD","acronym":"CONCHKAP","status":"WITHDRAWN","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2023-12-31","completion_date":"2023-12-31","last_update":"2024-03-12","substances":"ketamine","conditions":"PTSD","sponsor":"University of New Mexico","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New Mexico","lsd_com_url":"https://lsd.com/trials/nct06036511","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06036511"},{"nct_id":"NCT06038409","title":"Ketamine Treatment Plans for Chronic Conditions","acronym":"","status":"RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":500,"start_date":"2023-01-01","completion_date":"2029-01-01","last_update":"2024-11-26","substances":"ketamine","conditions":"Chronic Pain; Depressive Disorder; Anxiety Disorders; Chronic Disease","sponsor":"RIVER Foundation","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Montana","lsd_com_url":"https://lsd.com/trials/nct06038409","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06038409"},{"nct_id":"NCT06041152","title":"Does Psilocybin Change Synaptic Density in Amnestic Mild Cognitive Impairment","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2023-11-27","completion_date":"2026-02-19","last_update":"2026-10-05","substances":"psilocybin","conditions":"Amnestic Mild Cognitive Impairment","sponsor":"Centre for Addiction and Mental Health","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06041152","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06041152"},{"nct_id":"NCT06044675","title":"MDMA-Assisted CBCT for PTSD vs CBCT RCT","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2024-11-15","completion_date":"2027-03-31","last_update":"2026-08-19","substances":"mdma","conditions":"Post Traumatic Stress Disorder","sponsor":"Remedy","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06044675","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06044675"},{"nct_id":"NCT06048263","title":"The Perinatal Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms. A Case Series","acronym":"SMILES","status":"WITHDRAWN","phases":"PHASE2; PHASE3","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2025-10-15","completion_date":"2025-10-15","last_update":"2025-10-29","substances":"ketamine","conditions":"Postpartum Depression","sponsor":"Washington University School of Medicine","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Missouri","lsd_com_url":"https://lsd.com/trials/nct06048263","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06048263"},{"nct_id":"NCT06051721","title":"A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":36,"start_date":"2024-05-10","completion_date":"2025-10-14","last_update":"2026-08-13","substances":"dmt","conditions":"Generalized Anxiety Disorder","sponsor":"Cybin IRL Limited","sponsor_class":"INDUSTRY","has_results":false,"site_count":6,"countries":"United States","us_states":"Florida; Georgia; Illinois; Utah","lsd_com_url":"https://lsd.com/trials/nct06051721","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06051721"},{"nct_id":"NCT06060210","title":"Impact of Ketamine On Depressive Symptoms In Patients Undergoing Lumbo-peritoneal Shunt Insertion","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":110,"start_date":"2023-10-29","completion_date":"2025-09-01","last_update":"2026-01-08","substances":"ketamine","conditions":"Depression, Anxiety","sponsor":"Benha University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Egypt","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06060210","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06060210"},{"nct_id":"NCT06066853","title":"MDMA-assisted Therapy for Fibromyalgia","acronym":"","status":"RECRUITING","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2026-09-15","completion_date":"2026-12","last_update":"2026-08-26","substances":"mdma","conditions":"Fibromyalgia","sponsor":"Spaulding Rehabilitation Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct06066853","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06066853"},{"nct_id":"NCT06067737","title":"Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder","acronym":"BIPOD-Out","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":90,"start_date":"2024-02-08","completion_date":"2028-07","last_update":"2026-07-17","substances":"psilocybin","conditions":"Opioid Use Disorder","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct06067737","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06067737"},{"nct_id":"NCT06069843","title":"Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":15,"start_date":"2024-11-01","completion_date":"2025-09","last_update":"2025-01-29","substances":"ketamine","conditions":"Depression; Mild Cognitive Impairment","sponsor":"Icahn School of Medicine at Mount Sinai","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct06069843","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06069843"},{"nct_id":"NCT06070649","title":"The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)","acronym":"","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":63,"start_date":"2025-08-04","completion_date":"2027-08-01","last_update":"2026-09-10","substances":"dmt","conditions":"Alcohol Use Disorder (AUD); Alcohol-Related Disorders; Alcohol Use","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct06070649","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06070649"},{"nct_id":"NCT06070766","title":"RIVER At Home Ketamine Protocols","acronym":"","status":"RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":50000,"start_date":"2023-10-01","completion_date":"2028-10-01","last_update":"2024-11-26","substances":"ketamine","conditions":"Chronic Condition; Chronic Pain; Chronic Disease; Major Depressive Disorder; Post Traumatic Stress Disorder; Anxiety Disorders","sponsor":"RIVER Foundation","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"United States","us_states":"Montana","lsd_com_url":"https://lsd.com/trials/nct06070766","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06070766"},{"nct_id":"NCT06072898","title":"A Randomized Neuroimaging Trial of Psilocybin in Depression","acronym":"EMBRACE","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2025-05-28","completion_date":"2028-05","last_update":"2026-03-30","substances":"psilocybin","conditions":"Depressive Disorder; Major Depressive Disorder","sponsor":"Sunnybrook Health Sciences Centre","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06072898","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06072898"},{"nct_id":"NCT06073015","title":"Effect of Esketamine on Reducing Postoperative Anxiety and Depression in Adolescent Patients","acronym":"","status":"UNKNOWN","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":200,"start_date":"2023-10-10","completion_date":"2024-12-10","last_update":"2023-10-10","substances":"ketamine","conditions":"Anxiety-depression","sponsor":"Henan Provincial People's Hospital","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06073015","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06073015"},{"nct_id":"NCT06077487","title":"Ketamine-assisted Therapy for Advanced GI Cancer","acronym":"","status":"TERMINATED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":1,"start_date":"2024-05-17","completion_date":"2025-01-31","last_update":"2025-05-21","substances":"ketamine","conditions":"Pancreatic Ductal Adenocarcinoma; Pain, Acute; Gastrointestinal Cancers; Demoralization","sponsor":"Brian Anderson, MD","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct06077487","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06077487"},{"nct_id":"NCT06081179","title":"Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":122,"start_date":"2023-10-24","completion_date":"2025-09-22","last_update":"2025-11-19","substances":"psilocybin; mdma","conditions":"Healthy","sponsor":"University of Zurich","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06081179","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06081179"},{"nct_id":"NCT06085937","title":"Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department","acronym":"","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2024-05-01","completion_date":"2026-04","last_update":"2026-04-15","substances":"ketamine","conditions":"Suicide; Suicidal Ideation; Depression","sponsor":"Lindsay Maguire, MD","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"United States","us_states":"Kansas","lsd_com_url":"https://lsd.com/trials/nct06085937","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06085937"},{"nct_id":"NCT06090422","title":"Ketamine for Combined Depression and Alcohol Use Disorder","acronym":"KeDA","status":"RECRUITING","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":34,"start_date":"2025-01-20","completion_date":"2027-07-01","last_update":"2026-06-23","substances":"ketamine","conditions":"Depression; Alcohol Use Disorder","sponsor":"University Hospital of North Norway","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Norway","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06090422","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06090422"},{"nct_id":"NCT06094907","title":"Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":14,"start_date":"2023-10-09","completion_date":"2024-01-15","last_update":"2024-05-08","substances":"dmt","conditions":"Depressive Disorder; Depression, Unipolar","sponsor":"Universidade Federal do Rio Grande do Norte","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Brazil","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06094907","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06094907"},{"nct_id":"NCT06102434","title":"Safety Profile of Psilocybin for Cocaine Use Disorder","acronym":"","status":"SUSPENDED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2029-02-01","completion_date":"2029-05","last_update":"2026-04-07","substances":"psilocybin","conditions":"Cocaine Use Disorder","sponsor":"University of California, Los Angeles","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct06102434","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06102434"},{"nct_id":"NCT06103760","title":"Positioning of Esketamine Treatment in the Real-world Management of Depression","acronym":"PoET","status":"RECRUITING","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":162,"start_date":"2023-10-31","completion_date":"2027-12-15","last_update":"2026-08-12","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Royal North Shore Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Australia","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06103760","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06103760"},{"nct_id":"NCT06111339","title":"Ketamine for OUD and Suicidal Ideation in the ED","acronym":"","status":"TERMINATED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":4,"start_date":"2024-06-14","completion_date":"2025-03-11","last_update":"2025-04-08","substances":"ketamine","conditions":"Opioid Use Disorder; Suicidal Ideation","sponsor":"Brigham and Women's Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct06111339","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06111339"},{"nct_id":"NCT06117306","title":"MDMA-assisted Massed Prolonged Exposure for PTSD","acronym":"MDMA-PE","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2024-10-25","completion_date":"2027-03","last_update":"2026-08-26","substances":"mdma","conditions":"Post-Traumatic Stress Disorder","sponsor":"Healing Breakthrough","sponsor_class":"UNKNOWN","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct06117306","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06117306"},{"nct_id":"NCT06132178","title":"Psilocybin rTMS for Treatment Resistant Depression","acronym":"PSILOBSD","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":100,"start_date":"2025-01-10","completion_date":"2029-12-31","last_update":"2025-11-26","substances":"psilocybin","conditions":"Treatment Resistant Depression; MDD; Major Depressive Disorder; Recurrent Depression; Depression","sponsor":"University of Texas at Austin","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct06132178","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06132178"},{"nct_id":"NCT06133309","title":"Phenomenological Explorations of the Esketamine-Induced Transient Dissociative State","acronym":"EXPEDIE","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":15,"start_date":"2024-03-19","completion_date":"2025-12-01","last_update":"2026-07-07","substances":"ketamine","conditions":"Depressive Disorder","sponsor":"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"France","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06133309","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06133309"},{"nct_id":"NCT06138691","title":"KET-RO Plus RO DBT for Treatment Resistant Depression","acronym":"KET-RO","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2023-10-04","completion_date":"2025-01-11","last_update":"2026-03-30","substances":"ketamine","conditions":"Treatment Resistant Depression","sponsor":"Washington University School of Medicine","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Missouri","lsd_com_url":"https://lsd.com/trials/nct06138691","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06138691"},{"nct_id":"NCT06139016","title":"Using Virtual Reality to Control the Audio-visual Inputs During Ketamine/Esketamine Treatment","acronym":"VR-KET","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":7,"start_date":"2024-07-11","completion_date":"2024-11-27","last_update":"2026-07-31","substances":"ketamine","conditions":"Depression","sponsor":"Yale University","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct06139016","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06139016"},{"nct_id":"NCT06140446","title":"Effect of eHealth on AB Use of Children With Acute, Uncomplicated URTIs","acronym":"","status":"UNKNOWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":411,"start_date":"2023-12","completion_date":"2024-05","last_update":"2023-11-21","substances":"dmt","conditions":"Upper Respiratory Tract Infection","sponsor":"Max Nieuwdorp","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Netherlands","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06140446","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06140446"},{"nct_id":"NCT06141876","title":"Evaluation of Psilocybin-Assisted Psychotherapy in Treating Severe Depression in Patients With PTSD","acronym":"SUMMIT-90","status":"UNKNOWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":160,"start_date":"2023-12-15","completion_date":"2025-06-15","last_update":"2023-11-29","substances":"psilocybin","conditions":"Post-traumatic Stress Disorder; Depression","sponsor":"Apex Labs Ltd.","sponsor_class":"INDUSTRY","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06141876","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06141876"},{"nct_id":"NCT06150859","title":"Ayahuasca Assisted Psychotherapy for Grief","acronym":"PSICODUELAYA","status":"UNKNOWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":84,"start_date":"2021-10-15","completion_date":"2024-04-15","last_update":"2023-12-11","substances":"dmt","conditions":"Bereavement","sponsor":"Beckley Med Foundation","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Spain","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06150859","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06150859"},{"nct_id":"NCT06160232","title":"Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder","acronym":"","status":"UNKNOWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":62,"start_date":"2024-02-15","completion_date":"2025-12-15","last_update":"2024-08-07","substances":"psilocybin","conditions":"Severe Alcohol Use Disorder","sponsor":"Brugmann University Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Belgium","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06160232","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06160232"},{"nct_id":"NCT06160284","title":"Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)","acronym":"","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2025-05-28","completion_date":"2027-01","last_update":"2026-07-07","substances":"psilocybin","conditions":"Opioid Use Disorder","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct06160284","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06160284"},{"nct_id":"NCT06164756","title":"Long Term Follow Up KET-PD","acronym":"","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":49,"start_date":"2023-10-18","completion_date":"2026-03-16","last_update":"2026-09-28","substances":"ketamine","conditions":"Parkinson's Disease; Depression","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct06164756","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06164756"},{"nct_id":"NCT06179485","title":"Effect of Ketamine and Etomidate During RSI on Long Term Outcomes","acronym":"RSI-LTO","status":"ENROLLING_BY_INVITATION","phases":"","study_type":"OBSERVATIONAL","enrollment":1756,"start_date":"2022-04-06","completion_date":"2027-01","last_update":"2026-08-20","substances":"ketamine","conditions":"Post-Traumatic Stress Disorder; Acute Respiratory Failure","sponsor":"Vanderbilt University Medical Center","sponsor_class":"OTHER","has_results":false,"site_count":6,"countries":"United States","us_states":"Alabama; Colorado; Minnesota; North Carolina; Tennessee","lsd_com_url":"https://lsd.com/trials/nct06179485","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06179485"},{"nct_id":"NCT06180759","title":"Acute Analgesic Effects of DMT on Experimentally Induced Pain in Healthy Participants","acronym":"DPS","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":17,"start_date":"2025-01-23","completion_date":"2025-09-29","last_update":"2026-04-02","substances":"dmt","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06180759","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06180759"},{"nct_id":"NCT06189027","title":"Epigenetics and MDMA-Assisted Psychotherapy for PTSD","acronym":"","status":"COMPLETED","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":45,"start_date":"2018-11-20","completion_date":"2023-11-01","last_update":"2026-05-04","substances":"mdma","conditions":"PTSD","sponsor":"University of Southern California","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct06189027","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06189027"},{"nct_id":"NCT06199011","title":"Effect of Esketamine on Depressive Symptoms of Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy","acronym":"EDSOP","status":"UNKNOWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":400,"start_date":"2024-01-01","completion_date":"2025-10-01","last_update":"2024-01-10","substances":"ketamine","conditions":"Depressive Symptoms","sponsor":"The Second Hospital of Anhui Medical University","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06199011","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06199011"},{"nct_id":"NCT06200155","title":"Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":48,"start_date":"2024-04-16","completion_date":"2026-12-31","last_update":"2026-09-11","substances":"psilocybin","conditions":"Depression, Anxiety; Psilocybin-Assisted Psychotherapy; Advanced Cancer","sponsor":"M.D. Anderson Cancer Center","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct06200155","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06200155"},{"nct_id":"NCT06206265","title":"Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":14,"start_date":"2024-01-17","completion_date":"2026-03-01","last_update":"2026-02-05","substances":"psilocybin","conditions":"Irritable Bowel Syndrome","sponsor":"TRYP Therapeutics","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct06206265","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06206265"},{"nct_id":"NCT06213324","title":"Neural Circuit Effects of Ketamine in Depression","acronym":"","status":"RECRUITING","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":120,"start_date":"2024-01-31","completion_date":"2028-03-30","last_update":"2025-07-03","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Icahn School of Medicine at Mount Sinai","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct06213324","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06213324"},{"nct_id":"NCT06225232","title":"Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study","acronym":"PSI_CUD","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2025-03-21","completion_date":"2026-12","last_update":"2026-08-31","substances":"psilocybin","conditions":"Cannabis Use Disorder, Moderate; Cannabis Use Disorder, Severe","sponsor":"McMaster University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06225232","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06225232"},{"nct_id":"NCT06228391","title":"Ketamine Treatment for PTSD and MDD in TBI","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2024-03","completion_date":"2026-12","last_update":"2024-01-29","substances":"ketamine","conditions":"PTSD, Post Traumatic Stress Disorder; Major Depressive Disorder; Traumatic Brain Injury","sponsor":"Minneapolis Veterans Affairs Medical Center","sponsor_class":"FED","has_results":false,"site_count":1,"countries":"United States","us_states":"Minnesota","lsd_com_url":"https://lsd.com/trials/nct06228391","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06228391"},{"nct_id":"NCT06230757","title":"Psilocybin for Treatment-Resistant Depression","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2024-07-08","completion_date":"2026-05-08","last_update":"2026-05-22","substances":"psilocybin","conditions":"Major Depressive Disorder; Anhedonia; Treatment Resistant Depression","sponsor":"University of Colorado, Denver","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Colorado","lsd_com_url":"https://lsd.com/trials/nct06230757","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06230757"},{"nct_id":"NCT06232291","title":"Observation of Safety and Tolerability Within 1 Year of the Use of R-ketamine / Placebo in Drug-resistant Depression","acronym":"","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":3,"start_date":"2023-04-21","completion_date":"2024-05-24","last_update":"2024-05-29","substances":"ketamine","conditions":"Treatment-Resistant Depression; Major Depressive Disorder","sponsor":"Medical University of Gdansk","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Poland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06232291","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06232291"},{"nct_id":"NCT06233344","title":"Mindfulness-Assisted Psychedelic Therapy","acronym":"MAPT","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2025-07-30","completion_date":"2027-08","last_update":"2026-08-06","substances":"psilocybin","conditions":"Mental Health","sponsor":"University of Southern California","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct06233344","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06233344"},{"nct_id":"NCT06235411","title":"Psilocybin in Alcohol Use Disorder With Comorbid Depression","acronym":"PAD","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2024-02-05","completion_date":"2024-11-19","last_update":"2025-03-19","substances":"psilocybin","conditions":"Alcohol-Related Disorders; Depressive Disorder; Addiction","sponsor":"Centre Hospitalier Universitaire de Nīmes","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"France","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06235411","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06235411"},{"nct_id":"NCT06237569","title":"Dose Low Dose Ketamine in Casesarian","acronym":"","status":"UNKNOWN","phases":"","study_type":"OBSERVATIONAL","enrollment":150,"start_date":"2024-06-01","completion_date":"2024-08-01","last_update":"2024-02-01","substances":"ketamine","conditions":"Postoperative Pain; Postpartum Depression","sponsor":"Inonu University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Turkey (Türkiye)","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06237569","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06237569"},{"nct_id":"NCT06247839","title":"The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder","acronym":"","status":"RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2024-09-10","completion_date":"2028-06-30","last_update":"2026-08-13","substances":"psilocybin","conditions":"Major Depressive Disorder","sponsor":"Sharmin Ghaznavi","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct06247839","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06247839"},{"nct_id":"NCT06252506","title":"Molecular Imaging Study of Harmine/DMT: a Basic Research Approach","acronym":"HaD-PET","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":17,"start_date":"2024-01-22","completion_date":"2025-02-17","last_update":"2025-03-19","substances":"dmt","conditions":"Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine","sponsor":"Insel Gruppe AG, University Hospital Bern","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06252506","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06252506"},{"nct_id":"NCT06258031","title":"PsilOCD: A Pharmacological-Challenge Feasibility Study","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":19,"start_date":"2022-10-28","completion_date":"2024-06-28","last_update":"2024-11-06","substances":"psilocybin","conditions":"Obsessive-Compulsive Disorder","sponsor":"Imperial College London","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06258031","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06258031"},{"nct_id":"NCT06278779","title":"Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression","acronym":"TREK","status":"RECRUITING","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":162,"start_date":"2024-06-03","completion_date":"2027-04","last_update":"2026-05-29","substances":"ketamine","conditions":"Treatment Resistant Depression","sponsor":"The George Institute","sponsor_class":"OTHER","has_results":false,"site_count":7,"countries":"Australia","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06278779","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06278779"},{"nct_id":"NCT06299319","title":"Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD","acronym":"PAP-OCD","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2024-09-01","completion_date":"2026-09-04","last_update":"2026-09-24","substances":"psilocybin","conditions":"Obsessive-Compulsive Disorder","sponsor":"Centre for Addiction and Mental Health","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06299319","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06299319"},{"nct_id":"NCT06303739","title":"Psilocybin-Assisted Therapy in Treatment-Resistant Depression","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2024-04-19","completion_date":"2026-04-09","last_update":"2026-05-06","substances":"psilocybin","conditions":"Refractory Depression; Treatment Resistant Depression","sponsor":"University of North Carolina, Chapel Hill","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"North Carolina","lsd_com_url":"https://lsd.com/trials/nct06303739","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06303739"},{"nct_id":"NCT06308653","title":"Psilocybin for Major Depressive Disorder (MDD)","acronym":"uAspire","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":238,"start_date":"2024-03-13","completion_date":"2026-01-05","last_update":"2026-07-23","substances":"psilocybin","conditions":"Depressive Disorder, Major","sponsor":"Usona Institute","sponsor_class":"OTHER","has_results":false,"site_count":29,"countries":"United States","us_states":"Alabama; Arkansas; California; Colorado; Connecticut; Florida; Georgia; Illinois; Maryland; Missouri; Nebraska; New Jersey; New Mexico; New York; Texas; Utah; Washington","lsd_com_url":"https://lsd.com/trials/nct06308653","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06308653"},{"nct_id":"NCT06317636","title":"Propofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression","acronym":"PEAK","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2025-01-28","completion_date":"2026-11","last_update":"2025-10-02","substances":"ketamine","conditions":"Chronic Pain; Depression","sponsor":"Stanford University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct06317636","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06317636"},{"nct_id":"NCT06319378","title":"Cancer Related Major Depression Treated With a Single Dose of Psilocybin","acronym":"CAPSI","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":100,"start_date":"2024-04-19","completion_date":"2026-12","last_update":"2026-04-13","substances":"psilocybin","conditions":"MDD","sponsor":"Section for Affective Disorders; Northern Stockholm Psychiatry","sponsor_class":"OTHER","has_results":false,"site_count":4,"countries":"Sweden","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06319378","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06319378"},{"nct_id":"NCT06326606","title":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2024-03-27","completion_date":"2024-07-08","last_update":"2024-10-09","substances":"psilocybin","conditions":"Healthy Volunteers","sponsor":"MycoMedica Life Sciences PBC","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"Australia","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06326606","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06326606"},{"nct_id":"NCT06340958","title":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","acronym":"SOLEO","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":99,"start_date":"2024-03-18","completion_date":"2025-06-06","last_update":"2026-06-23","substances":"ketamine","conditions":"Adjunctive Treatment of Major Depressive Disorder (MDD)","sponsor":"Clexio Biosciences Ltd.","sponsor_class":"INDUSTRY","has_results":true,"site_count":23,"countries":"United States","us_states":"California; Florida; Georgia; Illinois; Maryland; Mississippi; Missouri; New Jersey; Ohio; Oklahoma; Texas; Utah; Washington","lsd_com_url":"https://lsd.com/trials/nct06340958","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06340958"},{"nct_id":"NCT06341426","title":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin","acronym":"PSI-1V2","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":92,"start_date":"2024-02-05","completion_date":"2026-07-28","last_update":"2026-07-09","substances":"psilocybin","conditions":"Major Depressive Disorder; Depression; Treatment-Resistant Depression; Mood Disorders","sponsor":"University Health Network, Toronto","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06341426","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06341426"},{"nct_id":"NCT06349083","title":"Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":200,"start_date":"2026-09-01","completion_date":"2030-05","last_update":"2026-09-02","substances":"psilocybin","conditions":"Alcohol Use Disorder","sponsor":"NYU Langone Health","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct06349083","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06349083"},{"nct_id":"NCT06353282","title":"MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents","acronym":"","status":"WITHDRAWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2025-07-01","completion_date":"2026-01-31","last_update":"2025-04-10","substances":"mdma","conditions":"PTSD, Post Traumatic Stress Disorder; Adolescents; Psychotherapy","sponsor":"University of California, Los Angeles","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct06353282","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06353282"},{"nct_id":"NCT06355180","title":"Esketamine vs ECT for Acute Suicidality","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":340,"start_date":"2024-04-16","completion_date":"2025-06-13","last_update":"2025-09-05","substances":"ketamine","conditions":"Mood Disorders; Suicidal Ideation; Depressive Episode","sponsor":"Capital Medical University","sponsor_class":"OTHER","has_results":false,"site_count":6,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06355180","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06355180"},{"nct_id":"NCT06355414","title":"Psilocybin in Chronic Low Back Pain and Depression","acronym":"","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2024-04-22","completion_date":"2026-12-30","last_update":"2026-09-04","substances":"psilocybin","conditions":"Chronic Low-back Pain; Depression","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct06355414","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06355414"},{"nct_id":"NCT06366334","title":"Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation","acronym":"KSI","status":"UNKNOWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2024-01-15","completion_date":"2024-05-29","last_update":"2024-06-05","substances":"ketamine","conditions":"Suicidal Ideation; Suicidal Ideas","sponsor":"Children's Hospital of Eastern Ontario","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06366334","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06366334"},{"nct_id":"NCT06367738","title":"Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults","acronym":"","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2025-11","completion_date":"2026-12-30","last_update":"2025-10-21","substances":"psilocybin","conditions":"Aging","sponsor":"University of California, Berkeley","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct06367738","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06367738"},{"nct_id":"NCT06368492","title":"The Impact of Psilocybin on Pain in Fibromyalgia Patients","acronym":"PsiloFM","status":"RECRUITING","phases":"NA","study_type":"INTERVENTIONAL","enrollment":35,"start_date":"2024-05-03","completion_date":"2025-12","last_update":"2025-09-15","substances":"psilocybin","conditions":"Fibromyalgia","sponsor":"Maastricht University","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"Netherlands","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06368492","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06368492"},{"nct_id":"NCT06372197","title":"Low-Income Group Psilocybin Assisted Therapy for Depression","acronym":"LIGPATD","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2024-08-01","completion_date":"2025-05-14","last_update":"2025-06-05","substances":"psilocybin","conditions":"Depression","sponsor":"Matthew Hicks","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Oregon","lsd_com_url":"https://lsd.com/trials/nct06372197","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06372197"},{"nct_id":"NCT06378229","title":"Psilocybin for Hospitalized Patients with Treatment-resistant Depression","acronym":"PSIHOS-D","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":100,"start_date":"2024-05-21","completion_date":"2026-03","last_update":"2024-09-19","substances":"psilocybin","conditions":"Treatment Resistant Depression","sponsor":"University Hospital, Ghent","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Belgium","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06378229","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06378229"},{"nct_id":"NCT06378528","title":"Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP)","acronym":"","status":"SUSPENDED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":5,"start_date":"2026-09","completion_date":"2027-09","last_update":"2026-03-25","substances":"ketamine","conditions":"Posttraumatic Stress Disorder","sponsor":"University of Wisconsin, Madison","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Wisconsin","lsd_com_url":"https://lsd.com/trials/nct06378528","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06378528"},{"nct_id":"NCT06386003","title":"Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":15,"start_date":"2026-06-01","completion_date":"2028-01","last_update":"2026-10-06","substances":"psilocybin","conditions":"Post Traumatic Stress Disorder; PTSD; Chronic PTSD","sponsor":"Unity Health Toronto","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06386003","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06386003"},{"nct_id":"NCT06394284","title":"Examining 3,4-methylenedioxymethamphetamine (MDMA) Effects on Psychological, Relational and Hyperarousal-Related Neural Reactivity Mechanisms in Veterans With PTSD and Moral Injury","acronym":"","status":"RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2024-02-18","completion_date":"2027-12-31","last_update":"2024-05-01","substances":"mdma","conditions":"PTSD, Post Traumatic Stress Disorder; Moral Injury","sponsor":"Herzog Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Israel","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06394284","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06394284"},{"nct_id":"NCT06399263","title":"Study of Psilocybin for Anorexia in Young Adults","acronym":"SPANYA","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2024-11-18","completion_date":"2029-11","last_update":"2026-03-03","substances":"psilocybin","conditions":"Anorexia Nervosa","sponsor":"Marissa Raymond-Flesch, MD, MPH","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct06399263","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06399263"},{"nct_id":"NCT06402955","title":"Imaging Depression in Parkinson's Disease","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":120,"start_date":"2024-09-01","completion_date":"2029-01-01","last_update":"2026-03-10","substances":"ketamine","conditions":"Parkinson's Disease; Major Depressive Disorder","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct06402955","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06402955"},{"nct_id":"NCT06405607","title":"Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial","acronym":"Psi or Ket","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":80,"start_date":"2025-06-12","completion_date":"2028-04","last_update":"2025-11-28","substances":"psilocybin; ketamine","conditions":"Alcohol Use Disorder; Alcohol Dependence; Alcohol Abuse","sponsor":"University of Iowa","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Iowa","lsd_com_url":"https://lsd.com/trials/nct06405607","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06405607"},{"nct_id":"NCT06407635","title":"A Study of Psilocybin for PTSD","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2024-06-07","completion_date":"2026-03-09","last_update":"2026-06-22","substances":"psilocybin","conditions":"Post Traumatic Stress Disorder","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct06407635","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06407635"},{"nct_id":"NCT06410599","title":"Pharmacologic Treatment Augmentation in Chronic Depression","acronym":"Ket+CBASP","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2024-04-29","completion_date":"2026-05","last_update":"2025-03-27","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"University Hospital Tuebingen","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"Germany","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06410599","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06410599"},{"nct_id":"NCT06414356","title":"The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD","acronym":"","status":"RECRUITING","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2024-10-02","completion_date":"2025-04","last_update":"2025-02-25","substances":"ketamine","conditions":"Neuropathic Pain; PTSD","sponsor":"Margaux M. Salas, PhD","sponsor_class":"FED","has_results":false,"site_count":1,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct06414356","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06414356"},{"nct_id":"NCT06416085","title":"Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":15,"start_date":"2024-06-06","completion_date":"2026-12-15","last_update":"2026-06-22","substances":"psilocybin","conditions":"Advanced Cancer; Stage IV Solid Tumor Cancer; Stage IV Sarcoma of Bone; Stage IV Lymphoma; Stage IV Melanoma; Endocrine Cancer","sponsor":"University Health Network, Toronto","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06416085","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06416085"},{"nct_id":"NCT06418178","title":"Dose Optimization of MDMA-Assisted Therapy for PTSD","acronym":"DosOp","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2025-06-03","completion_date":"2029-10","last_update":"2025-06-26","substances":"mdma","conditions":"Posttraumatic Stress Disorder","sponsor":"Bronx VA Medical Center","sponsor_class":"FED","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct06418178","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06418178"},{"nct_id":"NCT06419439","title":"Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":44,"start_date":"2025-12-03","completion_date":"2028-12-01","last_update":"2025-12-18","substances":"ketamine","conditions":"Chronic Low Back Pain; Depression","sponsor":"VA Office of Research and Development","sponsor_class":"FED","has_results":false,"site_count":1,"countries":"United States","us_states":"Michigan","lsd_com_url":"https://lsd.com/trials/nct06419439","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06419439"},{"nct_id":"NCT06430541","title":"Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence","acronym":"","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2024-11-21","completion_date":"2026-12","last_update":"2026-09-04","substances":"psilocybin","conditions":"Breast Cancer; Ovarian Cancer","sponsor":"University of Colorado, Denver","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"United States","us_states":"Colorado","lsd_com_url":"https://lsd.com/trials/nct06430541","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06430541"},{"nct_id":"NCT06431386","title":"Behavioural Activation Therapy and Esketamine for Resistant Depression","acronym":"","status":"TERMINATED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":6,"start_date":"2024-06-11","completion_date":"2025-09-17","last_update":"2025-10-01","substances":"ketamine","conditions":"Depressive Disorder, Treatment-Resistant; Depressive Disorder, Major; Bipolar Disorder","sponsor":"The Royal's Institute of Mental Health Research","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06431386","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06431386"},{"nct_id":"NCT06432322","title":"(GluEsk) Glutamate and Esketamine","acronym":"GluEsk","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2024-06-14","completion_date":"2025-03-26","last_update":"2025-06-08","substances":"ketamine","conditions":"Depression","sponsor":"University of Oxford","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06432322","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06432322"},{"nct_id":"NCT06442423","title":"Open-Label Psilocybin Study in Transdiagnostic Population","acronym":"","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2024-10-17","completion_date":"2027-12","last_update":"2026-03-11","substances":"psilocybin","conditions":"Transdiagnostic; Depression - Major Depressive Disorder; Anxiety; PTSD Symptoms; PTSD; Substance Use; Substance Use Disorder (SUD); OCD","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct06442423","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06442423"},{"nct_id":"NCT06444243","title":"Psilocybin-assisted Therapy for Alcohol Use Disorder","acronym":"","status":"UNKNOWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":90,"start_date":"2024-09","completion_date":"2025-07","last_update":"2024-06-10","substances":"psilocybin","conditions":"Alcohol Use Disorder; Alcohol Dependence; Depression; Anxiety","sponsor":"University of Sydney","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06444243","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06444243"},{"nct_id":"NCT06450210","title":"Safety for Home Administration of Microdose Psilocybin Use","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":17,"start_date":"2024-12-06","completion_date":"2026-07-31","last_update":"2026-08-14","substances":"psilocybin","conditions":"Psychedelic Experiences","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct06450210","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06450210"},{"nct_id":"NCT06455293","title":"Psilocybin Therapy for Depression in Parkinson's Disease","acronym":"PDP2","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2024-08-19","completion_date":"2027-06","last_update":"2026-08-07","substances":"psilocybin","conditions":"Parkinson Disease; Depression","sponsor":"Joshua Woolley, MD, PhD","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct06455293","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06455293"},{"nct_id":"NCT06464367","title":"Mechanistic Studies of Psilocybin in Headache Disorders","acronym":"","status":"RECRUITING","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2025-05-19","completion_date":"2027-12-31","last_update":"2026-07-13","substances":"psilocybin","conditions":"Migraine","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct06464367","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06464367"},{"nct_id":"NCT06464393","title":"Opioid-based Versus Opioid-free Endotracheal Intubation","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":70,"start_date":"2024-03-20","completion_date":"2025-03-20","last_update":"2025-07-22","substances":"ketamine","conditions":"Anesthesia; Anesthesia Intubation; Opioid Use; Analgesic Non-narcotic; Fentanyl","sponsor":"Aretaieion University Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Greece","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06464393","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06464393"},{"nct_id":"NCT06471959","title":"Psychedelic-assisted Group Program for First Responders","acronym":"","status":"UNKNOWN","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":32,"start_date":"2025-01-01","completion_date":"2025-07-01","last_update":"2024-06-24","substances":"psilocybin","conditions":"Psilocybin; Psychotherapy, Group","sponsor":"Empower Research Inc","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06471959","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06471959"},{"nct_id":"NCT06480201","title":"Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression","acronym":"","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":100,"start_date":"2024-01-01","completion_date":"2026-12-31","last_update":"2026-09-15","substances":"ketamine","conditions":"Healthy; Major Depressive Disorder; Treatment Resistant Depression","sponsor":"Texas A&M University","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct06480201","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06480201"},{"nct_id":"NCT06480500","title":"i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial","acronym":"Ket-CBT","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":76,"start_date":"2024-01-02","completion_date":"2027-03-31","last_update":"2026-10-06","substances":"ketamine","conditions":"Major Depressive Disorder; Suicide; Treatment Resistant Depression","sponsor":"University Health Network, Toronto","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06480500","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06480500"},{"nct_id":"NCT06480981","title":"Multiple Ascending Dose Noribogaine PK/PD in Healthy Volunteers","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":55,"start_date":"2024-06-20","completion_date":"2024-12-23","last_update":"2026-01-22","substances":"ibogaine","conditions":"Pharmacokinetics","sponsor":"DemeRx NB","sponsor_class":"INDUSTRY","has_results":true,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06480981","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06480981"},{"nct_id":"NCT06488586","title":"IV Ketamine vs. IN Esketamine for MDD TRD","acronym":"","status":"RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":80,"start_date":"2023-03-20","completion_date":"2026-03-20","last_update":"2024-07-10","substances":"ketamine","conditions":"Treatment Resistant Depression","sponsor":"Gustavo Vazquez","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06488586","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06488586"},{"nct_id":"NCT06496750","title":"Ketamine for Methamphetamine Use Disorder","acronym":"KMD","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":120,"start_date":"2024-09-11","completion_date":"2026-09-06","last_update":"2026-09-21","substances":"ketamine","conditions":"Substance Use Disorders; Substance Use; Methamphetamine Abuse","sponsor":"University of Texas Southwestern Medical Center","sponsor_class":"OTHER","has_results":false,"site_count":5,"countries":"United States","us_states":"California; New Mexico; New York; South Carolina; Texas","lsd_com_url":"https://lsd.com/trials/nct06496750","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06496750"},{"nct_id":"NCT06506019","title":"Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression","acronym":"Psilo-BD","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2024-10-09","completion_date":"2026-09-01","last_update":"2026-08-10","substances":"psilocybin","conditions":"Bipolar Depression","sponsor":"University Health Network, Toronto","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06506019","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06506019"},{"nct_id":"NCT06508710","title":"Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients","acronym":"MOODBOOSTER","status":"RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2024-10-20","completion_date":"2026-03","last_update":"2025-09-03","substances":"ketamine","conditions":"Major Depressive Episode","sponsor":"Assistance Publique - Hôpitaux de Paris","sponsor_class":"OTHER","has_results":false,"site_count":4,"countries":"France","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06508710","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06508710"},{"nct_id":"NCT06511908","title":"Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2024-11-06","completion_date":"2027-07-01","last_update":"2026-10-05","substances":"ketamine","conditions":"Suicide; Depressive Disorder, Treatment-Resistant; Ketamine; Molecular Mechanisms of Pharmacological Action; Neurotransmitter Agents; Excitatory Amino Acid Agents; Physiological Effects of Drugs; Depressive Disorder, Major; Depressive Disorder; Depression; Mental Disorders; Mood Disorders; Behavioral Symptoms","sponsor":"National Institute of Mental Health (NIMH)","sponsor_class":"NIH","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct06511908","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06511908"},{"nct_id":"NCT06511947","title":"Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects","acronym":"","status":"UNKNOWN","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":52,"start_date":"2024-08-01","completion_date":"2025-02","last_update":"2024-08-07","substances":"dmt","conditions":"Healthy Volunteers","sponsor":"GH Research Ireland Limited","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06511947","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06511947"},{"nct_id":"NCT06512194","title":"Investigation to Understand and Optimize Psilocybin","acronym":"OPTIMIZE","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":141,"start_date":"2025-05-13","completion_date":"2029-05","last_update":"2026-08-10","substances":"psilocybin","conditions":"Depression","sponsor":"Charles Raison","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Colorado","lsd_com_url":"https://lsd.com/trials/nct06512194","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06512194"},{"nct_id":"NCT06512220","title":"Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)","acronym":"SYNVEST","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2025-04-21","completion_date":"2027-04","last_update":"2026-07-30","substances":"psilocybin","conditions":"Treatment Resistant Depression","sponsor":"Centre for Addiction and Mental Health","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06512220","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06512220"},{"nct_id":"NCT06518720","title":"Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)","acronym":"TRANSCEND","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2025-04-01","completion_date":"2027-03","last_update":"2026-07-30","substances":"psilocybin","conditions":"Treatment Resistant Depression; Chronic Pain","sponsor":"Centre for Addiction and Mental Health","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06518720","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06518720"},{"nct_id":"NCT06526078","title":"Cognitive Training as an Adjunct to Ketamine in Real-world Clinics","acronym":"","status":"RECRUITING","phases":"NA","study_type":"INTERVENTIONAL","enrollment":600,"start_date":"2024-11-12","completion_date":"2029-05-31","last_update":"2026-08-19","substances":"ketamine","conditions":"Depression","sponsor":"University of Pittsburgh","sponsor_class":"OTHER","has_results":false,"site_count":3,"countries":"United States","us_states":"California; Illinois; Texas","lsd_com_url":"https://lsd.com/trials/nct06526078","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06526078"},{"nct_id":"NCT06529939","title":"The Effects of Psilocybin on Shared Experience in Film Processing","acronym":"","status":"UNKNOWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2024-11","completion_date":"2025-09","last_update":"2024-09-27","substances":"psilocybin","conditions":"Disorders of Consciousness; Psychedelic Experiences","sponsor":"Western University, Canada","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06529939","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06529939"},{"nct_id":"NCT06530706","title":"Effect of Esketamine on Anxiety State in Patients Undergoing Abdominal Tumor Surgery","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":185,"start_date":"2024-08-05","completion_date":"2025-05-30","last_update":"2025-09-16","substances":"ketamine","conditions":"Anxiety State; Esketamine","sponsor":"Zhejiang Cancer Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06530706","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06530706"},{"nct_id":"NCT06557239","title":"Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy","acronym":"PAP_OXT","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":10,"start_date":"2024-08-05","completion_date":"2024-12-11","last_update":"2025-05-16","substances":"lsd","conditions":"Depression, Anxiety","sponsor":"Tatiana Aboulafia Brakha","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06557239","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06557239"},{"nct_id":"NCT06559826","title":"Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression","acronym":"KAP","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":70,"start_date":"2025-01-10","completion_date":"2027-08","last_update":"2025-07-15","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Icahn School of Medicine at Mount Sinai","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct06559826","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06559826"},{"nct_id":"NCT06560658","title":"Optimizing Microdosing and Meditation","acronym":"OMM","status":"WITHDRAWN","phases":"NA","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2024-10-01","completion_date":"2025-10-01","last_update":"2025-06-05","substances":"psilocybin","conditions":"Meditation; Microdosing","sponsor":"National University of Natural Medicine","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Oregon","lsd_com_url":"https://lsd.com/trials/nct06560658","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06560658"},{"nct_id":"NCT06564818","title":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","acronym":"APPROACH","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":220,"start_date":"2024-12-17","completion_date":"2026-09-04","last_update":"2026-09-28","substances":"psilocybin","conditions":"Major Depressive Disorder","sponsor":"Cybin IRL Limited","sponsor_class":"INDUSTRY","has_results":false,"site_count":45,"countries":"United States","us_states":"Arizona; California; Colorado; Florida; Georgia; Illinois; Louisiana; Maryland; Massachusetts; Nevada; New Jersey; New York; North Carolina; Ohio; Pennsylvania; Tennessee; Texas; Utah","lsd_com_url":"https://lsd.com/trials/nct06564818","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06564818"},{"nct_id":"NCT06565494","title":"MDMA-Assisted Therapy for Pathological Narcissism","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2024-08-27","completion_date":"2026-08-15","last_update":"2026-02-17","substances":"mdma","conditions":"Narcissism","sponsor":"University of Washington","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Washington","lsd_com_url":"https://lsd.com/trials/nct06565494","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06565494"},{"nct_id":"NCT06575075","title":"Pilot Study of RR-HNK in OCD","acronym":"(HNKO)","status":"RECRUITING","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":45,"start_date":"2026-01-23","completion_date":"2028-11-30","last_update":"2026-08-12","substances":"ketamine","conditions":"Obsessive-Compulsive Disorder","sponsor":"Carolyn Rodriguez","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct06575075","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06575075"},{"nct_id":"NCT06592833","title":"Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2025-02-25","completion_date":"2028-03-01","last_update":"2025-05-14","substances":"psilocybin","conditions":"Major Depressive Disorder","sponsor":"Icahn School of Medicine at Mount Sinai","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct06592833","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06592833"},{"nct_id":"NCT06597695","title":"A Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression","acronym":"","status":"RECRUITING","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2025-07-23","completion_date":"2027-07-01","last_update":"2026-09-10","substances":"ketamine","conditions":"Depression","sponsor":"Juliana Zambrano, MD, MPH","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct06597695","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06597695"},{"nct_id":"NCT06608030","title":"Effect of Esketamine on Perioperative Negative Mood in Patients Undergoing Cardiac Valve Surgery","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":142,"start_date":"2024-09-23","completion_date":"2025-04-07","last_update":"2025-11-25","substances":"ketamine","conditions":"Depression, Anxiety; Cardiac Surgery; S-ketamine","sponsor":"Chinese PLA General Hospital","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06608030","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06608030"},{"nct_id":"NCT06608277","title":"Ketamine, SGB and Combination Treatment for TBI-associated Headache or PTSD","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":175,"start_date":"2025-07-02","completion_date":"2027-12-30","last_update":"2026-05-01","substances":"ketamine","conditions":"Posttraumatic Headache; Posttraumatic Stress Disorder","sponsor":"Northwestern University","sponsor_class":"OTHER","has_results":false,"site_count":3,"countries":"United States","us_states":"Illinois; Maryland; North Carolina","lsd_com_url":"https://lsd.com/trials/nct06608277","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06608277"},{"nct_id":"NCT06613243","title":"Different Doses of Dexmedetomidine Combined With Esketamine in Women Undergoing Cesarean Delivery","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":120,"start_date":"2024-10-08","completion_date":"2024-12-02","last_update":"2024-12-30","substances":"ketamine","conditions":"Cesarean Delivery; Esketamine; Neuropsychiatric Symptoms; Dexmedetomidine","sponsor":"Peking University First Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06613243","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06613243"},{"nct_id":"NCT06615908","title":"Treatment of Persisting Symptoms After Concussion With Psilocybin Assisted Therapy","acronym":"PatACT","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2025-05-27","completion_date":"2027-06-30","last_update":"2026-09-09","substances":"psilocybin","conditions":"Persisting Symptoms After Concussion","sponsor":"University of Calgary","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06615908","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06615908"},{"nct_id":"NCT06620042","title":"FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2024-11-12","completion_date":"2025-10-31","last_update":"2025-11-10","substances":"ketamine","conditions":"Bipolar Depression; Treatment Resistant Bipolar Depression","sponsor":"Brian Barnett","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"United States","us_states":"Ohio","lsd_com_url":"https://lsd.com/trials/nct06620042","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06620042"},{"nct_id":"NCT06620276","title":"ACT_for Alcohol Use Disorder and Depression","acronym":"","status":"RECRUITING","phases":"NA","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2025-05-01","completion_date":"2026-12-01","last_update":"2026-03-05","substances":"ketamine","conditions":"Depression - Major Depressive Disorder; Alcohol Use Disorder","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06620276","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06620276"},{"nct_id":"NCT06624137","title":"Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics","acronym":"","status":"TERMINATED","phases":"","study_type":"OBSERVATIONAL","enrollment":5,"start_date":"2024-12-12","completion_date":"2026-06-14","last_update":"2026-07-09","substances":"lsd; psilocybin; dmt","conditions":"OCD; Major Depressive Disorder (MDD); Alcohol Use Disorder (AUD); Healthy Volunteer; Migraine; PTSD; PTSD - Post Traumatic Stress Disorder; Addiction; Tobacco Use Disorder; Obsessive Compulsive Disorder (OCD); Opioid Use Disorder","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct06624137","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06624137"},{"nct_id":"NCT06624878","title":"Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":568,"start_date":"2024-10-08","completion_date":"2026-01-14","last_update":"2026-02-27","substances":"ketamine","conditions":"Ovarian Cancer; Cytoreductive Surgery; Depressive Symptom","sponsor":"Zhejiang Cancer Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06624878","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06624878"},{"nct_id":"NCT06626139","title":"Investigating the Interaction of Psilocybin and Context of Its Administration in Healthy Volunteers","acronym":"SnS","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":120,"start_date":"2024-10-20","completion_date":"2027-11-30","last_update":"2026-06-04","substances":"psilocybin","conditions":"Healthy Participants With Lower-than-average Mental Well-being","sponsor":"Robin Carhart-Harris, PhD, MA","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct06626139","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06626139"},{"nct_id":"NCT06630065","title":"Study of the Neural Circuits Underlying the Negative Emotional Bias of Depressive Disorders and Their Response to Ketamine","acronym":"EMOKET","status":"RECRUITING","phases":"NA","study_type":"INTERVENTIONAL","enrollment":96,"start_date":"2023-03-13","completion_date":"2026-04-13","last_update":"2024-10-08","substances":"ketamine","conditions":"Depressive Disorder","sponsor":"Centre Hospitalier St Anne","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"France","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06630065","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06630065"},{"nct_id":"NCT06643637","title":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy Participants","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2024-11-08","completion_date":"2025-03-12","last_update":"2025-06-12","substances":"psilocybin","conditions":"Healthy Volunteers","sponsor":"MycoMedica Life Sciences PBC","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"Australia","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06643637","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06643637"},{"nct_id":"NCT06644170","title":"A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":15,"start_date":"2024-11-19","completion_date":"2025-09-30","last_update":"2025-10-14","substances":"psilocybin","conditions":"Hematopoietic and Lymphatic System Neoplasm; Metastatic Malignant Solid Neoplasm","sponsor":"University of Washington","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Washington","lsd_com_url":"https://lsd.com/trials/nct06644170","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06644170"},{"nct_id":"NCT06647056","title":"Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic Seizures","acronym":"CRIPSY","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":4,"start_date":"2024-12-19","completion_date":"2025-01-03","last_update":"2025-08-21","substances":"psilocybin","conditions":"Psychogenic Nonepileptic Seizures; Psilocybin","sponsor":"Centre Hospitalier Universitaire de Nīmes","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"France","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06647056","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06647056"},{"nct_id":"NCT06650800","title":"Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression","acronym":"PSILODAC","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2024-11-19","completion_date":"2025-03-26","last_update":"2025-08-20","substances":"psilocybin","conditions":"Depressive Disorder; Depressive Disorder, Treatment-Resistant; Hallucinogens; Reinforcement, Psychology","sponsor":"Centre Hospitalier Universitaire de Nīmes","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"France","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06650800","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06650800"},{"nct_id":"NCT06656702","title":"Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis","acronym":"","status":"RECRUITING","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2025-04-09","completion_date":"2027-01-30","last_update":"2026-08-11","substances":"psilocybin","conditions":"Amyotrophic Lateral Sclerosis","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct06656702","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06656702"},{"nct_id":"NCT06660381","title":"Psilocybin-assisted Treatment for Cannabis Use Disorder","acronym":"","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2024-11-08","completion_date":"2026-11","last_update":"2026-03-18","substances":"psilocybin","conditions":"Cannabis Use Disorder","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct06660381","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06660381"},{"nct_id":"NCT06665568","title":"Effects of Intranasal Ketamine on Depression and Anxiety in Palliative Care Cancer Patients","acronym":"Keta-Care","status":"NOT_YET_RECRUITING","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":100,"start_date":"2025-04","completion_date":"2025-12","last_update":"2025-05-01","substances":"ketamine","conditions":"Depressive Symptoms Mild to Moderate in Severity; Anxiety; Quality of Life (QOL); Caregiver Burden; Sleep Quality","sponsor":"University of Zurich","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06665568","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06665568"},{"nct_id":"NCT06666010","title":"PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study","acronym":"PATSUD","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":86,"start_date":"2025-01","completion_date":"2028-01","last_update":"2024-10-30","substances":"psilocybin","conditions":"Stimulant Use Disorder","sponsor":"Filament Health Corp.","sponsor_class":"INDUSTRY","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06666010","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06666010"},{"nct_id":"NCT06668571","title":"Intravenous Ketamine for Treatment-Resistant Depression","acronym":"G2K","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2025-02-10","completion_date":"2027-12-31","last_update":"2025-10-14","substances":"ketamine","conditions":"Depressive Disorder, Treatment-Resistant; Treatment Resistant Depression (TRD)","sponsor":"Mayo Clinic","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Minnesota","lsd_com_url":"https://lsd.com/trials/nct06668571","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06668571"},{"nct_id":"NCT06671977","title":"Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans","acronym":"DMT-Bolus","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2025-03-14","completion_date":"2027-12-01","last_update":"2026-06-16","substances":"dmt","conditions":"Major Depression Disorder; Depression","sponsor":"Deepak C. D'Souza","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct06671977","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06671977"},{"nct_id":"NCT06683014","title":"MDMA in Borderline Personality Disorder","acronym":"MDMA in BPD","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2025-09-05","completion_date":"2026-09","last_update":"2026-01-22","substances":"mdma","conditions":"Borderline Personality Disorder","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct06683014","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06683014"},{"nct_id":"NCT06692192","title":"The RECAP2 Study: Midazolam and Psilocybin","acronym":"","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2025-08-07","completion_date":"2027-12","last_update":"2026-08-13","substances":"psilocybin","conditions":"Psilocybin","sponsor":"University of Wisconsin, Madison","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Wisconsin","lsd_com_url":"https://lsd.com/trials/nct06692192","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06692192"},{"nct_id":"NCT06698848","title":"Integrating Ketamine Effects on Neuronal Molecular Signatures and the Brain Functional and Structural Connectome","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":120,"start_date":"2025-01-01","completion_date":"2030-06-01","last_update":"2026-05-22","substances":"ketamine","conditions":"Depression; Suicide","sponsor":"Massachusetts General Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct06698848","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06698848"},{"nct_id":"NCT06706232","title":"Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2025-07-07","completion_date":"2027-08","last_update":"2026-08-12","substances":"psilocybin","conditions":"Bipolar II Disorder; Depression, Bipolar; Suicidality","sponsor":"The University of Texas Health Science Center, Houston","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct06706232","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06706232"},{"nct_id":"NCT06713616","title":"PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study","acronym":"","status":"RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":400,"start_date":"2025-01-27","completion_date":"2030-12-31","last_update":"2026-09-08","substances":"ketamine","conditions":"Depression","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":8,"countries":"United States","us_states":"Connecticut; Georgia; Michigan; Oklahoma; Tennessee; Texas; Washington","lsd_com_url":"https://lsd.com/trials/nct06713616","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06713616"},{"nct_id":"NCT06724289","title":"Psilocybin for Prolonged Grief Disorder","acronym":"","status":"RECRUITING","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2026-03-24","completion_date":"2027-08","last_update":"2026-06-23","substances":"psilocybin","conditions":"Prolonged Grief Disorder","sponsor":"University of Virginia","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Virginia","lsd_com_url":"https://lsd.com/trials/nct06724289","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06724289"},{"nct_id":"NCT06725277","title":"The OBSERVE Protocol","acronym":"","status":"RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":450,"start_date":"2024-01-21","completion_date":"2029-12","last_update":"2026-09-03","substances":"ketamine","conditions":"Major Depression Disorder","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":8,"countries":"United States","us_states":"Connecticut; Georgia; Michigan; Oklahoma; Tennessee; Texas; Washington","lsd_com_url":"https://lsd.com/trials/nct06725277","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06725277"},{"nct_id":"NCT06731335","title":"Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN","acronym":"PEACE-PAIN","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2025-03-05","completion_date":"2026-08","last_update":"2025-03-30","substances":"psilocybin","conditions":"Chronic Neuropathic Pain; Pain Management","sponsor":"Unity Health Toronto","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06731335","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06731335"},{"nct_id":"NCT06731621","title":"Psilocybin for Treatment-Resistant Depression in Autism","acronym":"PAT-DA","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2024-11-01","completion_date":"2026-12","last_update":"2026-08-06","substances":"psilocybin","conditions":"Treatment Resistant Depression; Autism Spectrum Disorder","sponsor":"Centre for Addiction and Mental Health","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06731621","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06731621"},{"nct_id":"NCT06732089","title":"Digital Interventions for Adults with Treatment-Resistant Depression: a Pilot Study","acronym":"","status":"RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":200,"start_date":"2024-12-16","completion_date":"2026-10","last_update":"2024-12-13","substances":"ketamine","conditions":"Major Depressive Disorder (MDD); Major Depressive Episode; Treatment-Resistant Major Depressive Disorder","sponsor":"Unity Health Toronto","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06732089","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06732089"},{"nct_id":"NCT06736769","title":"Ketamine Effects on Learning In Eating Disorders","acronym":"KETTLE","status":"ENROLLING_BY_INVITATION","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2025-06-05","completion_date":"2027-06","last_update":"2026-06-12","substances":"ketamine","conditions":"Anorexia Nervosa; Atypical Anorexia Nervosa","sponsor":"Amanda Downey, MD","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct06736769","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06736769"},{"nct_id":"NCT06741228","title":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":214,"start_date":"2024-12-11","completion_date":"2026-07-15","last_update":"2026-09-25","substances":"lsd","conditions":"Generalized Anxiety Disorder","sponsor":"Definium Therapeutics US, Inc.","sponsor_class":"INDUSTRY","has_results":false,"site_count":34,"countries":"United States","us_states":"Arizona; California; Colorado; Florida; Georgia; Illinois; Massachusetts; New Jersey; New York; Ohio; Oregon; Pennsylvania; South Carolina; Tennessee; Texas; Utah; Vermont; Washington","lsd_com_url":"https://lsd.com/trials/nct06741228","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06741228"},{"nct_id":"NCT06746441","title":"Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2024-12-01","completion_date":"2025-06-01","last_update":"2025-09-02","substances":"psilocybin","conditions":"Major Depressive Disorder","sponsor":"Khyber Medical University Peshawar","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Pakistan","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06746441","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06746441"},{"nct_id":"NCT06752759","title":"Nebulized Ketamine for the Treatment of Major Depressive Disorder","acronym":"","status":"RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2024-10-16","completion_date":"2027-09-30","last_update":"2026-04-24","substances":"ketamine","conditions":"Severe Depression; Moderate Depression; Ketamine; Midazolam; Peripheral Nervous System Agents; Central Nervous System Agents; Neurotransmitter Agents; Physiologic Effects of Drugs; Sensory System Agents; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Depressive Symptom; Hypnotics and Sedatives; Anti-anxiety Agents; Tranquilizing Agents; Psychotropic Drugs; Anesthetics Agent","sponsor":"Theresa Jacob, PhD, MPH","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct06752759","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06752759"},{"nct_id":"NCT06760533","title":"Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)","acronym":"","status":"NOT_YET_RECRUITING","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2026-08","completion_date":"2026-12","last_update":"2026-03-05","substances":"psilocybin","conditions":"IBS - Irritable Bowel Syndrome","sponsor":"NYU Langone Health","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct06760533","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06760533"},{"nct_id":"NCT06767566","title":"Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery","acronym":"PREPARE-2","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2025-03-28","completion_date":"2027-12-07","last_update":"2026-10-02","substances":"ketamine","conditions":"Pain; Postpartum Depression","sponsor":"University of Utah","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"United States","us_states":"Pennsylvania; Utah","lsd_com_url":"https://lsd.com/trials/nct06767566","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06767566"},{"nct_id":"NCT06768944","title":"Subjective Experience Following Psilocybin","acronym":"SEP-1","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":128,"start_date":"2026-05-15","completion_date":"2027-12","last_update":"2026-09-02","substances":"psilocybin","conditions":"Investigating the Importance of the Subjective Psychedelic Experience","sponsor":"University of Calgary","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06768944","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06768944"},{"nct_id":"NCT06772753","title":"Investigation of Psychedelic Effects in Psychoactive Substances","acronym":"","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2025-02-05","completion_date":"2027-06","last_update":"2026-02-23","substances":"psilocybin; mdma; dmt","conditions":"Psychedelic Effects in Healthy Volunteers","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct06772753","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06772753"},{"nct_id":"NCT06774274","title":"Analgesic Efficacy of Intravenous Ketamine as a Continuous Infusion vs PCA in the Management of Acute Postoperative Pain in Major Orthopedic Surgery.","acronym":"","status":"RECRUITING","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":120,"start_date":"2025-03-01","completion_date":"2026-03-30","last_update":"2025-04-11","substances":"ketamine","conditions":"Pain, Postoperative; Opioid Use; Major Surgery","sponsor":"Universidad de Antioquia","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Colombia","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06774274","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06774274"},{"nct_id":"NCT06781697","title":"InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression","acronym":"TREASURE","status":"RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":31,"start_date":"2026-05-03","completion_date":"2027-12","last_update":"2026-08-13","substances":"ketamine","conditions":"Treatment Resistant Depression","sponsor":"Sunnybrook Health Sciences Centre","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06781697","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06781697"},{"nct_id":"NCT06782724","title":"Psilocybin Therapy for Psychological Distress in Palliative Patients","acronym":"PsyPal","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":108,"start_date":"2025-07-01","completion_date":"2027-01-01","last_update":"2026-05-08","substances":"psilocybin","conditions":"COPD (Chronic Obstructive Pulmonary Disease); ALS (Amyotrophic Lateral Sclerosis); MS (Multiple Sclerosis); Major Depressive Disorder (MDD); Atypical Parkinson Disease","sponsor":"University Medical Center Groningen","sponsor_class":"OTHER","has_results":false,"site_count":4,"countries":"Czechia; Denmark; Netherlands; Portugal","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06782724","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06782724"},{"nct_id":"NCT06784388","title":"Personalized DBS Targeting for Treating Depression","acronym":"","status":"RECRUITING","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":5,"start_date":"2025-01-05","completion_date":"2027-12-30","last_update":"2026-04-27","substances":"ketamine","conditions":"Treatment-resistant Depression (TRD)","sponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06784388","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06784388"},{"nct_id":"NCT06786325","title":"Wellcome Leap Psilocybin for OUD","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":36,"start_date":"2025-10-07","completion_date":"2027-06","last_update":"2025-10-29","substances":"psilocybin","conditions":"Opioid Use Disorder","sponsor":"Anna Rose Childress, Ph.D.","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Pennsylvania","lsd_com_url":"https://lsd.com/trials/nct06786325","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06786325"},{"nct_id":"NCT06788249","title":"Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine","acronym":"","status":"RECRUITING","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2026-04-01","completion_date":"2026-09-15","last_update":"2026-09-10","substances":"ketamine","conditions":"Major Depressive Disorder (MDD)","sponsor":"University of Pennsylvania","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Pennsylvania","lsd_com_url":"https://lsd.com/trials/nct06788249","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06788249"},{"nct_id":"NCT06789705","title":"Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls","acronym":"OxyMAX","status":"RECRUITING","phases":"NA","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2025-01-27","completion_date":"2026-12","last_update":"2025-02-19","substances":"mdma","conditions":"Central Diabetes Insipidus","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06789705","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06789705"},{"nct_id":"NCT06793397","title":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","acronym":"EMBRACE","status":"RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":330,"start_date":"2025-12-10","completion_date":"2027-06-07","last_update":"2026-10-05","substances":"psilocybin","conditions":"Major Depressive Disorder (MDD); Depression in Adults; Depression - Major Depressive Disorder; Depression Disorders; Depression Disorder; Depression","sponsor":"Cybin IRL Limited","sponsor_class":"INDUSTRY","has_results":false,"site_count":79,"countries":"Australia; Czechia; Germany; Greece; Ireland; Poland; United Kingdom; United States","us_states":"Alabama; Arizona; Arkansas; California; Connecticut; Florida; Georgia; Illinois; Louisiana; Maryland; Massachusetts; Minnesota; Nevada; New Jersey; New York; Oklahoma; Pennsylvania; Texas; Washington","lsd_com_url":"https://lsd.com/trials/nct06793397","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06793397"},{"nct_id":"NCT06795659","title":"Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)","acronym":"","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":4,"start_date":"2025-06-09","completion_date":"2026-01-16","last_update":"2026-01-28","substances":"ketamine","conditions":"Post Traumatic Stress Disorder PTSD","sponsor":"The University of Texas Health Science Center at San Antonio","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct06795659","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06795659"},{"nct_id":"NCT06796062","title":"Psilocybin for Opioid Use Disorder (OUD)","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":480,"start_date":"2025-12-17","completion_date":"2029-02","last_update":"2026-01-23","substances":"psilocybin","conditions":"Opioid Use Disorder","sponsor":"NYU Langone Health","sponsor_class":"OTHER","has_results":false,"site_count":5,"countries":"United States","us_states":"New Mexico; New York","lsd_com_url":"https://lsd.com/trials/nct06796062","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06796062"},{"nct_id":"NCT06796361","title":"Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness","acronym":"PDR","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2025-04-21","completion_date":"2026-08","last_update":"2025-05-28","substances":"psilocybin","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06796361","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06796361"},{"nct_id":"NCT06798636","title":"PsiloIMAGINE: A Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm","acronym":"PsiloIMAGINE","status":"RECRUITING","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2025-10-01","completion_date":"2026-08-31","last_update":"2025-12-05","substances":"psilocybin","conditions":"Self Harm","sponsor":"Imperial College London","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06798636","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06798636"},{"nct_id":"NCT06801041","title":"TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2025-05-23","completion_date":"2027-03-31","last_update":"2026-08-12","substances":"psilocybin","conditions":"Depression; Anxiety; Cancer","sponsor":"M.D. Anderson Cancer Center","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct06801041","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06801041"},{"nct_id":"NCT06806475","title":"Sustained Ketamine Effectiveness for Suicidal Ideation","acronym":"SKESI","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":128,"start_date":"2023-12-01","completion_date":"2024-09-23","last_update":"2025-03-30","substances":"ketamine","conditions":"Depression - Major Depressive Disorder; Suicide","sponsor":"University Hospital, Montpellier","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"France","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06806475","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06806475"},{"nct_id":"NCT06809595","title":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":245,"start_date":"2025-01-29","completion_date":"2026-08-13","last_update":"2026-09-04","substances":"lsd","conditions":"Generalized Anxiety Disorder","sponsor":"Definium Therapeutics US, Inc.","sponsor_class":"INDUSTRY","has_results":false,"site_count":36,"countries":"Czechia; France; Germany; Poland; United Kingdom; United States","us_states":"Arkansas; California; Florida; Georgia; Maryland; Massachusetts; New Jersey; Ohio; Texas; Washington","lsd_com_url":"https://lsd.com/trials/nct06809595","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06809595"},{"nct_id":"NCT06810310","title":"Psilocybin on Brain Mechanisms of Motivation in OUD","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2025-12-22","completion_date":"2027-05-01","last_update":"2026-07-09","substances":"psilocybin","conditions":"Opioid Use Disorder","sponsor":"University of Pennsylvania","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Pennsylvania","lsd_com_url":"https://lsd.com/trials/nct06810310","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06810310"},{"nct_id":"NCT06810765","title":"Trifecta Research Study","acronym":"","status":"WITHDRAWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2025-09","completion_date":"2026-12","last_update":"2025-08-22","substances":"dmt; ibogaine","conditions":"PTSD - Post Traumatic Stress Disorder; Cognitive Dysfunction; Brain Trauma; Brain Injuries","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct06810765","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06810765"},{"nct_id":"NCT06812221","title":"Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI","acronym":"5-MeO-DMT","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2024-12-15","completion_date":"2025-02-15","last_update":"2025-04-09","substances":"dmt","conditions":"Mild Cognitive Impairment; Anxiety State; Depression Anxiety Disorder","sponsor":"Biomind Labs Inc.","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"Argentina","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06812221","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06812221"},{"nct_id":"NCT06814522","title":"Psilocybin-Assisted Therapy for Physician Well-Being and Burnout","acronym":"PAT-B","status":"RECRUITING","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2025-01-13","completion_date":"2028-06","last_update":"2026-09-02","substances":"psilocybin","conditions":"Burnout; Burnout, Healthcare Workers","sponsor":"University of California, San Diego","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct06814522","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06814522"},{"nct_id":"NCT06815653","title":"Digital Intervention for Psychedelic Preparation (DIPP): Comparing Meditation and Music-Based Programs","acronym":"(DIPP-RCFT)","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2025-03-01","completion_date":"2026-03","last_update":"2025-11-26","substances":"psilocybin","conditions":"Healthy","sponsor":"University College, London","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06815653","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06815653"},{"nct_id":"NCT06816433","title":"Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002","acronym":"","status":"SUSPENDED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":200,"start_date":"2028-05","completion_date":"2029-05","last_update":"2026-05-20","substances":"ketamine","conditions":"Post Traumatic Stress Disorder","sponsor":"Global Coalition for Adaptive Research","sponsor_class":"OTHER","has_results":false,"site_count":9,"countries":"United States","us_states":"Florida; Georgia; Hawaii; Kentucky; Maryland; New York; Texas; Virginia; Washington","lsd_com_url":"https://lsd.com/trials/nct06816433","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06816433"},{"nct_id":"NCT06816667","title":"Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety","acronym":"5-MeO-DMT","status":"COMPLETED","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2024-10-21","completion_date":"2025-02-14","last_update":"2025-03-05","substances":"dmt","conditions":"Healthy Volunteers","sponsor":"Biomind Labs Inc.","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"Argentina","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06816667","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06816667"},{"nct_id":"NCT06818994","title":"Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer","acronym":"","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":15,"start_date":"2026-04-01","completion_date":"2027-06-01","last_update":"2026-03-18","substances":"psilocybin","conditions":"Demoralization; Safety","sponsor":"Gustavo Vazquez","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06818994","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06818994"},{"nct_id":"NCT06820723","title":"A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2026-08-01","completion_date":"2028-09","last_update":"2026-07-23","substances":"psilocybin","conditions":"Depression; Anxiety; Major Depressive Disorder","sponsor":"Ohio State University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Ohio","lsd_com_url":"https://lsd.com/trials/nct06820723","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06820723"},{"nct_id":"NCT06824532","title":"Veteran's Perceptions of Ketamine-Assisted Psychotherapy for Depression and End-of-Life","acronym":"KAP","status":"RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":30,"start_date":"2024-11-08","completion_date":"2025-03","last_update":"2025-02-13","substances":"ketamine","conditions":"Depression","sponsor":"Albany Research Institute, Inc.","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct06824532","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06824532"},{"nct_id":"NCT06827054","title":"Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2026-09-15","completion_date":"2027-05-05","last_update":"2026-08-12","substances":"psilocybin","conditions":"Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm","sponsor":"Roswell Park Cancer Institute","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct06827054","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06827054"},{"nct_id":"NCT06835699","title":"Psilocybin Brain Stimulation and Imaging Pilot Study","acronym":"OPTE","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2025-04-18","completion_date":"2026-05-21","last_update":"2026-08-07","substances":"psilocybin","conditions":"Healthy Volunteers","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct06835699","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06835699"},{"nct_id":"NCT06853431","title":"Determination of ED50 and ED95 With Clinical Efficacy of Intranasal Dexmedetomidine Combined With Esketamine for Preoperative Sedation in Pediatric General Anesthesia","acronym":"","status":"RECRUITING","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":80,"start_date":"2025-03-01","completion_date":"2025-11-30","last_update":"2025-12-02","substances":"ketamine","conditions":"Preoperative Anxiety; Preoperative Sedation; Children; Dexmedetomidine; Esketamine; ED95; ED50; Preoperative Sedation of Children","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06853431","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06853431"},{"nct_id":"NCT06853912","title":"PsiloStudy: Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)","acronym":"Psi-PS","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2025-06-01","completion_date":"2026-11-01","last_update":"2026-08-13","substances":"psilocybin","conditions":"Alcohol Use Disorder (AUD); PTSD","sponsor":"Nathan Brashares Sackett","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Washington","lsd_com_url":"https://lsd.com/trials/nct06853912","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06853912"},{"nct_id":"NCT06884514","title":"Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects","acronym":"MDMA-Psilo","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2025-04-03","completion_date":"2026-05-13","last_update":"2026-06-25","substances":"psilocybin; mdma","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06884514","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06884514"},{"nct_id":"NCT06885996","title":"Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence","acronym":"PsiPTSD","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":76,"start_date":"2026-10-01","completion_date":"2028-08-01","last_update":"2026-09-08","substances":"psilocybin","conditions":"Post Traumatic Stress Disorder PTSD; Intimate Partner Violence (IPV)","sponsor":"University of Calgary","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06885996","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06885996"},{"nct_id":"NCT06887426","title":"Cladribine Tablets as an Exit Therapy Strategy","acronym":"CLADREXIT","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":450,"start_date":"2025-10-17","completion_date":"2026-06-01","last_update":"2026-10-06","substances":"dmt","conditions":"Multiple Sclerosis; Relapsing Remitting Multiple Sclerosis; Secondary Progressive Multiple Sclerosis","sponsor":"University Hospital, Strasbourg, France","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"France","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06887426","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06887426"},{"nct_id":"NCT06888128","title":"State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma","acronym":"STARLIGHT","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":15,"start_date":"2025-01-30","completion_date":"2026-12-15","last_update":"2026-01-22","substances":"psilocybin","conditions":"PTSD","sponsor":"Baylor College of Medicine","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct06888128","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06888128"},{"nct_id":"NCT06891300","title":"Understanding and Treating Suicidal Ideation With Ketamine","acronym":"","status":"RECRUITING","phases":"PHASE2; PHASE3","study_type":"INTERVENTIONAL","enrollment":36,"start_date":"2025-04-08","completion_date":"2026-10","last_update":"2026-05-19","substances":"ketamine","conditions":"Suicidal Ideation; Major Depressive Disorder (MDD)","sponsor":"The Royal's Institute of Mental Health Research","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06891300","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06891300"},{"nct_id":"NCT06898606","title":"Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression","acronym":"COGUNILA","status":"RECRUITING","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2024-09-05","completion_date":"2026-08-20","last_update":"2026-03-27","substances":"psilocybin","conditions":"Depressive Disorder","sponsor":"Federal University of Latin American Integration","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Brazil","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06898606","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06898606"},{"nct_id":"NCT06899165","title":"Psilocybin-Assisted Therapy for Intergenerational Trauma","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":100,"start_date":"2026-08-28","completion_date":"2029-05-31","last_update":"2026-08-13","substances":"psilocybin","conditions":"Psychological Stress; Depression; Anxiety","sponsor":"Rachel Yehuda","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct06899165","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06899165"},{"nct_id":"NCT06899334","title":"Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants","acronym":"LPD","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2025-04-01","completion_date":"2026-08-01","last_update":"2025-03-27","substances":"lsd; psilocybin; dmt","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06899334","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06899334"},{"nct_id":"NCT06899594","title":"Psilocybin for Methamphetamine Addiction","acronym":"","status":"RECRUITING","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2025-04-04","completion_date":"2027-03","last_update":"2025-10-07","substances":"psilocybin","conditions":"Methamphetamine Use Disorder","sponsor":"Kevin Murnane","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Louisiana","lsd_com_url":"https://lsd.com/trials/nct06899594","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06899594"},{"nct_id":"NCT06902974","title":"Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD","acronym":"SUN004","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":70,"start_date":"2026-05-23","completion_date":"2027-11","last_update":"2026-07-01","substances":"psilocybin","conditions":"Post Traumatic Stress Disorder; PTSD","sponsor":"Sunstone Medical","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct06902974","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06902974"},{"nct_id":"NCT06903819","title":"Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients","acronym":"","status":"RECRUITING","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":90,"start_date":"2025-11-06","completion_date":"2027-05","last_update":"2026-03-24","substances":"ketamine","conditions":"Orthopedic Trauma Surgery Patients; Postoperative Pain; Opioid Use; Depression; Post-traumatic Stress Disorder (PTSD)","sponsor":"Texas Tech University Health Sciences Center","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct06903819","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06903819"},{"nct_id":"NCT06905652","title":"Comparative Acute Effects of R-MDMA and S-MDMA in Healthy Participants","acronym":"R-S-","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":26,"start_date":"2025-07-29","completion_date":"2026-05-12","last_update":"2026-05-15","substances":"mdma","conditions":"Healthy","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06905652","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06905652"},{"nct_id":"NCT06919640","title":"Psilocybin With Intracranial Neural Sensing","acronym":"PINS","status":"ENROLLING_BY_INVITATION","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2025-06-01","completion_date":"2028-04-30","last_update":"2025-06-06","substances":"psilocybin","conditions":"Chronic Pain","sponsor":"Joshua Woolley, MD, PhD","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct06919640","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06919640"},{"nct_id":"NCT06927076","title":"Antidepressant Response of DMT Masked With Propofol","acronym":"DMT4D","status":"RECRUITING","phases":"NA","study_type":"INTERVENTIONAL","enrollment":112,"start_date":"2025-08-05","completion_date":"2029-03","last_update":"2026-04-02","substances":"dmt","conditions":"Major Depressive Disorder; Psychedelic Experiences","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06927076","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06927076"},{"nct_id":"NCT06935552","title":"Ketamine and Lidocaine Infusion in Refractory Chronic Migraine","acronym":"","status":"NOT_YET_RECRUITING","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":44,"start_date":"2025-06-01","completion_date":"2026-11","last_update":"2025-04-20","substances":"ketamine","conditions":"Refractory Chronic Migraine","sponsor":"Assiut University","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06935552","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06935552"},{"nct_id":"NCT06941844","title":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":149,"start_date":"2025-04-14","completion_date":"2026-05-20","last_update":"2026-08-28","substances":"lsd","conditions":"Major Depressive Disorder","sponsor":"Definium Therapeutics US, Inc.","sponsor_class":"INDUSTRY","has_results":false,"site_count":22,"countries":"United States","us_states":"Arkansas; California; Colorado; Florida; Illinois; Maryland; Massachusetts; Missouri; New Jersey; New York; Ohio; Pennsylvania; Tennessee; Texas; Utah; Vermont","lsd_com_url":"https://lsd.com/trials/nct06941844","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06941844"},{"nct_id":"NCT06943573","title":"Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder","acronym":"PAT-BD-01","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":90,"start_date":"2026-06-15","completion_date":"2028-12","last_update":"2026-09-15","substances":"psilocybin","conditions":"Bipolar II Depression","sponsor":"Lakshmi N Yatham","sponsor_class":"OTHER","has_results":false,"site_count":3,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06943573","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06943573"},{"nct_id":"NCT06943859","title":"Ketamine for Opioid Use Disorder","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2026-02-04","completion_date":"2028-08-31","last_update":"2026-08-31","substances":"ketamine","conditions":"Opioid Use Disorder","sponsor":"University of Maryland, Baltimore","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct06943859","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06943859"},{"nct_id":"NCT06954025","title":"High-Intensity Inpatient MDMA-Assisted Psychotherapy for PTSD","acronym":"HI-MAP","status":"ENROLLING_BY_INVITATION","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2025-05-16","completion_date":"2026-12","last_update":"2025-07-24","substances":"mdma","conditions":"Posttraumatic Stress Disorder (PTSD)","sponsor":"ARQ National Psychotrauma Centre","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Netherlands","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06954025","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06954025"},{"nct_id":"NCT06957704","title":"Evaluation of the Efficacy and Safety of Subcutaneous Ketamine in the Treatment of Depressive Episode With Suicidal Ideation and/or Behavior in Adolescents","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2025-05","completion_date":"2028-04","last_update":"2025-05-04","substances":"ketamine","conditions":"Depressive Disorder; Suicidal Ideas","sponsor":"Federal University of São Paulo","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06957704","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06957704"},{"nct_id":"NCT06968624","title":"Ketamine for Postherpetic Neuralgia With Depression","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2025-06-15","completion_date":"2026-04-01","last_update":"2025-06-03","substances":"ketamine","conditions":"Depression Disorders; Herpetic Neuralgia","sponsor":"Huazhong University of Science and Technology","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06968624","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06968624"},{"nct_id":"NCT06969170","title":"Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2025-05-16","completion_date":"2027-12-31","last_update":"2026-08-12","substances":"psilocybin","conditions":"Generalized Anxiety Disorder (GAD)","sponsor":"Claudio N Soares","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06969170","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06969170"},{"nct_id":"NCT06969937","title":"Ketamine and Neurofeedback as Combined Therapeutic Interventions to Target Glutamatergic Neurotransmission in Alcohol Use Disorder","acronym":"Nektar","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":75,"start_date":"2025-06-01","completion_date":"2026-12","last_update":"2025-12-05","substances":"ketamine","conditions":"Alcohol Abuse/Dependence; Alcohol Use Disorder (AUD); Alcoholism","sponsor":"Dr. med. Marcus Herdener","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06969937","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06969937"},{"nct_id":"NCT06985069","title":"Outcome of Multimodal Anesthesia Bern","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":240,"start_date":"2025-06-16","completion_date":"2025-09-18","last_update":"2025-11-18","substances":"ketamine","conditions":"Opioid Use; Pain, Postoperative; Postoperative Complications; Postoperative Nausea","sponsor":"Insel Gruppe AG, University Hospital Bern","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct06985069","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06985069"},{"nct_id":"NCT06988319","title":"Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study","acronym":"","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":15,"start_date":"2026-11-01","completion_date":"2027-12-31","last_update":"2026-09-23","substances":"psilocybin","conditions":"Chronic Pelvic Pain","sponsor":"Oregon Health and Science University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Oregon","lsd_com_url":"https://lsd.com/trials/nct06988319","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06988319"},{"nct_id":"NCT06989957","title":"Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)","acronym":"PAM-VET","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2025-09-17","completion_date":"2028-08","last_update":"2026-09-04","substances":"psilocybin; mdma","conditions":"Posttraumatic Stress Disorder","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct06989957","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06989957"},{"nct_id":"NCT06992999","title":"Psilocybin for Treatment of OCD-2","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2026-09-08","completion_date":"2028-12","last_update":"2026-05-12","substances":"psilocybin","conditions":"Obsessive - Compulsive Disorder","sponsor":"Francisco A Moreno","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Arizona","lsd_com_url":"https://lsd.com/trials/nct06992999","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06992999"},{"nct_id":"NCT06997549","title":"Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments","acronym":"","status":"RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":12000,"start_date":"2025-05-15","completion_date":"2035-12","last_update":"2026-04-09","substances":"ketamine","conditions":"Depression; OCD; Anxiety Depression","sponsor":"Neuronetics","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Pennsylvania","lsd_com_url":"https://lsd.com/trials/nct06997549","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT06997549"},{"nct_id":"NCT07001033","title":"Dance Movement Therapy for Radio-oncological Patients","acronym":"DANCE-RT-01","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":8,"start_date":"2025-02-22","completion_date":"2025-04-20","last_update":"2025-06-03","substances":"dmt","conditions":"Cancer Patients and Physical Activity","sponsor":"University of Erlangen-Nürnberg Medical School","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Germany","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07001033","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07001033"},{"nct_id":"NCT07002684","title":"Metabolic Profiling of Esketamine Treatment in Depressive Disorder","acronym":"","status":"RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":100,"start_date":"2023-04-01","completion_date":"2025-12-31","last_update":"2025-06-03","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"University of Zagreb","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Croatia","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07002684","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07002684"},{"nct_id":"NCT07009158","title":"Ketamine Assisted Psychotherapy for Treating Comorbid Chronic Pain and PTSD","acronym":"","status":"RECRUITING","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2026-03-31","completion_date":"2029-09","last_update":"2026-09-15","substances":"ketamine","conditions":"Chronic Pain; Posttraumatic Stress Disorder (PTSD)","sponsor":"Dr. Yuliya Knyahnytska","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07009158","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07009158"},{"nct_id":"NCT07017478","title":"Mood Effects of Serotonin Agonists: Depression","acronym":"MESA-D","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":41,"start_date":"2025-06-09","completion_date":"2026-06-01","last_update":"2026-07-10","substances":"lsd","conditions":"LSD; Major Depressive Disorder; Depression","sponsor":"University of Chicago","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Illinois","lsd_com_url":"https://lsd.com/trials/nct07017478","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07017478"},{"nct_id":"NCT07048743","title":"Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients With Advanced Cancer","acronym":"PEARL-C1","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":15,"start_date":"2025-07-16","completion_date":"2027-12-02","last_update":"2026-06-23","substances":"psilocybin","conditions":"Caregiver Distress","sponsor":"University Health Network, Toronto","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07048743","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07048743"},{"nct_id":"NCT07050368","title":"A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2025-07-28","completion_date":"2026-01-13","last_update":"2026-02-13","substances":"psilocybin","conditions":"Healthy Volunteer","sponsor":"MycoMedica Life Sciences PBC","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07050368","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07050368"},{"nct_id":"NCT07053345","title":"A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression","acronym":"","status":"COMPLETED","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":47,"start_date":"2025-06-09","completion_date":"2026-07-13","last_update":"2026-08-03","substances":"ketamine","conditions":"Depressive Disorder, Treatment-Resistant","sponsor":"Janssen Korea, Ltd., Korea","sponsor_class":"INDUSTRY","has_results":false,"site_count":6,"countries":"South Korea","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07053345","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07053345"},{"nct_id":"NCT07053917","title":"Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability","acronym":"PHATHOM","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2026-02-09","completion_date":"2027-02","last_update":"2026-02-13","substances":"psilocybin","conditions":"Stroke; Chronic Stroke; Intracerebral Haemorrhage; Intracerebral Haemorrhage (ICH); Intracerebral Hemorrhage Basal Ganglia; Ischemic Stroke; Ischemic Stroke and Hemorrhagic Stroke; Hemiparesis After Stroke; Hemiplegia Following Ischemic Stroke; Hemiplegia and Hemiparesis; Hemiplegia and/or Hemiparesis Following Stroke; Middle Cerebral Artery Stroke","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct07053917","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07053917"},{"nct_id":"NCT07059429","title":"Ketamine Administration for Postoperative Pain Management in Patients Undergoing Knee Arthroplasty","acronym":"KETARTHRO","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":100,"start_date":"2025-07-01","completion_date":"2025-12-31","last_update":"2026-03-02","substances":"ketamine","conditions":"Knee Arthroplasty; Postoperative Pain; Pain Management; Analgesia; Opioid Use; Ketamine","sponsor":"State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia","sponsor_class":"OTHER","has_results":true,"site_count":1,"countries":"Russia","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07059429","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07059429"},{"nct_id":"NCT07061886","title":"Drug Effects on Mood and Behavior - Expectancy","acronym":"MESA-X","status":"COMPLETED","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":42,"start_date":"2025-06-26","completion_date":"2026-06-05","last_update":"2026-07-09","substances":"lsd","conditions":"LSD","sponsor":"University of Chicago","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Illinois","lsd_com_url":"https://lsd.com/trials/nct07061886","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07061886"},{"nct_id":"NCT07063862","title":"Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT)","acronym":"","status":"RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":120,"start_date":"2026-01-28","completion_date":"2027-08","last_update":"2026-07-10","substances":"psilocybin","conditions":"Psychological Distress","sponsor":"Bruyère Health Research Institute.","sponsor_class":"OTHER","has_results":false,"site_count":7,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07063862","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07063862"},{"nct_id":"NCT07072728","title":"Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":87,"start_date":"2025-10-01","completion_date":"2026-12-30","last_update":"2026-03-03","substances":"psilocybin","conditions":"Adjustment Disorder; Adjustment Disorder With Anxious Mood; Cancer; Cancer Cachexia; Cancer of Endometrium; Cancer of Kidney; Cancer of Prostate; Cancer of the Breast; Cancer of Stomach; Cancer Melanoma Skin; Cancer Pancreas","sponsor":"Psyence Australia Pty Ltd","sponsor_class":"INDUSTRY","has_results":false,"site_count":3,"countries":"Australia","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07072728","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07072728"},{"nct_id":"NCT07079852","title":"The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":48,"start_date":"2026-09","completion_date":"2028-08","last_update":"2026-06-15","substances":"psilocybin","conditions":"Healthy","sponsor":"Manoj Doss","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct07079852","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07079852"},{"nct_id":"NCT07079930","title":"Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers","acronym":"","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2025-12-11","completion_date":"2026-11","last_update":"2026-02-05","substances":"psilocybin","conditions":"Healthy Volunteers","sponsor":"Hadassah Medical Organization","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Israel","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07079930","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07079930"},{"nct_id":"NCT07088380","title":"Ketamine Augmentation of ECT in Treatment-Resistant Depression","acronym":"Ketamina","status":"RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2025-07-10","completion_date":"2026-08","last_update":"2026-05-11","substances":"ketamine","conditions":"Major Depressive Disorder; Treatment Resistant Depression","sponsor":"Università Vita-Salute San Raffaele","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Italy","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07088380","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07088380"},{"nct_id":"NCT07097025","title":"2-Year Study of Vagus Nerve Stimulation for Higher-Grade Treatment-Resistant Depression: Clinical Outcomes and Policy Recommendation","acronym":"VNS TRD HG-TRD","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":19,"start_date":"2020-01-01","completion_date":"2025-06-30","last_update":"2025-08-05","substances":"ketamine","conditions":"Treatment Resistant Depression (TRD); Depression - Major Depressive Disorder; Bipolar Depression","sponsor":"Dr.Yoav Domany","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"Israel","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07097025","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07097025"},{"nct_id":"NCT07099235","title":"Chart Review of Patients Undergoing Ketamine Treatments for Depression","acronym":"","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":250,"start_date":"2022-04-01","completion_date":"2025-06-29","last_update":"2025-08-01","substances":"ketamine","conditions":"Depression - Major Depressive Disorder","sponsor":"Sunnybrook Health Sciences Centre","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07099235","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07099235"},{"nct_id":"NCT07102576","title":"MDMA-Assisted Therapy for Mental Healthcare Providers","acronym":"","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2026-02-11","completion_date":"2029-09-21","last_update":"2026-03-27","substances":"mdma","conditions":"Mental Wellbeing","sponsor":"Rachel Yehuda","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct07102576","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07102576"},{"nct_id":"NCT07104916","title":"Mindfulness-based Psilocybin Therapy for PTSD","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2026-07-01","completion_date":"2029-09","last_update":"2026-06-25","substances":"psilocybin","conditions":"Post Traumatic Stress Disorder; Depression - Major Depressive Disorder","sponsor":"Anthony P King","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Ohio","lsd_com_url":"https://lsd.com/trials/nct07104916","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07104916"},{"nct_id":"NCT07118332","title":"Psilocybin as a Treatment for Chronic Pain in Smokers","acronym":"","status":"RECRUITING","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2026-07-06","completion_date":"2027-10-01","last_update":"2026-08-03","substances":"psilocybin","conditions":"Smokers With Chronic Pain","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct07118332","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07118332"},{"nct_id":"NCT07118839","title":"MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder","acronym":"MAP VETS","status":"RECRUITING","phases":"PHASE2; PHASE3","study_type":"INTERVENTIONAL","enrollment":80,"start_date":"2026-05-18","completion_date":"2030-05-01","last_update":"2026-06-02","substances":"mdma","conditions":"Post Traumatic Stress Disorder; Alcohol Use Disorder","sponsor":"VA Office of Research and Development","sponsor_class":"FED","has_results":false,"site_count":2,"countries":"United States","us_states":"Connecticut; Rhode Island","lsd_com_url":"https://lsd.com/trials/nct07118839","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07118839"},{"nct_id":"NCT07120477","title":"Esketamine Versus Crisis Response Planning Versus Enhanced Treatment as Usual for Suicide Prevention: A Pragmatic Randomized Trial in a Brazilian Municipality (SAVE)","acronym":"SAVE","status":"RECRUITING","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":478,"start_date":"2026-06-01","completion_date":"2028-12","last_update":"2026-09-16","substances":"ketamine","conditions":"Suicide Prevention; Ketamine; Crisis Response Plan","sponsor":"University of Sao Paulo","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Brazil","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07120477","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07120477"},{"nct_id":"NCT07139106","title":"Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2026-10-01","completion_date":"2028-10-01","last_update":"2026-08-03","substances":"ketamine","conditions":"Major Depressive Disorder (MDD)","sponsor":"New York State Psychiatric Institute","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct07139106","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07139106"},{"nct_id":"NCT07146503","title":"Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression","acronym":"ESKPSY","status":"RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":100,"start_date":"2022-11-01","completion_date":"2026-07","last_update":"2026-03-31","substances":"ketamine","conditions":"Depression and Quality of Life; Treatment Resistant Depression (TRD); Anhedonia; Apathy; Anxiety; Cognition; Temperament; Psychiatric Comorbidities","sponsor":"Riccardo Guglielmo","sponsor_class":"OTHER","has_results":false,"site_count":5,"countries":"Italy","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07146503","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07146503"},{"nct_id":"NCT07153406","title":"Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients","acronym":"CESAR","status":"NOT_YET_RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":220,"start_date":"2025-09-15","completion_date":"2026-09-15","last_update":"2025-09-04","substances":"ketamine","conditions":"Depressive Disorder","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","sponsor_class":"OTHER","has_results":false,"site_count":9,"countries":"Spain","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07153406","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07153406"},{"nct_id":"NCT07164287","title":"Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":376,"start_date":"2020-06-01","completion_date":"2025-04-30","last_update":"2025-10-02","substances":"lsd; psilocybin","conditions":"Major Depressive Disorder (MDD); Anxiety Disorders; Substance Use Disorder (SUD); PTSD - Post Traumatic Stress Disorder","sponsor":"University Hospital, Geneva","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07164287","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07164287"},{"nct_id":"NCT07164755","title":"Measurement of Serum Inflammatory Markers in Patients Treatment-resistant Depression Given Psilocybin","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":46,"start_date":"2021-06-21","completion_date":"2026-09","last_update":"2025-09-10","substances":"psilocybin","conditions":"Depression - Major Depressive Disorder","sponsor":"King's College London","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United Kingdom","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07164755","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07164755"},{"nct_id":"NCT07169747","title":"Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young Adults With Anorexia Nervosa","acronym":"psiAN","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2026-07-20","completion_date":"2027-10-01","last_update":"2026-08-14","substances":"psilocybin","conditions":"Anorexia Nervosa","sponsor":"Region Skane","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Sweden","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07169747","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07169747"},{"nct_id":"NCT07179913","title":"The Improvement of Low-dose Esketamine on Postoperative Depression in Patients Undergoing Bariatric Surgery With Preoperative Depression","acronym":"esketamine","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2026-05-01","completion_date":"2026-11-20","last_update":"2026-05-08","substances":"ketamine","conditions":"Depressed; Bariatric Surgery","sponsor":"The First Hospital of Jilin University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07179913","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07179913"},{"nct_id":"NCT07180095","title":"Children of Age 2-6years Undergoing Elective Surgery Will be Divided Into Two Groups Randomly. This Study Aims to Evaluate if Intranasal Dexmedetomidine is Better Than Intranasal Ketamine in Producing Sedation and Reducing Parent Separation Anxiety Before Surgery.","acronym":"DREAM-Kids","status":"NOT_YET_RECRUITING","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2026-01-01","completion_date":"2026-06-30","last_update":"2025-09-18","substances":"ketamine","conditions":"Sedation; Preoperative Anxiety Experienced by the Pediatric Patient; Anxiolytic Effect; Sedation and Analgesia","sponsor":"Liaquat National Hospital & Medical College","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07180095","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07180095"},{"nct_id":"NCT07180108","title":"PRoMiSS: Psilocybin and the Role of Music in Set and Setting","acronym":"PRoMiSS","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":100,"start_date":"2025-08-12","completion_date":"2028-06","last_update":"2026-09-15","substances":"psilocybin","conditions":"Psilocybin; Music Intervention","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct07180108","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07180108"},{"nct_id":"NCT07183748","title":"Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2025-12-01","completion_date":"2027-06-01","last_update":"2025-11-19","substances":"psilocybin","conditions":"Treatment Resistant Depression","sponsor":"Beersheva Mental Health Center","sponsor_class":"OTHER_GOV","has_results":false,"site_count":1,"countries":"Israel","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07183748","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07183748"},{"nct_id":"NCT07189299","title":"Microdosing LSD in Women With Premenstrual Disorders","acronym":"L4Her","status":"NOT_YET_RECRUITING","phases":"NA","study_type":"INTERVENTIONAL","enrollment":150,"start_date":"2025-10-01","completion_date":"2029-11-01","last_update":"2025-09-23","substances":"lsd","conditions":"PMS; PMDD","sponsor":"Friederike Holze","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07189299","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07189299"},{"nct_id":"NCT07189988","title":"Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":20,"start_date":"2025-03-05","completion_date":"2026-06-10","last_update":"2025-09-24","substances":"psilocybin","conditions":"Alcohol Use Disorder","sponsor":"Healing Advocacy Fund","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Oregon","lsd_com_url":"https://lsd.com/trials/nct07189988","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07189988"},{"nct_id":"NCT07193901","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":98,"start_date":"2025-05-27","completion_date":"2026-04-10","last_update":"2026-09-09","substances":"ketamine","conditions":"Major Depressive Disorder (MDD","sponsor":"Sichuan Purity Pharmaceutical Technology Co., Ltd.","sponsor_class":"INDUSTRY","has_results":false,"site_count":15,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07193901","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07193901"},{"nct_id":"NCT07199179","title":"Link Between Reduction of Suicide Ideation by Esketamine in Add-On and Initial Levels of Psychological Pain and Anhedonia","acronym":"IODA","status":"ACTIVE_NOT_RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":456,"start_date":"2024-11-24","completion_date":"2025-11-24","last_update":"2025-09-30","substances":"ketamine","conditions":"Depression - Major Depressive Disorder; Depression Disorder; Suicide","sponsor":"University Hospital, Montpellier","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"France","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07199179","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07199179"},{"nct_id":"NCT07210112","title":"Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)","acronym":"PSILOTRAZ","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":112,"start_date":"2026-06-30","completion_date":"2029-12-31","last_update":"2026-09-21","substances":"psilocybin","conditions":"Depression - Major Depressive Disorder; Treatment-resistant Depression (TRD)","sponsor":"Centre Hospitalier St Anne","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"France","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07210112","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07210112"},{"nct_id":"NCT07211399","title":"Transition From Acute to Chronic Opioid Use and Chronic Pain","acronym":"","status":"WITHDRAWN","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2026-07-01","completion_date":"2030-12-01","last_update":"2026-06-30","substances":"ketamine","conditions":"Opioid Use Disorder","sponsor":"Jacques E. Chelly","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Pennsylvania","lsd_com_url":"https://lsd.com/trials/nct07211399","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07211399"},{"nct_id":"NCT07211438","title":"Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression","acronym":"PSI-TNT","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2026-07-03","completion_date":"2028-07","last_update":"2026-08-21","substances":"psilocybin","conditions":"Treatment-Resistant Depression","sponsor":"Centre for Addiction and Mental Health","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07211438","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07211438"},{"nct_id":"NCT07212946","title":"Ayahuasca and Esketamine for Major Depression","acronym":"","status":"COMPLETED","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":22,"start_date":"2022-10-30","completion_date":"2024-10-30","last_update":"2025-12-29","substances":"ketamine; dmt","conditions":"Major Depression Severe","sponsor":"University of Sao Paulo","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Brazil","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07212946","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07212946"},{"nct_id":"NCT07216404","title":"Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2026-01-01","completion_date":"2027-10-31","last_update":"2026-05-14","substances":"psilocybin","conditions":"Lung Non-Small Cell Carcinoma; Unipolar Depression","sponsor":"Alan Davis","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Ohio","lsd_com_url":"https://lsd.com/trials/nct07216404","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07216404"},{"nct_id":"NCT07226232","title":"Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression","acronym":"PIVOT","status":"RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":240,"start_date":"2026-08-03","completion_date":"2030-12-02","last_update":"2026-08-14","substances":"psilocybin","conditions":"Major Depression","sponsor":"VA Office of Research and Development","sponsor_class":"FED","has_results":false,"site_count":5,"countries":"United States","us_states":"Alabama; Oregon; Pennsylvania; Washington","lsd_com_url":"https://lsd.com/trials/nct07226232","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07226232"},{"nct_id":"NCT07226570","title":"Mapping Ibogaine Neural Dynamics in Opioid Use Disorder","acronym":"MIND-OUD","status":"RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":20,"start_date":"2025-09-08","completion_date":"2027-05","last_update":"2026-05-18","substances":"ibogaine","conditions":"Opioid Use Disorder (OUD)","sponsor":"University of California, Irvine","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct07226570","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07226570"},{"nct_id":"NCT07227454","title":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","acronym":"AVENUE","status":"RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":258,"start_date":"2026-01-08","completion_date":"2031-04-09","last_update":"2026-09-25","substances":"ketamine","conditions":"Depressive Disorder, Major","sponsor":"Janssen Research & Development, LLC","sponsor_class":"INDUSTRY","has_results":false,"site_count":44,"countries":"Brazil; Hungary; Italy; Romania; Spain; Taiwan; United States","us_states":"Alabama; District of Columbia; Georgia; Illinois; Maryland; Massachusetts; Minnesota; Ohio; Rhode Island; Texas","lsd_com_url":"https://lsd.com/trials/nct07227454","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07227454"},{"nct_id":"NCT07227909","title":"NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":83,"start_date":"2026-11-04","completion_date":"2029-01-31","last_update":"2026-10-05","substances":"psilocybin","conditions":"Psilocybin; Neuropathy","sponsor":"M.D. Anderson Cancer Center","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Texas","lsd_com_url":"https://lsd.com/trials/nct07227909","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07227909"},{"nct_id":"NCT07247006","title":"Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":25,"start_date":"2026-12","completion_date":"2028-03","last_update":"2026-09-24","substances":"ketamine","conditions":"Treatment Resistant Depression (TRD); Chronic Pain","sponsor":"University of Rochester","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct07247006","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07247006"},{"nct_id":"NCT07247370","title":"Ketamine-Enhanced Therapy for Individuals With Alcohol Use Disorder and Depression: A Pilot Study (KET-DUAL)","acronym":"KET-DUAL","status":"NOT_YET_RECRUITING","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2025-12-10","completion_date":"2027-04-10","last_update":"2025-11-25","substances":"ketamine","conditions":"Alcohol Use Disorder (AUD); Major Depressive Disorder (MDD); Comorbidities and Coexisting Conditions","sponsor":"South West Sydney Local Health District","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Australia","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07247370","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07247370"},{"nct_id":"NCT07247968","title":"Subanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study","acronym":"","status":"RECRUITING","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":220,"start_date":"2025-11-25","completion_date":"2026-11-20","last_update":"2026-01-07","substances":"ketamine","conditions":"Esketamine; ECT; Depression; Adolescent","sponsor":"Min Su","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07247968","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07247968"},{"nct_id":"NCT07251491","title":"Psilocybin to Treat Depression in Spinal Cord Injury","acronym":"STOP","status":"RECRUITING","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2026-08-06","completion_date":"2028-03-01","last_update":"2026-08-10","substances":"psilocybin","conditions":"Spinal Cord Injury; Depression - Major Depressive Disorder; Veteran","sponsor":"James J. Peters Veterans Affairs Medical Center","sponsor_class":"FED","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct07251491","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07251491"},{"nct_id":"NCT07269964","title":"At-Home tDCS as Maintenance Therapy","acronym":"MaintenanceDC","status":"RECRUITING","phases":"NA","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2024-10-01","completion_date":"2026-08-29","last_update":"2025-12-08","substances":"ketamine","conditions":"MDD; Severe Depression; Major Depressive Episode","sponsor":"Technical University of Munich","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"Germany","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07269964","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07269964"},{"nct_id":"NCT07273851","title":"Comparison of Propofol and Ketofol as Induction Agents for Electroconvulsive Therapy","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":80,"start_date":"2025-07-01","completion_date":"2025-12-10","last_update":"2025-12-12","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Fauji Foundation Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Pakistan","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07273851","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07273851"},{"nct_id":"NCT07275970","title":"Safety and Preliminary Efficacy of Organic Whole Psilocybin-Containing Mushrooms to Treat Patients Suffering From PTSD","acronym":"PASSAGE","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2026-03-20","completion_date":"2026-07-30","last_update":"2026-07-29","substances":"psilocybin","conditions":"PTSD","sponsor":"Scottsdale Research Institute","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Arizona","lsd_com_url":"https://lsd.com/trials/nct07275970","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07275970"},{"nct_id":"NCT07281352","title":"RCT of Psilocybin-assisted CBT for Depression","acronym":"","status":"RECRUITING","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2026-01-05","completion_date":"2027-11-30","last_update":"2026-02-12","substances":"psilocybin","conditions":"Major Depressive Diorder","sponsor":"University of California, Los Angeles","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct07281352","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07281352"},{"nct_id":"NCT07288151","title":"MDMA-Assisted Massed Exposure Therapy for PTSD","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":200,"start_date":"2026-07","completion_date":"2030-01","last_update":"2026-05-26","substances":"mdma","conditions":"Post Traumatic Stress Disorder","sponsor":"Emory University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Georgia","lsd_com_url":"https://lsd.com/trials/nct07288151","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07288151"},{"nct_id":"NCT07296094","title":"Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":36,"start_date":"2026-11-15","completion_date":"2029-12-01","last_update":"2026-09-24","substances":"psilocybin","conditions":"Alcohol Use Disorder","sponsor":"Brigham and Women's Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct07296094","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07296094"},{"nct_id":"NCT07296328","title":"Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":25,"start_date":"2026-01-15","completion_date":"2027-04-01","last_update":"2025-12-22","substances":"psilocybin","conditions":"Stuttering","sponsor":"NYU Langone Health","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct07296328","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07296328"},{"nct_id":"NCT07301632","title":"Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial","acronym":"EASEPain","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2026-01-30","completion_date":"2027-12-01","last_update":"2026-07-29","substances":"mdma","conditions":"Chronic Neuropathic Pain","sponsor":"Unity Health Toronto","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07301632","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07301632"},{"nct_id":"NCT07303907","title":"A Phase 2A Trial of DT402 for Autism Spectrum Disorder","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2025-12-03","completion_date":"2027-08","last_update":"2026-09-02","substances":"mdma","conditions":"Autism Spectrum Disorder; ASD","sponsor":"Definium Therapeutics US, Inc.","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct07303907","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07303907"},{"nct_id":"NCT07306364","title":"Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":45,"start_date":"2026-10","completion_date":"2029-06","last_update":"2026-08-19","substances":"psilocybin","conditions":"Chronic Low Back Pain (CLBP); Physical Therapy; Psilocybin","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct07306364","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07306364"},{"nct_id":"NCT07307768","title":"Ketamine Biomarker Validation","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2025-12-20","completion_date":"2027-12-01","last_update":"2025-12-29","substances":"ketamine","conditions":"Treatment Resistant Depression (TRD)","sponsor":"Soterix Medical","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct07307768","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07307768"},{"nct_id":"NCT07309471","title":"Pharmacokinetics of Didehydro-LSD (DDH-LSD) Compared With LSD","acronym":"DDH-LSD","status":"RECRUITING","phases":"NA","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2026-03-06","completion_date":"2028-07","last_update":"2026-03-10","substances":"lsd","conditions":"LSD Reaction","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07309471","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07309471"},{"nct_id":"NCT07317206","title":"Ayahuasca, Esketamine and PTSD","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2025-12-20","completion_date":"2026-06","last_update":"2026-01-05","substances":"ketamine; dmt","conditions":"Posttraumatic Stress Disorder (PTSD)","sponsor":"University of Sao Paulo","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Brazil","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07317206","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07317206"},{"nct_id":"NCT07317219","title":"Ayahuasca, Esketamine and Body Image Perception","acronym":"","status":"RECRUITING","phases":"NA","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2025-12-20","completion_date":"2026-06","last_update":"2026-01-05","substances":"dmt","conditions":"Healthy Women Volunteers","sponsor":"University of Sao Paulo","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Brazil","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07317219","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07317219"},{"nct_id":"NCT07317232","title":"Ayahuasca, Esketamine and Premenstrual Symptoms","acronym":"","status":"RECRUITING","phases":"NA","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2025-12-20","completion_date":"2026-06","last_update":"2026-01-05","substances":"dmt","conditions":"Healthy Women Volunteers","sponsor":"University of Sao Paulo","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Brazil","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07317232","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07317232"},{"nct_id":"NCT07332143","title":"Psilocybin-Assisted Therapy","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":150,"start_date":"2026-06-08","completion_date":"2027-03","last_update":"2026-10-01","substances":"psilocybin","conditions":"PTSD","sponsor":"Emory University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Georgia","lsd_com_url":"https://lsd.com/trials/nct07332143","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07332143"},{"nct_id":"NCT07336238","title":"Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":18,"start_date":"2026-05-19","completion_date":"2026-12-01","last_update":"2026-07-31","substances":"psilocybin","conditions":"Anxiety; Depression; Hematopoietic and Lymphatic System Neoplasm; Metastatic Malignant Solid Neoplasm","sponsor":"University of Washington","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Washington","lsd_com_url":"https://lsd.com/trials/nct07336238","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07336238"},{"nct_id":"NCT07347405","title":"Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.","acronym":"Mushroom-OCD","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2026-05-18","completion_date":"2028-12-31","last_update":"2026-07-23","substances":"psilocybin","conditions":"Obsessive-Compulsive Disorder","sponsor":"Francisco A Moreno","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Arizona","lsd_com_url":"https://lsd.com/trials/nct07347405","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07347405"},{"nct_id":"NCT07360301","title":"Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":120,"start_date":"2026-10","completion_date":"2028-02","last_update":"2026-09-29","substances":"psilocybin","conditions":"Well-Being, Psychological; Psychedelic Experiences","sponsor":"University of Wisconsin, Madison","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Wisconsin","lsd_com_url":"https://lsd.com/trials/nct07360301","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07360301"},{"nct_id":"NCT07367542","title":"Effect of Esketamine on Perioperative Negative Emotions in Patients Undergoing Breast Cancer Surgery","acronym":"","status":"NOT_YET_RECRUITING","phases":"NA","study_type":"INTERVENTIONAL","enrollment":218,"start_date":"2026-01-17","completion_date":"2027-02-01","last_update":"2026-01-27","substances":"ketamine","conditions":"Depression; Anxiety; S-ketamine; Breast Cancer","sponsor":"Chinese PLA General Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07367542","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07367542"},{"nct_id":"NCT07369089","title":"Targeting Treatment-Resistant OUD With Ketamine-Assisted Mindfulness Oriented Recovery Enhancement","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":88,"start_date":"2026-02","completion_date":"2028-01","last_update":"2026-02-03","substances":"ketamine","conditions":"Opioid Use Disorder","sponsor":"University of California, San Diego","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"United States","us_states":"California; Utah","lsd_com_url":"https://lsd.com/trials/nct07369089","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07369089"},{"nct_id":"NCT07369102","title":"Esketamine With or Without Integration Therapy for Treatment-Resistant Depression","acronym":"KIND-PR","status":"RECRUITING","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2026-02-01","completion_date":"2026-12-01","last_update":"2026-01-27","substances":"ketamine","conditions":"Treatment-resistant Depression (TRD)","sponsor":"University of Puerto Rico","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"Puerto Rico","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07369102","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07369102"},{"nct_id":"NCT07373535","title":"Understanding Music and Mindfulness Preferences in Psilocybin-Assisted Psychotherapy","acronym":"PPP","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":16,"start_date":"2026-05","completion_date":"2028-07","last_update":"2026-04-22","substances":"psilocybin","conditions":"Treatment-Resistant Major Depressive Disorder","sponsor":"Kyle Greenway","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07373535","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07373535"},{"nct_id":"NCT07374198","title":"Effect of Continuous Intraoperative Esketamine Infusion on Perioperative Negative Emotions in Breast Cancer Surgery Patients With Mild-to-Severe Depression","acronym":"","status":"NOT_YET_RECRUITING","phases":"NA","study_type":"INTERVENTIONAL","enrollment":142,"start_date":"2026-01-18","completion_date":"2026-01-18","last_update":"2026-01-28","substances":"ketamine","conditions":"Depression; Anxiety; S-ketamine; Breast Cancer","sponsor":"Chinese PLA General Hospital","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07374198","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07374198"},{"nct_id":"NCT07374211","title":"Effect of Esketamine on Perioperative Negative Emotions in Breast Cancer Surgery Patients With Severe Depression","acronym":"","status":"NOT_YET_RECRUITING","phases":"NA","study_type":"INTERVENTIONAL","enrollment":242,"start_date":"2026-01-18","completion_date":"2026-01-18","last_update":"2026-01-28","substances":"ketamine","conditions":"Depression; Anxiety; S-ketamine; Breast Cancer","sponsor":"Chinese PLA General Hospital","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07374211","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07374211"},{"nct_id":"NCT07386730","title":"A Study of Psychedelics in Healthy Older Adults With Low Well-being","acronym":"OAD1","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":80,"start_date":"2026-06-01","completion_date":"2030-02","last_update":"2026-09-09","substances":"psilocybin","conditions":"Anhedonia in Healthy Volunteers; Older Adults (50-90 Years)","sponsor":"Jennifer Mitchell","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct07386730","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07386730"},{"nct_id":"NCT07391332","title":"Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a Pilot Study","acronym":"PASSENGER","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2026-04-01","completion_date":"2029-01-01","last_update":"2026-02-05","substances":"psilocybin","conditions":"Gambling Disorder","sponsor":"Nantes University Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"France","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07391332","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07391332"},{"nct_id":"NCT07396220","title":"Psychotherapy Combined With Intranasal Esketamine for the Treatment of Suicidal Ideation","acronym":"PIK-SI","status":"ENROLLING_BY_INVITATION","phases":"NA","study_type":"INTERVENTIONAL","enrollment":56,"start_date":"2026-01-09","completion_date":"2028-01","last_update":"2026-02-09","substances":"ketamine","conditions":"Suicidal Ideation","sponsor":"University of California, San Diego","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct07396220","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07396220"},{"nct_id":"NCT07396272","title":"A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression","acronym":"KET01-IIT03","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2026-03-13","completion_date":"2026-07-06","last_update":"2026-06-18","substances":"ketamine","conditions":"Major Depressive Disorder (MDD)","sponsor":"Daniel Lindqvist","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Sweden","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07396272","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07396272"},{"nct_id":"NCT07399756","title":"Mitochondrial Function After Ketamine","acronym":"","status":"NOT_YET_RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":30,"start_date":"2026-02","completion_date":"2026-09","last_update":"2026-02-10","substances":"ketamine","conditions":"Major Depressive Disorder","sponsor":"Sheba Medical Center","sponsor_class":"OTHER_GOV","has_results":false,"site_count":1,"countries":"Israel","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07399756","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07399756"},{"nct_id":"NCT07405606","title":"Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2026-03","completion_date":"2028-03","last_update":"2026-02-12","substances":"psilocybin","conditions":"Major Depressive Disorder (MDD); Alcohol Use Disorder (AUD)","sponsor":"Centre for Addiction and Mental Health","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07405606","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07405606"},{"nct_id":"NCT07406828","title":"Psilocybin After Trauma Surgery for Pain","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":70,"start_date":"2027-12-31","completion_date":"2029-04","last_update":"2026-08-06","substances":"psilocybin","conditions":"Pain Management; Postoperative Pain","sponsor":"Trent Emerick","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Pennsylvania","lsd_com_url":"https://lsd.com/trials/nct07406828","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07406828"},{"nct_id":"NCT07415395","title":"Acute Effects of Aerobic Exercise Intensity on Lower-Limb Muscle Strength and Power in Youth Gymnasts","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":18,"start_date":"2024-03-18","completion_date":"2024-05-18","last_update":"2026-02-17","substances":"lsd","conditions":"Acute Neuromuscular Responses to Aerobic Exercise in Elite Youth Gymnasts","sponsor":"Chaoran Han","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07415395","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07415395"},{"nct_id":"NCT07422519","title":"Virtual Reality-Based Mindfulness as an Adjunct to Treatment as Usual in Treatment-Resistant Depression","acronym":"","status":"RECRUITING","phases":"NA","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2025-09-18","completion_date":"2026-12-15","last_update":"2026-02-27","substances":"ketamine","conditions":"Depression - Major Depressive Disorder; Depression Disorder; Depression Chronic; Treatment-Resistant Major Depressive Disorder","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Spain","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07422519","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07422519"},{"nct_id":"NCT07433452","title":"The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers.","acronym":"PSILOBIOMARKER","status":"NOT_YET_RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2026-09-01","completion_date":"2028-09-01","last_update":"2026-02-25","substances":"psilocybin","conditions":"Healthy Participants; Placebo - Control; Psilocybin","sponsor":"Gabriella Gobbi","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07433452","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07433452"},{"nct_id":"NCT07444788","title":"Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants","acronym":"MEOS","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2026-03-31","completion_date":"2028-03-01","last_update":"2026-03-03","substances":"dmt","conditions":"5-methoxy-dimethyltryptamine (5-MeO-DMT)","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07444788","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07444788"},{"nct_id":"NCT07449351","title":"Psilocybin Microdosing on Cognition, Mood and Quality of Life","acronym":"","status":"NOT_YET_RECRUITING","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2026-10-01","completion_date":"2028-04-01","last_update":"2026-09-24","substances":"psilocybin","conditions":"Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct07449351","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07449351"},{"nct_id":"NCT07461532","title":"Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD","acronym":"","status":"RECRUITING","phases":"NA","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2026-04-01","completion_date":"2027-09-30","last_update":"2026-03-31","substances":"lsd","conditions":"Cirrhosis; Splenectomy; Portal Vein Thrombosis; Hypertension, Portal","sponsor":"Northern Jiangsu People's Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07461532","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07461532"},{"nct_id":"NCT07463911","title":"Treatment Response In ECT Patients","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":65,"start_date":"2025-05-20","completion_date":"2027-05-20","last_update":"2026-03-13","substances":"ketamine","conditions":"Major Depression; Bipolar Affective Disorder; Bipolar Depression Depressed Phase","sponsor":"Nurdan Sağbaş","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Turkey (Türkiye)","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07463911","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07463911"},{"nct_id":"NCT07469098","title":"Group vs Individual MDMA-Assisted Therapy for PTSD After the October 7, 2023 Events","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":168,"start_date":"2025-12-24","completion_date":"2028-12-31","last_update":"2026-03-13","substances":"mdma","conditions":"PTSD","sponsor":"Sheba Medical Center","sponsor_class":"OTHER_GOV","has_results":false,"site_count":2,"countries":"Israel","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07469098","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07469098"},{"nct_id":"NCT07474246","title":"A Innovative Web-based Dance Movement Therapy","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":67,"start_date":"2024-08-01","completion_date":"2025-07-31","last_update":"2026-03-16","substances":"dmt","conditions":"Breast Cancer","sponsor":"Chin-Tsung Shen","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Taiwan","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07474246","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07474246"},{"nct_id":"NCT07479550","title":"Study of Psilocybin Under Anesthesia Controlled by EEG","acronym":"SPACE","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2026-07","completion_date":"2027-07","last_update":"2026-05-06","substances":"psilocybin","conditions":"Major Depression","sponsor":"Stanford University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct07479550","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07479550"},{"nct_id":"NCT07484906","title":"Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies","acronym":"PRE-EMPT","status":"WITHDRAWN","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":0,"start_date":"2026-05-01","completion_date":"2029-08-31","last_update":"2026-03-20","substances":"psilocybin","conditions":"Suicidal Ideation","sponsor":"University of New Mexico","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07484906","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07484906"},{"nct_id":"NCT07490353","title":"Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects","acronym":"","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":85,"start_date":"2025-11-01","completion_date":"2028-05-31","last_update":"2026-03-24","substances":"psilocybin","conditions":"Depression - Major Depressive Disorder; Anhedonia","sponsor":"Medical University of Vienna","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Austria","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07490353","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07490353"},{"nct_id":"NCT07490405","title":"Long-term Efficacy and Safety of LSD Versus TIPS for Cirrhotic Portal Hypertension Bleeding and Hypersplenism","acronym":"LSD、TIPS","status":"NOT_YET_RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":140,"start_date":"2026-06-01","completion_date":"2031-03-01","last_update":"2026-05-18","substances":"lsd","conditions":"Liver Cirrhosis","sponsor":"Northern Jiangsu People's Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07490405","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07490405"},{"nct_id":"NCT07494214","title":"Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants","acronym":"MDPS","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2026-03-09","completion_date":"2027-03-09","last_update":"2026-03-27","substances":"mdma","conditions":"Healhty","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07494214","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07494214"},{"nct_id":"NCT07499583","title":"Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2026-08-01","completion_date":"2031-01-01","last_update":"2026-03-30","substances":"psilocybin","conditions":"Treatment Resistant Depression; Substance Use Disorders","sponsor":"Indiana University","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"United States","us_states":"Indiana","lsd_com_url":"https://lsd.com/trials/nct07499583","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07499583"},{"nct_id":"NCT07503002","title":"Shortened LSD Intervention for Major Depressive Disorder","acronym":"SLIM","status":"NOT_YET_RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2026-10-01","completion_date":"2027-07-01","last_update":"2026-09-22","substances":"lsd","conditions":"Major Depression Moderate; Major Depression Severe; Major Depression","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct07503002","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07503002"},{"nct_id":"NCT07506395","title":"Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder","acronym":"GPAT","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":36,"start_date":"2026-05-01","completion_date":"2027-05-01","last_update":"2026-05-22","substances":"psilocybin","conditions":"PTSD","sponsor":"University of New Mexico","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New Mexico","lsd_com_url":"https://lsd.com/trials/nct07506395","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07506395"},{"nct_id":"NCT07516405","title":"Safety and Tolerability Trial of Psilocybin in Healthy Older Adults","acronym":"Psil-Pk","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2026-04-01","completion_date":"2028-03","last_update":"2026-09-16","substances":"psilocybin","conditions":"Healthy Volunteer; Older Adults (65-85 Years)","sponsor":"University of Colorado, Denver","sponsor_class":"OTHER","has_results":false,"site_count":6,"countries":"United States","us_states":"California; Colorado; Georgia; Massachusetts; Nebraska; New York","lsd_com_url":"https://lsd.com/trials/nct07516405","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07516405"},{"nct_id":"NCT07526454","title":"Electroconvulsive Therapy Versus Intravenous Ketamine in Treatment-Resistant Major Depressive Disorder","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":70,"start_date":"2025-07-01","completion_date":"2026-02-01","last_update":"2026-04-13","substances":"ketamine","conditions":"Electroconvulsive Therapy; Intravenous Ketamine; Treatment-Resistant; Major Depressive Disorder","sponsor":"Tanta University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Egypt","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07526454","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07526454"},{"nct_id":"NCT07528014","title":"ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1","acronym":"ATLAS-1","status":"RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":5000,"start_date":"2026-03-25","completion_date":"2036-03","last_update":"2026-04-14","substances":"ketamine","conditions":"Depressed Mood","sponsor":"Salma Health, Inc.","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct07528014","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07528014"},{"nct_id":"NCT07540494","title":"Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2026-04","completion_date":"2026-05","last_update":"2026-04-20","substances":"dmt","conditions":"Healthy Adult","sponsor":"GH Research Ireland Limited","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United States","us_states":"Florida","lsd_com_url":"https://lsd.com/trials/nct07540494","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07540494"},{"nct_id":"NCT07542145","title":"MDMA Assisted Therapy for BN","acronym":"","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2026-05-22","completion_date":"2028-04-30","last_update":"2026-06-22","substances":"mdma","conditions":"Bulimia Nervosa","sponsor":"Icahn School of Medicine at Mount Sinai","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct07542145","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07542145"},{"nct_id":"NCT07555132","title":"Circulating Oxytocin Changes in Response to MDMA vs. Placebo in Adult Patients With Autism Spectrum Disorder and Matched Healthy Controls","acronym":"OxySPECTRUM","status":"NOT_YET_RECRUITING","phases":"NA","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2026-06","completion_date":"2028-06","last_update":"2026-04-29","substances":"mdma","conditions":"Autism Spectrum Disorder","sponsor":"University Hospital, Basel, Switzerland","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Switzerland","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07555132","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07555132"},{"nct_id":"NCT07562191","title":"Inhaled DMT for Major Depressive Disorder","acronym":"DMT-MDD","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":140,"start_date":"2026-08-01","completion_date":"2027-02-01","last_update":"2026-07-13","substances":"dmt","conditions":"MDD; Major Depressive Disorder (MDD); Major Depression; Suicidal Ideation; Suicide","sponsor":"Universidade Federal do Rio Grande do Norte","sponsor_class":"OTHER","has_results":false,"site_count":5,"countries":"Brazil","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07562191","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07562191"},{"nct_id":"NCT07563296","title":"KALM-B: Ketamine-assisted Psychotherapy (KAP) to Lessen Morbidity After Burn Injury","acronym":"KALM-B","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2026-08-24","completion_date":"2027-12-01","last_update":"2026-08-27","substances":"ketamine","conditions":"PTSD and Trauma-related Symptoms","sponsor":"Irma Fleming","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Utah","lsd_com_url":"https://lsd.com/trials/nct07563296","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07563296"},{"nct_id":"NCT07563868","title":"Coaching as an Adjunct to Ketamine Therapy for Treatment-Resistant Depression","acronym":"","status":"RECRUITING","phases":"NA","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2026-04-17","completion_date":"2027-04-01","last_update":"2026-07-23","substances":"ketamine","conditions":"Treatment Resistant Depression (TRD)","sponsor":"Massachusetts General Hospital","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct07563868","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07563868"},{"nct_id":"NCT07565493","title":"Psilocybin Administration With 5-HT1a Blockade","acronym":"PsilBlock1","status":"RECRUITING","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":18,"start_date":"2026-08-12","completion_date":"2028-06-15","last_update":"2026-09-14","substances":"psilocybin","conditions":"Psychedelic Effects in Healthy Volunteers","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct07565493","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07565493"},{"nct_id":"NCT07565909","title":"Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":72,"start_date":"2026-06","completion_date":"2027-12","last_update":"2026-05-04","substances":"psilocybin","conditions":"Depression; Anxiety","sponsor":"University of Washington","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07565909","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07565909"},{"nct_id":"NCT07566104","title":"Group PACBT for Depression","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2027-01","completion_date":"2028-12","last_update":"2026-05-04","substances":"psilocybin","conditions":"Depression - Major Depressive Disorder; Psilocybin; Cognitive Behavioral Therapy","sponsor":"University of California, Los Angeles","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct07566104","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07566104"},{"nct_id":"NCT07569159","title":"MDMA Therapy in Veterans With PTSD","acronym":"","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":52,"start_date":"2026-06-30","completion_date":"2027-04-01","last_update":"2026-07-01","substances":"mdma","conditions":"Post Traumatic Stress Disorder","sponsor":"Sunstone Medical","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct07569159","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07569159"},{"nct_id":"NCT07569198","title":"Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)","acronym":"KET-DBT","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":120,"start_date":"2026-07-16","completion_date":"2029-01","last_update":"2026-07-29","substances":"ketamine","conditions":"Borderline Personality Disorder (BPD); Treatment-Resistant Major Depressive Disorder; Treatment-resistant Bipolar Depression; Major Depressive Disorder (MDD); Bipolar Disorder (BD); Bipolar Disorder I or II; Suicidal Ideation","sponsor":"Joshua Rosenblat","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07569198","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07569198"},{"nct_id":"NCT07570654","title":"Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder","acronym":"Redefine","status":"RECRUITING","phases":"PHASE2; PHASE3","study_type":"INTERVENTIONAL","enrollment":300,"start_date":"2026-09","completion_date":"2028-11","last_update":"2026-10-06","substances":"psilocybin","conditions":"PTSD - Post Traumatic Stress Disorder; PTSD; PTSD Symptoms; PTSD, Post Traumatic Stress Disorder","sponsor":"COMPASS Pathways","sponsor_class":"INDUSTRY","has_results":false,"site_count":8,"countries":"Canada; United States","us_states":"Florida; Illinois; Minnesota; Nebraska; Nevada; New York","lsd_com_url":"https://lsd.com/trials/nct07570654","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07570654"},{"nct_id":"NCT07582120","title":"Psilocybin-Assisted Therapy as a Treatment for Depression","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2026-06","completion_date":"2031-06","last_update":"2026-05-20","substances":"psilocybin","conditions":"Depression","sponsor":"Washington University School of Medicine","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Missouri","lsd_com_url":"https://lsd.com/trials/nct07582120","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07582120"},{"nct_id":"NCT07584720","title":"Study of Midomafetamine in Healthy Adults","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":32,"start_date":"2026-04-23","completion_date":"2026-07-23","last_update":"2026-06-29","substances":"mdma","conditions":"Healthy Volunteers","sponsor":"Resilient Pharmaceuticals","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United States","us_states":"Kansas","lsd_com_url":"https://lsd.com/trials/nct07584720","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07584720"},{"nct_id":"NCT07585786","title":"Effect of LSD on Renal Function in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)","acronym":"LSD-RFPH","status":"NOT_YET_RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":30,"start_date":"2026-05-01","completion_date":"2029-02-28","last_update":"2026-05-18","substances":"lsd","conditions":"Cirrhosis, Liver; Splenectomy; Status; Renal Function Abnormal; Portal Hypertension","sponsor":"Northern Jiangsu People's Hospital","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07585786","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07585786"},{"nct_id":"NCT07588334","title":"Effect of LSD on Lipid Profiles in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)","acronym":"LSD-LPPH","status":"NOT_YET_RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":30,"start_date":"2026-05-01","completion_date":"2029-02-28","last_update":"2026-05-14","substances":"lsd","conditions":"Cirrhosis, Liver; Splenectomy; Status; Portal Hypertension; Lipid Profiles","sponsor":"Northern Jiangsu People's Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07588334","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07588334"},{"nct_id":"NCT07592689","title":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","acronym":"","status":"RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":165,"start_date":"2026-05-10","completion_date":"2027-09","last_update":"2026-10-05","substances":"lsd","conditions":"Major Depressive Disorder","sponsor":"Definium Therapeutics US, Inc.","sponsor_class":"INDUSTRY","has_results":false,"site_count":30,"countries":"United States","us_states":"Arkansas; California; Colorado; Florida; Georgia; Illinois; Massachusetts; Missouri; Nevada; New York; Ohio; Pennsylvania; South Carolina; Texas; Utah; Vermont; Washington","lsd_com_url":"https://lsd.com/trials/nct07592689","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07592689"},{"nct_id":"NCT07602153","title":"Multimodal Pharmacological Study of Clinical Cohorts for Major Depressive Disorder","acronym":"","status":"NOT_YET_RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":130,"start_date":"2026-05-30","completion_date":"2027-12-31","last_update":"2026-05-22","substances":"ketamine","conditions":"Major Depressive Disorder (MDD","sponsor":"Shanghai Mental Health Center","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07602153","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07602153"},{"nct_id":"NCT07607938","title":"Psilocybin as a Novel Therapy for Residual Anhedonia","acronym":"","status":"RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":90,"start_date":"2026-09","completion_date":"2030-08-01","last_update":"2026-09-15","substances":"psilocybin","conditions":"Anhedonia; Emotional Blunting","sponsor":"NYU Langone Health","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct07607938","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07607938"},{"nct_id":"NCT07610135","title":"Psilocybin Efficacy With or Without Pimavanserin Pretreatment","acronym":"PRISMatic","status":"RECRUITING","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2026-10-30","completion_date":"2028-06","last_update":"2026-10-01","substances":"psilocybin","conditions":"Mood (Psychological Function); Well Being; Mood; Healthy","sponsor":"Johns Hopkins University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct07610135","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07610135"},{"nct_id":"NCT07610369","title":"The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease","acronym":"PSI-PD","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":40,"start_date":"2026-07-10","completion_date":"2030-07","last_update":"2026-09-28","substances":"psilocybin","conditions":"Depression; Parkinson's Disease (PD)","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct07610369","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07610369"},{"nct_id":"NCT07614581","title":"Intra-Sessional Autonomic Arc Detection in Ketamine-Assisted Therapy for PTSD: A Signal Characterisation Pilot Study","acronym":"OMS-KAT","status":"NOT_YET_RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":5,"start_date":"2026-07-15","completion_date":"2026-08-31","last_update":"2026-05-29","substances":"ketamine","conditions":"Post-Traumatic Stress Disorder","sponsor":"Adriaan Dirk van der Wart","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07614581","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07614581"},{"nct_id":"NCT07638553","title":"Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms","acronym":"ERPPAD","status":"RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":172,"start_date":"2026-06-30","completion_date":"2030-06","last_update":"2026-07-01","substances":"psilocybin","conditions":"Alcohol Use Disorder; Depressive Sympotoms; Psilocybin","sponsor":"Centre Hospitalier Universitaire de Nīmes","sponsor_class":"OTHER","has_results":false,"site_count":8,"countries":"France","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07638553","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07638553"},{"nct_id":"NCT07639099","title":"Intranasal Esketamine-dexmedetomidine Combination and Postpartum Depression","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":164,"start_date":"2026-06","completion_date":"2029-10","last_update":"2026-06-15","substances":"ketamine","conditions":"Parturients; Depressive Symptoms; Esketamine; Dexmedetomidine; Intranasal Administration; Postpartum Depression","sponsor":"Peking University First Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07639099","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07639099"},{"nct_id":"NCT07639359","title":"Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients","acronym":"KID-ICU","status":"RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2026-05-14","completion_date":"2028-05-01","last_update":"2026-09-02","substances":"ketamine","conditions":"Critical Illness; Depressive Symptoms","sponsor":"Hospital Italiano de Buenos Aires","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"Argentina; United States","us_states":"Florida","lsd_com_url":"https://lsd.com/trials/nct07639359","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07639359"},{"nct_id":"NCT07644767","title":"Adjunctive Oral KET-AD Capsules in Treatment Resistant Bipolar Depression","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":160,"start_date":"2026-10-30","completion_date":"2028-01-30","last_update":"2026-06-12","substances":"ketamine","conditions":"Treatment Resistant Bipolar Depression","sponsor":"Neurocentrx Pharma Pty Ltd","sponsor_class":"INDUSTRY","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07644767","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07644767"},{"nct_id":"NCT07680140","title":"Biomarker-Guided Antidepressant Selection","acronym":"BioSelect","status":"RECRUITING","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":27,"start_date":"2026-08-10","completion_date":"2028-09","last_update":"2026-09-23","substances":"ketamine","conditions":"Depression - Major Depressive Disorder; Treatment-resistant Depression (TRD); rTMS; Ketamine; fMRI","sponsor":"Weill Medical College of Cornell University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"New York","lsd_com_url":"https://lsd.com/trials/nct07680140","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07680140"},{"nct_id":"NCT07683988","title":"Oral and Sublingual Ketamine","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":10,"start_date":"2026-10-01","completion_date":"2027-08-01","last_update":"2026-07-06","substances":"ketamine","conditions":"Major Depression Severe","sponsor":"Western University, Canada","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07683988","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07683988"},{"nct_id":"NCT07693153","title":"The Effects of Psilocybin on Social Connectedness","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":51,"start_date":"2026-08-31","completion_date":"2031-12-15","last_update":"2026-07-09","substances":"psilocybin","conditions":"Loneliness; Grief","sponsor":"Yale University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Connecticut","lsd_com_url":"https://lsd.com/trials/nct07693153","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07693153"},{"nct_id":"NCT07693257","title":"Neural Effects of Intravenous N,N-dimethyltryptamine (DMT)","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":20,"start_date":"2026-09-01","completion_date":"2028-09-01","last_update":"2026-07-09","substances":"dmt","conditions":"Healthy Participants Study","sponsor":"Jon Dean","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct07693257","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07693257"},{"nct_id":"NCT07703722","title":"Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder","acronym":"","status":"RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2026-04-01","completion_date":"2027-10-22","last_update":"2026-07-14","substances":"psilocybin","conditions":"Major Depressive Disorder; Post-Traumatic Stress Disorder (PTSD)","sponsor":"Khyber Medical University Peshawar","sponsor_class":"OTHER","has_results":false,"site_count":3,"countries":"Pakistan","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07703722","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07703722"},{"nct_id":"NCT07704762","title":"Clinical Trial of MDMA-Assisted Therapy for Military Service Members With Posttraumatic Stress Disorder","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":86,"start_date":"2026-10-01","completion_date":"2028-01-01","last_update":"2026-07-15","substances":"mdma","conditions":"PTSD; Post Traumatic Stress Disorder PTSD; Post Traumatic Stress Disorder","sponsor":"U.S. Army Medical Research and Development Command","sponsor_class":"FED","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07704762","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07704762"},{"nct_id":"NCT07706478","title":"Working Mechanisms and Effectiveness of IV Ketamine-assisted Psychotherapy on Depression in TRD Clients","acronym":"","status":"RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":120,"start_date":"2025-06-01","completion_date":"2033-01","last_update":"2026-07-15","substances":"ketamine","conditions":"Treatment Resistant Depression","sponsor":"Senz","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Netherlands","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07706478","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07706478"},{"nct_id":"NCT07710027","title":"Identification of a Safe and Non-Psychedelic Dose of Psilocybin","acronym":"","status":"COMPLETED","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":56,"start_date":"2021-10-19","completion_date":"2022-03-12","last_update":"2026-07-17","substances":"psilocybin","conditions":"Healthy Controls","sponsor":"Diamond Therapeutics Inc.","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07710027","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07710027"},{"nct_id":"NCT07716098","title":"A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression","acronym":"","status":"RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":348,"start_date":"2026-07-23","completion_date":"2028-12-27","last_update":"2026-09-25","substances":"ketamine","conditions":"Depressive Disorder, Treatment-Resistant","sponsor":"Janssen Research & Development, LLC","sponsor_class":"INDUSTRY","has_results":false,"site_count":22,"countries":"Japan; Taiwan; United States","us_states":"California; Georgia; Illinois; New York; Washington","lsd_com_url":"https://lsd.com/trials/nct07716098","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07716098"},{"nct_id":"NCT07717866","title":"Trifecta Research Study","acronym":"","status":"ACTIVE_NOT_RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":52,"start_date":"2022-08-01","completion_date":"2026-02-01","last_update":"2026-07-21","substances":"dmt; ibogaine","conditions":"PTSD - Post Traumatic Stress Disorder; Cognitive Dysfunction; Brain Injury; Depression - Major Depressive Disorder; Suicidal Ideation","sponsor":"Axial Therapeutic Research","sponsor_class":"INDUSTRY","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct07717866","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07717866"},{"nct_id":"NCT07719088","title":"Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life","acronym":"LONG-LIFE","status":"NOT_YET_RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":50,"start_date":"2026-12","completion_date":"2028-04","last_update":"2026-08-17","substances":"psilocybin","conditions":"Aging; Longevity; Biomarkers of Aging","sponsor":"Charles Raison","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Colorado","lsd_com_url":"https://lsd.com/trials/nct07719088","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07719088"},{"nct_id":"NCT07721467","title":"Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":200,"start_date":"2026-10-11","completion_date":"2030-12-31","last_update":"2026-10-06","substances":"psilocybin","conditions":"Alzheimer's Disease","sponsor":"National Institute on Aging (NIA)","sponsor_class":"NIH","has_results":false,"site_count":1,"countries":"United States","us_states":"Maryland","lsd_com_url":"https://lsd.com/trials/nct07721467","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07721467"},{"nct_id":"NCT07723066","title":"Biomarker Discovery for Suicide Precision Circuit Therapeutics","acronym":"","status":"NOT_YET_RECRUITING","phases":"","study_type":"OBSERVATIONAL","enrollment":60,"start_date":"2026-07","completion_date":"2029-07","last_update":"2026-07-23","substances":"ketamine","conditions":"Suicidal Thoughts and Behaviors; Major Depressive Episode (MDE)","sponsor":"Massachusetts General Hospital","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07723066","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07723066"},{"nct_id":"NCT07732166","title":"Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin.","acronym":"","status":"RECRUITING","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":100,"start_date":"2026-04-01","completion_date":"2027-08-01","last_update":"2026-07-28","substances":"psilocybin","conditions":"Healthy Adults","sponsor":"Pontifícia Universidade Católica do Rio de Janeiro","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Brazil","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07732166","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07732166"},{"nct_id":"NCT07737054","title":"Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for PTSD","acronym":"TiPAP-PTSD","status":"RECRUITING","phases":"EARLY_PHASE1","study_type":"INTERVENTIONAL","enrollment":13,"start_date":"2025-07-22","completion_date":"2026-12-01","last_update":"2026-07-30","substances":"psilocybin","conditions":"Post-Traumatic Stress Disorder, PTSD","sponsor":"Tel-Aviv Sourasky Medical Center","sponsor_class":"OTHER_GOV","has_results":false,"site_count":1,"countries":"Israel","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07737054","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07737054"},{"nct_id":"NCT07737990","title":"Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression","acronym":"PSI-GROUP","status":"ENROLLING_BY_INVITATION","phases":"NA","study_type":"INTERVENTIONAL","enrollment":65,"start_date":"2026-07-01","completion_date":"2029-12-31","last_update":"2026-07-30","substances":"psilocybin","conditions":"Treatment-resistant Depression (TRD)","sponsor":"Joshua Rosenblat","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07737990","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07737990"},{"nct_id":"NCT07745569","title":"Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies","acronym":"PRE-EMPT","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":150,"start_date":"2026-08-31","completion_date":"2030-06-30","last_update":"2026-08-04","substances":"psilocybin","conditions":"PTSD; PTSD - Post Traumatic Stress Disorder; Major Depression; Suicidality","sponsor":"University of New Mexico","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07745569","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07745569"},{"nct_id":"NCT07747324","title":"Effects of a Sigle Dose of Ayahuasca in Patients With Psychogenic Non-epileptic Seizures: an Open Label Clinical Trial","acronym":"","status":"RECRUITING","phases":"PHASE1; PHASE2","study_type":"INTERVENTIONAL","enrollment":15,"start_date":"2026-07-01","completion_date":"2027-08-30","last_update":"2026-08-05","substances":"dmt","conditions":"Non Epileptic Seizures","sponsor":"University of Sao Paulo","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Brazil","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07747324","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07747324"},{"nct_id":"NCT07753772","title":"Dexmedetomidine-Esketamine Combination on Depression and Anxiety After Laparoscopic Ureteral Reconstruction","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE4","study_type":"INTERVENTIONAL","enrollment":658,"start_date":"2026-08","completion_date":"2029-07","last_update":"2026-08-14","substances":"ketamine","conditions":"Ureteral Stricture; Dexmedetomidine; Esketamine; Depressive Symptoms; Anxiety","sponsor":"Peking University First Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07753772","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07753772"},{"nct_id":"NCT07756736","title":"Psilocybin Therapy for Methamphetamine Use Disorder and HIV","acronym":"PRISM","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":30,"start_date":"2026-11","completion_date":"2029-04","last_update":"2026-08-11","substances":"psilocybin","conditions":"Methamphetamine Use Disorder; Human Immunodeficiency Virus (HIV)","sponsor":"Nicky Mehtani, MD, MPH","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"California","lsd_com_url":"https://lsd.com/trials/nct07756736","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07756736"},{"nct_id":"NCT07765693","title":"MDMA-AT for PTSD in Young Adults With Childhood Trauma","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":15,"start_date":"2026-10-31","completion_date":"2028-01-30","last_update":"2026-08-20","substances":"mdma","conditions":"Posttraumatic Stress Disorder (PTSD)","sponsor":"Jenna M. Traynor","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Massachusetts","lsd_com_url":"https://lsd.com/trials/nct07765693","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07765693"},{"nct_id":"NCT07768618","title":"Electrophysiologic Mechanisms of Ketamine Antidepressant Response","acronym":"Ketamine-sEEG","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":37,"start_date":"2026-12","completion_date":"2031-12","last_update":"2026-08-17","substances":"ketamine","conditions":"Epilepsy; Depressive Symptoms","sponsor":"Emory University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Georgia","lsd_com_url":"https://lsd.com/trials/nct07768618","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07768618"},{"nct_id":"NCT07774702","title":"Psilocybin for Methamphetamine Use Disorder","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":42,"start_date":"2027-02-01","completion_date":"2032-02-01","last_update":"2026-09-21","substances":"psilocybin","conditions":"Methamphetamine Use Disorder","sponsor":"Peter Hendricks","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Alabama","lsd_com_url":"https://lsd.com/trials/nct07774702","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07774702"},{"nct_id":"NCT07791901","title":"MB-PAT for Demoralization in Advanced Cancer ('PAT-MIND') Trial","acronym":"PAT-MIND","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2026-10-30","completion_date":"2027-12-20","last_update":"2026-09-02","substances":"psilocybin","conditions":"Advanced Cancer; Demoralization; Existential Distress; Psychological Distress","sponsor":"University of Calgary","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07791901","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07791901"},{"nct_id":"NCT07792538","title":"Psilocybin-Assisted Psychotherapy for Veterans With PTSD","acronym":"PsiVet","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":12,"start_date":"2026-12","completion_date":"2028-12","last_update":"2026-08-28","substances":"psilocybin","conditions":"Posttraumatic Stress Disorder (PTSD)","sponsor":"ARQ National Psychotrauma Centre","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Netherlands","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07792538","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07792538"},{"nct_id":"NCT07800026","title":"Effectiveness of Dance Therapy for Students With Mild Autism Spectrum Disorder in China","acronym":"","status":"NOT_YET_RECRUITING","phases":"NA","study_type":"INTERVENTIONAL","enrollment":96,"start_date":"2026-09-20","completion_date":"2027-01-20","last_update":"2026-09-02","substances":"dmt","conditions":"Autism Spectrum Disorder (ASD)","sponsor":"Universiti Putra Malaysia","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07800026","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07800026"},{"nct_id":"NCT07801703","title":"Behavioural Activation Therapy and Ketamine for Treatment-Resistant Depression","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE2; PHASE3","study_type":"INTERVENTIONAL","enrollment":60,"start_date":"2026-09","completion_date":"2029-09","last_update":"2026-09-03","substances":"ketamine","conditions":"Treatment Resistant Depression; Major Depressive Disorder (MDD)","sponsor":"The Royal's Institute of Mental Health Research","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07801703","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07801703"},{"nct_id":"NCT07810023","title":"Intramuscular Ketamine for Suicidal Patients in the Evanston Hospital Emergency Department for Suicidal Distress","acronym":"KEDS-C","status":"ENROLLING_BY_INVITATION","phases":"NA","study_type":"INTERVENTIONAL","enrollment":8,"start_date":"2026-09-10","completion_date":"2027-03","last_update":"2026-09-09","substances":"ketamine","conditions":"Suicidal; Suicidal Ideation; Suicidal Ideation and Behavior; Depression / Major Depressive Disorder","sponsor":"Endeavor Health","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Illinois","lsd_com_url":"https://lsd.com/trials/nct07810023","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07810023"},{"nct_id":"NCT07811700","title":"Effect of LSD on Lipid Profiles Within 1 Year Postoperatively in Cirrhosis Patients With Portal Hypertension Bleeding","acronym":"LSD-LPPH","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":150,"start_date":"2022-05-01","completion_date":"2025-05-01","last_update":"2026-09-10","substances":"lsd","conditions":"Lipid Profiles; Cirrhosis, Liver; Portal Hypertension; Splenectomy; Status","sponsor":"Northern Jiangsu People's Hospital","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"China","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07811700","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07811700"},{"nct_id":"NCT07811713","title":"Effect of LSD on Renal Function in Cirrhotic Patients With Portal Hypertension","acronym":"","status":"COMPLETED","phases":"","study_type":"OBSERVATIONAL","enrollment":496,"start_date":"2012-02","completion_date":"2026-02","last_update":"2026-09-10","substances":"lsd","conditions":"Cirrhosis, Liver; Splenectomy; Status; Renal Function Abnormal; Portal Hypertension","sponsor":"Northern Jiangsu People's Hospital","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07811713","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07811713"},{"nct_id":"NCT07818564","title":"Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":24,"start_date":"2026-11","completion_date":"2027-11","last_update":"2026-09-14","substances":"psilocybin","conditions":"Phase I","sponsor":"Brown University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Rhode Island","lsd_com_url":"https://lsd.com/trials/nct07818564","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07818564"},{"nct_id":"NCT07818720","title":"MLS101 Study in PMDD","acronym":"","status":"NOT_YET_RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":32,"start_date":"2026-12","completion_date":"2027-09","last_update":"2026-09-14","substances":"psilocybin","conditions":"Premenstrual Dysphoric Disorder ( PMDD); PMDD","sponsor":"MycoMedica Life Sciences PBC","sponsor_class":"INDUSTRY","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07818720","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07818720"},{"nct_id":"NCT07820033","title":"Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial","acronym":"PEARL RCT","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":46,"start_date":"2026-09-14","completion_date":"2028-12-30","last_update":"2026-09-15","substances":"psilocybin","conditions":"Advanced Cancer; Stage IV Solid Tumor Cancer; Stage IV Sarcoma of Bone; Stage IV Lymphoma; Stage IV Melanoma; Endocrine Cancer","sponsor":"University Health Network, Toronto","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"Canada","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07820033","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07820033"},{"nct_id":"NCT07824973","title":"Ketamine Treatment for Treatment-Resistant Depression - the Role of Framing","acronym":"KetSet","status":"NOT_YET_RECRUITING","phases":"NA","study_type":"INTERVENTIONAL","enrollment":120,"start_date":"2026-09","completion_date":"2029-12","last_update":"2026-09-17","substances":"ketamine","conditions":"Treatment Resistant Depression (TRD)","sponsor":"Valdemar Landgren","sponsor_class":"OTHER_GOV","has_results":false,"site_count":1,"countries":"Sweden","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07824973","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07824973"},{"nct_id":"NCT07833761","title":"ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disorder","acronym":"ADEPT","status":"NOT_YET_RECRUITING","phases":"PHASE1","study_type":"INTERVENTIONAL","enrollment":18,"start_date":"2026-12-01","completion_date":"2029-12-31","last_update":"2026-09-22","substances":"psilocybin","conditions":"Borderline Personality Disorder; Borderline Personality Pathology; Depressive Symptoms; Emotion Dysregulation; Suicidal Ideation","sponsor":"University of Minnesota","sponsor_class":"OTHER","has_results":false,"site_count":2,"countries":"United States","us_states":"Minnesota","lsd_com_url":"https://lsd.com/trials/nct07833761","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07833761"},{"nct_id":"NCT07839338","title":"A Study Comparing Oral Ketamine With Oral Midazolam for the Treatment of Major Depressive Episodes","acronym":"KOMET","status":"NOT_YET_RECRUITING","phases":"PHASE3","study_type":"INTERVENTIONAL","enrollment":220,"start_date":"2026-10","completion_date":"2029-10","last_update":"2026-10-01","substances":"ketamine","conditions":"Major Depressive Episode","sponsor":"Jawaharlal Institute of Postgraduate Medical Education & Research","sponsor_class":"OTHER_GOV","has_results":false,"site_count":5,"countries":"India","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07839338","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07839338"},{"nct_id":"NCT07843407","title":"Investigation of Psychosocial Effects of Dance/Movement Therapy in Children With Specific Learning Disorders","acronym":"","status":"COMPLETED","phases":"NA","study_type":"INTERVENTIONAL","enrollment":46,"start_date":"2024-06-15","completion_date":"2025-03-11","last_update":"2026-09-28","substances":"dmt","conditions":"Specific Learning Disorder","sponsor":"Lokman Hekim University","sponsor_class":"OTHER_GOV","has_results":false,"site_count":1,"countries":"Turkey (Türkiye)","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07843407","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07843407"},{"nct_id":"NCT07852572","title":"Online Mindfulness-based Dance/Movement Therapy on Physical Activity and Whole-Person Health in Older Adults","acronym":"MOVE WELL","status":"NOT_YET_RECRUITING","phases":"NA","study_type":"INTERVENTIONAL","enrollment":204,"start_date":"2027-03-01","completion_date":"2031-01-31","last_update":"2026-10-01","substances":"dmt","conditions":"Physical Activity and Wellbeing; Whole Health","sponsor":"Drexel University","sponsor_class":"OTHER","has_results":false,"site_count":1,"countries":"United States","us_states":"Pennsylvania","lsd_com_url":"https://lsd.com/trials/nct07852572","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07852572"},{"nct_id":"NCT07852832","title":"Effects of Psilocybin on Craving in Nicotine Dependence","acronym":"SCANS-PSIL","status":"NOT_YET_RECRUITING","phases":"PHASE2","study_type":"INTERVENTIONAL","enrollment":3,"start_date":"2027-01","completion_date":"2027-12","last_update":"2026-10-01","substances":"psilocybin","conditions":"Nicotine Dependence","sponsor":"University of British Columbia","sponsor_class":"OTHER","has_results":false,"site_count":0,"countries":"","us_states":"","lsd_com_url":"https://lsd.com/trials/nct07852832","clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT07852832"}]}